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ABSTRACT 
 
The global pharmaceutical biotechnology industry is continually growing and increased amounts of protein 
and peptide-based therapeutics are entering into the market. Conventionally, these therapeutic proteins 
and peptides are administered intravenously, subcutaneously or intramuscularly as oral routes of 
administration may result in their degradation in the gastrointestinal tract (O’ Connor, 2009). The parenteral 
route limits patient acceptability and convenience. Oral dosage forms, particularly tablets, are considered 
one of the most common and widely used routes of drug administration and accounts for approximately 
50% of all dosage forms on the market (Oh et al., 2012). Thus, the development of oral technologies for 
therapeutic proteins and peptides remain a dynamic research field despite its many challenges. Successful 
oral delivery of proteins and peptides require the accomplishment of three key tasks: protection of the 
macromolecules from degradation in the gastrointestinal tract (GIT), permeation through the intestinal 
barrier and the absorption of molecules into the systemic circulation. Currently, no clinically useful oral 
formulations have been approved but several attempts have been made to overcome the challenges of 
low oral bioavailability resulting from poor absorption, poor permeation and enzymatic degradation of the 
proteins and peptides in the GIT. Present strategies attempt to provide structural protection of the proteins 
and peptides and improved absorption through the use of enzyme inhibitors, absorption enhancers, novel 
polymeric delivery systems and chemical modification. However, each of these technologies possesses 
limitations that preclude the successful oral delivery of proteins and peptides. 
 
The design and development of the novel Tri-functionalized OCMT attempts to breakthrough this market 
by triple targeting the major challenges governing successful oral delivery of proteins and peptides. 
Essentially, the Tri-functionalized OCMT is made up of three distinct functional components; the core-
eutectic region, the outer polymer shell and the ‘smart’ polymeric sheet. Triple targeting was achieved by 
incorporating the bioactive into a core-melt archetype within the tablet and facilitating the process of in situ 
crosslinking which significantly affects the way the bioactive is protected within the compressed tablet 
matrix as well providing desirable bioactive release kinetics. In addition, the incorporation of a co-inhibitory 
‘smart’ polymeric sheet provided added protection and enabled an improved absorption by virtue of its 
intrinsic properties and co-inhibition of the major determinants, CYP3A4 and Pgp, of poor absorption and 
low oral bioavailability. Lastly, targeting of enzymatic degradation was achieved by incorporation of a pH 
modifier that functions to transiently lower the micro-environmental pH and reduce the optimal environment 
for enzyme activity.  
 
The combination of the distinct formulatory components contained within the Tri-functionalized OCMT was 
extensively evaluated through in-depth in vitro physicochemical and physicomechanical characterization, 
ex vivo analyses and in vivo performance. In vitro and ex vivo characterization enabled the optimization of 
design variables and promoted the achievement of desirable functionalities for the attainment of optimum 
in vivo performance. In vivo analyses of the Tri-functionalized OCMT in the Large White pig model 
revealed an enhanced oral bioavailability of the incorporated peptides, octreotide and exenatide, following 
oral administration, as compared to their conventionally administered subcutaneous counterparts. In 
addition, pharmacokinetic analysis of the Tri-functionalized OCMT confirmed the maintenance of 
sustained, therapeutic levels of both octreotide and exenatide over the 24 hour period, supporting a 
convenient once-daily dosing.  
 
The rate at which protein and peptide-based therapeutics are developing is astounding, and this 
consequently increases the demand and focus towards achieving a simpler and more effective oral 
delivery of therapeutic proteins and peptides. The Tri-functionalized OCMT has successfully demonstrated 
its feasibility in enhancing the oral delivery of therapeutic proteins and peptides up to a preclinical stage. It 
may potentially serve as a viable alternative to the conventional parenteral route of administration for the 
treatment of various disease conditions by incorporating a multitude of proteins and peptides into its 
versatile design. The advancement of the Tri-functionalized OCMT to the clinical stage and beyond may 
ultimately improve patient outcomes and change the face of therapeutic protein and peptide delivery 
globally.   
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CHAPTER 1 
INTRODUCTION AND MOTIVATION FOR STUDY 
 
1.1. Background to the Study 
The oral delivery of drugs, particularly tablets, is considered one of the most common and 
widely used routes of drug administration and accounts for approximately 50% of all dosage 
forms on the market (Oh et al., 2013). Tablets are a safe and cost-effective drug delivery system 
that provides good physical and chemical stability, high level of patient acceptability and ease of 
accurate dosing (Al-Hilal et al., 2012). However, oral drug delivery can be particularly 
challenging when considering the variations that occur in the absorption of a drug due to 
interactions with food and gastric contents/secretions as well as the varying rates of intestinal 
transit, gastric emptying and tablet dissolution, particularly with respect to delivery of gastro-
sensitive biotech drug molecules (Marques et al., 2011). Biotech drug molecules are unlike 
conventional medicines, in that they are biopharmaceutical agents such as proteins and 
peptides that are produced using biotechnology (Schellack, 2010). Biotech drugs are primarily 
administered intravenously, subcutaneously or intramuscularly as oral routes of administration 
may result in its degradation in the gastrointestinal tract (O’ Connor, 2009).  
 
Therapeutic proteins and peptides have gained increased popularity, owing to advances in 
biotechnology that enables them to be the molecules of choice for multiple disease conditions 
(Park et al., 2011; Chin et al., 2012). The industry is continually growing and a multitude of 
protein and peptide-based medicines are entering into the market, significantly increasing the 
demand and focus towards achieving simpler and more effective delivery routes. Although 
significant progress has been made towards the development of oral delivery systems for 
proteins and peptides, the field is limited by the low membrane permeability of these high 
molecular mass compounds, as well as their hydrophilicity, instability and rapid enzymatic 
degradation in the GIT (Donovan et al., 1990; Camenich et al., 1998; Park et al., 2011). Present 
strategies attempt to provide structural protection of the proteins and peptides and improved 
absorption through the use of enzyme inhibitors, absorption enhancers, novel polymeric delivery 
systems and chemical modification (Park et al., 2011). However, each of these technologies 
possesses limitations that prevent their successful delivery. No clinically useful oral formulations 
have been approved and thus advancements towards successful oral delivery of proteins and 
peptides through protection and increased absorption remains an active area of research.  
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The subject of eutectics in polymeric protein delivery systems has not been researched and the 
microstructure, that is typical of polymer eutectics, has not yet been fully explored as a means of 
increasing absorption and improving bioavailability of protein and peptide therapeutics 
(Tuntarawongsa and Phaechamud, 2012). A eutectic mixture is a physical mixture of two 
crystalline components which are completely miscible in the liquid state but to a very limited 
extent in the solid state.  Eutectics have a melting point that is lower than that of any of the 
components contained in the mixture (Arnikar et al., 1992; Sharma et al., 2012). A recent study 
investigated the effects of a borneol/menthol eutectic mixture for enhanced bioavailability in the 
delivery of a polypeptide (daidzein) used in the treatment of breast and colon cancer (Shen et 
al., 2011). The results from this study depicted the potential use of eutectic mixtures for 
enhancing the absorption of peptide-based therapeutics.  
 
This research attempts to bridge the gap between the indispensable protein and peptide-based 
therapies that are available and their safe and effective administration through the pragmatic 
design of an effective oral delivery system. The proposed Tri-functionalized OCMT may 
enhance the oral delivery of therapeutic proteins and peptides and possibly provide a viable 
alternative to the parenteral route of administration by virtue of its characteristic functional 
components which include; a core eutectic region, an outer polymer shell and a ‘smart’ 
polymeric sheet. The premise of the design is based on the achievement of a core eutectic 
region within a tablet that contains the incorporated protein or peptide and suitable crosslinking 
agents which provides structural protection and ensures controlled release of the biotech drug 
molecule due to in situ crosslinking within the tablet core, facilitated by the proposed melting of 
the core eutectic region at body temperature (37°C). Furthermore, the outer polymer shell of the 
tablet with incorporated pH modifier is expected to facilitate the controlled release of protein and 
peptide molecules, in addition to influencing the micro-environmental pH. The design of an 
additional prolamine-based ‘smart’ polymeric sheet with incorporated cytochrome P450 and P-
gp efflux pump intestinal inhibitor may further protect the incorporated protein and peptide and 
enhance its oral bioavailability. The proposed configuration of the Tri-functionalized OCMT is 
such that it will enable the site-specific, improved oral delivery of proteins and peptides.  
 
Moreover, the design of the Tri-functionalized OCMT is expected to provide an intrinsic 
versatility that will enable the incorporation of a multitude of protein and peptide molecules. This 
could prove to be efficacious in the delivery of biopharmaceuticals such as; enfuvirtide (a 
synthetic peptide that inhibits the process of HIV-1 entry into the cell), octreotide (used for the 
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treatment of acromegaly and the symptoms of gastro-intestinal tumours) , cyclosporine (a cyclic 
peptide that functions as a potent immunosuppressive agent), insulin and exenatide (used in 
diabetes) and peptide antibiotics such as polymixin and colistin (used for Pseudomonas 
aeruginosa infections)  (Edwards et al., 1999). In addition, this technology could provide a useful 
intervention for overcoming some of the challenges of Biopharmaceutics Classification System 
(BCS) Class drugs including those with low oral bioavailability (<30%), such as the calcium 
channel blockers (e.g. felodipine and nimodipine) used in the treatment of hypertension and 
angina (Cadario and Leathem, 2003). 
 
1.2. Rationale and Motivation for this Study 
The GIT epithelium acts as a physical and chemical barrier towards the absorption of proteins 
and peptides (Lee, 2002; Antunes et al., 2013). Typically, proteins and peptides possess a high 
susceptibility to proteolytic enzymes which are present at various regions along the GIT (Zhou, 
1994). The acidic nature of the gastric media results in denaturation and degradation of protein 
molecules through acquisition of similar charges causing internal repulsion or loss of attractive 
forces that previously held the protein molecule together (Cantor, 1994). Moreover, enzyme 
activity assists in the hydrolytic, irreversible cleavage of proteins and peptides into amino acids 
and small, absorbable oligopeptides (Fei et al., 1994; Zhou, 1994). Chemical digestion of 
proteins in the stomach is also triggered by pepsin with minimal absorption due to the small 
surface area and non-absorptive nature of the epithelium (Lee, 2002). Majority of the absorption 
occurs within the small intestine, however, pancreatic and brush-border enzymes such as 
trypsin, chymotrypsin, exopeptidases and endopeptidases contribute to the breakdown of 
proteins and peptides into non-essential amino acids (Zhou, 1994; Lee, 2002). In addition, 
cytochrome P450 facilitated metabolism of drug substances and P-glycoprotein mediated efflux 
of drug molecules from inside the cell back into the intestinal lumen account for the reduced 
absorption and low oral bioavailability of proteins and peptides (Liu et al., 2009).  
 
In addition, the mucosal surface of the GIT is a large interface that is protected by a monolayer 
of epithelial cells, connected by tight junctions that provide an effective barrier against the 
absorption of proteins and peptides. Essentially, it represents a physical gatekeeper that 
selectively restricts the entry of large molecules into the systemic circulation (Neutra and 
Kraehenbuhl, 1993; Antunes et al., 2013). The combination of all these factors lead to the 
identification of three major challenges governing the successful oral delivery of proteins and 
peptides which include; 1) the exposure of proteins and peptides to unfavorable conditions 
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within the GIT 2) poor absorption through the GIT membrane and 3) enzymatic degradation 
within the GIT (Antunes et al., 2013). Thus, the proposed triple targeting by the Tri-
functionalized OCMT may prove to be invaluable in overcoming the major challenges governing 
the successful oral delivery of proteins and peptides.  
 
Figure 1.1a represents a schematic of the OCMT concept depicting the tablet during the 
formulation stages with the outer shell of the core-melt containing a porous polymer that allows 
the ingress of fluid, while still maintaining its characteristic shape and enabling in situ 
crosslinking. The outer polymer shell will undergo surface erosion, facilitating the controlled 
release of drug molecules as depicted in the insert. The characteristic feature of the eutectic 
component within the core-melt region of the tablet enables it to remain solid at room 
temperature and melt upon entering the body at temperatures of 37°C. This proposed melting in 
combination with the ingress of fluid through the outer polymer shell facilitates the process of in 
situ crosslinking within the tablet core. The in situ crosslinking will facilitate prolonged drug 
delivery due to formation of bonds between the salt and polymer chains resulting in a slower 
chain relaxation within polymer networks due to crosslinks, thereby initiating a delayed bioactive 
release profile (Hennink and van Nostrum, 2002). Furthermore, the components of the eutectic 
region are expected to enhance the permeation of drug across the intestinal tissue. Figure 1.1b 
depicts the tablet during compression where the bottom layer of the shell surrounding the core-
melt matrix will be compressed under low pressure and the top layer under high pressure to 
form a single tablet with an inner core-melt matrix as shown in Figure 1.1c.  
 
Moreover, the incorporation of a pH modifier facilitates indirect inhibition of enzyme activity at 
the brush border by transiently lowering the micro-environmental pH and subsequently reducing 
the optimal environment for enzyme activity. Further encapsulation of the OCMT with a co-
inhibitory prolamine-based ‘smart’ polymeric sheet possessing hydrophobic, mucoadhesive, 
lipid-binding characteristics and interacting well with hydrophilic molecules (i.e. proteins and 
peptides) will function to enable passage of the proteins and peptides through the GIT 
membrane. The sheet provides a protective function within the stomach and has sustained 
release capabilities in direct tablet compression. Cytochrome P450 enzymes are responsible for 
metabolism of drug substances with the most potent enzyme being CYP3A4 which are at levels 
in the small intestine of generally 10-15% of those found in the liver. Additionally, the Pgp (P-
glycoprotein) efflux pump is an ATP dependent transmembrane pump that actively transports 
molecules out of the cell. Both CYP3A4 and Pgp account for the reduced absorption and low 
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oral bioavailability of proteins and peptides. Thus, co-inhibition of CYP3A4 and Pgp will enable 
increased absorption by reducing the metabolism and inhibiting transmembrane efflux.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Schematic representation of the OCMT that is shown in a) in the formulation stages 
b) during compression and c) after compression, in situ. 
 
While the OCMT provides critical structural protection, the incorporation of a pH modifier and a 
co-inhibitory ‘smart’ polymeric sheet may overcome the enzymatic degradation at the brush 
border and the poor absorption through the GIT membrane. This results in the formation of a 
Tri-Functionalized ‘Smart’ Polymer Modulated Co-inhibitory (Cytochrome P450 and P-
glycoprotein) pH Modified Oral Core-Melt Tablet (OCMT), as shown in Figure 1.2,  that aims to 
collectively and optimally target the three major challenges governing successful oral protein 
and peptide delivery. This device ultimately creates a platform for the structural protection of the 
incorporated protein and peptide, control of enzymatic degradation and improvement in the 
absorption of the incorporated protein or peptide by up to 70-90%. 
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Figure 1.2: Schematic representation of the Tri-functionalized OCMT, highlighting the different 
components and the challenges they address. 
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1.3. Mechanism by which the Tri-functionalized OCMT will Achieve Enhanced Delivery of 
Gastro-sensitive Proteins and Synthetic Peptides 
The mechanism of action of the Tri-functionalized OCMT is critical towards understanding the 
impact of different components and their functional effects. The proposed mechanism of action 
of the entire system from ingestion of the tablet right through to its passage along the GIT and 
ultimate absorption is illustrated in Figure 1.3.  
 
Figure 1.3: Diagrammatic representation of the proposed modus operandi of the Tri-
Functionalized OCMT. 
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1.4. Novelty of the Study 
The novelty of the study lies in its characteristic ability to enhance the oral delivery of protein 
and peptides by the achievement of a Tri-functionalized component system. It provides a unique 
core-eutectic region in the tablet that enables the incorporation of proteins and peptides. In 
addition, it provides a platform for controlled release and enhanced protein and peptide 
protection by facilitating in situ crosslinking between the outer polymer shell and the core-
eutectic region. The initiation of in situ crosslinking by a combination of the melting of the 
crosslinker-containing core eutectic region at 37°C, as well as fluid ingress into the outer 
polymer shell further supports its innovativeness. The novelty of the system is further extended 
by the incorporation of a micro-environmental pH modifier and a co-inhibitory ‘smart’ polymeric 
sheet. Ultimately, the conceptualized design characteristics will innovatively associate to provide 
an orally bioavailable, sustained release of the incorporated protein and peptide that will 
potentially serve as a unique alternative to the conventional parenteral route of administration 
for the treatment of multiple disease conditions. 
 
1.5. Possible Therapeutic Applications of the Delivery System 
A recent report by the Pharmaceutical Research and Manufacturers of America (PhRMA) on 
“Biologic Medicines in Development” identified over 900 protein and peptide-based medicines in 
development, targeting more than 100 diseases, of which 353 for cancer and related conditions, 
187 for infectious diseases, 69 for autoimmune diseases and 59 for cardiovascular diseases. 
Thus, this expands on the potential of the Tri-functionalized OCMT to possibly target a multitude 
of disease conditions that require treatment with protein and peptide-based therapeutics. In 
addition, due to its proposed ability to enhance oral absorption, it can possibly improve the 
clinical outcomes of BCS Class drugs and those with oral bioavailabilities of <30%. 
Furthermore, the versatility of the device enables easy adaptability for the incorporation of drugs 
requiring controlled release over extended periods of time.  
 
1.6. Aim and Objectives 
The aim of this study is the design of a Tri-Functionalized ‘Smart’ Polymer Modulated Co-
inhibitory (Cytochrome P450 and P-glycoprotein) pH Modified Oral Core-Melt Tablet (OCMT) for 
enhanced oral delivery of gastro-sensitive proteins and peptides through the mechanistic action 
of characteristic functional components, serving to expand the limited number of available 
administration methods for these sensitive molecules. Accomplishment of the following 
objectives was critical towards the fulfilment of the aim:  
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1. To design and formulate the OCMT through the process of eutectic formation, in situ 
crosslinking initiator selection and component assemblage.  
2. To characterize the OCMT via physicochemical and physicomechanical tests, including 
advanced bench-top Magnetic Resonance Imaging, porositometric analysis, textural 
profiling, thermal analysis and rheological characterization to determine matrix durability 
and tensile strength.  
3. To design a co-inhibitory ‘smart’ polymeric sheet surrounding a pH-modified OCMT to 
achieve Tri-functionalization, ultimately producing the Tri-functionalized OCMT, for 
enhanced oral delivery of gastro-sensitive proteins and peptides via structural protection, 
enhanced absorption and prevention of enzymatic degradation. 
4. To comprehensively analyze the in vitro capabilities of the Tri-functionalized OCMT 
through extensive physicochemical and physicomechanical profiling, in vitro bioactive 
release analysis, extensive cellular characterization and cytotoxicity determinations. 
5. Following the successful design and testing of the prototype Tri-functionalized OCMT 
and its ability to meet design criteria in vitro, its clinical potential was assessed in the 
Large White Pig to determine the in vivo release mechanisms, pharmacokinetics and the 
establishment of an in vitro-in vivo correlation. 
 
1.7. Synopsis of the Thesis  
The thesis was deconstructed as follows to provide a logical and rational overview of the 
processes involved in the design and development of the Tri-functionalized OCMT.  
 
Chapter 1 provides an introduction and background to this study, highlighting the rationalization 
and novelty of the research undertaken, as well as the aim and objectives and potential benefit 
of this study. 
 
Chapter 2 critically reviews the advanced oral drug delivery technologies facilitating the 
protection and absorption of protein and peptide molecules. It discusses current approaches to 
overcome GIT absorption barriers and assimilates the non-parenteral routes of protein and 
peptide delivery. Furthermore, the chapter critically elaborates on the advanced oral 
macromolecular technologies developed and in clinical trials, as well as providing an analysis of 
their inherent pharmacokinetic profiles. Lastly it outlines future challenges and opportunities for 
ideal oral protein and peptide delivery. 
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Chapter 3 presents the results obtained from a proof-of-concept study depicting a menthol-
based solid dispersion technique for enhanced solubility and dissolution of drug from an oral 
tablet matrix. The chapter characteristically demonstrates the ability of menthol to improve the 
solubility of a poorly soluble drug and control the release rate from an oral tablet matrix. In 
addition, it conclusively highlights the possibility of a menthol-based eutectic transformation.  
 
Chapter 4 takes it cue from the previous chapter and leads to the synthesis of a menthol-based 
eutectic powder blend for the preliminary design of an in situ cross-linked eutectic tablet for 
enhanced oral protein and peptide delivery.  The chapter investigates the attributes of the in situ 
cross-linked eutectic tablet through establishment of a Box-Behnken experimental design. 
Extensive physicochemical and physicomechanical characterization, as well as the in vitro 
release of a model protein from the eutectic tablet is presented. Furthermore, statistical 
optimization via response surface analysis was undertaken.  
 
Chapter 5 alludes to the characterization of the optimized OCMT, following statistical 
optimization of the eutectic tablet in Chapter 3 and the subsequent incorporation of a 
therapeutic peptide. The chapter highlights the in vitro physicochemical and physicomechanical 
characterization of the optimized OCMT and its pertinent characteristics in achieving an ideal in 
vitro profile for optimum in vivo performance.  
 
Chapter 6 describes the preparation of the co-inhibitory ‘smart’ polymeric sheet surrounding the 
pH-modified OCMT for Tri-functionalization. The applicability of the components were assessed 
through the establishment of a Face-Centered Central Composite Design (FCCCD). 
Physicochemical and physicomechanical characterization was undertaken to explicate the 
delivery of the advanced components. In addition, the chapter determines the optimum 
concentration required for co-inhibition of CYP3A4 and Pgp. A response surface analysis, 
embodied by the FCCCD design, was undertaken to optimize the system.  
 
Chapter 7 follows from the intensive device optimization by providing a comprehensive 
characterization of the statistically optimized Tri-functionalized OCMT for ultimate enhancement 
of oral protein and peptide delivery. The chapter elucidates on the modus operandi by in-depth 
analysis of the pertinent physicochemical and physicomechanical properties. Furthermore, 
cytotoxicity studies were undertaken to determine the safety of the synthesized device 
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components. Ultimately, this chapter provides a summative assessment of the prototype device 
prior to evaluating its performance in vivo. 
 
Chapter 8 details the in vivo evaluation of peptide release from the Tri-functionalized OCMT in 
the Large White Pig model. The chapter includes a comparative analysis of the Tri-
functionalized OCMT with the conventional, marketed formulations. Moreover, comprehensive 
pharmacokinetic analysis was undertaken and an in vitro-in vivo correlation (IVIVC) was 
established. 
 
Chapter 9 presents the conclusions drawn regarding the success of the investigation, followed 
by the recommendations for scale-up and manufacture and further investigations required to 
bring to fruition the commercial potential of the Tri-functionalized OCMT. 
 
1.8. Concluding Remarks  
This chapter highlighted the need for overcoming the limitations associated with the oral delivery 
of proteins and peptides, owing to widespread use of these biotech drug molecules for the 
treatment of multiple disease conditions. The overall design strategy and rationalization for 
development of a prototype oral system was presented. In summary, this investigation is 
centered on the design of a Tri-functionalized OCMT that would collectively and optimally target 
the three major challenges governing successful oral protein and peptide delivery.  
 
Reviewing oral protein and peptide technologies before ensuing with experimental device 
synthesis is important as it provides crucial insight into the possibility for modification and 
improved functionalization. Ultimately, it creates a platform for the fabrication of a device with 
unique characteristics. Thus, the following chapter attempts to identify, unravel and critically 
analyze these technologies.  
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Abstract  
The oral delivery of proteins and peptides is a dynamic research field despite the numerous 
challenges limiting their effective delivery. Successful oral delivery of proteins and peptides 
requires the accomplishment of three key tasks: protection of the macromolecules from 
degradation in the gastrointestinal tract (GIT), permeation through the intestinal barrier and 
absorption of molecules into the systemic circulation. Currently, no clinically useful oral 
formulations have been developed but several attempts have been made to overcome the 
challenges of low oral bioavailability resulting from poor absorption, poor permeation and 
enzymatic degradation of the proteins and peptides in the GIT. Present strategies attempt to 
provide structural protection of the proteins and peptides and improved absorption through the 
use of enzyme inhibitors, absorption enhancers, novel polymeric delivery systems and chemical 
modification. However, each of these technologies has their limitations despite showing positive 
results. This review attempts to discuss the physical and chemical barriers of the GIT with 
particular emphasis on the current approaches employed to overcome these barriers, including 
the evaluation of other non-parenteral routes of protein and peptide delivery. In addition, this 
review assimilates oral formulation strategies under development and within the clinical trial 
stage in relation to their benefits and drawbacks with regards to facilitating optimal protection 
and absorption of proteins and peptides, as well as pertinent future challenges and opportunities 
governing oral drug delivery. 
 
Keywords: oral drug delivery; therapeutic proteins and peptides; bioavailability; gastrointestinal 
barrier; advanced oral biotechnology 
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2.1. Introduction 
The oral delivery of proteins and peptides, although a highly attractive approach, remains a 
significant challenge in drug delivery technology, as a result of their unfavorable 
physicochemical properties (Catnach et al., 1994; Hamman et al., 2005; Park et al., 2011). 
Administering drugs by the oral route is preferred due to its improved convenience and patient 
compliance (Brayden and O’Mahony, 1998; Park et al., 2011). However, oral drug delivery can 
be particularly challenging when considering the variations that occur in the absorption of a 
molecule due to interactions with gastric contents/secretions, membrane permeability, intestinal 
transit and gastric emptying. This is particularly with respect to the delivery of sensitive proteins 
and peptides (Marques et al., 2011).  
 
Therapeutic proteins and peptides are gaining increased popularity, owing to advances in 
biotechnology that enables them to be the molecules of choice for an assortment of diseases 
(Park et al., 2011; Chin et al., 2012). The high specificity and activity of proteins and peptides 
makes them applicable for targeted delivery in clinical practice (Brayden and O’Mahony, 1998; 
Park et al., 2011; Chin et al., 2012). The new 2013 Pharmaceutical Research and 
Manufacturers of America (PhRMA) report on “Biologic Medicines in Development” identified 
over 900 protein and peptide-based medicines in development, targeting more than 100 
diseases, of which 353 for cancer and related conditions, 187 for infectious diseases, 69 for 
autoimmune diseases and 59 for cardiovascular diseases. This significantly increases the 
demand and focus towards achieving effective and simple routes of delivering proteins and 
peptides via the oral route. 
 
Conventionally, therapeutic proteins and peptides are administered intravenously, 
subcutaneously or intramuscularly since the oral route of administration may result in 
degradation in the gastrointestinal tract (GIT) (O’ Connor, 2009; Schiffter, 2011). Although 
significant progress has been made towards the development of oral delivery systems for 
proteins and peptides, the field is limited by the low membrane permeability of these high 
molecular mass compounds, as well as their hydrophilicity, instability and rapid enzymatic 
degradation in the GIT (Donovan et al., 1990; Camenich et al., 1998; Park et al., 2011). 
Proposed technologies and approaches targeting the complications in the oral delivery of 
proteins and peptides although useful in some instances, nevertheless hold limitations that 
enable successful delivery (Park et al., 2011). 
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Therapeutic proteins and peptides have gained a significant market interest owing to their 
increased development and applicability to multiple disease conditions (Park et al., 2011; Chin 
et al., 2012). Consequently, advancements towards successful oral delivery of proteins and 
peptides through protection and increased absorption remains an active area of research and 
researchers have intensified their research towards achieving this goal (Chiasma Inc.; Cosmo 
Pharmaceuticals, Inc.; Diabetology Ltd.; Emisphere Technology, Inc.; Enteris BioPharma, Inc; 
Merrion Pharmaceuticals, Ltd.; Oramed Pharmaceuticals, Inc.; Proxima Concepts, Ltd; Tarsa 
Therapeutics, Inc). This review article summarizes the major challenges facing oral protein and 
peptide delivery as well as the various attempts at overcoming these challenges. Current and 
new technologies within this dynamic field of research will be discussed, including the potential 
benefits of each technology and possible limitations that exist. Potential for improvement is a 
key focus in the development of new formulation strategies and technologies.   
 
2.2. The Gastrointestinal Barrier: A Physical and Chemical Impediment to Oral Protein 
and Peptide Delivery 
The GIT epithelium acts as a physical and chemical barrier towards the absorption of proteins 
and peptides (Lee, 2002; Antunes et al., 2013). The mucosal surface of the GIT is a large 
interface that is protected by a monolayer of epithelial cells, connected by tight junctions that 
provides an effective barrier against the absorption of proteins and peptides and thus, 
represents a physical gatekeeper that selectively restricts the entry of large molecules into the 
systemic circulation (Neutra and Kraehenbuhl, 1993; Antunes et al., 2013). Owing to the large 
molecular mass and hydrophilic properties of proteins and peptides, transport across the 
intestinal epithelium becomes extremely challenging (Lee, 2002). Nevertheless, studies have 
suggested that the transport of macromolecules across the intestinal epithelium is possible 
provided that there is minimal degradation of the protein or peptide molecule in the GIT through 
the use of permeation enhancers, physicochemical modification strategies and stimuli-
responsive and mucoadhesive polymeric systems. (Lundin and Vilhardt, 1986; Takaori et al., 
1986; Walker et al., 1990).  
 
2.2.1. The GIT as a physical barrier for protein and peptide absorption 
The possible mechanisms by which proteins and peptides are absorbed from the GIT include 
passive transport, active transport and endocytosis (Potocky et al., 2003; Artursson et al., 
2007). The passive transport of molecules across the intestinal membrane occurs through 
simple or facilitated diffusion, along a concentration gradient, independent of chemical energy 
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and principally dependent on the intrinsic physicochemical properties of the transported 
molecule, including its ability to diffuse across cellular barriers (Stein, 1986). The low lipophilicity 
and large molecular mass of proteins and peptides limits its absorption by this mechanism. 
However, it proves beneficial for the absorption of di/tripeptides (Catnach et al., 1994). In 
contrast, active transport of molecules is a process involving chemical expenditure, occurring 
against a concentration gradient for the transport of molecules across the GIT epithelium (Stein, 
1986). Lastly, molecules may be transported through endocytosis which is an energy-
consuming process involving the engulfment of molecules for absorption (Potocky et al., 2003; 
Artursson et al., 2007). 
 
The pathways available for the potential transport of proteins and peptides through these 
mechanisms include the transcellular pathway and paracellular route as shown in Figure 2.1 
(Ménard et al., 2012). The transcellular pathway involves the transport of molecules across cells 
which can take place by either passive diffusion, a specific carrier or through trancystosis and 
receptor-mediated endocytosis (Ménard et al., 2012). Transcellular passive diffusion is 
dependent on the physico-chemical properties of the molecule such as size, charge and 
lipophilicity in order to facilitate the passive flux of molecules through the lipophilic, apical and 
basolateral membranes of the intestinal epithelium (Liu et al., 2009). Molecules may also be 
absorbed transcellularly using specific carriers such as peptide and amino acid transporters that 
transport molecules such from the intestinal lumen into the cell (Liu et al., 2009; Antunes et al., 
2013). 
  
Intact di- and tripeptides can be actively transported for absorption in the small intestine by 
specific carrier systems, distinctive from the typical amino acid transporters (Catnach et al., 
1994). The intestinal peptide carrier has an extensive substrate specificity that is energized by 
an internal proton gradient resulting in the transfer of a positive charge across the intestinal 
epithelium (Ganapathy et al., 1985; Takuwa et al., 1985). Studies undertaken on peptide 
mimetic drugs such as cyclosporine, β-lactams and angiotensin-converting enzyme inhibitors 
also displayed positive evidence for their transport by di- and tripeptide carriers (Nakashima et 
al., 1984; Sinko and Amidon, 1988; Friedman and Amidon, 1989; Kramer et al., 1990). The 
intestinal peptide system has an unrecognized potential for the transport of peptide and peptide-
like drugs across the intestinal membrane and a greater understanding of its molecular 
specificity could prove to be favorable for the synthesis of orally active peptides (Bai and 
Amidon, 1992). However, compounds that are absorbed through the transcellular pathway are 
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substrates for p-glycoprotein-mediated efflux which transports the molecules from inside the cell 
back into the intestinal lumen (Liu et al., 2009). The lipophilicity of a molecule is one of the main 
factors that governs transport via the transcellular route as molecules need to pass through the 
lipid bilayer of the intestinal membrane and thus, the transport of proteins and peptides through 
this pathway poses a significant challenge. 
 
 
Figure 2.1: Schematic of the multiple transport mechanisms through the intestinal epithelium 
and pathways available for protein and peptide absorption, a) transcellular transport via passive 
cellular diffusion, b) carrier-mediated transport, c) paracellular transport via cell-cell junctions, d) 
transcytosis and receptor-mediated endocytosis, e) absorption into lymphatic circulation via M-
cells of Peyer’s patches and f) p-glycoprotein efflux of drug into the intestinal lumen [Adapted 
from Goldberg and Gomez-Orellana, 2003 with permission from Macmillan Publishers Ltd. © 
2003 and from Li, 2001 with permission from Elsevier Science Ltd. © 2001]. 
 
The transepithelial transport of macromolecules by intestinal epithelial cells occurs to a limited 
extent through absorption into the lymphatic circulation via M-cells of Peyer’s patches (Neutra 
and Kraehenbuhl, 1993). The surface of the M-cells are densely populated with microvilli  and 
contain limited lysosomes, making it readily accessible to proteins and peptides and enabling 
the intact transport of macromolecules with minimal degradation during transit through the cells 
(Ho et al., 1990; Takeuchi and Gonda, 2004). Furthermore, the close proximity of the 
lymphocytes to the M-cells, as well as, to the apical surface of the intestinal membrane reduces 
the resident pathway for absorption of macromolecules (Ho et al., 1990). Absorption through 
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Peyer’s patches appears to be a promising mechanism, however, limited information is 
available regarding the quantities of proteins and peptides that are absorbed through this route 
(Shakweh et al., 2005). 
 
Absorption via the paracellular route is typically restricted by the narrow space between 
adjacent enterocytes and the presence of tight junctions that are implicated in the adherence 
mechanism between adjacent cells (Stevenson and Keon, 1998; Baum and Georgiou, 2011; 
Oda and Takeichi, 2011). The paracellular pathway does not rely as much on the lipophilicity 
and hydrogen bonding capacity of molecules compared with the transcellular pathway as it 
inherently involves the transport of peptides across the aqueous channels in cell junctions (Oda 
and Takeichi, 2011). However, the paracellular route is not an ideal option for the absorption of 
macromolecules as it is restricted to relatively small hydrophilic molecules of <100-200 daltons 
(Rubas et al., 1996; Antunes et al., 2013). The addition of a novel functionality to the protein and 
peptide molecules or the use of novel delivery systems may be necessary to enable optimal 
absorption (Catnach et al., 1994; Wang and Zhang, 2004). 
 
2.2.2. The GIT as a chemical barrier for protein and peptide absorption  
The fluid contents of the GIT, the functioning environment and the secretion of degradative 
enzymes are major factors that make oral delivery of proteins and peptides tremendously 
challenging (Lee, 2002). Proteins possess a high susceptibility to proteolytic enzymes which are 
present at various regions along the GIT (Zhou, 1994). The acidic nature of the gastric media 
results in denaturation and degradation of protein molecules through acquisition of similar 
charges causing internal repulsion or loss of attractive forces that previously held the protein 
molecule together (Cantor, 1994). Moreover, enzyme activity assists in the hydrolytic, 
irreversible cleavage of proteins and peptides into amino acids and small, absorbable 
oligopeptides (Fei et al., 1994; Zhou, 1994). Chemical digestion of proteins in the stomach is 
also triggered by pepsin with minimal absorption due to the small surface area and 
nonabsorptive nature of the epithelium (Lee, 2002). Majority of the absorption occurs within the 
small intestine, however, pancreatic and brush-border enzymes such as trypsin, chymotrypsin, 
exopeptidases and endopeptidases contribute to the breakdown of proteins and peptides into 
non-essential amino acids (Zhou, 1994; Lee, 2002).  
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2.3. Potential Sites for Non-Parenteral Delivery of Proteins and Peptides  
Possible non-parenteral administration routes for the delivery of protein and peptides include the 
nasal, buccal, vaginal, rectal, transdermal, pulmonary, ocular and oral routes of delivery (Zhou 
and Li Wan Po, 1991; Antosova et al., 2009). The parenteral administration of proteins and 
peptides is necessary for achieving a therapeutic outcome. However, low patient acceptability 
and tolerance towards continuous intramuscular, intravenous or subcutaneous injections has 
led to poor patient compliance an increased interest in alternative extra-parenteral protein and 
peptide delivery systems (Zhou, 1994).  
 
Permeation enhancers, enzyme inhibitors and appropriate formulation vehicles are essential in 
the application of non-invasive routes as the absence thereof makes them much less effective 
as compared to the parenteral route of administration (Banga and Chien, 1988; Sharma et al., 
2011). Therapeutic proteins and peptides are conventionally designed for parenteral 
administration, primarily relying on bypassing first pass metabolism (Fogueri and Singh, 2009). 
Thus, non-parenteral routes for the delivery of proteins and peptides need to be evaluated for 
their ease of development, impact on the physicochemical properties of the molecules and 
bioavailability and toxicity of their individual routes. Table 2.1 summarizes the various non-
parenteral routes for protein and peptide delivery, their bioavailability, proteolytic barriers and 
the various challenges in delivery through each route. 
 
Non-parenteral routes of delivery possess low bioavailability and display various challenges in 
the successful delivery of proteins and peptides. Regardless of these challenges, the oral route 
of delivery still holds preference over other non-parenteral routes for systemic administration of 
active compounds as it is the most acceptable and convenient for the patient (Brown, 2005). 
The non-parenteral oral delivery of therapeutic proteins and peptides is by far the most popular 
route of delivery, making it an active area of research for many researchers and academic 
laboratories and is therefore the focus of this review (Zhou and Li Wan Po, 1991).  
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Table 2.1: Summary of the various challenges facing the delivery of proteins and peptides 
through non-parenteral routes. 
Routes of 
delivery 
Bioavailability Proteolytic barrier Challenges in delivery References 
Nasal  Variable 
bioavailability 
(<1%; >30%) 
Enzyme leucine 
aminopeptidase ↓ 
bioavailability of 
protein/peptide drugs 
 
 
Requires the use of 
permeation enhancers, 
enzyme degradation, 
variable absorption, 
nasal mucosal irritation 
following prolonged use 
Zhou and Li Wan Po, 
1991; Valensi et al., 
1996; Taylor, 1997; 
Brown, 2005; Fogueri 
and Singh, 2009 
Ocular  <10% Proteinases 
such as neutral protease 
and aminopeptidase 
↑ Tear turnover,  drug-
binding to tear proteins, ↓ 
residence time, possible 
corneal irritation, low 
patient acceptability, 
protease degradation 
Zhou and Li Wan Po, 
1991; Fogueri and 
Singh, 2009;  El 
Sanhawari et al., 
2010 
Pulmonary  ~10% Proteases, peroxidases, 
inflammatory and 
immunomodulatory 
mediators secreted by 
alveoli macrophages 
Restrictive alveolar 
epithelium, mucociliary 
clearance, protease 
degradation, removal by 
alveolar macrophages, 
limited dosing, 
permeability challenges 
in diseased and smoking 
patients  
Banga and 
Chien,1988; Adjei 
and Gupta, 1994; 
Zhou, 1994; Brown, 
2005; Antosova et al., 
2009; Fogueri and 
Singh, 2009 
Rectal  
 
~10-20% with  
substantial 
increases following 
administration of 
absorption 
enhancers 
Proteolytic enzymes such as 
enkephalinase, protease, 
cathepsin B and H, 
urokinase and collagen and 
protease-like peptidases 
Low patient acceptability, 
limited surface area for 
absorption, possible first-
pass metabolism, 
expulsion of formulation 
during bowel movements 
Zhou and Li Wan Po, 
1991; Muranishi et 
al.,  1993; Brown, 
2005; Fogueri and 
Singh, 2009 
Transdermal  Variable to very low 
bioavailability, 
iontophoresis and 
microneedle 
technologies ↑ the 
bioavailability up to 
30% 
Low proteolytic activity, 
minimal amounts of leucine 
aminopeptidase 
Poor permeability 
(stratum corneum 
barrier), limitations in 
surface area and rate of 
administration, local 
irritation at administration 
site 
Chien et al., 1990; 
Zhou and Li Wan Po, 
1991; Cormier et al., 
2004; Fogueri and 
Singh, 2009; 
Chiranjib et al., 2010  
Buccal  <1%, improved by 
use of permeation 
enhancers  
Mucosal and proteolytic 
enzymes, oxidases, 
reductase, 
cyclooxygenases, 
peptidases; 
Uncertain reproducibility, 
enzymatic degradation, 
penetrability, ↓ dosage 
form retention  
Zhou and Li Wan Po, 
1991; Brown, 2005; 
Antosova et al., 2009; 
Fogueri and Singh, 
2009; Sharma et al., 
2011 
Oral  <2% Pepsin and brush-border 
peptidases 
Acid-catalyzed 
degradation in stomach, 
intestinal epithelial cell 
barrier, proteolytic 
breakdown, poor 
permeability  
Zhou and Li Wan Po, 
1991; Brown, 2005; 
Antosova et al., 2009; 
Fogueri and Singh, 
2009; Sharma et al., 
2011 
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2.4. Current Approaches Employed for the Oral Delivery of Proteins and Peptides for 
Enhanced GIT Absorption 
Numerous strategies have been investigated in an effort to effectively deliver proteins and 
peptides via the oral route (Fogueri and Singh, 2009). Most of these systems target the GIT 
barrier in an attempt to overcome its restrictive nature and subsequently increase the oral 
bioavailability (Brown, 2005; Fogueri and Singh, 2009). Enteric coating has also been used to 
enable protection of the protein or peptide from pepsin digestion in the stomach, however, the 
reliability and efficiency of enteric coating is variable due to the presence of a wide range of pH 
values and enzymes present in the GIT (Hussan et al., 2012). In addition, polymers used for 
enteric coating may undergo uncontrolled polymerization, during handling and storage, resulting 
in failure to release the molecule at the target site (Fawzi et al., 1991). Therefore, protection 
from proteolytic enzymes and improved absorption of these molecules through the intestinal 
epithelium requires the use of more advanced pharmaceutical technologies (Brown, 2005).  
 
Several key approaches that are available for maximizing oral protein and peptide absorption 
include: (1) the co-administration of protease inhibitors and absorption enhancers to inhibit 
enzymatic degradation and improve permeability, respectively; (2) modification of the 
physicochemical nature of the macromolecules to improve membrane permeability and 
proteolytic stability; (3) design of particulate drug delivery systems such as nanoparticles, 
microparticles and liposomes that protects the fragile molecules from enzymatic degradation 
and the harsh environment of the GIT; (4) mucoadhesive polymeric drug delivery systems to 
prolong the residence time at the target site and ; (5) site-specific delivery to the colon, where 
proteolytic activity is low (Chien, 1992; Ichikawa and Peppas, 2003; Malik et al., 2007; Kumar 
and Mishra, 2008; Aungst, 2011). These technologies may be used singly or in combination to 
achieve an optimal oral delivery system for proteins and peptides. The following is a detailed 
discussion of each of the key approaches with examples in each case. 
  
2.4.1. The use of  permeation enhancers 
It is known that absorption of a protein or peptide is improved by the co-administration of 
amphiphilic, low molecular mass permeation enhancers (Lee, 1990; Sinko et al., 1999; Del 
Curto et al., 2011). These are functional adjuvants that are included to function as membrane 
permeating enhancers (Aungst, 2011). Generally, permeation enhancers improve protein and 
peptide absorption by a combination of several mechanisms, including (1) the disruption and 
opening of tight junctions to increase paracellular permeability, (2) decrease in mucus viscosity 
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and (3) increase in membrane fluidity specific to their class (Anilkumar et al., 2011; Aungst, 
2011; Antunes et al., 2013). Table 2.2 lists the different classes of intestinal permeation 
enhancers, including examples of agents in each class. 
 
Table 2.2: Classification of intestinal permeation enhancers 
Type Examples References 
Surfactants 
 
Ionic: Sodium lauryl sulphate 
Nonionic: Polysorbitate, Tween 80 
Xia and Onyuksel, 2000; Anilkumar 
et al., 2011 
Bile Salts Sodium glycholate, sodium 
deoxycholate 
Sakai et al., 1997; Maher and 
Brayden, 2012 
Fatty Acids Sodium caprate, acyl carnites, oleic 
acid, lauric acid 
Anilkumar et al., 2011; Park et al., 
2011 
Chitosan and derivatives N-trimethyl chitosan chloride Dodane and Vilivalam, 1998; Maher 
and Brayden, 2012 
Chelating agents 
 
EDTA, salicylates, citric acid Thanou et al., 2001; Park et al., 2011 
Other enhancers Zonula occludens toxin, PCP-
cysteine 
Anilkumar et al., 2011; Maher and 
Brayden, 2012  
 
Surfactants disrupt the intestinal membrane, leading to increased permeability of proteins and 
peptides crossing the cell epithelium through the transcellular pathway (Xia and Onyuksel, 
2000). Bile salts increases drug permeability through the decrease in mucus viscosity and 
peptidase activity, phospholipid acyl chain disruption and formation of mixed micelles (Sakai et 
al., 1997). Similarly, fatty acids result in the formation of mixed micelles and contribute towards 
modulating paracellular permeability by increasing intracellular calcium levels that cause 
contraction of junction-associated microfilaments (Anilkumar et al., 2011).  
 
Chelating agents interfere with the calcium ions present between intestinal epithelial cells and 
its ability to maintain the structural feature of the intercellular space, subsequently opening tight 
junctions (Thanou et al., 2001). Chitosan and its derivatives improve permeability of 
macromolecules by bioadhesion and reduction of tight junction integrity (Dodane and Vilivalam, 
1998). Other enhancers which include zonula occludens toxin and polycarbophyl cysteine 
conjugate (PCP-cys) enable the reversible opening of tight junctions by interacting with specific 
receptors on the surface of epithelial cells that activate a cascade of events leading to tight 
junction permeability and increased phosphorylated occludin via glutathione to increase tight 
junction opening, respectively (Anilkumar et al., 2011). Several studies have shown an increase 
in the permeability of proteins such as human growth hormone, insulin, interferon and calcitonin 
following co-administration with permeation enhancers (Bernkop-Schnürch, 2000; Stoll et al., 
2000; Lee, 2002; Kidron et al., 2004; Lee et al., 2005). 
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The three main factors that influence the efficacy of permeation enhancers includes: (1) the type 
of protein or peptide and its ability to cross the intestinal membrane, (2) the intrinsic nature of 
the permeation enhancer and its capability to increase permeation and, (3) the delivery system 
which can possibly affect the rate of release of the enhancer in relation to the physicochemically 
different protein or peptide (Okada et al., 1982; Nishihata et al., 1984). In addition to these three 
factors, due consideration needs to be given to the potential toxicities of permeation enhancers 
as well as the direct toxic effects to the intestinal epithelial cells (Antunes et al., 2013). A few 
permeation enhancers transiently disrupt tight junctions and result in the unwanted permeation 
of luminal contents and potentially toxic molecules (Tscheik et al., 2013). Major toxicity issues 
include the ulceration of the intestinal epithelium with ‘pin-point’ membrane erosions, 
immunological concerns and the rapid accessibility of a pathway for bacteria and viruses to gain 
entry into the systemic circulation (Anilkumar et al., 2011). Although permeation enhancers are 
an attractive approach for increasing the oral bioavailability of proteins and peptides, the safety 
of these adjuvants needs to be addressed and more safer alternatives of permeation enhancers 
are readily required to be applicable for chronic therapy (Zhou, 1994). 
 
2.4.2. The use of protease/enzyme inhibitors 
The co-administration of enzyme inhibitors assists in targeting the enzymatic barrier hindering 
the successful oral absorption of proteins and peptides (Lee, 1990). Enzyme inhibitors exert 
their effects by binding reversibly/irreversibly to the target enzyme, inactivating it and thereby 
decreasing its activity (Copeland, 2013). Various enzyme inhibitors are available for intestinal 
enzyme inhibition with the appropriate selection being dependent on the target enzyme that is 
required to be inactivated (Lee, 1990). Examples of intestinal protease inhibitors include; 
aprotinin (inhibitor of trypsin and chymotrypsin), soybean trypsin inhibitor (inhibitor of pancreatic 
endopeptidases), FK448 (chymotrypsin inhibitor) and chicken ovamucoid (trypsin inhibitor) 
(Hussain et al., 1989; Zhou, 1994; Bai, 1995). Furthermore, indirect enzyme inhibition can occur 
through the use of pH modifiers that subsequently reduces the optimal environment for enzyme 
activity (Bai et al., 1995). 
 
Studies have shown the positive effects of delivering of insulin orally, in vivo and in vitro, 
following co-administration of specific enzyme inhibitors (Fujii et al., 1985; Morishita et al., 1992; 
Langguth et al., 1994; Yamamoto et al., 1994). Nevertheless, its individual administration with 
proteins or peptides may prove inadequate in improving the absorption due to the high enzyme 
activity at the intestinal membrane site (Lee, 2002). A combination of protease inhibitors with 
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permeation enhancers may prove to be more feasible in improving bioavailability since the 
protease inhibitors will inhibit the enzymes causing degradation of the protein while the 
permeation enhancer facilitates absorption through the intestinal membrane (Araújo et al., 
2012). Figure 2.2 depicts the use of permeation enhancers and protease inhibitors as 
formulation strategies for enhancing protein and peptide delivery. Similarly, as with permeation 
enhancers, cognizance of the safety of these agents is critical as it may lead to non-specific 
interaction with dietary proteins, intestinal mucosal damage and feedback-regulated protease 
secretion following chronic therapy (Lee, 1990; Yamamoto et al., 1994). Therefore, safer 
alternatives need to be considered to enable the safe use of protease inhibitors for chronic 
therapy. 
 
 
Figure 2.2: Formulation strategies for enhancing protein and peptide delivery, a) permeation 
enhancers and b) protease inhibitors. 
 
2.4.3. Modification of the physicochemical properties of proteins and peptides to 
improve oral absorption 
Physicochemical modification of proteins and peptides can be achieved by the addition of 
functional groups or by conjugation to polymers for improving the proteolytic stability and/or 
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membrane permeability (Herman et al., 1995). Chemical modification can also serve as a 
strategy for reducing the ability of proteins and peptides to induce an immune response 
(Herman et al., 1995). PEGylation, hydrophibization and amino acid alterations are some of the 
key approaches that can result in protein modifications (Brown, 2005). The general 
requirements for polymers used in protein-polymer conjugation are that they be water-soluble, 
non-immunogenic, biocompatible and devoid of any biological activity (Grover and Maynard, 
2010). Ideally, the polymer selected should enhance the intrinsic properties of the 
macromolecules and not increase its toxicity or minimize its biological activity (Grover and 
Maynard, 2010). N-(-2-hydroxypropyl) methylacrylamide and poly(ethylene glycol) are polymers 
that display the ideal properties with the latter being the polymer of choice for protein 
conjugation (Grover and Maynard, 2010). 
 
PEGylation, or covalent attachment of poly(ethylene glycol) (PEG) to proteins is widely used in 
parenteral formulations for enhancing their therapeutic potential (Lewis et al., 2004; Alconcel et 
al., 2011). However, its applicability in the oral delivery of proteins and peptides has been 
reported (Jensen-Pippo et al., 1996; Rekha and Sharma, 2013). PEGylation results in the 
formation of a steric shield that protects the macromolecule from recognition by the body’s 
immune system as well as increasing their enzymatic stability (Werle and Berknop-Schńurch, 
2006; Alconcel et al., 2011). In addition, the increase in molecular size results in a reduction in 
renal clearance of the protein or peptide (Werle and Berknop-Schńurch, 2006). Results from a 
study conducted on PEGylation of recombinant human granulocyte colony stimulating factor 
(PEG-G-CSF) indicated that oral delivery of PEG-G-CSF may be feasible and possibly favored 
to the unmodified form of the protein (Jensen-Pippo et al., 1996). 
 
A replacement of one or more L-amino acids with D-amino acids which are known to be inclined 
to enzymatic cleavage is another strategy to delay degradation and increase enzymatic stability 
of proteins/peptides (Werle and Berknop-Schńurch, 2006; Yang, 2013). An example of chemical 
modification of a peptide utilizing this strategy is the various analogues of the endogenous 
opioid pentapeptide methionine (Met)-enkephalin (Bohner et al., 1994). Metabolism of the Met-
enkephalin analogues by brush-border membrane vesicles displayed significant differences in 
degradation rates as well as effective permeability across Caco-2 cells (Bohner et al., 1994). An 
alternative approach is the surface modification of proteins by hydrophobization which can occur 
either by including more hydrophobic amino acids within the peptide backbone or by covalent 
conjugation with lipophilic moieties that can enhance the transcellular uptake (des Rieux et al., 
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2006; Yuan et al., 2011). For example, significant increase in intestinal membrane permeability 
was observed by covalent conjugation of fatty acids such as lauric, palmitic and butyric acid with 
insulin and desmopressin (Muranishi, 1991; Hashizume et al., 1992; Kahns et al., 1993; Michael 
et al., 2000). Although valuable to increasing transport of macromolecules, these methodologies 
possess a major risk of weakening the biological activity of the protein/peptide as a result of the 
chemical modification (Grover and Maynard, 2010). 
 
2.4.4. The use of specialized particulate formulation vehicles 
Several specialized strategies have been proposed to overcome the GIT barrier by the use of 
microemulsions, liposomes, nanoparticles and microspheres to successfully deliver proteins and 
peptides via the oral route (Zhou, 1994; Lasic, 1998; Yin et al., 2009). Thermodynamically 
stable microemulsions protect proteins and peptides from chemical and enzymatic degradation 
due to solid-oil-in-water (S/O/W) emulsions which enhance GIT penetration and absorption 
(Toorisaka et al., 2003). Studies undertaken on the oral delivery of S/O/W emulsions showed an 
increase in hypoglycemic activity following administration of insulin to diabetic rats with 
decreased enzymatic degradation and enhanced permeability (Toorisaka et al., 2003; Park et 
al., 2011). However, in order to enable optimal design and development of microemulsions for 
the delivery of proteins and peptides, several challenges need to be overcome such as its 
reduced loading capacity and low physicochemical stability during long term storage (Park et al., 
2011). 
 
An alternate particulate delivery system used is liposomes as protein and peptide carriers 
(Torchilin, 2005). Such lipid-based delivery systems have been extensively studied for 
improving the absorption of proteins and peptides (Constantinides et al., 1994; 1995; Del Curto 
et al., 2003; Martins et al., 2007). Although promising results have shown an increased plasma 
half-life and decreased blood glucose levels in diabetic mice after intravenous administration, 
the use of conventional liposomes in oral protein and peptide delivery is still limited (Lasic, 
1998). Alternatively, archeosomes which is a specialized lipid-based oral delivery system 
characteristically composed of archaeobacterial membrane lipids containing diether and/or 
tetraether lipids may prove valuable for oral protein or peptide delivery (Li et al., 2010). These 
archeosomes display increased stability against low pH and the action of bile salts and 
pancreatic lipases, thereby increasing the hypoglycemic effect in diabetic mice following insulin 
administration (Lasic, 1998; Li et al., 2010; Park et al., 2011).  
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Another approach for improving liposomes is the use of nanotechnology systems at the surface 
of liposomes as is for silica nanoparticle coated liposomes (Mohanraj et al., 2010). This system 
increases protein encapsulation and provides protection against enzymatic degradation 
(Mohanraj et al., 2010). Amongst the different particulate-based delivery strategies employed, 
nanoparticles (10-1000nm) have captured the majority of interest as a promising approach for 
protein and peptide delivery (Lee, 2002; Lewis et al., 2004). The size, surface charge and 
nature of the encapsulated nanoparticles influences the absorption of proteins through the 
intestinal epithelium, especially through Peyer’s patches as shown by Lee, 2002. Various 
natural and synthetic polymers such as poly(lactic-coglycolic acid) (PLGA), poly(methyl 
methacrylate) (PMMA), poly(lactic acid) (PLA), alginate, cyclodextrins, chitosan and its 
derivatives have been utilized for the production of nanoparticles that encapsulate proteins and 
peptides (Tobio et al., 2000; Li et al., 2001; Reis et al., 2007; Sarmento et al., 2007). Inorganic 
nanoparticles are also receiving increased interest owing to their desirable properties and their 
ability to incorporate proteins and peptides (Xu et al., 2006). Although nanotechnology appears 
to be seemingly flawless, it does have some challenges with regard to the low protein and 
peptide incorporation efficiency, uncontrolled molecule release, susceptibility to particle 
aggregation and possible accumulation of non-biodegradable polymers in tissues (Park et al., 
2011). 
 
Microspheres (1-1000μm) can be employed as another strategy for enhancing oral protein or 
peptide delivery (Park et al., 2011; Prasanth et al., 2011). The major advantage of microspheres 
is their provision of stability for labile compounds that are easily degraded in the intestinal 
epithelium (Degim and Celebi, 2007). Many possible mechanisms may be considered for the 
release of proteins or peptides from microparticles, namely; surface or bulk erosion, diffusion 
though pores and pulsed delivery (Couvreur and Puisieux, 1993). Figure 2.3 illustrates the 
biphasic release of luteinizing hormone releasing hormone (LHRH) from polylactic co-glycolic 
acid (PLGA) microspheres depicting an initial burst release, lag phase and subsequent bulk 
erosion leading to a second phase of release (Sanders et al., 1985).  
 
Microparticles and nanoparticles have shown potential for protein and peptide delivery, however 
their differences should be noted when deciding on the appropriate selection of a particulate 
system. The physicochemical properties of proteins and peptides is a major challenge in the 
formulation process of micro- and nanoparticle encapsulation (Couvreur and Puisieux, 1993). 
Most work that has been undertaken on microencapsulation has shown its compatibility with the 
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handling of numerous peptides (Couvreur and Puisieux, 1993). In contrast, limited examples 
exist for the incorporation of peptides into nanoparticles owing to the complexity and 
incompatibility of the formulation process with the physicochemical conditions required for 
peptide stability (Couvreur and Puisieux, 1993). Additionally, different mechanisms may be 
considered for the release of proteins and peptides from micro- and nanoparticles (Couvreur 
and Puisieux, 1993). Nanoparticles may be more suitable for controlled delivery of proteins and 
peptides whereas microparticles may be employed for immediate and pulsed release. (Sanders 
et al., 1985; Couvreur and Puisieux, 1993). A clear understanding of the in vitro release 
mechanism is required for appropriate selection of micro- or nanoparticle systems. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Illustration of the biphasic release of LHRH from PLGA microspheres. Black dots 
represent the drug-LHRH and curved lines represent the polymer-PLGA [Adapted from 
Couvreur and Puisieux, 1993, with permission from Elsevier Science Ltd. © 1993]. 
 
2.4.5. Stimuli-responsive hydrogels and mucoadhesive polymeric systems for enhanced 
oral absorption of proteins and peptides 
Stimuli-responsive hydrogels represent suitable formulation vehicles for the protection of 
proteins and peptides (Malik et al., 2007). Hydrogels are highly absorbent polymers that can 
respond to changes in pH by remaining unswollen at gastric pH and releasing their incorporated 
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protein or peptide only in the small intestine, thereby protecting the protein or peptide from the 
harsh gastric environment (Malik et al., 2007). In addition, mucoadhesive polymeric systems are 
of great interest in the delivery of proteins and peptides as they retain their contact with the 
mucus membrane, enabling prolonged residence time at the absorption site (Peppas, 2004). 
Thiolated polymers are a representative example of mucoadhesive systems that provides a 
sharp drug concentration gradient at the absorption site and display additional permeation 
enhancing effects (Peppas, 2004). Various stimuli-responsive  polymers (sometimes referred to 
as ‘smart polymers’) which are sensitive to temperature, phase, pH, electric charge, light, and 
biochemicals are available for controlling the release of incorporated proteins and peptides to 
achieve improved plasma levels (Fogueri and Singh, 2009). Table 2.3 lists the different stimuli-
responsive polymers applied to the oral delivery of proteins and peptides with a brief description 
of each type. 
 
Table 2.3: ‘Smart’ polymers for controlled oral delivery of proteins and peptides. 
‘Smart’ Polymers Description 
Temperature sensitive polymer Sol-to-gel transition responding to changes in pH from ambient to    physiological 
temperatures; possess low critical solution temperature (LCST) or high critical 
solution temperature (HCST) (Sophie et al., 2008; Fogueri and Singh, 2009). 
pH sensitive polymer Contains acidic or basic groups that either accept or donate protons in response 
to environmental pH (Bawa et al., 2009; Fogueri and Singh, 2009). 
Biochemical sensitive polymers Highly sensitive to signals generated by a disease and releases drug in 
accordance with the magnitude of the signal (Chourasia and Jain, 2004; Fogueri 
and Singh, 2009). 
 
2.4.6. Site-specific delivery of proteins and peptides to the colon 
The common belief that absorption is uniform throughout the GIT is frequently challenged as 
increasing confirmatory evidence shows site-specific absorption (Neutra and Forstner, 1987). 
Colonic delivery appears to be advantageous for the absorption of proteins and peptides owing 
to their prolonged transit time, decreased enzyme activity and higher receptiveness towards 
permeation enhancers (Brayden and O’Mahony, 1998; Hamman et al., 2007). In addition, the 
alkaline pH of the colon makes it an attractive target for absorption as it may lead to reduced 
degradation of the protein or peptide compared with the luminal digestion/degradation within the 
acidic gastric environment (Gazzaniga et al., 2006). Examples of oral colon delivery systems for 
insulin release are based on microflora, pH and time-dependent strategies to enable enhanced 
protein absorption (Saffran et al., 1986; Touitou and Rubinstein, 1986; Maroni et al., 2009). 
Similarly, as with other approaches for enhancing protein or peptide delivery, oral colonic 
delivery has several challenges (Lee, 2002). Amongst these are the adherence of bacteria to 
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solid surfaces resulting in the formation of biofilm barriers that can affect release as well as 
variable transit times ranging from a few hours to several days (Lee, 2002). 
 
2.4.7. Alternative approaches for enhancing the absorption of proteins and peptides 
Other less common, but nevertheless significant approaches towards achieving optimum oral 
delivery of proteins and peptides include the use of eutectic mixtures and cell penetrating 
peptides which assist in increasing the solubility and permeation of proteins and peptides as 
well as enabling transport across cellular membranes, respectively (Mäe and Langel, 2006; 
Shen et al., 2011). The subject of eutectics in polymeric delivery systems has hardly been 
researched and the microstructure that is typical of polymer eutectics, has not yet been fully 
explored (Tuntarawongsa and Phaechamud, 2012). A more recent study investigated the 
effects of a borneol/menthol eutectic mixture for enhanced bioavailability in the delivery of a 
polypeptide (daidzein) used for the treatment of breast and colon cancer (Shen et al., 2011). 
The results from this study showed the potential use of eutectic mixtures for enhancing the 
absorption of protein and peptide drugs. However, since the borneol/menthol eutectic mixture is 
a permeation-enhancing system it may disrupt tight junctions and result in the unwanted 
permeation of luminal contents and potentially toxic molecules (Tscheik et al., 2013). 
 
Cell-penetrating peptides (CPPs) also represent a possibility for the oral delivery of protein and 
peptides by enhancing the permeability through the intestinal epithelial cells (Foged and 
Nielson, 2008). CPPs work by improving the delivery of macromolecules into the cells when 
conjugated to a specific protein or peptide (Massodi et al., 2005). A study undertaken by 
Morishita and co-workers, (2007) to determine the ability of the CPPs to increase intestinal 
absorption of insulin revealed positive results. Insulin absorption showed a marked increase in 
intestinal permeability when co-administered with the CPP oligoarginine (Morishita et al., 2007). 
However, relatively high doses of the CPP are required which may pose a safety risk following 
multiple administrations (Morishita et al., 2007; Kamei et al., 2008). Thus, there is a need for 
more safer and effective CPPs for the oral delivery of proteins and peptides (Kamei et al., 
2008). 
 
2.5. Advanced Oral Protein and Peptide Technology Platforms for Clinical Application 
There are several oral protein and peptide technologies produced by pharmaceutical companies 
for application in various clinical situations (Park et al., 2011). Although most of the formulations 
based on these technologies are in the development phase, many have progressed to the 
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clinical trial stage (Park et al., 2011). The technologies are summarized below, highlighting their 
favorable characteristics that would improve their absorption and oral bioavailability as well as 
their potential limitations. 
  
2.5.1. Oramed POD™ (Protein Oral Delivery) technology for oral delivery of insulin 
Oramed Pharmaceuticals, Inc. (Jerusalem, Israel) have developed a POD™ technology to 
significantly enhance the absorption of proteins and peptides across the GIT epithelium by 
exploiting the action of protease inhibitors and absorption enhancers. ORMD-0801 is an oral 
insulin formulation based on POD™ technology that is currently undergoing U.S. Phase 2a 
clinical trials (Oramed Pharmaceuticals, 2014). The orally ingestible insulin capsule (ORMD-
0801) produced positive results upon assessment of its glucose-lowering effect (Eldor et al., 
2013; Oramed Pharmaceuticals, 2014). The formulation composition is not precisely known but 
it is thought to be composed of an enteric coated oral capsule comprising a protease inhibitor, 
absorption enhancer and emulsifier (Eldor et al., 2013; Oramed Pharmaceuticals, 2014). 
According to Kidron, (2011), the emulsifier, protease inhibitor and absorption enhancer could be 
omega 3 fatty acids, soybean as a trypsin inhibitor and EDTA, respectively (Kidron, 2011). This 
approach although promising, has several disadvantages such as the increased paracellular 
permeability of possible toxic molecules and the safety considerations associated with EDTA 
salts used orally (Kidron, 2011; Tscheik et al., 2013). 
 
2.5.2. Transient Permeability Enhancer (TPE™) system for oral delivery of octreotide  
TPE™ is an absorption-enhancing system produced by Chiasma, Inc. (Jerusalem, Israel), 
consisting of an oily suspension of a medium-chain fatty acid salt, embodied by sodium 
caprylate and a matrix-forming polymer in a hydrophobic glyceryl triglyceride medium (Salama 
et al., 2010; Chiasma, 2014). TPE™ system not only functions to protect the proteins and 
peptides from the GIT environment, but also acts on the GIT wall to enhance permeation 
(Salama et al., 2010). TPE™ functions by a paracellular mechanism through transient opening of 
tight junctions between adjacent epithelial cells (Salama et al., 2010; Chiasma, 2014). It was 
able to improve the bioavailability of the peptide octreotide in a study by Tuvia and co-workers, 
(2012). Octreolin® is an oral octreotide capsule produced by Chiasma for the treatment of 
acromegaly that is based on their proprietary TPE™ system (Chiasma, 2014). Octreolin® is 
currently in Phase 3 trials for acromegaly and if successful is expected to be launched in 2015 
(Chiasma, 2014). A comparative disadvantage of this technology is the use of various excipients 
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in an emulsion format to form the TPE™ as compared to simple admixed formulations (Salama 
et al., 2010).  
 
2.5.3. Eligen® Technology for oral delivery of vitamin B12, calcitonin, heparin and insulin 
Emisphere Technologies, Inc. (Roseland, New Jersey, United States) have produced a 
proprietary oral drug delivery platform knows as the Eligen® Technology which enhances the 
transcellular permeation across intestinal cell membranes (Aungst, 2011; Emisphere 
Technologies, 2014). This technology is based on sodium N-[8-(2-hydroxybenzoyl) 
aminocaprylate] (SNAC) which is proposed to interact with the drug molecule by forming weak, 
non-covalent complexes that enables transcellular absorption, without altering the tight junctions 
as depicted in Figure 2.4a (Ding et al., 2004; Aungst, 2011; Park et al., 2011). This approach 
has been shown to reversibly and safely deliver macromolecules without altering the drug, 
damaging epithelial membranes or creating new toxicities (Goldberg and Gomez-Orellana, 
2003). Emisphere Technologies, Inc. has developed an oral formulation of Eligen® B12 for 
vitamin B12 deficient individuals and is currently in the process of evaluating results from clinical 
trials and market research (Emisphere Technologies, 2014). Eligen® technology has served as 
a hydrophobic carrier for the delivery of various macromolecules such as heparin, insulin and 
calcitonin, thereby increasing their lipophilicity (Goldberg and Gomez-Orellana, 2003). Novo 
Nordisk® (Bagsvaerd, Denmark) has partnered with Emisphere Technologies, Inc. to develop 
and commercialize Novo Nordisk’s insulin and GLP-1 agonists (Emisphere Technologies, 
2014). In 2013, Novo Nordisk® announced that it had commenced its first Phase 2 clinical trial 
with a long-acting oral GLP-1 analog (Emisphere Technologies, 2014). However, although this 
technology has shown promising results in oral protein and peptide delivery, its clinical 
application is difficult since it causes nausea in patients. In addition the technology requires co-
administration of higher amounts of delivery agent as compared to the protein or peptide which 
ultimately decreases patient compliance (Hoffman and Qadri, 2008).  
 
2.5.4. Chronotropic™: a “two-pulse” colonic device for oral delivery of insulin 
A “two-pulse” delivery system comprising a tablet core surrounded by an inner 
swellable/erodible hydroxypropyl methylcellulose (HPMC) layer that is enclosed by an 
intermediate adjuvant layer and an additional HPMC outer coating was designed by Dexcel 
Pharma Technologies, Ltd. (Jerusalem, Israel) (Gazzaniga et al., 1994; Maroni et al., 2009; Del 
Curto et al., 2011).  This technology may prove useful for the oral delivery of insulin (Del Curto 
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et al., 2011). Studies undertaken have shown that the “two-pulse” colonic release of insulin, the 
protease inhibitor (camostat mesilate) and absorption enhancer (sodium glycocholate) was able 
to produce acceptable lag phases between the release of the adjuvant and the protein. The 
adjuvant is released prior to the protein, creating a more stable environment in advance 
(Gazzaniga et al., 1994; Maroni et al., 2009; Del Curto et al., 2011). The Chronotopic™ device 
consists of inner and outer HPMC coatings that are meant to delay the release of adjuvants and 
the protein (Del Curto et al., 2011). The major drawback of this multilayered system is that it is 
complex, requiring numerous polymer coating steps and adjuvants making formulation 
extremely cumbersome. In addition this system would require an enteric coating to enable time-
dependent colon delivery which is a challenge when considering that the reliability and 
efficiency of enteric coating is variable due to the presence of a wide range of pH values and 
enzymes present in the GIT (Del Curto et al., 2011; Hussan et al., 2012).  
 
2.5.5. CODES™ (Colon Specific Delivery System) technology for oral delivery of insulin 
CODES™ Technology was produced for colonic specific delivery by Yamanouchi 
Pharmaceutical Co., Ltd. (Tokyo, Japan) and consists of lactulose-containing tablet that is 
coated with two acrylic films that display pH-dependent solubility (Katsuma et al., 2002). The 
acrylic films comprise an inner acid-soluble polymer (Eudragit® E) and an outer enteric soluble 
polymer (Eudragit® L), that are separated by an HPMC layer (Yang et al., 2003). The principle 
underpinning this technology is based on the knowledge that the enteric soluble polymer 
protects the tablet form the harsh gastric conditions within the stomach but rapidly dissolves 
within the intestine (Kotla and Shivapooja, 2014). The Eudragit® E coating subsequently 
protects the tablet through its passage within the alkaline environment of the small intestine 
(Yang et al., 2003). On arrival within the colon, the bacteria present enzymatically degrades the 
lactulose into an organic acid (Katsuma et al., 2004). As a result, the pH surrounding the tablet 
is lowered sufficiently to enable the dissolution of the acid soluble polymer and initiate drug 
release (Yang et al., 2003). Figure 2.4b depicts the different layers of the CODES™ technology 
and its response in various GIT media. This technology may prove significant for oral insulin 
delivery as studies undertaken showed decreased blood glucose levels with supplementary use 
of absorption enhancers and sustained delivery (Katsuma et al., 2004). 
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Figure 2.4: a) Emisphere Eligen™ Technology [Adapted from Park et al., 2011, with permission 
from Elsevier Science Ltd. © 2011]. b) Illustration of the CODES™ technology depicting the 
different layers of the tablet and their response within each GIT media [Adapted from Katsuma 
et al., 2004, with permission from John Wiley and Sons © 2004]. 
 
2.5.6.  GIPET™ (Gastrointestinal Permeation Enhancement Technology) for oral delivery 
of acyline, heparin, insulin and GLP-1 agonists 
Merrion Pharmaceuticals, Ltd. (Dublin, Ireland) GIPET™ technology utilizes medium chain fatty 
acids, salts and their derivatives to enhance the protein and peptide absorption from the small 
intestine (Leonard et al., 2006). A few of the products in the pipeline by Merrion 
Pharmaceuticals, Ltd. that utilizes GIPET™ technology include acyline and ultra-low molecular 
weight heparin (uLMWH) (Leonard et al., 2006; Merrion Pharmaceuticals, 2014). Acyline (MER-
104), an oral GnRH antagonist used for oncology and other indications as well as MER-102 
which is a unique tablet of uLMWH used in the treatment of deep vein thrombosis is currently 
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under development (Merrion Pharmaceuticals, 2014). This technology is preferably delivered 
using an enteric-coated formulation containing the main adjuvant, sodium caprate which has 
shown to enhance the bioavailability of heparin as compared to conventional delivery systems 
(Leonard et al., 2006). In addition, Merrion Pharmaceuticals, Ltd. has partnered with Novo 
Nordisk® (Bagsvaerd, Denmark) to develop and commercialize Novo Nordisk’s insulin and GLP-
1 agonists using GIPET™ (Merrion Pharmaceuticals, 2014). However, this technology, as is the 
case with many permeation-enhancement technologies, result in an enhancement in absorption 
of toxic molecules causing damage to the intestinal epithelium which presents a significant 
disadvantage (Tshceik et al., 2013). 
  
2.5.7. Axcess™ oral delivery system for insulin 
Proxima Concepts, Ltd. (London, United Kingdom) have developed an Axcess™ delivery system 
to enhance the oral absorption of proteins, peptides and other macromolecules across the GIT 
epithelium without chemical modification (Diabetology, 2014).  The system is based on an oral 
capsule that contains the protein or peptide as well as registered pharmacopoeial excipients 
such as permeation enhancers and solubilizers to enhance transcellular absorption (Proxima 
Concepts, 2014). Capsulin™ IR (Insulin Replacement) is an enteric-coated insulin capsule that 
is produced by Diabetology, Ltd. (London, United Kingdom) in partnership with Proxima 
Concepts, Ltd (Luzio et al., 2010). The capsule is based on Proxima’s proprietary Axcess™ 
delivery system and has completed Phase 2a clinical trials (Luzio et al., 2010). Despite the 
simplicity of this technology, the use of permeation enhancers could prove to be a challenge as 
it may disrupt tight junctions between epithelial cells causing the permeation of potentially toxic 
molecules (Tshceik et al., 2013). 
  
2.5.8.  Peptelligence™ technology for oral delivery of salmon calcitonin 
Enteris BioPharma, Inc. (Boonton, New Jersey, United States) has developed the clinically 
proven Peptelligence™ Technology that enables the oral delivery of peptides (Carl et al., 2013). 
Peptelligence™ Technology comprises an enteric-coated tablet with two key components; a 
permeation enhancer and the main excipient citric acid (Enteris BioPharma, 2014).  The enteric 
coating prevents the tablet from disintegration within the stomach and enables dissolution within 
the intestinal pH (Carl et al., 2013). The two key components are released within the small 
intestine (Carl et al., 2013). The permeation enhancer loosens tight junctions between intestinal 
epithelial cells and promotes paracellular transport while the citric acid functions to transiently 
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decrease intestinal pH to prevent degradation of the peptide by intestinal proteases and 
peptidases, which generally function optimally at neutral to alkaline pH (Carl et al., 2013; Enteris 
BioPharma, 2014; Steinbach, 2014). This mechanism of release from Peptelligence™ 
Technology functions to facilitate oral peptide delivery. Tarsa Therapeutics, Inc. (Philadelphia, 
United States) has developed and oral salmon calcitonin formulation (Oracal®) used for the 
treatment of osteoporosis (Binkley et al., 2012). The preferred formulation composition is a 
tablet containing salmon calcitonin, granular citric acid and an enteric coating of Eudragit® 
(Stern and Gilligan, 1999; Tarsa Therapeutics, 2014). Phase III clinical trials of Oracal® showed 
enhanced safety and efficacy results in women with postmenopausal osteoporosis, depicting 
better outcomes as compared to placebo and nasal calcitonin spray in enhancing bone mineral 
density in the lumbar spine after 48 weeks (Binkley et al., 2012). Despite these positive results, 
the loosening of tight junctions caused by permeation enhancers presents a significant 
disadvantage as it may enable passage of potentially toxic molecules. In addition, polymers 
used for enteric coating may undergo uncontrolled polymerization, during handling and storage, 
resulting in failure to release the molecule at the target site (Fawzi et al., 1991). 
 
2.5.9. Multi Matrix MMX® technology for oral delivery of low molecular weight heparin 
The MMX® Technology was designed by Cosmo Pharmaceuticals, Inc. (Lainate, Italy) for the 
oral delivery of active pharmaceutical agents into the lumen of the colon through tablets which 
delay and control release (Cosmo Pharmaceuticals, 2014). The tablets are enteric coated with 
pH-resistant acrylic copolymers which delay the release until the tablet reaches the target site 
(Pastorelli et al., 2008). The coating allows for the protection of the molecule from adverse pH 
conditions and enzymes within the GIT (Cosmo Pharmaceuticals, 2014). In addition, the 
technology enables the controlled release of molecules over the length of the colon (Pastorelli et 
al., 2008; Fiorino et al., 2010). Low molecular weight (LMW) heparin MMX® is a novel oral colon 
release formulation produced by Cosmo Pharmaceuticals, Inc. for the treatment of mild to 
moderate ulcerative colitis (Pastorelli et al., 2008). A study undertaken by Pastorelli and co-
workers, (2008) showed positive results for the delivery of the LMWH Parnaprin with the MMX® 
Technology by avoiding the systemic action of the drug while allowing its local therapeutic 
action. LMW heparin MMX® Technology also has potential in the treatment of inflammatory 
bowel disease as a phase 2b clinical trial demonstrated that LMW heparin MMX® when 
associated with 5-ASA is more effective than 5-ASAs alone (Cosmo Pharmaceuticals, 2014). 
Although this technology enables the oral delivery of proteins and peptides, it does not contain 
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any pharmacopoeial excipients which may promote absorption or protection of the incorporated 
protein or peptide. The only protection it offers is the enteric coating which may pose a 
challenge when considering that the reliability and efficiency of enteric coating is variable due to 
the presence of a wide range of pH values and enzymes present in the GIT (Hussan et al., 
2012). 
 
2.6. Advancement in Pharmacokinetic Profiles of Peptide Therapeutics through 
Specialized Platforms for Clinical Applications 
Pharmacokinetics is an essential scientific discipline that governs applied therapeutics (Tripathi, 
2013). The study of the Absorption, Distribution, Metabolism and Excretion (ADME) of proteins 
and peptides from drug delivery platforms are key pharmacokinetic parameters that determine 
the response of the body towards the incorporated macromolecules (Tripathi, 2013). 
Fundamental pharmacokinetic information is required to improve the pharmacodynamic 
response (Tripathi, 2013). Thus, a critical analysis of the pharmacokinetic profiles of the 
advanced technology platforms mentioned above is necessary in determining their efficacy in 
various clinical situations. The pharmacokinetic advancement contributed by different 
technologies is briefly discussed below, highlighting the key findings. 
 
An open-label pilot study was used to assess the safety, tolerability and pharmacokinetic profile 
of Oramed POD™ technology for the oral delivery of insulin (Eldor et al., 2010).  The study 
revealed lower values of post administration mean AUC (AUC60-300) of 6.1-14% for c-peptide 
and 3.3-5% for glucose as compared to the AUC0-60 (Eldor et al., 2010). In addition, insulin 
peaks characterized by a 1.5-2.4 fold increase from basal readings were observed 120 minutes 
after drug administration (Eldor et al., 2010). The technology offered better antiproteolytic and 
absorption enhancement by means of inert and safe adjuvants in comparison to the response 
obtained from other chemical adjuvants. This increase may be attributed to the action of 
protease inhibitors and absorption enhancers present within the formulation. However, despite 
the presence of absorption enhancers, hepatic uptake of insulin is highly variable and can 
exceed 80% of the portal delivered insulin reflecting poorly on oral insulin absorption (Eldor et 
al., 2010). 
 
The pharmacokinetic profile of the oral formulation Octreolin® was investigated by Tuvia and co-
workers, (2012) in comparison to the subcutaneous injection of octreotide.  Oral octreotide 
(20mg) and subcutaneous octreotide injection (0.1mg) depicted comparable pharmacokinetic 
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parameters (mean Cmax= 3.77±0.25 vs. 3.97±0.19 ng/ml; mean AUC= 16.2±1.25 vs. 12.1±0.45 h 
x ng/ml; and median time of ≥0.5 ng/ml, 7.67 vs. 5.88 h, respectively) (Tuvia et al., 2012). In 
addition, the orally administered octreotide resulted in effective growth hormone suppression in 
basal and GHRH-stimulated patients by 49 and 80%, respectively (Tuvia et al., 2012).  In 
general  Octreolin® has similar pharmacokinetic characteristics in comparison to subcutaneous 
octreotide which could be attributed to the its characteristic TPE™ system which protects the 
incorporated peptide in addition to enhancing permeation through the GIT wall (Tuvia et al., 
2012). 
 
A comparative study of pharmacokinetic evaluation of salmon calcitonin was carried out using 
oral formulation (Eligen® technology) and conventional nasal spray. An investigation into the 
effect of water intake and timing of dose on the pharmacokinetic parameters of an oral 
formulation of salmon calcitonin (sCT) based on Eligen® technology was conducted by Karsdal 
and co-workers (2008). The oral formulation was compared to a conventional nasal spray. The 
study indicated a two-fold increase in Cmax and AUC0-4, when administered with 50mL of water 
ranging from 46.0-86.5pg/ml x hrs depending on dosing time pre-meal as compared to 200mL 
(25.3-38.1pg/ml x hrs). In addition, the AUC0-4 of oral sCT with 50mL of water was 4-fold higher 
than the conventional nasal spray. However, the time to reach peak plasma concentrations 
(Tmax) was equivalent for all formulations, including the nasal sCT. Hence, in addition to the 
enhanced transcellular permeation across intestinal cell membrane the Eligen® based oral sCT 
formulation (administered with 50mL of water and 60 minutes pre-meal) showed greater sCT 
bioavailability (Karsdal et al., 2008).  
 
CODES™ was orally administered to fasting and fed dogs to determine and evaluate the 
pharmacokinetic profile of lactulose. The values for Cmax and AUC were comparable in fasting 
and fed conditions, however, the Tmax was delayed by 9 hours in fed dogs when compared to 
fasting dogs. The peak plasma concentration in fasting and fed dogs was 3.1±0.2μg/ml and 
2.1±0.2μg/ml, respectively. The AUC in fasting conditions was 16.6±5.4μg/ml x h while in the 
fed conditions it was slightly lower with a value of 14.4±1.54μg/ml x h. However, in comparison 
to the pharmacokinetic profile of Timed-controlled release capsules, CODES™ technology, 
utilizing the action of enterobacteria, has a higher potential for colon-specific drug delivery 
(Katsuma et al., 2002). 
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A phase 1 study on a GIPET™ formulation of low molecular weight heparin (LMWH) was 
conducted to determine the increase in oral bioavailability as compared to the standard 
subcutaneous dose of 3200IU (Leonard et al., 2006). Results displayed an oral bioavailability of 
3.9% and 7.6% with respect to subcutaneous administration for LMWH-GIPET™ 45000IU and 
LMWH-GIPET™ 90000IU, respectively. The relatively low oral bioavailability may be attributed 
to the transient effects of the absorption enhancer, suggesting for the further improvement in 
design by enabling the co-release of the absorption enhancer and active protein or peptide to 
further increase oral bioavailability (Leonard et al., 2006). 
 
A randomized open study was conducted by Luzio and co-workers (2010) to determine the 
pharmacokinetic and pharmacodynamic properties of subcutaneous human insulin and 
Capsulin™ (oral insulin capsule) (Luzio et al., 2010). Results depicted lower insulin AUC0-6 for 
Capsulin™ as compared to the subcutaneous injection (910 ± 270 vs. 472 ± 245 pmol h/L for 
subcutaneous injection vs.  Capsulin™ 150IU; 950±446 vs. 433±218 pmol.h/L for subcutaneous 
injection vs. Capsulin™ 300IU). In addition, the peak plasma concentrations of Capsulin™ were 
lower than subcutaneous insulin injections. However, comparable AUC and peak plasma 
concentrations were noted for Capsulin™ 150IU and Capsulin™ 300IU (Luzio et al., 2010). 
Despite the significant hypoglycemic effect of Capsulin™, the low insulin plasma concentrations 
recorded may be attributed to the increased enzyme activity at the intestinal epithelium which 
can result in degradation of the protein. Capsulin™ does not target enzymes within the intestine 
and thus this creates a significant window for improvement. 
 
The efficacy of Peptelligence™ technology in delivering oral sCT was investigated by Carl and 
co-workers (2013). Even though absolute pharmacokinetic measurements were lacking in their 
study, the efficacy was demonstrated by an increase in baseline lumbar spine bone mineral 
density by 1.53% in women that were given oral sCT as compared to nasal spray (0.78%) or 
placebo (0.47%) administration (Carl et al., 2013). In addition, the oral sCT displayed greater 
improvements in trochanteric and total proximal femur bone mineral density as compared to 
nasal sCT (Carl et al., 2013). These positive results may be attributed to the action of the 
permeation enhancer and indirect enzyme inhibitor contained within the formulation. Similarly, 
studies conducted on the efficacy of MMX® technology in the oral delivery of LMWH yielded 
results that were not direct pharmacokinetic measurements (Pastorelli et al., 2008). However, 
Clinical activity index (CAI) and Disease activity index (DAI) measurements revealed a 
significant improvement from the baseline (Pastorelli et al., 2008). Despite these positive 
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results, extensive pharmacokinetic data is required to reliably determine the capability of the 
system to improve the bioavailability.  
 
2.7. Concluding Remarks 
Proteins and peptides display an increasingly important role as therapeutic agents for the 
treatment of various diseases (Zhou, 1994). Thus, improved non-parenteral delivery 
technologies are essential in ensuring optimal patient compliance and acceptance. The three 
major challenges with the delivery of proteins and peptides through non-parenteral routes 
(particularly the oral route) as assimilated in this review is their low bioavailability, susceptibility 
to enzymatic degradation and low membrane permeability (Maher and Brayden, 2012). Several 
oral delivery strategies have been proposed to enhance the permeation of protein and peptide 
molecules through the GIT. The aim of these strategies is to improve the oral bioavailability by 
either protecting the molecules from enzymatic degradation within the GIT or by improving their 
transport across intestinal cell barriers. Several technologies have been proposed which 
specifically target these barriers to successfully deliver oral proteins and peptides. Results from 
clinical trials conducted on the various technologies show positive results for its formulation into 
effective oral protein and peptide delivery systems. However, challenges still exist with each of 
the technologies proposed and these need to be addressed to enable optimal oral delivery. In 
general, the research and development of protein and peptide-based therapeutics is a dynamic 
field of research, with increasing numbers of candidates entering clinical studies in a wide 
variety of therapeutic categories. There is no doubt that pharmaceutical and biotechnology 
industries will continue to focus on these versatile molecules in association with the 
development of new oral formulations and delivery technologies. 
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CHAPTER 3 
A PROOF OF CONCEPT STUDY DEPICTING A MENTHOL-BASED SOLID DISPERSION 
TECHNIQUE FOR ENHANCED SOLUBILITY AND DISSOLUTION OF 
SULFAMETHOXAZOLE FROM AN ORAL TABLET MATRIX 
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Abstract 
A menthol-based solid dispersion was designed to improve the intrinsic solubility of the poorly 
soluble sulfamethoxazole - a class II drug molecule of Biopharmaceutics Classification System 
(BCS) displaying widespread antibacterial activity. Solid dispersions of menthol and 
sulfamethoxazole were compressed with hydroxypropylmethylcellulose (HPMC) into suitable 
sulfamethoxazole-loaded matrix tablets for oral drug delivery. The sulfamethoxazole-loaded 
solid dispersions and compressed tablets were characterized for their physicochemical and 
physicomechanical properties such as changes in crystallinity, melting point, molecular 
transitions and textural analysis for critical analysis of their effects on the solubility and 
dissolution of sulfamethoxazole. The formulations were further evaluated for swelling, 
degradation, solubility and in vitro drug release behavior. In vitro drug release from the 
sulfamethoxazole-loaded matrix tablets displayed a minimum and maximum fractional release 
of 0.714 and 0.970, respectively. The tablets further displayed different release rate profiles over 
the study periods of 12, 16, 48 and 56 hours which was attributed to the varying concentrations 
of menthol within each formulation. Menthol was determined as a suitable hydrophilic carrier for 
sulfamethoxazole since it functioned as a solubilizing and release-retarding agent for improving 
the solubility and dissolution of sulfamethoxazole as well as controlling the rate at which it was 
released. 
 
Keywords: crystallinity; menthol; oral solubility and dissolution; solid dispersion; 
sulfamethoxazole 
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3.1. Introduction 
The aqueous solubility of a drug molecule is a major pharmaceutical formulation challenge as it 
is critical for achieving optimal oral bioavailability (Savjani et al., 2012). Various approaches 
have been explored for improving the solubility of poorly soluble drug molecules such as 
sulfamethoxazole (SMX). SMX was selected for this study as it is a bacteriostatic antibiotic 
within the sulfonamide class of drugs with activity against a wide range of organisms including 
susceptible strains of Staphylococcus aureus, Streptococcus, Haemophilus influenza, 
Escherichia coli and Enterobacter (Petri, 2011). SMX is commonly used in combination with 
trimethoprim for urinary tract infections (UTIs) (Petri, 2011). Due to its limited aqueous solubility 
(610mg/L at 37°C), SMX is used at high doses which facilitates the development of resistance 
and as a result poses a significant drawback (Petri, 2011).  
 
The modification of the physicochemical property of the molecule, the use of supercritical fluid 
processes, surfactants, solubilizers and novel excipients are some of the approaches used to 
improve solubility of poorly soluble drug molecules (Sareen et al., 2004; Dohrn et al., 2007; 
Seedhar and Agarwal, 2009; Savjani et al., 2012). Modification of the physicochemical property 
of a molecule includes the reduction of the particle size to increase the surface area through 
micronization and nanosuspensions as well as crystal engineering to decrease the crystallinity 
through the formation of solid dispersions (Liu et al., 2006; Savjani et al., 2012). Chemical 
modification of a molecule comprises techniques such as change in pH, complexation and salt 
formation (Savjani et al., 2012). Although the reduction in particle size is most commonly used it 
often imparts an inordinate amount of physical stress on the drug molecule that results in 
degradation especially for thermosensitive and unstable molecules (Savjani et al., 2012). Solid 
dispersions have been considered as one of the most promising approaches to enhance the 
solubility, dissolution and subsequent oral bioavailability of poorly soluble drugs through various 
techniques (Liu et al., 2006; Savjani et al., 2012).  
 
Typically, solid dispersions refer to a group of solid products consisting of two different 
components (Chiou and Riegelman, 1971; Luener and Dressman, 2000). The two components 
are generally a hydrophobic drug, molecularly dispersed within a hydrophilic polymer which may 
be crystalline or amorphous in nature (Vasconceles et al., 2007). Solid dispersions can be 
classified into five main categories namely; simple eutectic mixtures, amorphous precipitations 
in a crystalline matrix, solid solutions, glass suspensions and glass solutions (Chiou and 
Riegelman, 1971). Sekiguchi and Obi, (1961) first demonstrated the use of solid dispersions by 
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creating a eutectic mixture for the delivery of the sulfonamide drug, sulfathiazole (aqueous 
solubility=373mg/L at 25°C). Subsequently, Levy (1963) established a basic and precise   
method for the preparation of solid dispersions and solid solutions. Conclusive results from both 
studies displayed the improvement of solubility and dissolution by the use of solid dispersions 
(Sekiguchi and Obi, 1961; Levy, 1963). Since its innovation in 1961, solid dispersions have 
become the cornerstone for improvement in the oral delivery of poorly water soluble drugs today 
(Bhatnagar et al., 2014).  
 
Solid dispersions for the improvement of poorly soluble SMX have not been investigated and 
thus the aim of this study was to improve the solubility and dissolution rate of SMX through the 
formation of a menthol-based solid dispersion. According to the BCS classification system, SMX 
is classified as a Class II molecule with poor solubility and high permeability (Lindenburg et al., 
2004; Safoon et al., 2011). SMX has limited solubility in water but is optimally soluble in alcohol, 
acetone and alkali hydroxides (Reynolds, 1993). Thus, this system demonstrates the solubility 
improvement of SMX through the use of hydrophilic menthol. SMX-loaded matrix tablets of the 
solid dispersions of menthol and SMX were formulated to significantly improve the oral delivery 
of SMX. This system may potentially decrease the dose required to achieve a therapeutic effect 
and improve resistance rates. The physicochemical and physicomechanical characteristics of 
the system as well as the solubility and in vitro evaluation of the solid dispersions have been 
investigated and presented in this chapter. 
 
3.2. Materials and Methods 
 
3.2.1. Materials 
Menthol(2-isopropyl-5-methylcyclohexanol,99% purity, MW=156.27g/mol), (hydroxypropyl)methyl 
cellulose (Methocel, viscosity grade=2%), sulfamethoxazole (SMX) (MW=253.28g/mol) and 
excipients such as sodium carboxymethylcellulose (CMC) and magnesium stearate were 
purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA). All other materials were of analytical 
grade and were employed as received. 
 
3.2.2. Preparation of the SMX-loaded solid dispersions 
Solid dispersions were prepared according to a co-melt method, involving the combination of 
menthol and SMX by a heating and mixing process as proposed by Arnikar and co-workers, 
(1992). The upper (10g) and lower (1g) limits of menthol for achievement of a solid dispersion 
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were determined based on preformulation studies. Various concentrations were selected within 
these limits as shown in Table 3.1. In addition, since SMX had an experimental aqueous 
solubility of 610mg/L at 37°C, an excess of ±10mg/mL was utilized to determine the 
improvement in solubility of SMX when formulated as a solid dispersion. Based on the upper 
and lower limits determined from preformulation studies, various concentrations of menthol were 
heated using a heated magnetic stirrer to a temperature of 37±0.5°C until a liquid melt was 
obtained. SMX (50mg) was subsequently added to the liquid melt (±5mL) and heated to a 
temperature of 160±0.5°C to enable the melting of SMX. The physical mixtures underwent 
constant magnetic stirring at a speed of 300rpm for ±30 minutes (maintained at a temperature of 
160±0.5°C) until homogenous solid dispersions were formed. Thereafter, a 5%w/w concentration 
of a cryoprotectant (sucrose) was added in equal volume to the solid dispersion. The resultant 
solid dispersions were placed in a freezer at -80°C for 24 hours. Thereafter, the frozen SMX-
loaded solid dispersions were lyophilized (Labconco Freeze-Dry Systems, Labconco Corp., 
Kansas City, MO, USA) for 48 hours to form freeze-dried SMX-loaded solid dispersion powders 
for physicochemical and physicomechanical characterization. Typically, lyophilization is used as 
a method for the sublimation of menthol from a formulation, however, the high percentage of 
cryoprotectant that was added to the solid dispersion was used to protect the menthol from 
freezing and desiccation stresses during the lyophilization process (Thakur and Gupta, 2006; 
Lee et al., 2009; Williams et al., 2012). As a result, excess menthol was absorbed onto the 
cryoprotectant thereby minimizing processing losses. The lyophilized solid dispersions were 
then combined with 100mg of HPMC, 12mg of CMC and 1mg of magnesium stearate before 
compression at 5 tons to form SMX-loaded matrix tablets with dimensions of ~10mm x 4.5mm 
(diameter x thickness) using a Carver Tableting Press (Wabash, Indiana, USA). 
 
Table 3.1:  Solid dispersions synthesized using the co-melt method 
Formulation no. Menthol (g) Sulfamethoxazole 
(mg) 
1 
2 
3 
4 
5 
6 
7 
1 
4 
4.5 
5 
5.5 
6 
10 
50 
50 
50 
50 
50 
50 
50 
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3.2.3. In-process validation of the SMX-loaded solid dispersions and the SMX-loaded 
matrix tablets 
The solid dispersions were analyzed with respect to their physical appearance, particle size and 
powder flow properties whilst the matrix tablets were evaluated for their uniformity in mass, 
thickness and friability. The physical appearance was assessed based on colour and texture 
and the average particle size was determined by ZetaSizer Nano ZS (Malvern Instruments Ltd., 
UK). The samples were thoroughly dispersed in 10mL of distilled water prior to filtering 2mL of 
the sample through a 0.22μm pore filter into a cuvette for analysis by Zetasizer. Measurement of 
the angle of repose and Carr’s compressibility index was used to classify the flow properties of 
the lyophilized SMX-loaded solid dispersions. The weight of each matrix tablet was determined 
using an analytical digital balance (Mettler, Model AE 240, Griefensee, Switzerland) while the 
thickness of the matrix tablets were determined using a digital caliper (25 × 0.01mm capacity) 
(Taizhou hangyu tools gauge and blades Co., Ltd., Wenqiao, Zhejiang, China). The friability was 
determined on a Friabilator (Erweka D-63150, Heusenstamm, Germany) at 25 rpm for 4 
minutes with 1% set as the upper limit of acceptability. 
 
3.2.4. Thermal analysis of the SMX-loaded solid dispersions 
Thermal analysis was performed on each of the SMX-loaded solid dispersions using 
Temperature Modulated Differential Scanning Calorimetry (TMDSC) (Mettler Toledo, DSC1, 
STAReSystem, Schwerzenback, Switzerland) to determine a change in the melting point of SMX 
when formulated as a solid dispersion. Accurately weighed samples (10±0.25mg) were placed 
in perforated 40μl aluminum crucibles which were hermetically sealed and ramped between a 
temperature range of 25-240°C at a constant rate of 10°C/min with a constant purge of N2 
atmosphere. The glass transition temperature (Tg), onset of melting (To), melting peak 
temperature (Tp), heat of fusion (ΔHm) and temperature of crystallization (Tc) were determined 
for each of the native molecules and the SMX-loaded solid dispersions. Thermogravimetric 
analysis (TGA) was used to determine the thermal degradation of the SMX-loaded solid 
dispersions upon heating. A Thermogravimetric Analyzer (TGA) (PerkinElmer TGA 4000, 
Llantrisant, Wales, UK) was used and samples were prepared by weighing 5mg of lyophilized 
powders within ceramic crucibles. The weights were tarred prior to running the samples and 
were heated from 25-900°C at a rate of 10°C/min with a constant purge of N2 atmosphere.  
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3.2.5. Determination of molecular and vibrational transitions of the SMX-loaded solid 
dispersions 
ATR-FTIR spectra were obtained for the native molecules, menthol and SMX, as well as the 
different concentrations of SMX-loaded solid dispersions to determine the presence of menthol 
and SMX within the solid dispersion. PerkinElmer Spectrum 2000 FTIR spectrophotometer with 
a single-reflection diamond MIRTGS detector (PerkinElmer Spectrum 100, Llantrisant, Wales, 
UK) was used. Samples were prepared and placed on the diamond crystal and processed by 
universal ATR polarization accessory for the FTIR spectrum series at a resolution of 4cm-1. 
Samples were analyzed between a scanning range of 4000-650cm-1 at a constant pressure of 
120psi with 32 accumulations. 
 
3.2.6. Determination of Matrix Hardness, Matrix Resilience and Deformation Energy of 
the SMX-loaded matrix tablets 
The SMX-loaded matrix tablets were analyzed with respect to Matrix Resilience (MR), Matrix 
Hardness (MH) and Deformation Energy (DE) to determine their structural integrity. A calibrated 
Texture Analyzer (TA.XT plus, Stable Microsystems, Surrey, UK) fitted with a flat-tipped steel 
probe (2mm diameter) was used for the determination of MR, MH and DE values. Data was 
captured at a rate of 200 points per second using Texture Exponent Software (V3.2). MR was 
computed as a percentage of the ratio between the Area under the Curve (AUC) of the peak to 
baseline (AUC2–3) and the baseline to peak (AUC1–2) from a Force-Time profile as displayed in 
Figure 3.1. The MH and DE values were both obtained from the gradient and AUC of the Force-
Distance profiles, respectively.  
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Figure 3.1: Typical Force-Time and Force-Distance profiles for determination of MR (Force-
Time profile; AUC2–3/AUC1–2), MH (gradient of a Force-Distance profile) and DE (AUC of a 
Force-Distance profile). 
 
The MH was calculated using the Brinell Hardness Number (BHN) (Equation 3.1). Textural 
analysis on all the SMX-loaded matrix tablets was performed in triplicate. The parameters 
employed for the analysis are listed in Table 3.2.  
 
 BHN =  2F
πD �D−√D2−d2�                                                                                                               (3.1) 
 
Where, BHN is Brinell Hardness Number; D is diameter of indenter (mm); F is elucidated from 
the gradient of the initial force and the final force obtained and d is diameter of indentation 
(mm). 
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Table 3.2: Textural profiling parameters used for determining the Matrix Hardness, Matrix 
Resilience and Deformation Energy of the SMX-loaded matrix tablets 
Parameters Matrix Hardness Matrix Resilience Deformation Energy 
Pre-test speed 1 mm/s 1 mm/s 1 mm/s 
Test speed 0.5 mm/s 0.5mm/s 0.5mm/s 
Post-test speed 1 mm/s 10mm/s 10mm/s 
Trigger type Auto Auto Auto 
Trigger force 0.05 N 0.05 N 0.05 N 
Compression strain N/A 40% N/A 
 
3.2.7. Qualitative and quantitative analysis of the crystallinity of the SMX-loaded solid 
dispersions 
The change in the percentage crystallinity of the SMX-loaded solid dispersions compared to the 
native molecules, menthol and SMX, were determined using an X-ray Diffractometer (XRD) 
fitted with a high speed silicon strip detector and operating at 600W X-ray source for high 
resolution scanning (Rigaku Miniflex Guidance 600W, Tokyo, Japan). This characterization test 
was used to determine the change in crystallinity of the native molecules as compared to the 
SMX-loaded solid dispersions. Samples were prepared by weighing ±10mg of lyophilized 
powders and placing them in aluminium sample holders. Each sample ran between an 
operating range of 0-80° 2-theta. Data was captured and analyzed using the Rigaku Powder 
Diffraction Analysis Software (PDXL2). Similarity of diffraction patterns, peak positions and 
percentage crystallinity were determined from the various profiles obtained. 
 
3.2.8. Morphological characterization of the SMX-loaded solid dispersions 
The surface morphology of the SMX-loaded solid dispersions were observed using a Scanning 
Electron Microscope (SEM) (FEI Company, Hillsboro, Oregon, USA) to determine characteristic 
changes in their crystalline and amorphous structures. Samples were fixated on aluminum stubs 
and sputter coated with gold for 60 seconds using a SPI-ModuleTM Sputter Coater (SPI 
Supplies, Structure Probe, West Chester, PA). Samples were then placed in the FEI Phenom™ 
Scanning Electron Microscope operated at 10kV in the electron imaging mode and observed at 
varying degrees of magnification.  
 
3.2.9. Degree of swelling and erosion of the SMX-loaded matrix tablets 
The degree of swelling of the SMX-loaded matrix tablets was determined using the weight gain 
method (Efentakis and Vlachou, 2000). Tablets were weighed initially and placed in 50mL of 
buffer at pH 6.8 over a period of 24 hours. At predetermined time intervals (0, 1, 2, 3, 6, 8, 12, 
16, 24 hours), samples were removed and reweighed to determine changes in swelling. The 
63 
 
degree of swelling at each time interval was determined using Equation 3.2. Erosion studies 
were conducted on the same samples after 24 hours by drying to a constant weight. The 
percentage erosion was calculated using Equation 3.3. 
 %  ∆ 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 =  𝑊𝑊𝑓𝑓−𝑊𝑊𝑖𝑖
𝑊𝑊𝑖𝑖
× 100                                                                                                  (3.2) 
                                  
Where, 𝑊𝑊𝑓𝑓 is the weight of the swollen tablet at time t and 𝑊𝑊𝑖𝑖 is the initial weight of the tablet. 
(N=3). 
 % 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝑆𝑆𝐸𝐸𝑆𝑆 = 𝑊𝑊𝑖𝑖−𝑊𝑊𝑓𝑓
𝑊𝑊𝑖𝑖
 × 100                                           (3.3) 
 
Where, 𝑊𝑊𝑖𝑖 is the initial weight of the tablet and 𝑊𝑊𝑓𝑓 is the final dried weight of the tablets after 24 
hours. (N=3).  
 
3.2.10. Determination of the comparative solubility of SMX and SMX-loaded solid 
dispersions  
The solubility of SMX was determined by separately dissolving 50mg of SMX in 20mL of 
menthol and simulated human intestinal fluid (SHIF) at pH 6.8 maintained at 37±0.5°C with 
constant magnetic stirring (300rpm) for 48 hours. SMX-loaded solid dispersions as listed in 
Table I were similarly dissolved in SHIF (pH 6.8) to determine the change in solubility of the 
solid dispersions as compared to the pure SMX dissolved in simulated intestinal medium. 
Sampling of 3mL was undertaken after 48 hours and the SMX content was determined using a 
UV spectrophotometer, at a wavelength of 271nm (Implen Nanophotometer™, Implen GmbH, 
München, Germany). All samples were filtered using a 0.45μm membrane filter prior to UV 
analysis. 
 
3.2.11.   In vitro drug release from SMX-loaded matrix tablets  
In vitro drug release studies were performed using a USP35 dissolution apparatus II (Caleva, 
Model 7ST, UK). The SMX-loaded matrix tablets were placed in 900mL SHIF at pH 6.8. Each 
tablet was placed beneath a ring mesh assembly within the dissolution vessel to prevent 
floatation. Dissolution was performed at a speed of 50rpm (37±0.5°C). Sampling of 3mL was 
undertaken at predetermined time intervals (0, 1, 2, 3, 6, 8, 10, 12, 16, 24, 48, 56 hours) and 
replaced with an equal quantity (3mL) of drug-free dissolution medium to maintain sink 
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conditions. The quantity of SMX released was determined using a UV spectrophotometer at a 
wavelength of 271nm (Implen Nanophotometer™, Implen GmbH, München, Germany). All 
samples removed were filtered using a 0.45μm membrane filter prior to UV analysis. Drug 
release was calculated as a mean of three determinations as all studies were conducted in 
triplicate. In addition, the mean dissolution time (MDT) (Equation 3.4) was calculated from 
dissolution data to determine the drug release rate (Sathish and Syed, 2013). 
 MDT = ∑ tmid ×∆Mi=ni=1
∑ ∆Mi=ni=1
                                                                                                                   (3.4) 
 
Where, MDT is Mean Dissolution Time; i is the dissolution sample number; n is the number of 
dissolution sample time; tmid is time at mid-point between i and i=1; ΔM is the additional amount 
of drug dissolved between i and i=1. 
 
In addition, the drug release data was fitted into various mathematical modelling equations in 
order to elucidate the mechanism of drug release. 
 
3.3. Results and Discussion 
 
3.3.1. In-process validation analysis of the SMX-loaded solid dispersions and matrix 
tablets 
SMX-loaded solid dispersions were prepared in accordance with the varying concentrations 
listed in Table 3.1. The lyophilized SMX-loaded solid dispersions were successfully formulated 
and produced white, crystalline powders with an average particle size of 110nm with a minimum 
and maximum particle size of 90nm and 200nm, respectively. The powder flow properties of the 
SMX-loaded solid dispersions were determined using the angle of repose and Carr’s 
compressibility index (McGlinchey, 2005). The average Carr’s compressibility index and angle 
of repose of the SMX-loaded solid dispersions were 9.17% and 19.29°, respectively. The 
minimum and maximum values of the solid dispersions for Carr’s compressibility index were 
8.93% and 9.21%, whereas the angle of repose was 18.99° and 19.54°. According to 
McGlinchey (2005), the values obtained indicated excellent powder flow properties as they fall 
within the range of 5-15% for Carr’s  compressibility index and <20° for angle of repose. The 
SMX-loaded matrix tablets were evaluated for uniformity of mass, thickness and friability. All the 
SMX-loaded matrix tablets were uniform in mass, each having an average weight of 
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550±0.5mg. The thickness ranged from 4.5±0.05mm to 5.1±0.03mm while the friability was at 
an average of 0.7% (i.e. within the set limit 1%), demonstrating desirable compressibility and 
resistance to chipping. 
 
3.3.2. Thermal analysis of the SMX-loaded solid dispersions  
SMX and menthol are pure, low molecular weight molecules (<500 g/mol) and thus the onset of 
melting (To) was considered as the melting temperature (Tm) (Gabott, 2008).  In addition, 
between the To and Tp (melting peak) the sample continues to melt (Gabott, 2008). The TMDSC 
thermograms of SMX and menthol are depicted in Figure 3.2a. SMX displayed a single, narrow, 
defined peak with an onset of melting (To) at 169.02°C which corresponded to the melting 
temperature (Tm). The quantity of heat per unit mass that was required to change the SMX from 
a solid to liquid at its melting point was 120.92Jg-1. In contrast, menthol displayed a heat of 
fusion (ΔHm) of 79.62Jg-1 with a melting onset at 37.19°C and a Tp at 40.44°C. The first 
endothermic shift that was noticed for menthol was indicative of the glass transition temperature 
(Tg) at approximately 28.36°C and corresponded to the softening of the menthol (Widmann, 
2000). In addition, another endothermic event was observed in the TMDSC thermogram for 
menthol at a temperature of 205.97°C confirming a phase change (sublimation) since menthol 
has a boiling point of 212°C (Neubert et al., 1997).  
 
On comparison of the TMDSC thermograms of the individual molecules with the SMX-loaded 
solid dispersions, a predictable melting peak was noticeable between 37-40°C for all 
formulations. The first endothermic events for F1-7 (Figure 3.2b) were identical to the peak 
observed for the individual menthol, thus indicating the melting of menthol within these 
formulations. Consequently, the endothermic event between 195.89-216.77°C in F1-7 was 
characteristic of the sublimation of menthol. The reduction in intensity and the shifting of the 
sharp melting peak of SMX in the solid dispersions were noticeable for F1-7. F1-3 (Figure 3.2b) 
displayed melting endotherms similar to the endothermic peak of SMX with a melting 
temperature of 149.24°C, 145.32°C and 150.48, respectively. Analysis of the SMX melting peak 
in F1-7 showed the successive decrease in intensity. This corresponded to the decreased ΔHm 
observed for each of the formulations with F1 showing the highest value (22.68Jg-1), F6 
displaying the lowest value (1.12Jg-1) and F7 showing a complete absence of the drug peak.  It 
was speculated that the decrease in intensity of the SMX peak is attributed to the dissolving of 
SMX within the melted menthol during DSC measurements and as a result distinct endothermic 
peaks corresponding to the melting of menthol was observed (Yamashita et al., 2003; Sinha et 
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al., 2010, Sharma et al., 2013). In addition, the results may indicate that the degree of 
crystallinity was substantially reduced and the SMX was present in an amorphous form within 
the solid dispersion, thus accounting for the reduced intensity and shifting peaks (Yamashita et 
al., 2003; Sinha et al., 2010).  
 
The results obtained for DSC were analogous to existing data that depicted the absence of drug 
peaks in the thermograms of solid dispersions of the poorly water soluble drugs, tacrolimus and 
piroxicam (Tantishaiyakul et al., 1999; Yamashita et al., 2003). This was attributed to its 
dissolution within the melted carrier during DSC measurements and only displayed the 
appearance of an endothermic peak corresponding to the melting of the carrier (Tantishaiyakul 
et al., 1999; Yamashita et al., 2003). 
 
The TGA profiles of SMX and menthol displayed the change in mass of the native molecules as 
a function of temperature (Figure 3.3a). Upon heating the samples, SMX displayed a stepped 
decrease in percentage weight with an initial loss of 21.827% at a temperature of 301.92°C. 
Subsequently, as the temperature increased to 400°C a 50% decrease in sample weight was 
noticed and at the end of the temperature range (894.87°C) only 27% of the sample had 
remained. In contrast, menthol displayed a complete decrease in mass of 99.092% at 194.27°C 
which was attributed to the vaporization of the menthol (Widmann, 2000). The TGA profiles of 
the native molecules were compared to the SMX-loaded solid dispersions and the differences 
were noted (Figure 3.3b). F1 depicted a similar stepped, but significantly larger decrease 
(97.869%) in the mass as compared to SMX. All the other curves were representative of F2-7 
(Figure 3.3b). The curves displayed were characteristically similar to menthol, displaying a 
significant mass loss (± 90%) within the temperature range of 188.30°C-203.85°C. These 
results corresponded to the decreased intensity of the SMX peaks and the prominent menthol 
peaks observed in the TMDSC thermograms. In summary, the concentration of menthol 
contained within each formulation directed the thermal degradation and melting behavior of F1-
7. TMDSC and TGA data confirmed the formation of a solid dispersion. 
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Figure 3.2: TMDSC thermal profiles for a) native SMX and menthol and b) SMX-loaded solid 
dispersions F1-7.  
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Figure 3.3: TGA profiles of a) native SMX and menthol and b) SMX-loaded solid dispersions 
F1-7. 
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3.3.3. Analysis of the ATR-FTIR spectra of the SMX-loaded solid dispersions 
Complete ATR-FTIR split transmittance spectra of menthol and SMX as well as the varying 
concentrations of SMX-loaded solid dispersions listed in Table 3.1 are shown in Figure 3.4 with 
characteristic peaks identified. Sucrose was used as the background spectrum for FTIR 
measurements and was subtracted from the sample spectrum so as to gain information about 
the solid dispersion only. Since menthol is a terpene alcohol it displayed a strong, broad peak at 
3270cm-1 which was indicative of -O-H stretching (Coates, 2000). In addition, absorption due to 
carbon-hydrogen stretching was observed between 2800cm-1 and 2900cm-1. At lower 
frequencies (1375cm-1 to 1470cm-1) menthol displayed carbon-hydrogen bending typical of 
methyl groups present within menthol. The defining peaks of SMX were observed between a 
wavelength of 3000cm-1 to 3500cm-1 and 1200cm-1 to 1500cm-1 which corresponded to –N-H 
and SO2 stretching vibrations, respectively (Coates, 2000).  
 
The distinct bands spanning from 3000cm-1 to 3500cm-1 in solid dispersions F1-3 were 
characteristic of –N-H stretching, identical to those found in SMX. The bands were narrower and 
less intense than –O-H bands of alcohols and phenols and thus diagnostic of primary amide 
groups present (Coates, 2000). A decrease in peak intensity within the wavelength range of 
3100cm-1 to 3200cm-1 was noticeable as the concentration of menthol increased from F1-3, with 
F3 showing the largest decrease in intensity as evidenced by the increased transmittance 
shown in Figure 3.4a). Smaller and more variable peaks appearing within the regions of 
2800cm-1 to 2960cm-1 in the split spectra of F1-3 indicated absorption due to –C-H stretching 
which occurred at the high-frequency end of the spectrum, typically indicating hybridization of 
the carbon (Coates, 2000). The bands were similar to those observed for the native molecule 
menthol, showing absorption peaks at 2918cm-1, 2951cm-1, 2867cm-1 and 2845cm-1.  Strong 
absorption peaks at 1090cm-1 and 1032cm-1 on the F1 spectrum, 1092cm-1 and 1030cm-1 on the 
F2 spectrum, and 1091cm-1 and 1025cm-1 on the F3 spectrum were characteristic of an overlap 
of primary alcohol –C-O stretching vibrations and primary amine –C-N stretching vibrations 
(Coates, 2000). Both the absorption bands were characteristically observed in the spectra for 
menthol and SMX, indicating the presence of both molecules within the solid dispersion. 
 
A pair of split absorption bands centered around 1500cm-1 and 1600cm-1 were present in all 
three spectra (F1-3) and corresponded to –C=C aromatic ring stretching vibrations, indicative of 
the presence of an aromatic ring which is a defining feature of SMX. The distinctive band 
observed at a wavelength of 1594cm-1 for all three spectra F1-3 indicated δ–N-H (amide II band) 
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stretching vibrations (Coates, 2000). Hetero-oxy stretching frequencies were observed within 
the main fingerprint spectral region of 1200cm-1-1470cm-1 in spectra F1-3 with peaks observed 
between the ranges of 1200-1250cm-1 and 1350-1470cm-1 indicating symmetrical and 
asymmetrical SO2 stretching vibrations (Coates, 2000). This confirmed the presence of a 
sulphur group within the three formulations which is a determining feature of SMX.  
 
FTIR absorption spectra of F4-7 had characteristic absorption bands identified which included, a 
broad band spanning from 3200cm-1 to 3600cm-1 which was as a result of the decrease in 
intensity and subsequent disappearance of the –N-H stretching vibrations (characteristic of the 
primary amide of SMX) corresponding to the increased concentrations of menthol from F4-7. 
Consequently, the appearance of the broad band indicated a hydrogen-bonded –OH stretching 
vibration comparable to that of menthol. In addition, the absorption peaks that were smaller and 
more variable within the region 2800cm-1 to 2960cm-1 for F1-3 appeared as strong, distinct 
peaks in the split spectra for F4-7 indicating definite –C-H stretching vibrations (Coates, 2000). 
 
The appearance of a new peak, uncharacteristic from either menthol or SMX, at 1735cm-1 on 
the F4 spectrum, 1745cm-1 on the F5 spectrum, 1745cm-1 on the F6 spectrum, and 1740cm-1 on 
the F7 spectrum indicated –C=O stretching vibrations (Coates, 2000). This strong band 
represented a carboxylic acid derivative and signified intense hydrogen-bonding between the –
OH group of menthol and –C-O group of SMX (Coates, 2000; Stoker, 2013). Although solid 
dispersions F1-3 depicted a peak within this region, the peak was slight and inconspicuous and 
thus its effect was considered unremarkable. Aromatic –C=C ring stretching  and –N-H bending 
vibrations in the regions of 1500-1600cm-1 and 1500-1650cm-1, respectively, were present for 
F4-7 showing decreasing intensities as the concentration of menthol increased. Other typical 
peaks occurred in the range of 1000-1090cm-1 due to –C-O/-C-N overlapping stretch vibrations 
and medium to weak δ–N-H loop bands within the region of 630-800cm-1 for F4-7 (Coates, 
2000). 
 
Comparison of the split transmittance spectra of F1-7 clearly depicted the altered molecular and 
vibrational transitions as the concentration of menthol increased in relation to the constant 
concentration of SMX. F1-3 depicted peaks significantly alike to that of SMX, whereas F4-7 
showed absorption spectrums similar to that of menthol confirming the increased concentrations 
contained within these formulations (Coates, 2000; Stoker, 2013). However, formation of a new 
71 
 
band and appearance of peaks characteristic to both menthol and SMX indicated successful 
combination of the two components in the formation of a solid dispersion (Coates, 2000).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: ATR-FTIR transmittance spectra: a) split spectra of menthol, SMX and SMX-loaded 
solid dispersions F1-3 and b) split spectra of SMX-loaded solid dispersions F4-7. Red blocks 
highlight the –N-H stretching vibrations (primary amide), orange blocks highlight the 
disappearance of the primary amide bond and appearance of an –O-H stretching vibration, 
black blocks indicate –C=O stretching and formation of the strong hydrogen bonding between 
menthol and SMX. 
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3.3.4. Textural profiling of the SMX-loaded matrix tablets 
Textural profiling of the SMX-loaded matrix tablets was performed to determine the MH, MR and 
DE using Force-Time and Force-Distance profiles. MR was calculated in order to determine the 
ability of the matrices to return to their original dimensions after being subjected to a 
compression strain by the textural probe (Pillay and Fassihi, 1999).  The MR decreased from F1 
to F3, corresponding to the decreased hardness and increased concentrations of menthol within 
the SMX-loaded solid dispersions. It was determined that at a consistent strain of 40%, F1 
proved to be the most resilient at 55.42%, compared to the slightly lower resilience percentages 
for F2 (50.04%) and F3 (44.80%) (Figure 3.5a). Results indicated that with higher 
concentrations of menthol, the flexibility of the formulations and its ability to return to its original 
state decreased. Accordingly, this would warrant that F4-7 would have correspondingly lower 
resilience values as compared to F1-3. However, this was not the case as results proved that 
F4 (52.80%) and F7 (57.70%) showed higher resilience values with the latter being the most 
resilient. This deviation was attributed to the formation of a strong hydrogen bond in F4-7 which 
imparted a structural flexibility typical of esters (Johnson, 1999). 
 
MH is a pertinent physicomechanical property essential towards controlling drug release, 
swelling, erosion and matrix stability. In this study, MH was represented as an index of the 
ability of the matrices to resist and overcome adhesive and cohesive forces (deformation). F1 
displayed the greatest hardness with a value of 240.40N.mm2 and correspondingly high 
deformation energy (0.011J), whereas F7 showed a hardness value of 55.67N.mm2 and a 
correspondingly low deformation energy (0.007J). MH decreased accordingly from F1-7 with 
increasing concentrations of menthol, creating relatively softer matrices that were more 
susceptible to matrix deformation.   
 
In addition, matrix rigidity (Figure 3.5b) was elucidated from the Force-Distance profiles of F1-7. 
Analysis of results depicted a predictably high matrix rigidity for F1 (95.08N.mm2) with F2-7 
displaying lower matrix rigidities. The decrease in rigidity was attributed to the distinct formation 
of an ester bond (Figure 3.4b) within subsequent formulations leading to a less rigid structure 
and lower melting point as compared to the corresponding amide band (Figure 3.4a) that was 
characteristic of SMX. In other words, as the concentration of menthol increased from F1-7 it 
resulted in the dampening of the characteristic structural features of SMX, thereby creating 
softer and less rigid structural matrices. 
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Figure 3.5: Graphical representation of the a) MH, MR and b) rigidity of SMX-loaded matrix 
tablet formulations F1-7. Significant differences noticed were F1 which achieved the highest 
matrix hardness (240.40N.mm2) with the lowest concentration of menthol (1g) and F7 achieved 
the lowest matrix hardness (55.67N.mm2) with the highest concentration of menthol (10g). 
 
3.3.5. Analysis of the crystal nature of the SMX-loaded solid dispersions 
The crystallinity of the SMX-loaded solid dispersions were assessed using XRD. All spectrums 
that were obtained displayed to varying degrees, diffraction peaks which were sharp and narrow 
indicating the crystallinity of the test sample with wider and flatter peaks indicating the 
amorphous component. The hydrophilic carrier menthol displayed a crystallinity percentage of 
30% with seven major crystalline diffraction peaks identified (Figure 3.6a). Conversely, the drug 
molecule SMX showed 12% crystallinity with four major crystalline diffraction peaks identified on 
the diffraction spectra (Figure 3.6b). The SMX-loaded solid dispersions were assessed 
according to their percentage crystallinity in relation to the native molecules, menthol and SMX. 
 
F1 (Figure 3.6c) depicted fewer diffraction peaks than menthol and SMX, displaying a high 
intensity Bragg diffraction peak at ±40°2-theta which was uncharacteristic of either menthol or 
SMX. F2 and F3 (Figure 3.6d-e) displayed characteristic Bragg peaks at ±20°2-theta, similar to 
that of SMX, with F2 showing an additional low intensity narrow peak at ±10°2-theta comparable 
to that of menthol. Bragg diffraction peaks were discernable for F4-7 (Figure 3.6f-j) at ±20°2-
theta and ±10°2-theta which was typical of the reference powder diffraction spectrums obtained 
for menthol and SMX. Furthermore, it was apparent that the intensities of the diffraction peaks 
varied with the different concentrations of menthol within each formulation. 
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Figure 3.6: XRD spectra of a) menthol, b) SMX and c-j) SMX-loaded solid dispersions F1-7. 
The diffraction spectrums are represented as a plot of the reflected intensities (cps) as a 
function of the diffraction angle 2-theta (deg). 
 
All the SMX-loaded solid dispersions displayed decreased percentage crystallinities within the 
range of 11-21%. The decrease in the crystallinity observed supports the idea that modification 
of the physical nature of the drug through the formation of solid dispersions decreases the 
crystallinity and thus results in the presence of more amorphous material which has a much 
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higher water affinity and solubility as compared to the crystalline counterpart (Council of Europe, 
2001; Liu et al., 2006; Savjani et al., 2012). The results obtained confirmed the analysis of the 
TMDSC thermograms (Figure 3.2b) and was consistent with the existence of a solid dispersion 
system. Critical analysis of XRD data on solid dispersions of carbamazepine and felodipine 
provided conclusive results on the potential decrease in crystallinity and presence of the 
amorphous state within the solid dispersion (Sethia and Squillante, 2004; Won et al., 2005). 
 
In addition, multivariate experimental techniques were applied to the analysis of the data 
obtained from DSC and XRD in order to comprehensively link the crystallinity data for the solid 
dispersions. Table 3.3 summarizes the crystallinity data obtained for DSC and XRD. The 
melting point decreases in the menthol and SMX peak noted in the solid dispersion 
thermograms in Figure 3.2 were represented in Table 3.3. The decrease in the melting 
temperature for the characteristic menthol and SMX peak indicated the increase in the 
amorphous constituent within the solid dispersions as compared to the crystalline counterpart 
and thus resulted in the easy melting of the formulation at lower temperatures (Yamashita et al., 
2003).  
 
Furthermore, the comparison of the XRD diffraction peaks of the native molecules with the solid 
dispersions depicted a decrease in intensity at the diffraction angles characterized in Table 3.3.  
These broad, low intensity peaks observed in the XRD spectrums of the solid dispersions 
indicated that the formulations were in the amorphous form (Sethia and Squillante, 2004). 
These summarized results further highlighted the expected decrease in crystallinity that is 
typical of solid dispersions (Tantishaiyakul et al., 1999; Sethia and Squillante, 2004). In 
correlating the results obtained for DSC and XRD, it was noted that the solid dispersions of 
SMX and menthol showed a significant decrease in the endothermic peak of SMX with a similar 
broadening and decreased intensity of the peaks derived from SMX in the XRD data (Yamashita 
et al., 2003). This indicated the presence of the amorphous state in all the solid dispersion 
formulations (Yamashita et al., 2003). 
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Table 3.3: Comparative analysis of the crystallinity obtained for DSC and XRD 
Formulation no. 
 
DSC melting points (°C)* XRD diffraction peaks 
 2-theta (deg) 
F1 35.43/149.24  10-20 
F2 35.82/145.32 25-40 
F3 34.74/150.48 9-17 
F4 33.86/145.19 23-34 
F5 33.05/absent peak 30-35 
F6 33.59/absent peak 20-40 
F7 32.60/absent peak 23-43 
* The DSC melting points are indicative of the menthol/SMX melting peak 
 
3.3.6. Surface morphological characterization of the SMX-loaded solid dispersions 
The SMX-loaded solid dispersions were analyzed using SEM and the images obtained are 
depicted in Figure 3.7. F1 displayed largely ordered, regular and distinct crystal forms in the 
SEM images (Figure 3.7a and b). In contrast, F4 (Figure 3.7c and d) depicted particles that 
were more spherical in shape with a less rugged surface structure. Furthermore, F7 (Figure 
3.7e and f) which contained the highest mass ratio of menthol (10g) depicted large, irregular 
smooth surfaces with minimal crystalline regions indicating homogeneity of the formulation. 
Noticeable changes were observed in the surface morphology on comparison of the various 
SMX-loaded solid dispersions. Most distinguishing features noted were the changes from a 
more rigid crystalline structure in F1 to a distinctly amorphous and smooth structure in F7. The 
results obtained corresponded to the decrease in crystallinity in subsequent formulations as 
confirmed by XRD spectra (Figure 3.6). It was deduced that as the concentration of menthol 
increased, the surface morphology displayed characteristically amorphous regions. The 
appearance of amorphous regions within the SEM images confirmed the decrease in 
crystallinity, characteristic to solid dispersions as highlighted in the SEM micrographs obtained 
for the solid dispersions of carvedilol and tacrolimus (Yamashita et al., 2003; Sharma et al., 
2013).  
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Figure 3.7: SEM images at high (left) and low magnifications (right) for (a-b) F1, (c-d) F4 and 
(e-f) F7. 
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3.3.7. Swelling and erosion studies on the SMX-loaded matrix tablets 
Swelling and erosion studies were performed on F1-7 of the SMX-loaded matrix tablets to 
obtain supplementary evidence for the observed drug release kinetics (Figure 3.8). F1 swelled 
to ±140% of its original size in the first hour with a steady increase over the following two hours 
to approximately 170% of the original mass. F2 swelled to approximately 119% of its original 
size in the first 3 hours with both F1 and F2 showing a sharp decrease in swelling after 4 hours 
(Figure 3.8a). The swelling profile obtained for F1 and F2 accounted for the 90% erosion 
obtained after 24 hours. F3 and F4 swelled to approximately 100% and 95% of its original size, 
respectively (Figure 3.8a). Likewise as for F1-2, F3-4 displayed increased erosion percentages 
after 24 hours (Figure 3.8c). The swelling profiles of F1-4 decreased steadily after 
approximately 4 hours while F5-7 steadily increased after 4 hours (Figure 3.8a-b). In addition, 
the erosion percentages for F5-7 was <50% (Figure 3.8c). All formulations displayed different 
swelling profiles regardless of their constant concentration of HPMC. Thus the changes were 
attributed to the varying concentrations of menthol contained in each formulation. 
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Figure 3.8: Profiles depicting (a-b) percentage swelling over a period of 24 hours for F1-7 and 
c) Percentage erosion for F1-F7 as a function of the dried weight of the tablets after 24 hours. 
 
3.3.8. Solubility analysis of SMX and SMX-loaded solid dispersions in SHIF 
The solubility of SMX in menthol as well as SHIF at pH 6.8 was determined and compared to 
the solubility of each of the SMX-loaded solid dispersions in SHIF at pH 6.8. Results indicated 
that the solubility of SMX in menthol at 37°C was 990μg/mL and the solubility of SMX in SHIF at 
pH 6.8 (37°C) was 790μg/mL. These results were compared to the solubility of the SMX-loaded 
solid dispersions (F1-7) which showed a marked increase in solubility as compared to pure SMX 
dissolved in SHIF at pH 6.8. Results depicted only slight differences in the solubility of pure 
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SMX in menthol as compared to the SMX-loaded solid dispersions in SHIF at pH 6.8. F1 
displayed the lowest solubility in SHIF whereas F7 depicted the highest solubility of 
998.75μg/mL and 1241.2μg/mL, respectively (Figure 3.9). F2 showed an approximate 9% 
increase in solubility as compared to F1. The solubility increased steadily from F3-6 with F7 
showing a ±6% increase in solubility as compared to F6. The results displayed in Figure 3.9 
suggested that a proportional increase in solubility was noted with increasing concentrations of 
menthol. F1 and F7 depicted the lowest and highest solubility from all the formulations as they 
contained the lowest (1g) and highest concentrations (10g) of menthol, respectively. The 
increase in solubility of a drug molecule when formulated as a solid dispersion is highlighted 
extensively in literature and is founding characteristic of solid dispersions (Tantishaiyakul et al., 
1999; Yamashita et al., 2003; Sinha et al., 2010; Sharma et al., 2013). 
 
According to Vasconcelos et al., (2007), solid dispersion directed decrease in particle size and 
change to an amorphous state increases the solubility of a drug molecule and thus enhances 
the bioavailability. The association between drug solubility, dissolution and its subsequent 
increase in bioavailability is theoretically described by the Noyes-Whitney Equation 3.5 (Martin, 
1993; Hattori et al., 2013): 
 
𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑
= 𝐷𝐷𝐷𝐷
ℎ
(𝐶𝐶𝑠𝑠 − 𝐶𝐶)                                                (3.5) 
 
Where, M is the mass of solute dissolved in time t; 𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑
 is the mass rate of dissolution 
(mass/time); D is the diffusion coefficient of the solute in solution; S is the surface area of the 
exposed solid; h is the thickness of the diffusion layer; Cs is the solubility of the solid; C is the 
concentration of solute in the bulk solution at time t. 
 
Therefore, according to Noyes-Whitney, an increase in the solubility of a drug molecule would 
correspond to an increased dissolution with subsequent increase in bioavailability (Martin, 
1993). The experimental measurements obtained showed a substantial increase in the solubility 
of the solid dispersions and comparative interpretations were made in relation to the solubility of 
the native molecule in the same dissolution medium.  
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Figure 3.9: Graphical representation of the solubility of SMX-loaded solid dispersions F1-7 in 
SHIF at pH 6.8 (37°C). 
 
3.3.9. In vitro drug release analysis  
In vitro SMX release was performed in SHIF (pH 6.8) and the fractional drug release profiles of 
the SMX-loaded matrix tablets is presented in Figure 3.10. Each formulation demonstrated 
diverse drug release behavior based on their varying solubility. In addition, the formulations 
displayed different time-release profiles. F1 and F2 released drug over a period of 12 hours with 
the maximum release being >50% (Figure 3.10a). F3 and F4 displayed prolonged release over 
16 hours, followed by F5 and F6 which released drug over a period of 48 hours (Figure 3.10b 
and c). F7 displayed the most prolonged drug release over a period of 56 hours (Figure 3.10d).  
 
Noticeable in all the drug release profiles was the burst release which was attributed to the initial 
swelling within the first 3 hours. Despite the decrease in swelling after 4 hours for F1-4 (Figure 
3.8a), the drug release increased accordingly (Figure 3.10a and b). This indicated that the drug 
release in the later phase was erosion-controlled. F5-7 (Figure 3.8b) displayed a more constant 
swelling profile following the initial burst swelling. The swelling profile of F5-7 corresponded to 
the increase in drug release displayed in Figure 3.10c and d. These results suggested that the 
release of SMX from F5-7 was swelling-controlled in contrast to F1-4. Typically, amorphous 
materials display increased erosion as compared to their crystalline counterparts, however, the 
atypical behavior observed was attributed to the distinct ester bond formation within F5-7 
(Figure 3.4) causing  a decreased susceptibility of the solid dispersion to hydrolytic cleavage 
and thus slower erosion as compared to F1-4 (Ratner et al., 2012).  
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Formulations having a higher concentration of menthol, such as F7 (10g), depicted the highest 
fractional release (0.97). This paralleled the increased solubility of F7 which enabled the 
increased dissolution of SMX. On the other extreme, the lowest fractional release (0.71) was 
noticed for formulations that had lower concentrations of menthol such as F1 (1g). Similarly, F1 
had the lowest solubility in SHIF at pH 6.8 (Figure 3.9). Consequently, it was concluded that the 
concentration of menthol used in each formulation impacted significantly on the drug release 
profiles obtained for the SMX-loaded solid dispersions F1-7. The solubility results (Figure 3.9) 
correlated with the drug release profiles (Figure 3.10a, b, c and d) showing that increases in 
solubility from F1-7 displayed correspondingly higher cumulative drug release percentages. The 
improved solubility and dissolution of the solid dispersions was attributed to the amorphization 
of the drug and the reduction in the particle size to the nanometer range. The particle size is 
inherently associated with the solubility of a drug molecule, therefore a reduction in particle size 
leads to an increase in the surface area with a consequently enhanced dissolution profile 
(Sareen et al., 2004). 
 
Since the quantity of HPMC remained constant within each formulation, it was determined that 
menthol served to control the release rate of SMX from each of the SMX-loaded matrix tablets 
by prolonging its release as was evidenced by the mean dissolution time (MDT) obtained for F1-
7. The MDT was used to depict the drug release rate from the SMX-loaded matrix tablets as 
well as the release-retarding ability of menthol (Roni et al., 2009; Wadher et al., 2011). Overall, 
the MDT gave an indication of the rate of the dissolution process (Sathish and Syed, 2013). The 
mean dissolution time at which 80% of drug was released (MDT80) for F7 was 15.044±1.5. This 
was the highest MDT80 from all formulations and it indicated that F7 had a higher drug release 
retarding ability and thus slower release of drug as compared to other formulations. Typically, 
F1 and F2 had the lowest MDT80 of 4.592±0.5 and 5.076±0.5, respectively and as a result the 
fastest release over 12 hours (Figure 3.10a). Thus, it was apparent that the increasing 
concentrations of menthol impacted on the release rate profile and served as a controlling agent 
that retarded drug release from the SMX-loaded matrix tablets.  
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Figure 3.10: Graphical representation of the fractional drug release of SMX from compressed 
matrix tablets F1-7. a) F1-2 releases over a period of 12 hours, b) F3-4 releases over a period 
of 16 hours, c) F5-6 releases over a period of 48 hours and d) F7 releases over a period of 56 
hours. 
 
3.3.10.  Mathematical modeling of drug release profiles 
The drug release profiles of the solid dispersions F1-F7 were fitted into various mathematical 
modeling equations to identify the release mechanism of the drug. The regression coefficients of 
F1-F7 for each of the algorithms are summarized in Table 3.4. The best-fit model for the 
formulations is based on the closeness of the regression coefficient to a value of 1. A model 
depicting a value closest to 1 amongst the formulations would demonstrate the appropriateness 
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of that model in explaining the drug release mechanism. The zero-order and first-order models 
are based on systems where the drug release is independent and dependent on drug 
concentrations, respectively (Singh and Singh, 2011). The zero-order and first-order models 
used are shown in Equation 3.6 and 3.7 (Siepmann and Siepmann, 2008). 
 
𝑄𝑄 = 𝐾𝐾0  𝑡𝑡                                                                                                                                   (3.6) 
 
Where, 𝑄𝑄 is the cumulative amount of drug released; 𝐾𝐾0  is the zero-order constant; t is the time.  
The regression coefficients were elucidated for the zero-order model by plotting a graph of 
cumulative drug release (%) versus time based on in vitro drug release data. 
 ln 𝑄𝑄𝑑𝑑 = ln 𝑄𝑄0 𝐾𝐾0𝑡𝑡                                                  (3.7) 
 
Where, 𝑄𝑄𝑑𝑑 is the cumulative amount of drug released; 𝑄𝑄0 is the initial amount of drug in the 
dissolution medium (usually zero); 𝐾𝐾0 is the first-order constant; t is the time. The regression 
coefficients for the first order model was determined by plotting a graph of the log of cumulative 
release versus time based on data obtained from in vitro drug release. 
  
Since the release of SMX was not concentration dependent it did not fit into the first-order   
release kinetic model as displayed in Table 3.4. Regardless of the nearness to linearity of the 
zero-order model, the results were not ideal and thus was not considered the best-fit model. In 
addition, the drug release data was fitted into the Higuchi model since it has been developed to 
describe the drug release from HPMC-based pharmaceutical delivery systems (Siepmann and 
Peppas, 2012). The Higuchi model is the most commonly used method to describe the release 
rate of drug from a matrix system and is represented by Equation 3.8 (Merchant et al., 2006). 
 
𝑄𝑄 = 𝐾𝐾𝐻𝐻𝑡𝑡1 2⁄                  (3.8) 
 
Where, 𝑄𝑄 is the cumulative amount of drug released; 𝐾𝐾𝐻𝐻 is the Higuchi dissolution constant; t is 
the time. A plot of the cumulative percentage released versus the square root of time of the drug 
release data, generated regression coefficients for the Higuchi model.  
 
Based on the regression coefficients, the Higuchi model displayed the best linearity for majority 
of the formulations with an R2 value of between 0.8497 and 0.9824 indicating that the drug 
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release mechanism was based on a square root of a time dependent process based on Fickian 
diffusion (Yadhav et al., 2013). Despite the Higuchi equation being the best-fit model, further 
mathematical analysis is required to obtain definite mechanistic deductions (Siepmann and 
Peppas, 2012). 
  
Table 3.4: Mathematical modelling of SMX release from the solid dispersions 
 
 
Formulation 
No. 
Zero-order 
 
First order Higuchi  
Regression 
Coefficient (R2) 
Regression 
Coefficient (R2) 
Regression 
Coefficient (R2) 
Best-fit Model 
F1 0.9473 0.8255 0.9795 Higuchi 
F2 0.9295 0.8031 0.9824 Higuchi 
F3 0.7107 0.6008 0.8497 Higuchi 
F4 0.8063 0.6475 0.9372 Higuchi 
F5 0.8693 0.7113 0.9669 Higuchi 
F6 0.8042 0.6201 0.9226 Higuchi 
F7 0.7641 0.5986 0.9079 Higuchi 
 
3.4. Concluding Remarks 
The menthol-based solid dispersions for improvement of the solubility and dissolution of SMX 
were successfully formulated as evidenced by the results obtained from physicochemical and 
physicomechanical characterization. SMX is used to treat various urinary tract pathogens and in 
combination with trimethoprim is considered the “gold standard” in the treatment of urinary tract 
infections (UTIs) (Petri, 2011). Thus, improvement in its solubility and dissolution is critical 
towards achieving optimal therapeutic effects. Characterization results confirmed successful 
formulation of the solid dispersions and its subsequent enhancement of the solubility and 
dissolution of SMX. A reduction in the particle size to the nanometer range for the solid 
dispersions resulted in an increased surface area and thus improved solubility and dissolution. 
Thermal analysis depicted a characteristic decrease in melting point for all the SMX-loaded solid 
dispersions. In addition, a decrease in the crystallinity and corresponding increase in the 
amorphous nature was apparent within the formulations as the concentration of menthol 
increased thus allowing for the increase in the water affinity and solubility of SMX. Results from 
erosion, swelling and solubility studies determined that the varying concentrations of menthol 
present within each formulation controlled the quantity of SMX released over time. The 
physicomechanical properties of MH and MR correlated with changes in crystallinity observed in 
the different formulations of SMX-loaded matrix tablets. Analysis of the molecular and 
vibrational transitions of the SMX-loaded solid dispersions determined the formation of new 
bonds resulting from the interaction between SMX and menthol. Solubility studies indicated the 
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significant intrinsic increase in solubility of SMX as a component of the solid dispersions 
(998.75μg/mL-1241.2μg/mL) as compared to native SMX in SHIF pH 6.8 (790μg/mL). In 
addition, in vitro drug release analysis displayed atypical, controlled drug release profiles for the 
various solid dispersions. This may be extremely useful within an oral drug delivery system 
where the properties of the system can be synchronously enhanced using a customizable solid 
dispersion. Selection of the best solid dispersion may be ascertained based on 
physicochemical, physicomechanical, drug release and release-rate profiles desired to meet the 
needs of the particular drug delivery system. In addition, eutectic, monotectic and peritectic 
transformation may be associated with a matrix solid dispersion system such as the menthol-
SMX combination. However, achievement of these transformations would require further 
investigation and evaluation that would commence with basic phase studies to determine the 
composition at which the menthol-SMX combination would exist as a eutectic mixture.  
 
Ultimately, this study led to the further investigation of menthol as a component in eutectic 
mixtures, evidenced by the design of the eutectic powder blend in Chapter 4.  
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CHAPTER 4 
PRELIMINARY DESIGN OF AN IN SITU CROSS-LINKED EUTECTIC TABLET FOR 
ENHANCED ORAL PROTEIN AND PEPTIDE DELIVERY 
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Abstract 
In the present chapter, a eutectic platform was designed as an In Situ Crosslinked Eutectic 
Tablet for structural protection, enhanced intestinal permeation and controlled release of 
proteins after oral administration. Physicochemical and physicomechanical analysis of the 
Eutectic Tablets were undertaken to elucidate the in situ crosslinking mechanism, thermal 
transitions, crystallinity, ex vivo permeation and in vitro release of the protein. Following thermal 
characterization, results revealed successful eutectic formation with a melting point to 37°C. 
Protein release from the formulation was controlled over 24 hours with a maximum fractional 
release of ±0.8 for all formulations. The release pattern alternated between phases of burst and 
slow release which was attributed to the combined effects of swelling, surface erosion and in 
situ crosslinking. Mathematical modelling of the protein release kinetics corresponded best with 
the Higuchi model with near zero-order (R2≈0.9787) release. The permeation enhancing effect 
of menthol contained within the eutectic powder blend was investigated and results showed an 
enhanced protein flux (0.0576-0.0720mg.cm−2h−1) across the intestinal tissue model compared 
with a control formulation. Extensive in vitro characterization highlighted the successful design 
of the Eutectic Tablets as a potential oral delivery system for proteins with structural protection, 
enhanced intestinal permeation and controlled release. 
 
Keywords: oral protein delivery; bovine serum albumin; controlled release; solid dispersion; 
intestinal absorption; eutectic mixture 
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4.1. Introduction 
Oral drug delivery, particularly tablets, is considered one of the most common and widely used 
routes of drug administration, accounting for approximately 50% of all dosage forms on the 
market (Oh et al., 2013). Tablets are considered safe and cost-effective with desirable physical 
and chemical stability, high levels of patient acceptability and ease of accurate dosing (Al-hilal et 
al., 2013). Despite its many advantages, oral drug delivery can be particularly challenging when 
considering enzymatic degradation of drug molecules within the gastrointestinal tract (GIT), low 
membrane permeability and limited absorption of drugs into the systemic circulation, especially 
for gastro-sensitive biotech drug molecules (Marques et al., 2011). Biotech drug molecules are 
unlike conventional drugs, in that they are biopharmaceutical agents such as proteins and 
peptides that are produced using biotechnology (Schellack, 2010). Owing to their complexity 
and inherent instability, biotech drug molecules are primarily administered parenterally (IV, SC 
or IM) as oral routes of administration may result in its degradation in the GIT (O’ Connor, 
2009).  
 
Therapeutic proteins and peptides have gained increased popularity as molecules of choice for 
multiple disease conditions (Park et al., 2011; Chin et al., 2012). Although significant progress 
has been made in the development of oral delivery systems for proteins and peptides, the field 
is limited by the GIT barrier which acts as a physical and chemical impediment in achieving 
successful oral drug delivery (Donovan et al., 1990; Camenich et al., 1998; Park et al., 2011). 
Pharmaceutical strategies and technologies targeting these limitations are faced with 
continuous challenges, preventing optimal delivery (Park et al., 2011).  To date, this remains an 
active area of research.  
 
The subject of eutectics in polymer-based protein delivery systems has not been fully explored. 
The microstructure that is typical of polymer eutectics still has to be explored as a strategy to 
increase absorption and improve the bioavailability of protein and peptide molecules 
(Tuntarawongsa and Phaechamud, 2012). A eutectic mixture is a physical blend of two 
crystalline components that are completely miscible in the liquid state but to a very limited extent 
in the solid state (Arnikar et al., 1992).  Eutectics have a melting point that is lower than that of 
any of the individual components contained in the mixture (Arnikar et al., 1992; Sharma et al., 
2011). A recent study by Shen et al, (2011) investigated the effects of a borneol/menthol 
eutectic mixture for enhancing the bioavailability in the delivery of a polypeptide (daidzein) used 
for the treatment of breast and colon cancer (Shen et al., 2011). The results from this study 
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depicted the potential use of a eutectic mixture for enhancing the absorption of peptide 
molecules. However, the mechanism of absorption still remains unclear, reflecting no significant 
effect on the efflux of daidzein with the addition of a P-gp inhibitor (Shen et al., 2011). 
 
Therefore, this study focused on the development of an in situ crosslinked eutectic tablet that 
provides an alternative to the parenteral route of administration for sensitive protein and peptide 
molecules. The premise is the design of a core eutectic region within the tablet using eutectic 
reagents and suitable crosslinking agents which structurally protects and ensures controlled 
release of the incorporated protein or peptide molecule. The structural protection is achieved by 
in situ crosslinking within the tablet core, arising from the proposed melting of the core eutectic 
region at body temperature (37°C) and the ingress of fluid into the tablet. In addition, the 
eutectic reagents within the core region of the tablet will enhance the permeation across the 
intestinal tissue. The outer shell of the tablet comprises a porous, fluid-absorbing polymer that 
maintains its characteristic shape and functions as a ‘sponge’ that controls the release of protein 
or peptide molecules from the core. Using a Box–Behnken experimental design approach, a 
series of formulations were synthesized and analyzed using bovine serum albumin as a 
prototype peptide for release and permeation studies. Bovine serum albumin has been widely 
used as a model protein in numerous studies and thus it was selected as a model for this study 
(Kim et al., 2005; Almeida and Suoto, 2007; Muller et al., 2012; Azimi et al., 2013; Zheng et al., 
2014). 
 
4.2. Materials and Methods 
 
4.2.1. Materials 
Menthol(2-isopropyl-5-methylcyclohexanol, 99% purity, MW=156,27g/mol), cetomacrogol 1000, 
poly(ethylene oxide) (PEO) (Polyox™, WSR-303), bovine serum albumin (BSA) (≥96%, agarose 
gel electrophoresis) and excipients, sodium carboxymethylcellulose (CMC), magnesium 
stearate and sucrose were purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA). The 
crosslinker sodium carbonate (NaCO3) was purchased from Associated Chemical Enterprises 
(ACE) (Pty) Ltd. (Johannesburg, Gauteng, South Africa). Pectin citrous (poly-D-galacturonic 
acid methyl ester) and the crosslinker di-potassium hydrogen orthophosphate anhydrous 
(K2HPO4; MW=174.18g/mol) were procured from Merck Chemicals (Pty) Ltd. (Modderfontein, 
Gauteng, South Africa). All other reagents were of analytical grade and were employed as 
received. 
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4.2.2. Synthesis of the lyophilized eutectic powder blend for the core region to the tablet 
The lyophilized eutectic powder melt was synthesized using a co-melt method adapted from 
Arnikar and co-workers, (1992). Menthol and cetomacrogol 1000 were used as the eutectic 
reagents for formation of the eutectic melt in a 3:1 mass ratio.  Menthol was initially melted at a 
temperature of 40±0.5°C by a calibrated magnetic stirrer with hotplate MSH 300 (Boeckel and 
Co., Hamburg, Germany). As soon as the liquid melt was obtained, cetomacrogol 1000 was 
added. Once the solid mass of cetomacrogol 1000 was also melted and homogenously 
distributed within the molten menthol, a 5%w/w concentration of sucrose (as a cryoprotectant) 
was added in equal volume to the eutectic melt. After uniform distribution, the eutectic melt was 
then removed from the heated magnetic stirrer and allowed to cool under constant agitation at 
300rpm for ±30 minutes. The resultant eutectic blend was placed in a freezer at -80°C for 24 
hours before lyophilization (Labconco Freeze-Dry Systems, Labconco Corp., Kansas City, MO, 
USA) for 48 hours to produce a lyophilized eutectic powder melt. Typically, lyophilization 
ensures the sublimation of menthol from the formulation. However, the high concentration of 
cryoprotectant that was added to the eutectic blend was used to protect the menthol from 
freezing and the associated desiccation stresses during the lyophilization process (Thakur and 
Gupta, 2006; Lee et al., 2009; Williams et al., 2012). As a result, excess menthol was absorbed 
onto the cryoprotectant thereby minimizing the processing losses of menthol from the eutectic 
blend. 
 
4.2.3. Formulation of the core eutectic region for the In Situ Cross-linked Eutectic Tablet 
The lyophilized eutectic powder blend together with the crosslinking agents (NaCO3 and 
K2HPO4) were weighed in accordance with a 3-factor Box–Behnken experimental design 
template (Minitab®V15 statistical software, Minitab®Inc., PA, USA) as shown in Table 4.1 (Aslan 
and Cebeci, 2007). The processing parameters included the concentration of crosslinking agent, 
concentration of the eutectic powder blend as well as the quantity of pectin. Functional 
components were weighed and blended with 20mg of BSA before compression at 5 tons using 
a Carver Tableting Press (Wabash, Indiana, USA) to produce a core eutectic tablet (5 x 2.5mm) 
as illustrated in Figure 4.1a. 
 
4.2.4. Formulation of the outer polymer shell of the In Situ Cross-linked Eutectic Tablet 
The bottom and top layers of the outer polymer shell were prepared by measuring and blending 
two separate sets of polymeric powder blends containing 100mg each of PEO, 12mg of CMC, 
1mg of magnesium stearate and specific quantities of pectin as shown in Table 4.1. 
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Table 4.1:  Formulation concentrations generated by the Box-Behnken design. 
Formulation 
No. 
Eutectic Powder 
Blend (%w/w) 
Crosslinkers* 
(%w/w) 
Pectin  
(mg) 
1 12 20 80 
2 12 20 65 
3 18 25 65 
4 18 15 65 
5 18 20 72.5 
6 18 20 72.5 
7 12 15 72.5 
8 18 25 80 
9 12 25 72.5 
10 24 15 72.5 
11 18 20 72.5 
12 24 20 80 
13 24 20 65 
14 24 25 72.5 
15 18 15 80 
*Crosslinker concentrations shown represent the total concentration of crosslinkers (sodium carbonate  
and di-potassium hydrogen orthophosphate anhydrous) added in equal parts (1:1). 
 
4.2.5. Assembly of the In Situ Cross-linked Eutectic Tablet  
A schematic of the Eutectic Tablet is shown in Figure 4.1b-c. The figure expands on the 
previously highlighted schematic represented in Chapter 1. The polymeric powder blend for the 
bottom layer of the outer polymer shell was directly compressed at 2 tons of pressure using a 
Carver Tableting Press (Wabash, Indiana, USA) loaded with punch and dies with a diameter of 
10mm to produce a loosely compressed layer. Subsequently, the core eutectic tablet was 
placed above this layer and centered using the tip of a needle. The polymeric powder blend for 
the top layer of the tablet was added above the core eutectic tablet and levelled out. The punch 
was then inserted and the tablet was compressed at 5 tons of pressure using a Carver Tableting 
Press (Wabash, Indiana, USA) fitted with a flat-faced punch and die (diameter of 10mm) to 
produce the Eutectic Tablet. To minimize processing variables, all tablets were produced under 
identical conditions. 
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Figure 4.1: Schematic representation of the Eutectic Tablet: (a) core eutectic region (b) top and 
bottom layer of the outer polymer shell surrounding the core eutectic region and (c) after 
compression forming a single tablet with proposed in situ crosslinking mechanism (insert). 
 
4.2.6. In-process validation tests on the In Situ Cross-linked Eutectic Tablet and the 
eutectic powder blend 
Uniformity in mass, friability and thickness analyses were undertaken on the eutectic tablets 
while the eutectic powder blend was evaluated for particle size, powder flow properties and 
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physical appearance. A sample of 5 units of each eutectic tablet was analyzed to determine the 
standardization of the tablet-assembly process. The weight of each eutectic tablet was 
determined using an analytical digital balance (Mettler, Model AE 240, Griefensee, Switzerland) 
and the thickness of the eutectic tablets were determined using a digital caliper (25 × 0.01mm 
capacity) (Taizhou hangyu tools gauge and blades Co., Ltd., Wenqiao, Zhejiang, China). The 
friability was determined using a Friabilator (Erweka D-63150, Heusenstamm, Germany) set at 
25 rpm for 4 minutes with 1% set as the upper limit of acceptability. Comparative evaluations of 
flow properties for the eutectic powder melt were determined by measuring the angle of repose 
and the Carr’s compressibility index (McGlinchey, 2005). The average particle size was 
determined by ZetaSizer Nano ZS (Malvern Instruments Ltd., UK). The samples were dispersed 
in 10mL of distilled water prior to filtering (2mL) of the sample through a 0.22μm pore filter into a 
cuvette for Zetasize analysis. 
 
4.2.7. Thermal characterization of the eutectic powder blend and construction of a 
eutectic phase diagram 
Assessment of the thermal transitions was performed on each of the eutectic reagents (menthol 
and cetomacrogol) and the eutectic powder blend to determine characteristic changes in the 
melting temperature by using a Temperature Modulated Differential Scanning Calorimetry 
(TMDSC) (Mettler Toledo, DSC1, STAReSystem, Schwerzenback, Switzerland). Accurately 
weighed samples (10±0.25mg) were placed in perforated 40μl aluminium crucibles which were 
hermetically sealed and ramped between a temperature range of 0-240°C at a constant rate of 
10°C/min with a constant purge of N2. Thermal events of significance included the glass 
transition temperature (Tg), onset of melting (To), melting peak temperature (Tp), heat of fusion 
(ΔHm) and temperature of crystallization (Tc) which was determined for each of the eutectic 
reagents and the eutectic powder blend. Thermogravimetric analysis was used to determine the 
thermal degradation of the eutectic powder blend upon heating. A Thermogravimetric Analyzer 
(TGA) (PerkinElmer TGA 4000, Llantrisant, Wales, UK) was used and 5mg samples were 
weighed and placed in ceramic crucibles. The weights were tarred prior to running the samples 
and were evaluated between a temperature range of 25-900°C at a rate of 10°C/min with a 
constant purge of N2. Furthermore, a phase diagram was constructed by employing the melting 
points of the eutectic reagents and the eutectic powder blend from the TMDSC results 
generated.  
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4.2.8. Characterization of molecular and vibrational transitions of the In Situ Cross-
linked Eutectic Tablet  
Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopy (ATR-FTIR) was used to 
determine the vibrational molecular transitions of the in situ cross-linked outer shell of the tablet 
with the inner core eutectic region. The eutectic tablets were compared with the native 
crosslinkers and polymers as well as an in vitro cross-linked formulation (PEO 1%; 50mg 
sodium carbonate; 50mg di-potassium hydrogen orthophosphate) to acquire important 
microstructural information via comprehensive analysis of the transmittance spectra. Results 
were recorded on a PerkinElmer Spectrum 2000 FTIR spectrophotometer with a single-
reflection diamond MIRTGS detector (PerkinElmer Spectrum 100, Llantrisant, Wales, UK) fitted 
with a universal ATR polarization accessory for the FTIR spectrum series at a resolution of 4cm-
1. Samples were prepared by immersing the prepared eutectic tablets (containing no pectin) in 
50mL of simulated human intestinal fluid (SHIF) pH 6.8 for ±5 hours to allow the process of in 
situ crosslinking. Thereafter, the eutectic tablets were removed from the SHIF and lyophilized 
(Labconco Freeze-Dry Systems, Labconco Corp., Kansas City, MO, USA) for 48 hours. The 
resultant lyophilized eutectic tablets were powdered, placed on a diamond crystal and analyzed 
between a scanning range of 4000-600cm-1 at a constant pressure of 120psi with 32 
accumulations. 
 
4.2.9. Physicomechanical characterization of the In Situ Cross-linked Eutectic Tablet 
The eutectic tablets were analyzed with respect to Matrix Hardness (MH), Matrix Resilience 
(MR) and Deformation Energy (DE) to determine the structural integrity of the eutectic tablets 
formulated. A calibrated Texture Analyzer (TA.XT plus, Stable Microsystems, Surrey, UK) fitted 
with a flat-tipped steel probe (2mm diameter) was used for surface determination of MH and MR 
values of the Eutectic Tablets. Further textural analyses of the eutectic tablets were undertaken 
using a needle-tipped steel probe (2mm diameter) for determination of the MH and DE through 
penetration of the complete thickness of the eutectic tablets. The samples were prepared and 
placed in a Temperature Controlled Peltier Cabinet (XT/PC) coupled to a Peltier Control Unit 
(PCU) (Stable Microsystems, Surrey, UK) for analysis by Texture Analyzer to mimic the internal 
body temperature environment. The Thermal Cabinet was equilibrated to 37°C (body 
temperature) to enable the melting of the core region of the eutectic tablet before testing was 
performed within the cabinet. Data was captured at a rate of 200 points per second using 
Texture Exponent Software (V3.2). MR was computed as a percentage of the ratio between the 
Area under the Curve (AUC) of the peak to baseline (AUC2–3) and the baseline to peak (AUC1–2) 
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from a Force-Time profile. The MH and DE values were both obtained from the gradient and 
AUC of the Force-Distance profiles, respectively. The MH was calculated using the Brinell 
Hardness Number (BHN) (Equation 4.1). Textural analyses on all the eutectic tablets were 
performed in triplicate. The parameters employed for the analysis are listed in Table 4.2. 
 
 BHN =  2F
πD �D−√D2−d2�                                                                                                (4.1) 
 
Where, BHN is Brinell Hardness Number; D is diameter of indenter (mm); F is elucidated from the 
gradient of the initial force and the final force obtained and d is diameter of indentation (mm). 
 
Table 4.2: Textural profiling parameters used for determining the Matrix Hardness, Matrix 
Resilience and Deformation Energy of the eutectic tablets 
Parameters Matrix Hardness Matrix Resilience Deformation Energy 
Pre-test speed 1 mm/s 1 mm/s 1 mm/s 
Test speed 0.5 mm/s 0.5mm/s 0.5mm/s 
Post-test speed 1 mm/s 10mm/s 10mm/s 
Trigger type Auto Auto Auto 
Trigger force 0.05 N 0.05 N 0.05 N 
Compression strain N/A 40% N/A 
*The distance for probe penetration into the tablet was set at 4mm for the needle-tipped steel probe 
 
4.2.10.  Crystallinity characterization of the eutectic powder blend 
The diffraction spectra of the eutectic powder blend was compared to the individual eutectic 
reagents, menthol and cetomacrogol, for determination of the change in the crystallinity. An X-
ray Diffractometer (XRD) fitted with a high-speed silicon strip detector and operating at 600W X-
ray source for high resolution scanning (Rigaku Miniflex Guidance 600W, Tokyo, Japan) was 
used for qualitative and quantitative crystallinity analysis. Samples were prepared by weighing 
±10mg of the eutectic reagents and eutectic powder blend and placing them in aluminium 
sample holders. Each sample ran between an operating range of 0-40° 2-theta. Data was 
captured and analyzed using the Rigaku Powder Diffraction Analysis Software (PDXL2). 
Similarity of diffraction patterns, peak positions and crystallinity were determined from the 
various profiles obtained. 
 
4.2.11. Swelling and erosion studies on the In Situ Cross-linked Eutectic Tablets 
The degree of swelling of the eutectic tablets was determined using the equilibrium weight gain 
method (Efentakis and Vlachou, 2000). The eutectic tablets were weighed initially and placed in 
50mL of simulated human intestinal fluid (SHIF) at pH 6.8 over a period of 24 hours. At 
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predetermined time intervals (0, 1, 2, 3, 6, 8, 12, 24 hours), the eutectic tablets were removed 
and reweighed to determine changes in swelling. The degree of swelling at each time interval 
was determined using Equation 4.2. Erosion studies were conducted on the same samples after 
24 hours by drying to a constant weight. The percentage erosion was calculated using Equation 
4.3. 
 %  ∆ 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 =  𝑊𝑊𝑓𝑓−𝑊𝑊𝑖𝑖
𝑊𝑊𝑖𝑖
× 100                                                                                                  (4.2)       
     
Where, 𝑊𝑊𝑓𝑓 is the weight of the swollen tablet at time t and 𝑊𝑊𝑖𝑖 is the initial weight of the tablet. 
(N=3). 
 % 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝑆𝑆𝐸𝐸𝑆𝑆 = 𝑊𝑊𝑖𝑖−𝑊𝑊𝑓𝑓
𝑊𝑊𝑖𝑖
 × 100                      (4.3) 
 
Where, 𝑊𝑊𝑖𝑖 is the initial weight of the tablet and 𝑊𝑊𝑓𝑓 is the final dried weight of the tablets after 24 
hours. (N=3). 
 
4.2.12. Morphological characterization of the eutectic powder blend 
The surface morphology of the eutectic powder blend was analyzed using a Scanning Electron 
Microscope (SEM) (FEI Company, Hillsboro, OR, USA) to determine characteristic changes in 
its crystalline and amorphous microstructures in relation to the blend of eutectic reagents 
employed. Samples were fixated on aluminum stubs and loose particles were removed by 
spraying with compressed air. Thereafter, the samples were sputter coated with gold for 60 
seconds using a SPI-ModuleTM Sputter Coater (SPI Supplies, Structure Probe, West Chester, 
PA). After coating, the samples were re-sprayed with compressed air and placed in the FEI 
Phenom™ Scanning Electron Microscope operated at 10kV in the electron imaging mode for 
subsequent viewing at varying degrees of magnification.  
 
4.2.13. In vitro protein release studies  
Intrinsic to the functioning of the eutectic tablets was its in vitro protein release performance. In 
vitro protein release studies were performed using a USP35 dissolution apparatus II (Caleva, 
Model 7ST, UK). The eutectic tablets were placed in 900mL SHIF at pH 6.8. Each eutectic 
tablet was placed beneath a ring mesh assembly within the dissolution vessel to prevent 
floatation. Dissolution was performed at a speed of 50rpm (37±0.5°C). Sampling of 3mL was 
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undertaken at predetermined time intervals (0, 1, 2, 3, 6, 8, 10, 12, 24) and replaced with an 
equal quantity (3mL) of drug-free dissolution medium to maintain sink conditions. The quantity 
of intact BSA released was determined using a UV spectrophotometer at a wavelength of 
285nm (Analytik JenaTM, Specord 40, United Scientific Pty., Ltd., South Africa, Natal) (Kim et al., 
2005; Muller et al., 2012; Azimi et al., 2013). All samples removed were filtered using a 0.45μm 
membrane filter prior to UV analysis. Protein release was calculated as a mean of three 
determinations as all studies were conducted in triplicate. In addition, the mean dissolution time 
(MDT) (Equation 4.4) was calculated from dissolution data to determine the protein release rate 
(Sathish and Syed, 2013). 
 
𝑀𝑀𝑀𝑀𝑀𝑀 = ∑ 𝑑𝑑𝑚𝑚𝑖𝑖𝑚𝑚 ×∆𝑑𝑑𝑖𝑖=𝑛𝑛𝑖𝑖=1
∑ ∆𝑑𝑑𝑖𝑖=𝑛𝑛𝑖𝑖=1
                                                                                                          (4.4) 
 
Where, MDT is Mean Dissolution Time; i is the dissolution sample number; n is the number of 
dissolution sample time; tmid is time at mid-point between i and i=1; ΔM is the additional amount 
of protein dissolved between i and i=1. 
 
In addition, the in vitro protein release data obtained were fitted into various mathematical 
modelling equations to determine the mechanism of protein release from the eutectic tablets.  
 
4.2.14.  Ex vivo permeation studies through the Large White Pig intestinal tissue model 
Intermediary ex vivo permeation studies were undertaken using intestinal tissue excised from a 
Large White Pig to determine the permeation-enhancing effects of menthol. The pig was 
euthanized according to standard operating procedures and the intestinal tissue was carefully 
removed. Following removal, the tissue was thoroughly cleaned and appropriately preserved 
until further use. Prior to experimental procedures, the adipose tissue and muscular layers were 
carefully incised to isolate the intestinal epithelium with attached blood vessels. To ensure the 
integrity of the tissue sections throughout the study, the potential difference across the intestinal 
tissue was measured before and after permeation studies. This was performed by passing a 
fixed current across the intestinal tissue sections using a Mettler Toledo Seven Multi GmbH 
Meter (Analytical CH-8603, Schwerzenbach, Switzerland) connected to an electrode that was 
adjusted to isotonic environments by placing the probe into isotonic PBS solution. Thereafter, 
the potential difference was recorded while the tissue was dispersed in distilled water. 
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A Franz Diffusion Cell apparatus (United Scientific Pty., Ltd., South Africa, KwaZuluNatal) 
containing a receptor compartment, donor compartment and membrane platform was the 
apparatus used for determination of the diffusion across the intestinal membrane. The tissue 
samples were incised to fit receptor compartments with a surface area of approximately 1.8cm2. 
The samples for the donor compartment were prepared by immersing the eutectic tablets 
(containing three different concentrations of eutectic powder blend as depicted in Table 4.1) in 
SHIF pH 6.8 over 24 hours until the tablet was completely dissolved. In addition, a tablet was 
prepared without the eutectic powder blend (control) and immersed in SHIF pH 6.8 over 24 
hours until the tablet was completely dissolved. This was done for comparison purposes in 
determining the permeation-enhancing effects of menthol. The resultant solutions with the 
completely dissolved tablets were stirred thoroughly and 2mL samples were removed for the 
donor compartment. Each receptor compartment was filled with 12mL of phosphate buffer 
solution (pH 7.4) to simulate the pH of blood which was further thermoregulated at 37°C by a 
water jacket throughout the study. Receptor compartments were constantly stirred using a 
magnetic stirrer.  
 
The prepared tissues were placed on the membrane platform between the receptor and donor 
compartments of the Franz Diffusion Cell apparatus. At predetermined intervals (0, 1, 2, 3, 6, 8, 
10, 12, 24), 0.1mL of sample was removed from the receptor compartment and replaced with an 
equal amount of fresh phosphate buffer solution. Samples were then evaluated using a UV 
spectrophotometer at a wavelength of 285nm (Analytik JenaTM, Specord 40, United Scientific 
Pty., Ltd., South Africa, Kwa Zulu Natal). Protein-free formulations were used as a 
reference/blank for UV analysis. The values obtained were computed as protein flux across the 
intestinal membrane. The flux (mg.cm−2 h−1) of BSA across the intestinal membrane was 
calculated per unit area by linear regression analysis of permeation data using Equation 4.5. 
 
 𝐽𝐽𝐸𝐸 =  𝑄𝑄𝑄𝑄
𝐴𝐴×𝑑𝑑                                                     (4.5) 
 
Where, Js is the flux of BSA; Qr (mg) is the quantity of drug which permeated across the 
intestinal membrane into the receptor compartment; A (cm2) is the effective cross-sectional area 
that is available for permeation; t (h) is the time of protein exposure to the intestinal tissue 
membrane. 
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4.3. Results and Discussion 
 
4.3.1. Formulation validation of the eutectic powder blend and Eutectic Tablets  
Synthesis of the eutectic powder blend yielded a soft, white, deliquesced powder with an 
average uniform particle size of 142.1nm and a Polydispersitiy Index (PDI) of 0.303. The flow 
properties of the eutectic powder blend was determined using the angle of repose and Carr’s 
compressibility index. The results obtained were atypical for the eutectic powder blend which 
displayed an angle of repose value and Carr’s compressibility index of 70.23° and 4.22%, 
respectively. These results indicated an easily consolidated powder with excellent 
compressibility characteristics18, thus displaying ideal characteristics for this system as it 
allowed for simple moulding and compression of the inner core eutectic region of the tablet. A 
uniformity of mass among the 5 units of each formulated eutectic tablet was displayed. Across 
formulations 1-15, the weight of the eutectic tablets was 500±0.6mg. The thickness was 
4.0±0.5mm while the friability was at an average of 0.6% which was within the set limit of 1%, 
indicating desirable compressibility and resistance to fracture. 
 
4.3.2. Assessment of the thermodynamic behavior of the eutectic powder blend 
Thermal analysis was used to characterize and compare pertinent transitions such as melting, 
glass transitions, phase changes and heat of fusion of the native eutectic reagents and the 
eutectic powder blend in order to determine the change in the melting point that is characteristic 
of eutectic mixtures. The TMDSC thermograms of the eutectic reagents, menthol and 
cetomacrogol, are depicted in Figure 4.2 (a-b). Menthol displayed a distinct melting peak (Tp) at 
40.44°C which indicated the melting temperature (Tm) of the eutectic reagent. The heat per unit 
mass that was required to change the menthol from a solid to a liquid at its Tm was quantified as 
73.55Jg-1. The first endothermic shift from the baseline noticeable in the menthol thermogram 
was indicative of the glass transition temperature (Tg) at 28.45°C, representing the softening of 
the material and melting of the amorphous regions within the menthol (Widmann et al., 2000) 
Continued heating of the menthol resulted in a transition with a distinct loss of weight, confirmed 
by the endothermic boiling point (Tb) peak at 205.97°C (Widmann et al., 2000; Gabbott, 2008). 
The melting temperature of the eutectic reagent cetomacrogol was defined by a Tp at 51.67°C 
and a heat of fusion (ΔHm) of 154.50Jg-1. In addition, cetomacrogrol displayed an onset of 
melting (To) at 46.07°C and an endothermic peak comparable to that of menthol at 36.45° which 
was indicative of the Tg.  
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Assessment of the TMDSC thermograms of the native eutectic reagents in comparison with the 
eutectic powder blend, yielded similar endothermic peaks with a measured decrease in the 
melting point (Figure 4.2c). The eutectic powder blend displayed a Tg at 33°C which incidentally 
corresponded to the onset of melting at 33.62°C. This indicated the change in the amorphous 
region of the eutectic powder blend to a more viscous and liquid-like condition (Widmann et al., 
2000). The eutectic powder blend displayed a shift in the Tp to a lower temperature 37.30°C 
(physiological) and a ΔHm of 9.56Jg-1 which was considerably lower than the Tp and ΔHm for 
either menthol or cetomacrogol. This indicated that less energy was required to convert the solid 
eutectic powder blend to a liquid at its melting temperature (Gabbott, 2008). The Tb for the 
eutectic powder blend was typically lower than that of menthol at 188.01°C, consistent with the 
lower melting temperature. The negligible peaks noticed between 210°C-230°C were artefacts 
resulting from the closing/opening of the crucible pan hole during the sublimation process 
(Gabbott, 2008).  
 
Furthermore, the change in mass of the eutectic reagents and the eutectic powder blend as a 
function of temperature was analyzed from thermogravimetric data obtained (Figure 4.3). TGA 
results displayed clear weight loss of menthol at 199.39°C with only 1.505% of sample 
remaining, following the rapid decrease in the sample weight upon heating at 121.28°C. These 
results obtained for menthol were synonymous with TMDSC data which indicated the boiling of 
menthol at 205.97°C with subsequent evaporation, resulting in sample weight loss. Menthol 
displayed typical thermal decomposition with the formation of gaseous reaction products 
(Widmann, 2001). 
 
Cetomacrogol displayed a similar one-stepped thermal decomposition at 235.73°C and an 
almost complete weight loss at 398.01°C. In contrast, the eutectic powder blend displayed multi-
step decomposition at notable temperatures characteristic of menthol and cetomacrogol. Each 
stepped increase in temperature displayed a 20-25% weight loss with the last step displaying a 
significant 35% weight loss with only 9.651% of sample remaining. 
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Figure 4.2: TMDSC thermograms for a) native eutectic reagent menthol, b) native eutectic 
reagent cetomacrogol and c) eutectic powder blend (menthol: cetomacrogol (3:1)). 
(a) 
(b) 
(c) 
Endo 
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           Peak: 205.97°C 
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Figure 4.3: TGA profiles displaying the main thermal degradation events of the eutectic 
reagents: menthol, cetomacrogol and the eutectic powder melt (menthol: cetomacrogol (3:1)).  
 
Complete thermal analysis was essential in determining pertinent information that supports the 
successful formulation of the eutectic powder blend. The results unmistakably displayed the 
decrease in the melting point of the eutectic powder blend which is a typical feature of eutectic 
mixtures (Widmann et al., 2000). The thermogravimetric analysis provided valuable degradation 
data in support of the TMDSC results generated. The results were further emphasized by the 
formation of a binary phase diagram (Figure 4.4). 
 
4.3.3. Binary phase diagram  
A binary phase diagram (Figure 4.4) was constructed based on the melting points of the eutectic 
reagents and the eutectic powder blend obtained from TMDSC thermograms (Figure 4.2). 
Typically within a eutectic system, the eutectic temperature (Te) is lower than the TmA and TmB, 
the melting point of the pure components A and B (Koningsveld et al., 2001).  The lowest 
temperature at which the liquid phase existed in the menthol-cetomacrogol eutectic powder melt 
system was 37.30°C (lower Tm than either component), occurring in a mixture with a eutectic 
composition of 70% menthol and 30% cetomacrogol. This point on the phase diagram was 
marked as the eutectic point in which the three phases (liquid, solid menthol and solid 
cetomacrogol) coexisted (Martin, 1993). Additional markers that were of importance were the 
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liquidus curve which seperated the entire liquid phase from the liquid-solid phase, the solidus 
curve which separated the complete solid phase from the liquid-solid phase and the liquid and 
solid markers which indicated the complete melt and crystals of A and B, respectively. In 
addition, the effect of the cryoprotectant on the phase behavior of the eutectic powder blend 
was considered to be neglible as it displayed no significant effect on the binary phase diagram 
constructed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4:  Binary phase diagram of the eutectic powder blend displaying the eutectic point of 
the melt containing eutectic reagents A (menthol) and B (cetomacrogol) at a 70%:30% 
composition.  
 
4.3.4. Chemical Structure Integrity Analysis of the In Situ Cross-linked Eutectic Tablets  
The transitions in the chemical structure of the native compound PEO, crosslinkers (NaCO3 and 
K2HPO4) and the eutectic powder blend in comparison to an in vitro crosslinked formulation 
(PEO 1%; 50mg sodium carbonate; 50mg di-potassium hydrogen orthophosphate) as well as 
the eutectic tablets containing varying crosslinker concentrations are displayed in the ATR-FTIR 
split spectra as a function of % transmittance against wavelength (Figure 4.5a-b). The spectra 
for the eutectic tablets are represented as crosslinker concentrations (15%w/w, 20%w/w and 
25%w/w) as all formulations displaying these varying concentrations of crosslinker displayed the 
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same transmittance spectra. The eutectic tablets displayed bands characteristic to all its 
components with a reduction as well as an increase in intensity of certain bands and the 
appearance of new bands, attributed to the in situ crosslinking initiated by the presence of the 
chemical crosslinkers (NaCO3 and K2HPO4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: ATR-FTIR transmittance spectra: a) split spectra of the native compound PEO, 
crosslinkers (NaCO3 and K2HPO4) and the eutectic powder blend and b) split spectra of the In 
Vitro Cross-linked (IVC) formulation (PEO 1%; 50mg NaCO3; 50mg K2HPO4) and the eutectic 
tablets containing 15%w/w, 20%w/w and 25%w/w crosslinker concentrations. In a) highlighted block 
indicates the characteristic sodium carbonate peaks that were observed in the IVC formulation 
and the 20%w/w and 25%w/w formulation concentrations of eutectic tablets. In b) highlighted 
block indicates the formation of a new band.  
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Summative bond designations of the in vitro cross-linked formulation and eutectic tablets are 
displayed in Table 4.3 with distinctive peaks identified in Figure 4.5b. The in vitro cross-linked 
formulation displayed similar peaks to that of the eutectic tablets, indicating successful intra- 
and intermolecular crosslink formation of PEO in situ. In addition, the eutectic tablets displayed 
a broad, low intensity peak at 3248cm-1, indicating the presence of menthol within the 
formulations (Sharma et al., 2013)  
 
Table 4.3: Bond designations for the In Vitro Cross-linked (IVC) formulation and the eutectic 
tablets (15%w/w, 20%w/w and 25%w/w) (Coates, 2000; Sharma et al., 2013).  
Bond origin Group Frequency  Assignment  Appearance 
>CH2 2877-2880cm-1 Aliphatic group, 
Methylene asym/sym 
stretch 
Medium to strong 
↓intensity (20%w/w, 
25%w/w) 
C=O 1595-1643cm-1 Carbonyl group, 
hydrogen-bonded 
carboxylic acid 
stretching 
Medium, new band 
 
CO32- 1453-1465cm-1 (IVC) 
1466cm-1 (15%w/w) 
1428cm-1 (20%w/w) 
1430cm-1 (25%w/w) 
Carbonate ion, in-plane 
and out-of-plane 
bending 
Broad, intense peak 
characteristic of 
sodium carbonate, 
↑intensity (IVC, 20%w/w 
and 25%w/w) 
>CH- 1341/1359cm-1 Aliphatic group, methyl 
bending vibrations 
Sharp, narrow peak, 
↓intensity (15% w/w, 
20%w/w and 25% w/w) at 
1341cm-1/ ↑intensity 
(IVC, 15%w/w, 20%w/w 
and 25%w/w) at 
1359cm-1 
C-O /P=O 1278-1279cm-1 Ethers, stretching 
vibrations/ 
phosphorous-oxy 
compounds, organic 
phosphate stretch 
Two peaks often 
overlapped 
C-H/ P-O-C 940-1058cm-1 Alkene, out-of-plane 
bending/ phosphorus-
oxy compounds, 
aliphatic phosphate 
stretch 
Multiple overlapping  
bands with varying 
intensities, ↓intensity 
(IVC, 20%w/w and 
25%w/w) at 945 cm-1 
CO32- 879-880cm-1 
670-701cm-1 
 
Carbonate ion, in-plane 
and out-of-plane 
bending 
Narrow, weak to 
medium intensity peaks 
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Several bond origins (>CH2, >CH-, C-O, C-H) characteristic to PEO were noticeable in the split 
transmittance spectra for the in vitro crosslinked formulation and the eutectic tablets as 
designated in Table 4.3.  A new peak, uncharacteristic from the polymer or crosslinker entities 
was observed in the formulation spectrums. The peak represented a C=O stretching vibration, 
characteristic of hydrogen-bonded carboxylic acids indicating crosslinks formed between PEO, 
NaCO3 and K2HPO4. Formulations containing a 20%w/w crosslinker concentration displayed the 
lowest transmittance (75.05%) for the new peak, suggesting an increased intensity and stronger 
bond formation. A characteristic sodium carbonate peak was observed between a frequency 
range of 1428-1466cm-1 for all formulations which resulted in the dwarfing of the narrow, low 
intensity peak of PEO for the in vitro crosslinked formulation and the eutectic tablets (20%w/w 
and 25%w/w). Disappearance of the native peak for PEO at 1413cm-1 for the in vitro cross-linked 
formulation and eutectic tablets (20%w/w and 25%w/w) was attributed to macromolecular 
interactions and substantiated the formation of the distinguishing sodium carbonate peak. 
 
Furthermore, carbonate ion bending was characterized by new bands at the lower end of the 
spectrum between 879-880cm-1 and 670-701cm-1 for the in vitro cross-linked formulation and 
eutectic tablets (20%w/w and 25%w/w) (Coates, 2000; Sharma et al., 2013). Typically, the first 
absorption for carbonate ions is broad and intense and the second absorption is narrow with a 
weak to medium intensity as was evidenced by the results obtained (Coates, 2000). The 
influence of K2HPO4 in the crosslinking process was evidenced by the overlapping organic (P=O 
conjugation) and aliphatic (P-O-C conjugation) phosphate stretching vibrations characterized in 
Table 4.3. The crosslinking process is expected to create an interpenetrating cross-linked 
interface in situ between the core region of the eutectic tablet and the outer shell, facilitating a 
controlled release rate and protection of the incorporated protein or peptide. 
 
Evidentiary results from ATR-FTIR molecular and vibrational transitions confirmed the in situ 
crosslinking within the eutectic tablets which was further supported by its comparativeness to 
the in vitro cross-linked formulation. The in vitro crosslinked formulation containing 20%w/v of 
crosslinker displayed transmittance peaks identical to the eutectic tablets containing 20%w/w of 
crosslinker. Formulation concentrations of 15%w/w were the lowest concentrations and displayed 
lower crosslinking ability as was demonstrated by the lower intensity of some peaks and 
absence of other peaks which were present in eutectic tablets containing 20%w/w and 25%w/w. In 
contrast, a 25%w/w crosslinker concentration displayed higher intensities for some peaks, 
however medium intensities were observed for the new bands as compared to a 20%w/w. 
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Consequently, a 20%w/w concentration of crosslinker was considered the optimal crosslinking 
concentration as it displayed higher intensities for the new bands indicating improved 
conjugation and superior crosslinking ability.  
 
4.3.5. Quantification of the physicomechanical behaviour of the In Situ Cross-linked 
Eutectic Tablets 
The physicomechanical behavior of the eutectic tablets was characterized with respect to MH, 
MR and DE in response to compressive and penetrative forces applied. The MH, MR and DE 
were quantified from Force-Time and Force-Distance profiles obtained for surface and core 
tablet textural profiling. Typical Force-Time and Force-Distance profiles for surface and core 
tablet textural profiling is displayed in Figure 4.6a-b. The force for the calculation of MH was 
determined from the steepness of the upward gradient of the Force-Distance profile up to the 
primary fracture point (between anchors 1 and 2). The initial gradient represented by the slight 
increase in force indicates a low resistance to adhesive and cohesive forces and thus a reduced 
strength matrix (Pillay and Danckwerts, 2002). Consequently, the steeper secondary gradient 
indicates an increased resistance to deformation and thus harder matrix. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Typical Force-Time and Force-Distance profiles generated from: a) compressive 
force and b) penetrative force. 
(a) 
(b) 
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The MH is a critical textural parameter that influences the drug release, swelling, erosion and 
stability of the tablet matrices. The surface hardness of the eutectic tablets was calculated and 
the results are presented in Figure 4.7. F9 displayed the greatest hardness value of 
227.76N.mm2 which corresponded to the lowest concentration of eutectic powder blend and 
highest crosslinker and pectin concentration (Table 4.1) within the eutectic tablet. The lower 
concentrations of eutectic powder melt with higher crosslinking concentrations create core 
eutectic tablets that are somewhat harder. In addition, the pectin contained within the outer shell 
of the tablet provides a degree of structural hardness due to its good compressibility and 
flowability and thus accounts for the greater hardness values obtained. Formulations containing 
higher concentrations of eutectic powder blend (F10, F12, F13 and F14) displayed lower 
hardness values, representative of relatively softer matrices with low resistance to deformation. 
The core matrix hardness was determined using a needle-probe which penetrated the full 
thickness of the tablet. Since the measurements for the core matrix hardness was determined in 
a temperature-controlled cabinet set at 37°C to mimic physiological temperature, the predictable 
melting of the core eutectic powder blend was inevitable as emphasized by TMDSC results in 
Figure 4.2. The melting of the core eutectic region created softer core matrices for the eutectic 
tablets (Figure 4.7a). F1-F15 displayed significantly lower hardness values for the core matrix 
as compared to the surface matrix of the eutectic tablets.  
  
The ability of the eutectic tablets to return to their original state after being subjected to a 
compression force was computed as the MR (Figure 4.7b) (Pillay and Fassihi, 1999). The 
corresponding MR in response to a compression strain of 40% was measured for F1-F15. F7 
demonstrated the highest resilience value (60.54%) while F10 displayed the lowest resilience 
(39.27%). These values corresponded to lower and higher and concentrations of eutectic 
powder blend, respectively. This indicated that with higher concentrations of eutectic powder 
blend, the flexibility of the formulation decreased due to the softer matrices. However, this was 
not the case for all formulations and results indicated comparatively good resilience values 
around the median of 50%.  
 
Typically, in the characterization of tablets, high values for matrix hardness and resilience are 
considered optimal. Nevertheless, the results obtained for the eutectic tablets reflect the 
proposed aim of the formulation and as such is considered ideal. The softer matrices of the core 
eutectic region at 37°C was the ultimate goal for facilitating in situ crosslinking. The surface 
matrix hardness and resilience was acceptable in providing suitable structural integrity. 
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Nonetheless, the results obtained does not reflect the process of in situ crosslinking which will 
provide a structural flexibility, improved hardness and higher fracture energy with improved 
resistance to cohesive and adhesive forces.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Graphical representation of textural analysis results of the eutectic tablets depicting: 
a) surface and core matrix hardness (N.mm2) and b) matrix resilience (%). 
 
4.3.6. Crystallinity analysis of the eutectic powder blend through qualitative and 
quantitative assessment  
The spectrum for the eutectic powder blend was compared to the XRD spectra for eutectic 
reagents menthol and cetomacrogol (Figure 4.8).  Typically, crystalline components appear as 
sharp and narrow peaks on the XRD spectrum stemming from the ordered and regular 
arrangement of the atoms. In contrast, the amorphous parts appear as flat and broad peaks 
reflecting the random and disordered arrangement of atoms. Following this, the eutectic 
reagents (menthol and cetomacrogol) were considered to be crystalline as they displayed sharp, 
narrow peaks with high intensities. In contrast, the eutectic powder blend displayed broad, low 
intensity peaks indicative of the presence of amorphous material. These differences in the 
eutectic powder blend were attributed to the increased concentration of menthol within the 
formulation which imparted an amorphous element. The formation of eutectic mixtures typically 
results in a decrease in crystallinity and the presence of more amorphous material with a higher 
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water affinity and improved solubility at all temperatures below the melting point of the mixture 
(Liu et al., 2006; Qui et al., 2009). Thermal analysis results further supports the XRD data 
obtained for the eutectic powder melt as the decrease in the melting point corresponded to the 
increase in the amorphous content within the eutectic powder blend which subsequently 
decreased the crystallinity and confirmed the presence of a eutectic system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: XRD spectra: a) eutectic reagent menthol, b) eutectic reagent cetomacrogol and c) 
eutectic powder blend (menthol: cetomacrogol/3:1) as a function of the reflected intensities (cps) 
versus the diffraction angle 2-theta (deg).  
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4.3.7. Assessment of the swelling and erosion behavior of the In Situ Cross-linked 
Eutectic Tablets 
The swelling and erosion of the eutectic tablets were analyzed by monitoring the change in 
weight over a predetermined period of time. All formulations displayed increased swelling over 
24 hours as was evidenced by the swelling profiles obtained in Figure 4.9 (a-c). The porous 
nature of the polymeric material PEO contained within the outer polymer shell was a major 
contributing factor towards the high water uptake observed for F1-F15. The PEO created pores 
within the eutectic tablets which facilitated increased water uptake when the tablet came into 
contact with the dissolution medium and thus ultimately affected the rate and extent of swelling 
observed (Vlachou et al., 2001; Ahuja and Pathak, 2009). F1-F15 swelled to ±1000% of its 
original mass over 24 hours with initial high water uptakes producing swelling behavior ranging 
between 150-250%  
 
Another major determinant of the swelling behavior is the degree of crosslinking that occurs 
(Pillay and Danckwerts, 2002). A higher degree of crosslinking decreases the overall swelling 
capacity as was evidenced by the results obtained. F7 displayed the highest swelling 
percentage (1354%) and correspondingly contained a lower concentration of crosslinker 
(15%w/w). Likewise, F8 depicted the lowest swelling percentage (1053.93) with a higher 
concentration of crosslinker (25%w/w). These results indicated that the swelling behavior was 
directly proportional the concentration of crosslinker contained within the formulations. All other 
formulations displayed similar results depending on the concentration of crosslinker contained 
within the eutectic tablet.               
 
The erosional behavior of the tablets was influenced by the different concentration of pectin 
present within each eutectic tablet. This was demonstrated by the results obtained in Figure 
4.9d which showed F1 as having an understandably higher erosion percentage (53.97%) as it 
contained 80mg of pectin as compared to the 65mg of pectin contained within F13 which 
showed a 20% lower erosion percentage of 33.96%. Overall, the results calculated for erosion 
of the tablets after 24 hours for all formulations were centered around a median value of 50% 
which indicated relatively controlled, surface erosion. The tablets maintained its characteristic 
shape after 24 hours and as a result achieved the proposed objective.  The swelling and erosion 
behavior was influenced by the porosity and crosslinking capabilities which in turn influenced 
the dissolution and rate of drug release in controlled release systems (Vlachou et al., 2001) 
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Figure 4.9: Profiles depicting: (a-c) percentage swelling over a period of 24 hours for F1-F15 
and d) percentage erosion of the eutectic tablets F1-F15 as a function of the dried weight of the 
tablets after 24 hours. 
 
4.3.8. Analysis of the surface morphologies of the eutectic powder blend 
The morphological characteristics of the eutectic powder blend and the native eutectic reagents, 
menthol and cetomacrogol, were analyzed using SEM. The images obtained before and after 
eutectic formation are shown in Figure 4.10 (a-c). The SEM images for the eutectic reagents 
before eutectic formation displayed large, irregular and sharp crystal forms as illustrated in 
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Figure 4.10 (a-b). However, upon analysis of the eutectic powder blend after formation at 
eutectic composition, distinct changes in the morphological structure were noted. The particles 
appeared to be more consistent in shape with almost spherical, smooth surface edges as 
compared to the rugged surface structure of the eutectic reagents (Figure 4.10c). The 
homogeneity of the eutectic powder blend was reflected in the images difficulty to isolate single 
drug crystals. The change in morphological structure from crystalline (before eutectic formation) 
to amorphous (after eutectic formation) was demonstrated in the SEM images obtained. The 
images obtained are characteristic to the formation of eutectic mixtures and incidentally mirror 
the results obtained for XRD (Figure 4.8) which displayed a phase change from crystalline to 
amorphous. 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: Scanning electron micrographs at ±2700x magnification showing the eutectic 
reagents before eutectic formation: a) cetomacrogol b) menthol and after eutectic formation c) 
eutectic powder blend at eutectic composition (menthol: cetomacrogol/3:1). 
 
4.3.9. In vitro protein release analysis  
In vitro release experiments were conducted in SHIF (pH 6.8) in order to obtain the protein 
release patterns of BSA from the eutectic tablets F1-F15. Since the active is assembled within 
the eutectic powder blend, the eutectic reagents would be expected to display release profiles 
corroborating with that of the active and thus was not investigated separately. All formulations 
displayed similar release patterns over the 24 hour period with variations in the crosslinkers, 
eutectic powder blend and pectin concentrations influencing the drug release patterns that were 
observed (Figure 4.11a-c). All formulations displayed controlled release over the 24 hour period. 
The protein release profiles displayed an initial burst release after 1 hour (0.128). This reflected 
the initial high swelling capacity of all the formulations after 1 hour as displayed in the swelling 
profiles shown in Figure 4.9. The following two hours displayed a slower release of BSA which 
(a) (b) (c) 
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corresponded to only slight changes in the swelling capacity. This was attributed to the 
formation of the crosslinked interface in situ which decreased the water uptake and swelling 
capacity and subsequently controlled the release of protein. The protein release pattern after 3 
hours displayed phases of slow release and burst release up to 24 hours. This was attributed to 
the combined effects of swelling, surface erosion and in situ crosslinking. The amorphous 
nature of the eutectic powder blend resulted in the diffusion of the protein out of the matrix 
network producing an enhanced dissolution and fractional release up to ±0.8. The eutectic 
powder blend and its decrease in particle size to the nanometer range (142.1nm) facilitated the 
enhanced dissolution due to the increase in surface area. In addition, the mean dissolution time 
(MDT) was used to represent the protein release rate from the eutectic tablets and provided 
supplementary evidence of the ability of in situ crosslinking in controlling the release rate (Roni 
et al., 2009; Wadher et al., 2011). Formulations containing 20%w/w of crosslinker displayed an 
MDT50 ranging from 5.2-6.5 which was higher than the MDT50 obtained for formulations that 
contained 15%w/w of crosslinker. This indicated that the higher crosslinking ability imparted by 
the increased concentration of crosslinker served to control the protein release and thus 
displayed a slower release rate. Ultimately, the MDT gave an indication of the rate of the 
dissolution process (Sathish and Syed, 2013).  In addition, the porosity of the outer polymer 
shell may have influenced the protein release rate from the eutectic tablets and this was 
noticeably apparent in the initial burst release observed with an increase in swelling after 1 hour. 
Based on the results obtained, it was evident that the protein release was influenced by the 
swelling and erosional behavior, crosslinking concentrations and amorphous nature of the 
eutectic powder blend.  
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Figure 4.11: Fractional release of BSA from eutectic tablets: a) formulations 1-5, b) 
formulations 6-10 and c) formulations 11-15. 
 
4.3.10. Mathematical modelling of protein release profiles 
The protein release profiles were fitted into various kinetic algorithms and the data obtained is 
shown in Table 4.4. The best-fit model for the protein release data observed was based on the 
kinetic modelling of the regression coefficients and its proximity to the numeral 1. A model 
depicting a value closest to 1 amongst the formulations would demonstrate the appropriateness 
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of that model in explaining the protein release mechanism. The zero-order and first-order 
models are based on systems where the protein release is independent and dependent on 
protein concentrations, respectively (Singhvi and Singh, 2011). The zero-order and first-order 
models used are shown in Equation 4.6 and 4.7 (Siepmann and Siepmann, 2008). 
 
𝑄𝑄 = 𝐾𝐾0  𝑡𝑡                                                                                                                                   (4.6) 
 
Where, 𝑄𝑄 is the cumulative amount of protein released; 𝐾𝐾0  is the zero-order constant; t is the 
time. The regression coefficients were elucidated for the zero-order model by plotting a graph of 
cumulative protein release (%) versus time based on in vitro protein release data. 
 ln 𝑄𝑄𝑑𝑑 = ln 𝑄𝑄0 𝐾𝐾0𝑡𝑡                                                  (4.7) 
 
Where, 𝑄𝑄𝑑𝑑 is the cumulative amount of protein released; 𝑄𝑄0 is the initial amount of protein in the 
dissolution medium (usually zero); 𝐾𝐾0 is the first-order constant; t is the time. The regression 
coefficients for the first order model was determined by plotting a graph of the log of cumulative 
release versus time based on data obtained from in vitro protein release. 
 
The protein release profiles obtained for the eutectic tablets F1-F15 did not fit into the first-order   
release kinetic model as displayed in Table 4.4 and thus indicated that the release was not 
concentration dependent. Controlled release, multilayered tablet systems typically display zero-
order or near zero-order release with a constant release of protein over time (Yadhav et al., 
2013). Since the eutectic tablets displayed almost phased release with alternating slow and 
burst release of protein (Figure 4.11a-c), the regression coefficients depicted a near zero-order 
release of between 0.8041 and 0.9356. In addition, the protein release data was fitted into the 
Higuchi and Korsmeyer–Peppas kinetic modeling equations to obtain the overall best-fit model 
for all the eutectic tablets F1-F15 (Yadhav et al., 2013). 
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Table 4.4: Mathematical modelling of BSA release from the eutectic tablets 
 
 
Formulation 
No. 
Zero-order  
 
First order Higuchi Korsmeyer–
Peppas 
 
Regression 
Coefficient (R2) 
Regression 
Coefficient (R2) 
Regression 
Coefficient (R2) 
Regression 
Coefficient (R2) 
Best-fit Model 
F1 0.8388 0.6362 0.9264 0.924 Higuchi 
F2 0.8744 0.8364 0.9502 0.9512 Korsmeyer–
Peppas 
F3 0.8627 0.7082 0.9519 0.9245 Higuchi 
F4 0.8041 0.7109 0.9007 0.9229 Korsmeyer–
Peppas 
F5 0.8431 0.6549 0.9427 0.9263 Higuchi 
F6 0.8471 0.6729 0.948 0.9296 Higuchi 
F7 0.8768 0.7366 0.9614 0.9695 Korsmeyer–
Peppas 
F8 0.9356 0.7781 0.97 0.9496 Higuchi 
F9 0.9107 0.7976 0.9422 0.9356 Higuchi 
F10 0.8141 0.6677 0.9061 0.949 Korsmeyer–
Peppas 
F11 0.8410 0.6767 0.956 0.9378 Higuchi 
F12 0.8732 0.7719 0.9655 0.967 Korsmeyer–
Peppas 
F13 0.9238 0.8049 0.9782 0.9489 Higuchi 
F14 0.9117 0.8111 0.9757 0.9686 Higuchi 
F15 0.8579 0.5709 0.9487 0.907 Higuchi 
 
The Higuchi model describes the release of protein from a matrix as a function of the square-
root of a time-dependent process based on Fickian diffusion and the equation is represented by 
Equation 4.8 (Merchant et al., 2006). 
 
𝑄𝑄 = 𝐾𝐾𝐻𝐻𝑡𝑡1 2⁄                  (4.8) 
 
Where, 𝑄𝑄 is the cumulative amount of protein released; 𝐾𝐾𝐻𝐻 is the Higuchi dissolution constant; t 
is the time. A plot of the cumulative percentage released versus the square root of time of the 
protein release data, generated regression coefficients for the Higuchi model. The Korsmeyer–
Peppas modeling equation (Equation 4.9) was used to describe the protein release mechanism 
from a polymeric system. 
 
 
𝑄𝑄𝑡𝑡
𝑄𝑄∞
= 𝐾𝐾𝑑𝑑𝑛𝑛                     (4.9) 
 
 
Where, 𝑄𝑄𝑡𝑡
𝑄𝑄∞
 is the cumulative amount of protein released per time t; 𝐾𝐾 is the rate constant; n is 
the release exponent. The regression coefficient was obtained by plotting a graph of the log of 
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cumulative release (first 60% of protein release data) versus the log of time of the protein 
release data. 
 
Based on the regression coefficients, the Higuchi model displayed the best linearity for majority 
of the formulations with an R2 value of between 0.9007 and 0.975 indicating that the protein 
release mechanism was based on Fickian diffusion. Although, the Korsmeyer–Peppas model 
displayed the best-fit for some formulations, limitations exist as the power law gives limited 
insight into the exact protein release mechanism (Siepmann and Peppas, 2012). Thus, the 
protein release kinetics corresponded best with the Higuchi model with near zero-order protein 
release obtained. 
 
4.3.11. Analysis of the ex vivo permeation through the Large White Pig intestinal tissue 
model 
Menthol is widely used as a flavouring and fragrance enhancer in oral and topical dosage forms 
with the major benefit of its use being its safety profile (FDA, 1973; Williams and Barry, 1991; 
Kommuru et al., 1998; Shojaei et al., 1999; Shen et al., 2011). However, its applicability as a 
permeation enhancer for transdermal and transbuccal drug delivery has been widely reported 
(FDA, 1973; Kommuru et al., 1998; Shojaei et al., 1999; Shen et al., 2011).  Thus, its effect on 
intestinal permeation as part of the Eutectic Powder Blend (EPB) was investigated. Results of 
protein flux obtained from permeation studies are displayed in Figure 4.12. Eutectic tablet 
formulations containing 12%w/w, 18%w/w and 24%w/w of EPB were compared to a tablet that was 
EPB-free. The results demonstrated the increased permeation of the formulations containing the 
EPB as compared to the EPB-free formulation which displayed a maximum protein flux of 
0.0289mg.cm−2 h−1 as compared to the EPM-containing formulations which displayed a protein 
flux between 0.0576-0.0720mg.cm−2h−1. In addition, it was noted that the permeation-enhancing 
effect of menthol was independent of the concentration of EPB contained within the eutectic 
tablets as they displayed similar protein flux results. Overall, the results proved that the menthol 
contained within the eutectic tablets as part of the EPB facilitated the permeation of BSA across 
the intestinal tissue model.  To ensure that the tissue maintained its integrity throughout the 
study, the transepithelial potential difference across the intestinal tissue was measured before 
and after permeation studies. The results (before permeation: 118.1mV; after permeation: 
116.1mV) displayed only slight differences in potential difference which indicated that the 
viability of the tissue was maintained (Söderholm et al., 1998; Ehrhardt and Kim, 2007; Antunes 
et al., 2013; Sarmento, 2015). 
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Figure 4.12:  Ex vivo permeation profiles of the BSA-loaded tablets comprising; a Eutectic 
Powder Blend (EPB)—free tablet, EPB-12%w/w, EPB-18%w/w and EPB-24%w/w.  
 
4.3.12. Constraint optimization and response surface analysis of the eutectic tablets  
Statistical optimization using a Box-Behnken design model was used to optimize the eutectic 
tablets. The design program generated responses from the results of each formulation to 
ascertain the ideal combination of eutectic powder blend, crosslinkers (NaCO3 and K2HPO4) and 
pectin required capable of attaining desirable MDT, swelling and erosion efficiencies. Minitab® 
V15 statistical software was used for the generation of the optimal responses as depicted by the 
plots in Figure 4.13. According to the predictions of the statistical design, the optimal tablet that 
would permit a desirable MDT, swelling and erosion would comprise concentrations of 
23.093%w/w (115.47mg) of crosslinkers (NaCO3 and K2HPO4), 12%w/w (60mg) of eutectic powder 
blend and 65.313mg of pectin. Response surface analysis plots were obtained using Minitab® 
V15 statistical software. The plots represented the functional relationship between the 
experimental design variables and the responses achieved. A maximal swelling, erosion and 
MDT value is favoured at the optimal concentrations of the design variables as shown in Figure 
4.13a. Notable interaction effects from the swelling response surface plots (Figure 4.13b) 
indicated that higher concentrations of crosslinker and EPB produced a lower swelling capacity. 
Alternatively, the erosion response surface plots (Figure 4.13c) revealed that higher 
concentrations of the surface-eroding agent (pectin) and correspondingly higher concentrations 
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of the crosslinking agents (NaCO3 and K2HPO4) produced a predictably greater erosion 
percentage. In addition, MDT was best promoted at higher concentrations of pectin and 
crosslinking agents as shown in Figure 4.13d.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13: Statistical optimization of the eutectic tablets: (a) desirability plots depicting the 
variables for producing a eutectic tablet with the desired targeted responses and response 
surface plots depicting the effects of variables on (b) percentage of swelling, (c) percentage of 
erosion and (d) mean dissolution time. 
 
4.4. Concluding Remarks 
The in situ cross-linked eutectic was designed for the purpose of creating an advanced oral 
delivery system for therapeutic proteins and peptides. Thus, it was essential that the design of 
the tablet overcame the barriers that enabled successful oral protein/peptide delivery. 
Physicochemical and physicomechanical characterization tests confirmed eutectic formation as 
was evidenced by the lowering of the melting point, the decreased crystallinity and the shift in 
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the SEM images to an amorphous structure. FTIR results highlighted the presence of in situ 
crosslinking within the core eutectic region (facilitated by the proposed melting of the core at 
37°C). Physicomechanical profiling displayed a decrease in the tablet hardness upon 
penetration into the core of the tablet due to the melting of the core eutectic region. The in vitro 
protein release behavior was influenced by the combined effects of swelling, surface erosion, in 
situ crosslinking and the amorphous nature of the eutectic powder blend. The amorphous 
transformation of the eutectic powder blend is an important tool in influencing the ADME profile 
of protein and peptide molecules. Due to the phased release of protein from the system, the 
protein release mechanism was based on Fickian diffusion and displayed near zero-order 
release. The permeation-enhancing effects of menthol was evident by the enhanced protein flux 
(0.0576-0.0720mg.cm−2h−1) obtained as compared to the control formulation (0.0289mg.cm−2 h−
1). Thus, it can be concluded that physicochemical and physicomechanical characterization that 
was undertaken was essential for delineating the in vitro attributes, optimizing the formulation 
variables, predicting the in vivo performance of the device and demonstrating the applicability of 
the design in improving the oral delivery of a multitude of proteins and peptides. 
 
The preliminary design of the In Situ Cross-linked Eutectic Tablet, discussed in this chapter, and 
its subsequent optimization led to the formation of the optimized Oral Core-Melt Tablet (OCMT) 
which will be extensively characterized in Chapter 5. 
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CHAPTER 5 
PHYSICOCHEMICAL AND PHYSICOMECHANICAL EVALUATION OF THE STATISTICALLY 
OPTIMIZED ORAL CORE-MELT TABLET (OCMT) 
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Bibi F. Choonara, Yahya E. Choonara, Pradeep Kumar, Lisa C. du Toit, Viness Pillay.  In Vitro and In 
Vivo Evaluation of a Novel Oral Core-Melt Tablet (OCMT). 
 
 
Abstract 
A complex polymer-eutectic platform was optimized as an Oral Core-Melt Tablet (OCMT), 
producing a novel oral controlled release system for the delivery of gastro-sensitive therapeutic 
proteins and synthetic peptides. Physicochemical and physicomechanical characterization 
techniques were undertaken to determine the rheological properties, in situ crosslinking 
mechanisms, porositometric evaluations, imagery and in vitro peptide release from the OCMT. 
The inherent transitions observed in the Fourier Transform Infrared Spectroscopy spectrums 
confirmed the presence of in situ crosslinking, facilitated by the porous structure promoting the 
ingress of fluid into the OCMT. This was corroborated with MRI which highlighted the device 
hydration over 24 hours as a significant predictor of the in vitro peptide release profile. The in 
vitro release of the peptide was influenced by the combined effects of swelling, surface erosion 
and in situ crosslinking, displaying a fractional release up to ±0.8. Owing to the complexity of the 
system, the mechanism of release was attributable to both the zero-order (R2=0.95) and Higuchi 
models (R2=0.98). Conclusive results from extensive in vitro characterization emphasized the 
applicability of the optimized OCMT in providing a controlled release alternative system capable 
of delivering peptides orally. 
  
Keywords: oral peptide delivery; octreotide; controlled release; eutectic powder blend; 
physicochemical properties; physicomechanical properties 
 
 
 
 
 
131 
 
5.1. Introduction  
Therapeutic proteins and peptides have become the front-runner in the treatment of multiple 
diseases conditions, significantly dominating research studies in the pharmaceutical industry 
(Park et al., 2011; Chin et al., 2012). This widespread interest has catapulted into the design of 
sophisticated pharmaceutical technologies primarily focused on achieving successful oral 
delivery of proteins and peptides (Park et al., 2011). The oral route of delivery, despite its 
numerous challenges, still remains the preferred route of delivery as compared to its 
conventional injectable counterpart (Park et al., 2011).  
 
The pragmatic design of the OCMT which has been previously highlighted, proposed the 
incorporation of an in situ crosslinked core eutectic region that structurally protects the 
incorporated protein or peptide and ensures controlled release (Choonara et al., 2016). The 
statistical design of the OCMT formulations and their corresponding responses was a critical 
factor in determining the ideal combinations of variables to produce an optimized OCMT 
(Choonara et al., 2016). The functional ability of the OCMT to deliver on its proposed 
characteristics was demonstrated using Octreotide as the incorporated therapeutic active. 
 
Octreotide is a synthetic octapeptide, similar to the naturally occurring somatostatin, responsible 
for inhibiting Growth Hormone (GH), insulin, glucagon and various other pituitary and 
gastroenteropancreatic hormones (Chen et al., 2000; Jabarian et al., 2012). Somatostatin’s 
clinical effectiveness is impeded by its short plasma half-life (1-3 min) and as a result its 
analogue, octreotide, has been found to be the most effective option thus far for the treatment of 
acromegaly and neuroendocrine tumors (Tuvia et al., 2012). However, octreotide has a major 
shortcoming with regards to its therapeutic use as it requires frequent and daily subcutaneous 
or intravenous injections resulting from rapid enzymatic degradation in plasma (Chen et al., 
2000).  
 
Several approaches have been investigated to eliminate the inconvenience and discomfort 
associated with frequent subcutaneous dosing with the most successful formulation being the 
intramuscular depot injection system (Jabarian et al., 2012). No clinically useful oral octreotide 
formulation has been approved despite the numerous approaches that have been explored. 
Thus, the need to create a therapeutically active oral octreotide formulation still remains an 
active area of research for the pharmaceutical industry. 
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Evaluation of the distinct properties of the optimized OCMT is essential in determining its ability 
to produce the desired therapeutic response both in vitro and in vivo. Prior to commencing with 
in vivo studies, it is of paramount importance that extensive in vitro analysis is undertaken to 
determine the effects of the physicochemical and physicomechanical properties on the peptide- 
release behavior and overall performance of the device. Thus, this study primarily focused on 
the overall pertinent characteristics of the optimized OCMT by undertaking various studies such 
as; swelling and erosion to determine the swelling capabilities and peptide-release mechanism, 
Fourier Transform Infrared Spectroscopy studies to determine the chemical structure 
composition, Textural Analysis to determine the tablet’s mechanical properties, Porosity and 
Magnetic Resonance Imaging to determine the morphology and physical structure of the OCMT 
and, in vitro pharmacokinetic analysis to determine the peptide-release profile. 
 
5.2. Materials and Methods 
 
5.2.1. Materials 
Menthol (2-isopropyl-5-methylcyclohexanol, 99% purity, MW=156,27g/mol), cetomacrogol 1000, 
poly(ethylene oxide) (PEO) (Polyox™, WSR-303) and excipients, sodium 
carboxymethylcellulose (CMC), magnesium stearate and sucrose were purchased from Sigma-
Aldrich Corp. (St. Louis, MO, USA). The crosslinker sodium carbonate (NaCO3) was purchased 
from Associated Chemical Enterprises (ACE) (Pty) Ltd. (Johannesburg, Gauteng, South Africa). 
Pectin citrous (poly-D-galacturonic acid methyl ester) and the crosslinker di-potassium hydrogen 
orthophosphate anhydrous (K2HPO4; MW=174.18g/mol) were procured from Merck Chemicals 
(Pty) Ltd. (Modderfontein, Gauteng, South Africa). Octreotide acetate (C49H66N10O10S2; 
Mw=1019.247g/mol) was purchased from Bolon Pharmachem Co., Ltd. (Taizhou, Zheijang, 
China). All other reagents were of analytical grade and were employed as received. 
 
5.2.2. Fabrication of the optimized OCMT 
The responses from a 3-factor Box–Behnken experimental design of the eutectic tablets 
generated an ideal combination of components that would produce the desired responses 
shown in Figure 5.1. The optimized OCMT comprised an outer polymer shell surrounding a core 
eutectic region. The core eutectic region of the tablet consisted of a compressed combination of; 
a Eutectic Powder Blend (EPB) that was prepared by a co-melt method in a 3:1 mass ratio of 
menthol: cetomacrogol, crosslinking agents (NaCO3 and K2HPO4) and 20mg Octreotide. The 
outer polymer shell consisted of a top and bottom layer each containing a polymeric blend of 
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100mg each of PEO, 12mg of CMC, 1mg of magnesium stearate and the optimum 
concentration of pectin as shown in Figure 5.1. Detailed methods on the synthesis of the EPB 
and formulation of the core eutectic region and outer polymer shell have been previously 
described in Choonara et al, (2016). 
 
The OCMT was assembled by directly compressing the polymeric powder blend of the bottom 
layer at 2 tons of pressure using a Carver Tableting Press (Wabash, Indiana, USA) loaded with 
punch and dies with a diameter of 10mm to produce a loosely compressed layer. Subsequently, 
the core eutectic tablet was placed above this layer and centered using the tip of a needle. The 
polymeric powder blend for the top layer of the tablet was added above the core eutectic tablet 
and levelled out. The punch was then inserted and the tablet was compressed at 5 tons of 
pressure using a Carver Tableting Press (Wabash, Indiana, USA) fitted with a flat-faced punch 
and die (diameter of 10mm) to produce the optimized OCMT. To minimize processing variables, 
all tablets were produced under identical conditions. 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Optimized formulation ID for the OCMT displaying desired targeted responses.  
 
5.2.3. In-process validation of the optimized OCMT  
Weight uniformity, thickness and friability analyses were performed on the optimized OCMT. A 
sample of 5 units of the OCMT was analyzed to determine the standardization of the tablet-
 High       25%w/w                24% w/w                 80.0 mg 
 Opt      [23.093%w/w]       [12%w/w]           [65.3139 mg] 
 Low        15%w/w                12%w/w              65.0 mg 
[NaCO3 and 
K2HPO4] 
[EPB] [Pectin] 
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assembly process. The weight of the OCMT was determined using an analytical digital balance 
(Mettler, Model AE 240, Griefensee, Switzerland) with readings recorded to 2 decimal places. 
The thickness of the OCMTs were determined using a digital caliper (25 × 0.01mm capacity) 
(Taizhou hangyu tools gauge and blades Co., Ltd., Wenqiao, Zhejiang, China). The friability was 
determined using a Friabilator (Erweka D-63150, Heusenstamm, Germany) set at 25 rpm for 4 
minutes with 1% set as the upper limit of acceptability. The friability was calculated as 
percentage loss using Equation 5.1. 
 
𝑊𝑊𝑊𝑊𝑑𝑑  = (𝑊𝑊0−   𝑊𝑊𝑡𝑡)𝑊𝑊0  × 100                                                                                                               (5.1) 
 
Where, WLt  is the total weight loss; W0 is the initial weight of the tablet and Wt is the final weight 
of the tablet. 
 
5.2.4. Rheological characterization of the eutectic powder blend 
Pertinent rheological properties such as the viscosity (η), storage (elastic) modulus (G’) and loss 
(viscous) modulus (G”) of the eutectic powder blend was determined using a Haake Modular 
Advanced Rheometer System (MARS) (ThermoFisher Scientific, Karlsruhe, Germany). Samples 
were placed on a sample plate fitted with a C35/1° titanium rotor sensor. Measurements were 
performed employing the rheological parameters shown in Table 5.1. Dynamic oscillatory 
temperature ramp measurements were performed from 25 to 45°C, at ramp rates of 1°C/min at 
an optimal frequency of 1 Hz. 
 
Table 5.1: Rheological parameters employed for the analysis of the EPB 
Parameter  Value 
Cone and plate gap 0.050mm 
Driver version 1.29 
Inertia 1.721 x 10-6 kg.m2 
A-factor 89051.00 Pa/Nm 
M-factor 57.010 (1/s)/((rad/s) 
Temperature 25°C-45°C 
Damping 30.00 
 
5.2.5. Chemical structure analysis of the optimized OCMT 
Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopy (ATR-FTIR) was used to 
determine the vibrational molecular transitions between the outer polymer shell of the OCMT 
with the inner core eutectic region following simulated in situ crosslinking. FTIR analysis was 
135 
 
conducted on the OCMT, the native crosslinkers and polymers as well as an in vitro crosslinked 
formulation (PEO 1%; 50mg sodium carbonate; 50mg di-potassium hydrogen orthophosphate) 
to acquire important microstructural information and provide validation of successful in situ 
crosslinking processes. Results were recorded on a PerkinElmer Spectrum 2000 FTIR 
spectrophotometer with a single-reflection diamond MIRTGS detector (PerkinElmer Spectrum 
100, Llantrisant, Wales, UK) fitted with a universal ATR polarization accessory for the FTIR 
spectrum series at a resolution of 4cm-1. Samples were prepared by hydrating the optimized 
OCMTs (containing no pectin) in simulated human intestinal fluid (SHIF) pH 6.8 for ±5 hours to 
simulate in situ crosslinking. Following the removal and lyophilization (Labconco Freeze-Dry 
Systems, Labconco Corp., Kansas City, MO, USA) of the OCMTs, the tablets were powdered 
and placed on a diamond crystal for analysis between a scanning range of 4000-600cm-1 at a 
constant pressure of 120psi with 32 accumulations. 
 
5.2.6. Evaluation of the swelling and erosion of the optimized OCMT 
The mean percentage swelling and erosion of the OCMT was determined by gravimetric 
analysis of the degree of swelling and erosion over a 24-hour period. The initial weight of the 
optimized OCMT was recorded prior to being placed in 50mL of SHIF pH 6.8 for 24 hours. At 
predetermined time intervals (0, 1, 2, 3, 6, 8, 12, 24 hours) the OCMTs were removed and 
blotted dry to remove surface water before being weighed on a calibrated electronic scale. The 
percentage increase in tablet weight, attributed to fluid uptake at each time point was 
determined using Equation 5.2. The erosion of the matrix, following its drying to a constant 
weight at each time interval was calculated using Equation 5.3. 
 % ∆ 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 =  𝑊𝑊𝑓𝑓−𝑊𝑊𝑖𝑖
𝑊𝑊𝑖𝑖
× 100                                                                                                  (5.2)       
 
Where, 𝑊𝑊𝑓𝑓 is the weight of the swollen tablet at time t and 𝑊𝑊𝑖𝑖 is the initial weight of the tablet. 
(N=3). 
 % 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝑆𝑆𝐸𝐸𝑆𝑆 = 𝑊𝑊𝑖𝑖−𝑊𝑊𝑓𝑓
𝑊𝑊𝑖𝑖
 × 100                                         (5.3) 
 
Where, 𝑊𝑊𝑖𝑖 is the initial weight of the tablet and 𝑊𝑊𝑓𝑓 is the final dried weight of the tablets after 24 
hours. (N=3). 
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5.2.7. Water content determination of the optimized OCMT employing Karl-Fischer 
analysis (KF) 
The optimized OCMT was analyzed using a Karl Fischer volumetric titrator (Mettler Toledo V30 
Volumetric KF Titrator, Mettler Toledo Instruments Inc., Greifensee, Switzerland) with a DN143-
SC electrode sensor attachment. The control parameters that were used in the volumetric KF 
titration are shown in Table 5.2. 
 
Table 5.2: Control parameters used for KF volumetric analysis 
Parameters 1-Comp titrant 
Sensor Ipol [μA] 24 
Stirrer speed [%] 35 
End point [mV] 100 
Control band [mV] 400 
Dosing rate (min) [μL/min] 80 
Dosing rate (max) [mL/min] 5 
Start Normal 
Driftstop relative [μg/min] 15 
 
Methanol was used as the moisture standard and water was quantified using electrical 
conductivity. Weighed samples were placed in the solvent holder and analysis was performed 
until the titration endpoint was reached. The water content determination was based on the Karl 
Fischer chemical reaction proposed by Scholz, E. (1982) as shown in Equation 5.4.  
𝑅𝑅𝑅𝑅𝑅𝑅 + 𝑆𝑆𝑅𝑅2 + 3𝑅𝑅𝑅𝑅 + 𝐼𝐼2 + 𝑅𝑅2𝑅𝑅 → (𝑅𝑅𝑅𝑅𝑅𝑅) ∙ 𝑆𝑆𝑅𝑅4𝑅𝑅 + 2(𝑅𝑅𝑅𝑅𝑅𝑅)𝐼𝐼                                                      (5.4) 
 
5.2.8. Correlative in vitro and ex vivo mucoadhesive strength determination of the 
optimized OCMT 
Mucoadhesive studies were performed for the optimized OCMT to determine the influence of 
the outer polymer shell on the amount of mucoadhesion provided by the OCMT. The in vitro 
mucoadhesive strength determination study involved the preparation of 0.1%w/v solution of 
mucin in SHIF pH 6.8. The optimized OCMT was incubated in this solution in an orbital shaker 
maintained at 37˚C and 50 rpm. The concentration of free mucin in the solution, after 6h 
duration, was determined by a UV spectrophotometer, at 201nm (IMPLEN NanophotometerTM, 
Implen GmbH, München Germany), using a 10 times dilution factor of path-length 0.1 mm. The 
difference in the concentration of the mucin solution before and after incubation was the 
indication of the amount crosslinked with the outer polymer shell as seen in Equation 5.5 (He et 
al., 1998). 
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Mucoadhesion% = [Mucin before]−[Mucin after][Mucin before] × 100                                                                    (5.5) 
 
Where, [Mucin before] is the concentration of the mucin solution before incubation and [Mucin 
after] is the concentration of the mucin solution after incubation. 
 
In addition, a Texture Analyzer (TA.XT plus, Stable Microsystems, Surrey, UK) was used to 
determine the ex vivo bioadhesivity of the OCMT. A mucoadhesion rig provided a vessel of a 
temperature-controlled (37°C) intestinal fluid and mucin environment for the pig intestinal tissue 
set-up. The OCMT was slightly hydrated in SHIF and attached to a cylindrical probe of the 
mucoadhesion rig using double-sided bioadhesive tape. The probe with attached OCMT was 
lowered at a constant speed of 0.1mm/s and bonded with the mucin-coated tissue at a 
predetermined compression force (0.08N) for a period of 120s. After the contact time, the probe 
withdrew at a constant speed (0.1mm/s) from the intestinal tissue and the adhesive properties 
were measured. A Force-time and Force-Distance profile was obtained and the tensile stress 
and work of adhesion were calculated using Equation 5.6 and 5.7 (Cevher et al., 2008). 
 Tensile stress (N. cm2) = F
πr2
                                        (5.6) 
 
Where, F is the detachment force and 𝜋𝜋𝐸𝐸2 is the surface area of the OCMT. 
 Work of adhesion (mJ. cm2) = AUCF−D
πr2
                                   (5.7) 
 
Where, AUC is the area under the curve of a Force-Distance profile and 𝜋𝜋𝐸𝐸2 is the surface area 
of the OCMT. 
 
5.2.9. Determination of the surface and core matrix hardness, matrix resilience and 
deformation energy of the optimized OCMT 
The physicomechanical properties of the optimized OCMT was assessed through textural 
profiling using a calibrated Texture Analyzer (TA.XT plus, Stable Microsystems, Surrey, UK) 
fitted with a 5kg load cell, for determination of Matrix Hardness (MH), Matrix Resilience (MR), 
Deformation Energy (DE) and rigidity. A flat-tipped steel probe (2mm diameter) was used for 
surface determination of MH and MR values of the OCMT. Further textural analyses of the 
OCMT were undertaken using a needle-tipped steel probe (2mm diameter) for determination of 
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the MH and DE through penetration of the complete thickness of the OCMT. The samples were 
prepared and placed in a Temperature Controlled Peltier Cabinet (XT/PC) coupled to a Peltier 
Control Unit (PCU) (Stable Microsystems, Surrey, UK) for analysis by Texture Analyzer to mimic 
the internal body temperature environment. The Thermal Cabinet was equilibrated to 37°C 
(body temperature) to enable the melting of the core region of the OCMT before testing was 
performed within the cabinet. Data was captured at a rate of 200 points per second using 
Texture Exponent Software (V3.2). MR was computed as a percentage of the ratio between the 
Area under the Curve (AUC) of the peak to baseline (AUC2–3) and the baseline to peak (AUC1–2) 
from a Force-Time profile as shown in Equation 5.8.  
 Resilience % = �Area 2:3
Area 1:2� × 100                                                                                                 (5.8) 
 
The DE and matrix rigidity were both obtained from the AUC and gradient of the Force-Distance 
profiles, respectively. The MH was calculated using the Brinell Hardness Number (BHN) 
(Equation 5.9). Textural analysis on the OCMT was performed in triplicate. The parameters 
employed for the analysis are listed in Table 5.3. 
 
 BHN =  2F
πD �D−√D2−d2�                                                                                                (5.9) 
 
Where, BHN is Brinell Hardness Number; D is diameter of indenter (mm); F is elucidated from the 
gradient of the initial force and the final force obtained and d is diameter of indentation (mm). 
 
Table 5.3: Textural profiling parameters used for determining the Matrix Hardness, Matrix 
Resilience and Deformation Energy of the OCMT 
Parameters Matrix Hardness, Deformation 
Energy & matrix rigidity 
Matrix Resilience 
Pre-test speed 1 mm/s 1 mm/s 
Test speed 0.5 mm/s 1mm/s 
Post-test speed 1 mm/s 1mm/s 
Trigger type Auto Auto 
Trigger force 0.05 N 0.05 N 
Compression strain N/A 40% 
*The distance for probe penetration into the tablet was set at 4mm for the needle-tipped steel probe 
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5.2.10. Porositometric analysis of the OCMT 
The surface porositometric analysis of the optimized OCMT was performed using a 
Porositometric Analyzer (Micrometritics ASAP 2020, Norcross, GA, USA). Quantifiable aspects 
of the OCMTs surface area, pore diameter, total pore volume and bulk and absolute densities 
were determined. Samples were prepared by placing the optimized OCMT in SHIF pH 6.8 for 4 
hours to allow the outer polymer shell to interact with the simulated fluid. Thereafter, the 
samples were removed and lyophilized (Labconco Freeze-Dry Systems, Labconco Corp., 
Kansas City, MO, USA) to expel excess fluid. The lyophilized samples were treated with a heat 
gradient and were evacuated with Nitrogen gas (N2) for the removal of surface moisture and gas 
particles. Samples were then weighed and inserted into sample tubes for degassing. The 
degassing parameters were set up and included evacuation and heating phases as shown in 
Table 5.4. 
 
Table 5.4: Evacuation and heating phase parameters employed for porositometric analysis 
Parameter Rate/Target 
Evacuation Phase  
Temperature ramp rate 10°C/min 
Target temperature 40°C 
Evacuation rate 50.0mmHg/s 
Unrestricted evacuation from 30mmHg 
Vacuum set point 500μmHg 
Evacuation time 60 min 
Heating Phase  
Temperature ramp rate 10°C/min 
Hold temperature 30°C 
Hold time 1320min 
 
Following complete degassing (21 hours), the sample tube was transferred to the analysis port 
where the Barrett, Joyner and Halenda (BJH) and Brunauer-Emmett-Teller (BET) adsorption 
and desorption relationships were subsequently generated. The determination of the surface 
area was based on the BET gas adsorption theory which is a widely used standard for porous 
materials (Singh et al., 1985). The BET equation was used in the linear form as shown in 
Equation 5.10. 
 
𝑝𝑝
𝑛𝑛𝑎𝑎 ∙ (𝑝𝑝𝑜𝑜−𝑝𝑝) = 1𝑛𝑛𝑚𝑚𝑎𝑎 ∙ 𝐶𝐶  + (𝐶𝐶−1)𝑝𝑝𝑛𝑛𝑚𝑚𝑎𝑎 ∙ 𝐶𝐶 𝑝𝑝𝑜𝑜                                                                                                (5.10) 
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Where, 𝑆𝑆𝑎𝑎  refers to the quantity of N2, 𝑝𝑝𝑝𝑝𝑜𝑜 refers to the relative pressure, 𝑆𝑆𝑚𝑚𝑎𝑎  was the monolayer 
capacity and C was exponentially related to the enthalpy of adsorption in the first adsorption 
layer. 
 
The total and specific surface area was determined from the monolayer capacity using Equation 
5.11 and 5.12, respectively. 
 
𝐴𝐴𝑠𝑠 (𝐵𝐵𝐸𝐸𝑀𝑀) = 𝑆𝑆𝑚𝑚𝑎𝑎 ∙ 𝑊𝑊 ∙ 𝑎𝑎𝑚𝑚                          (5.11)  
 
𝑎𝑎𝑠𝑠(𝐵𝐵𝐸𝐸𝑀𝑀) = 𝐴𝐴𝑠𝑠  (𝐵𝐵𝐸𝐸𝑀𝑀)/𝑚𝑚                                                                                 (5.12)    
 
Where, 𝐴𝐴𝑠𝑠 (𝐵𝐵𝐸𝐸𝑀𝑀) and 𝑎𝑎𝑠𝑠(𝐵𝐵𝐸𝐸𝑀𝑀) are the total and specific areas, respectively, of the adsorbent of 
mass (m) and 𝑊𝑊 is the Avogadro constant. 
 
5.2.11. Surface structure morphology of the outer polymer shell of the optimized OCMT 
The surface morphology of the outer polymer shell was analyzed using a Scanning Electron 
Microscope (SEM) (FEI Company, Hillsboro, OR, USA). Samples were prepared by placing the 
optimized OCMT in SHIF pH 6.8 for 4 hours to allow the outer polymer shell to interact with the 
simulated fluid. Thereafter, the samples were removed and lyophilized (Labconco Freeze-Dry 
Systems, Labconco Corp., Kansas City, MO, USA) to expel excess fluid. The lyophilized 
samples were fixated on aluminum stubs and loose particles were removed by spraying with 
compressed air. Thereafter, the samples were sputter coated with gold for 60 seconds using a 
SPI-ModuleTM Sputter Coater (SPI Supplies, Structure Probe, West Chester, PA). After coating, 
the samples were re-sprayed with compressed air and placed in the FEI Phenom™ Scanning 
Electron Microscope operated at 10kV in the electron imaging mode for subsequent viewing at 
varying degrees of magnification to determine the surface architectures and qualitatively 
determine the shape and size of the porous outer polymer shell. 
 
5.2.12. Magnetic Resonance Imaging (MRI) of the optimized OCMT 
Magnetic Resonance Imaging (MRI) was undertaken in SHIF (pH 6.8) to monitor the fate of the 
dosage form in vivo and correlate it with the in vitro behavior. Live-acquisition of the pH- 
responsive transitions of the OCMT was determined using a digital MARAN-i System configured 
with a DRX2 HF Spectrometer console (Oxford Instruments Magnetic Resonance, Oxon, UK) 
equipped with a compact 0.5 Tesla permanent magnet and stabilized at 37°C. The dynamics of 
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fluid ingress into a drug delivery system is a contributing factor towards controlling drug release 
(Tajiri et al., 2010). The hydrational morphological transitions of the OCMT were captured every 
5 min with MARAN-i version 1.0 software. MARAN-i software comprises image acquisition 
software and image analysis software. The image acquisition parameters are depicted in Table 
5.5. 
 
Table 5.5: MARAN-i image acquisition parameters employed for magnetic resonance imaging 
S.No. Parameter Value 
1. Imaging protocol FSHEF 
2. Requested gain (%) 4.17 
3. Signal strength 68.92 
4. Average 2 
5. Matrix size 128 
6. Repetition time (ms) 1000.00 
7. Spin Echo Tau (ms) 6.80 
8. Image acquired after 60min 
9. Total scans 64 
 
T1 weighted images were produced in the spin echo method and the signal intensity of the MRI 
images were defined according to Equation 5.13.  
 
𝑆𝑆 = MO + exp −TET2  × �1 − exp −TRT1 �                                (5.13) 
 
Where, MO is magnetization, T1 and T2 are relaxation times, TR is repetition time and TE is echo 
time. 
 
5.2.13. In vitro peptide release 
Intrinsic to the functioning of the OCMT was its in vitro peptide release performance. In vitro 
peptide release studies were performed using a USP35 dissolution apparatus II (Caleva, Model 
7ST, UK). The OCMT was placed in 900mL SHIF at pH 6.8, beneath a ring mesh assembly 
within the dissolution vessel to prevent floatation. Dissolution was performed at a speed of 
50rpm (37±0.5°C). Sampling of 3mL was undertaken at predetermined time intervals (0, 1, 2, 3, 
6, 8, 10, 12, 24) and replaced with an equal quantity (3mL) of peptide-free dissolution medium 
to maintain sink conditions. Samples were analyzed using a Peptide Enzyme Immunoassay 
(Peninsula Laboratories International, Inc. San Carlos, CA, USA) which is a high sensitivity 
absorbance assay specific for the detection of Octreotide.  Prior to sample analysis a standard 
curve was obtained by preparing the standards shown in Table 5.6. 
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Table 5.6: Standards prepared for construction of a calibration curve 
Standard Concentration (ng/ml) 
S1 10.00 
S2 2.50 
S3 0.63 
S4 0.16 
S5 0.04 
 
Peptide release was calculated as a mean of three determinations as all studies were 
conducted in triplicate. In addition, the mean dissolution time (MDT) (Equation 5.14) was 
calculated from dissolution data to determine the peptide release rate (Sathish and Syed, 2013). 
 
𝑀𝑀𝑀𝑀𝑀𝑀 = ∑ 𝑑𝑑𝑚𝑚𝑖𝑖𝑚𝑚 ×∆𝑑𝑑𝑖𝑖=𝑛𝑛𝑖𝑖=1
∑ ∆𝑑𝑑𝑖𝑖=𝑛𝑛𝑖𝑖=1
                                                                                                        (5.14) 
 
Where, MDT is Mean Dissolution Time; i is the dissolution sample number; n is the number of 
dissolution sample time; tmid is time at mid-point between i and i=1; ΔM is the additional amount 
of protein dissolved between i and i=1. 
 
In addition, the in vitro peptide release data obtained were fitted into various mathematical 
modelling equations to determine the mechanism of peptide release from the optimized OCMT. 
 
5.3. Results and Discussion 
 
5.3.1. Analysis of weight uniformity, thickness and friability of the optimized OCMT 
The optimized OCMTs (N=5) displayed a uniformity in mass, each having an average weight of 
514.34±0.75mg. Measurement of the thickness of the tablets displayed average readings of 
4.1±0.45mg, whilst evaluation of the friability of the OCMT revealed results of 0.68±0.02%. The 
friability value was within the 1% limit of acceptability as defined in the USP and as a result 
reflected positively on the ability of the OCMT to withstand external stresses during storage. The 
overall results obtained for weight uniformity, thickness and friability served as a reliable 
indicator of the reproducibility of the formulation methods and the tablet assembly process. 
Figure 5.2 displays the dimensions of the optimized OCMT with in-process validation results 
and a digital image of the optimized OCMT. 
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Figure 5.2: Schematic representation of the dimensions of a) the core eutectic region, b) the 
optimized OCMT and c) a digital image of the OCMT with the outer polymer shell surrounding 
the inner core eutectic region. 
 
5.3.2. Analysis of the pertinent rheological properties of the EPB 
Due to the unique features of the EPB; its characteristic melting at body temperature (37°C), 
change in crystallinity and surface morphological structure as detailed previously by Choonara 
and co-workers (2016), further investigations into its intrinsic properties became a necessity. 
Thus, the EPBs flow and deformation behavior in response to applied stresses was determined. 
The EPB was found to have both viscous and elastic properties as it transitions from a solid at 
room temperature (25°C) to a melt at body temperature (37°C). Consequently, particular 
attention was focused on the viscoelastic and thermo-mechanical characterization of the EPB.  
 
Dynamic oscillatory tests were performed to determine the rigidity and integrity of the EPBs 
internal structure resulting from macro- and micro-structural transitions over a temperature 
range (White, 1990). Figure 5.3 displays the basic principle of the oscillatory rheological 
measurements with its back and forth movement and sinusoidal signal applied to the sample. 
Typically measured parameters included; the complex viscosity [η*], the elastic (storage) 
modulus (Gʹ) and the viscous (loss) modulus (Gʺ) which respectively gives an indication of the 
solid-like and liquid-like properties of the substance in response to temperature (T) changes 
(Lippacher et al., 2002). 
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Figure 5.3: Schematic representation of the basic principles of oscillatory testing, displaying the 
back and forth movement of the cone and top plate and the sinusoidal stress or strain that is 
applied to the sample. 
 
A preliminary oscillatory stress sweep at a frequency of 1Hz was performed to determine the 
EPBs Linear ViscoElastic Region (LVER) as shown in Figure 5.4. The oscillatory stress sweep 
provides information about the rigidity and yield stress of a material (Lippacher et al., 2004). 
Initially, the stress applied to the sample is sufficiently low enough to preserve the structure of 
the material as indicated by the plateau shown in Figure 5.4. The internal breakdown of the 
material structure occurs as increasing amounts of stress are applied to the sample which 
results in a decrease in the elasticity (phase angle rises). Since the elastic modulus does not 
change within the LVER we know that this amount of stress is non-destructive to the material 
and thus, subsequent testing was kept within this LVER (Lippacher et al., 2004). 
 
An oscillatory temperature ramp was performed to determine the elastic and viscous modulus 
as well as the complex viscosity of the EPB as it changes from a solid at room temperature to a 
melt at 37°C. The inputted stress value for the temperature ramp needs to fall within the LVER 
and thus, several pre-tests were conducted to determine the optimum stress value. Figure 5.5a 
displays the typical rheological profile for the EPB obtained at a stress value of 1 Pa. It can be 
noted that at the beginning, the EPB is more solid-like and thus, has higher elastic properties 
than viscous properties as indicated by the higher storage modulus Gʹ versus the loss modulus 
Gʺ value (Hyun et al., 2006). As the temperature increases, both material functions decrease 
and it might even be seen that the material becomes more viscous. In Figure 5.5a, at 37°C, a 
significant 30% drop in the Gʹ value from 3610 Pa to 2508 Pa was noted. Proportionally a slight 
increase in the viscous modulus was noted at 37°C with both the Gʹ and Gʺ reaching equilibrium 
above 40°C. 
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Figure 5.4: Oscillatory stress sweep curve indicating the Linear ViscoElastic Region (LVER) 
and the subsequent structural breakdown of the material indicated by the sharp decrease in Gʹ. 
 
The rheological profile in Figure 5.5b was obtained at a stress value of 4 Pa to facilitate a 
clearer indication of the pertinent rheological transitions occurring. The rheological behavior of 
the EPB in response to increasing temperatures was evaluated and the relevant regions were 
highlighted (Jones, 1999). Initially, within the glassy region, the Gʹ value is greater than the Gʺ 
and the EPB was thought to be primarily elastic in nature. Upon increases in temperature, the 
mobility of the molecules increase causing the EPB to become more viscous and subsequently 
transition into a rubbery state (Jones, 1999; Menard, 2008). At 37°C, a critical crossover was 
noted where Gʺ ˃ Gʹ. This supports the intrinsic features of the EPB that remains solid at room 
temperature and softens at 37°C. Above 42°C, within the terminal region, the EPB becomes 
completely liquid-like and Gʺ primarily dominates. In addition, the complex viscosity [η*] of both 
profiles decreased significantly with an increase in temperature as compared to the initial 
viscosities.  
 
 
 
 
 
 LVER 
Phase δ 
rises 
146 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 5.5: Oscillatory temperature sweep profiles of the EPB displaying pertinent rheological 
transitions in a) obtained at a stress value of 1 Pa and b) obtained at a stress value of 4 Pa. 
 
The dynamic mechanical analysis of the EPB and its distinctive temperature-dependent effects 
on its viscoeleastic properties displayed typical amorphous material behavior (Jones, 1999). 
This was evidenced by the temperature-modulated change from a glassy state with restricted 
motion of molecules to a rubbery state with an enhanced molecular mobility, increased 
relaxation and decreased rigidity (Ward and Hardley, 1993; Jones, 1999). This resonates with 
the results previously emphasized in Choonara et al, (2016) where the EPB displayed 
characteristic changes in its thermal behavior, crystallinity and surface morphological structure. 
 
5.3.3. Analysis of the vibrational molecular transitions of the optimized OCMT 
FTIR studies confirmed the successful crosslinking between the outer polymer shell of the 
OCMT with the inner core eutectic region as evidenced by the ATR-FTIR spectra obtained. As 
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expected, the OCMT displayed bands characteristic to the molecular and vibrational transitions 
of all its components with a reduction and increase in intensity of certain bands as well as the 
appearance of new bands, accredited to the in situ crosslinking initiated by the presence of the 
chemical crosslinkers (NaCO3 and K2HPO4). The ATR-FTIR split transmittance spectra of the 
native polymers and components are displayed in Figure 5.6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6: ATR-FTIR split transmittance spectra of the native compound PEO, crosslinkers 
(NaCO3 and K2HPO4) and the eutectic powder blend. The two highlighted peaks are 
characteristic of carbonate ions. 
 
In addition, the characterization of an in vitro physically crosslinked formulation provided a 
measurable standard by which the in situ cross-linked formulation could be compared. The in 
vitro crosslinked formulation displayed peaks identical to that of the OCMT as shown in Figure 
5.7a, indicating the comparable crosslinking of PEO in situ. The process of in situ crosslinking is 
expected to create a crosslinked interface network between the core region of the OCMT and 
the outer polymer shell to primarily protect the incorporated protein or peptide and provide 
desirable controlled release behavior. The designated functional groups and fingerprint bond 
regions have been highlighted in Figure 5.7a.  
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Results from the ATR-FTIR spectra of the OCMT displayed a broad, low intensity peak at 
3235cm—1. This peak is characteristically indicative of a hydroxyl functional group and often 
indicates a high degree of association resulting from extensive inter and intra-molecular 
hydrogen bonding (Coates, 2000). The –OH group signified the presence of the menthol-
containing EPB within the OCMT and was predictably absent from the in vitro crosslinked 
formulation spectrum. A high intensity methylene (>CH2) symmetrical stretch at 2876cm-1  
further alluded to the presence of organic material with at least one saturated aliphatic portion 
(Coates, 2000). The appearance of a new carbonyl band in the functional group region at 
1599cm-1 as shown in Figure 5.7b is representative of a C=O stretching vibration, characteristic 
of carboxylic acid derivatives arising from crosslinks between PEO, NaCO3 and K2HPO4 
(Coates, 2000). 
 
In the analysis of the fingerprint region of the OCMT, typical sodium carbonate-type peaks as 
shown in Figure 5.6 were identified at 1464cm-1 and 839cm-1. Conventionally, carbonate ions 
(CO32-) present themselves at two absorption bands indicative of in-plane and out-of-plane 
bending (Coates, 2000; Sreedhar et al., 2012). Macromolecular interactions corroborated the 
formation of the distinguishing sodium carbonate peak at 1464cm-1 by dwarfing the native PEO 
peak at 1359cm-1.  Several bond origins (>CH2, >CH-, C-O, C-H) characteristic to PEO were 
noticeable in the transmittance spectra of the OCMT. Additionally, transformations originating 
from the influence of K2HPO4 in the crosslinking process was evidenced by the overlapping 
organic (P=O conjugation) and aliphatic (P-O-C conjugation) phosphate stretching vibrations 
(Coates, 2000). Overall bond designations and summations inferred from PEO interactions with 
NaCO3 and K2HPO4 at a 23%w/w concentration highlights the superior conjugation and 
crosslinking ability as observed in the FTIR spectra which were further corroborated by 
swellability and release kinetic results. 
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Figure 5.7: ATR-FTIR transmittance spectra: a) split transmittance spectra of the in vitro cross-
linked formulation and the optimized OCMT and b) expansive spectra of the OCMT with labeled 
peaks and highlighted distinguishable sodium carbonate peaks.  
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5.3.4. Analysis of the swelling and erosion behavior of the optimized OCMT 
The gravimetric swelling of the OCMT was analyzed by monitoring its change in weight over 24 
hours. The increased swelling percentages of the intact OCMT at each measured time interval 
is illustrated in Figure 5.8a. A high swelling rate was recorded for the first hour, followed by a 
linear progress of fluid absorption within the next two hours. Following three hours, the rate of 
weight gain drops and only slight increases in the swelling percentage was recorded.  After 4 
hours, the weighty increase in the rate and extent of swelling was considerably noted and 
subsequently resulted in the gradual formation of a thick swollen front as shown in the digital 
images in Figure 5.8a.  
 
The observed swelling results were primarily attributed to the porous configuration of the outer 
polymer shell which enabled fast and extensive swelling (Vlachou et al., 2001). However, the 
slow progression of swelling between the time periods of 3hr and 4hr as well as 6hr and 8hr 
may be attributed to the formation of the crosslinked interface in situ. Swelling measurements 
are the simplest level of analysis in determining the effects of different concentrations of 
crosslinkers on the swelling behaviour as was demonstrated in Choonara et al, (2016). The 
extent of swelling is indirectly proportional to the degree of crosslinking and thus, the retardation 
of swelling reflects the intra and inter-molecular interactions between the outer polymer shell 
and the inner core melt region (Mahkam and Doostie, 2008; Carbinatto et al., 2014). 
 
An equilibrium swelling was reached at 8 hours with the intact OCMT swelling up to ±750% of 
its original mass. After 8 hours, the effects of surface erosion became evident as the OCMT 
began to slowly lose its physical structure. The erosion percentage of the OCMT after 24 hours 
was just over half of its original mass at 53.94%. The erosion of the OCMT was recorded as a 
function of the dried weight of the tablet after 24 hours and thus is not reflected in the swelling 
profile results obtained. Pectin, contained within the outer polymer shell was responsible for the 
erosion characteristics of the OCMT by enabling controlled, surface erosion as was evident by 
the maintenance of a gelled mass of the tablet following 24 hours. Conclusive analysis of the 
swelling and erosion behavior generated results influenced by the porosity, crosslinking 
capabilities and surface erosion which may ultimately influence the dissolution and release 
kinetics in controlled release systems (Vlachou et al., 2001; Sriamornsak et al., 2007). 
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Figure 5.8: Swelling profile of the intact OCMT up to 8 hours in SHIF with insets displaying 
digital images of the swelled appearance, corresponding to each time point. 
 
5.3.5. Analysis of the moisture content of the optimized OCMT 
The determination of the moisture content is important as it has a significant effect on the 
chemical, physical and microbial properties of finished pharmaceutical products (Nokodchi, 
2005; Gerhardt, 2009). The moisture in tablets originates from various sources, including the 
water of crystallization and surface adsorption of pure chemicals as well as the presence of 
inactive excipients (Crouter and Briens, 2014). Results from Karl Fischer analysis of the 
optimized OCMT revealed a water content of 6.822 ± 0.1%. Ideally, the value was a median of 
the moisture content of all the components contained within the outer polymer shell ranging 
from <1% for some components to 12% for other components (Bhaskar et al., 1993; Rane et al., 
2013; Crouter and Briens, 2014).  This value was acceptable in terms of maintaining product 
stability and improving tablet compaction (Gerhardt, 2009). It is important to understand the 
capabilities of water and its effects on the pharmaceutical product as it provides valuable insight 
into combating these effects and ultimately improving the shelf life of the product. 
 
5.3.6. Interpretation of the in vitro and ex vivo mucoadhesion of the optimized OCMT  
Mucus covers several epithelial surfaces within the body, including the intestinal membrane. 
The ability of a molecule to attach to mucus-lined epithelial surfaces is termed mucoadhesion, a 
feature which enables the controlled delivery of drugs resulting from the close proximity of the 
system to the mucosal surface (Carreras et al., 2016). Mucin is the main component of mucus 
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and thus the interaction of the outer polymer shell of OCMT with mucin was investigated. 
Results from in vitro mucoadhesive studies revealed an average mucoadhesive percentage of 
71.87%. The intrinsic nature of polymers is a key factor towards achieving effective 
mucoadhesion which was clearly evident by the results obtained. The molecular weight, 
flexibility and degree of ionization of the polymers were the main influences for the observed 
polymer-mucin interactions (Carreras et al., 2016).  
 
The high molecular weight of PEO, flexibility and cationic nature of pectin and the anionic 
charge of CMC all contributed to the effective mucoadhesion percentage achieved. Typically, 
mucoadhesion increases with an increase in molecular weight with the chain flexibility being 
crucial in its ability to facilitate interpenetration (Lee et al., 2000; Carvalho et al., 2010). In 
addition, the ionic charge of the polymers significantly affects the mucoadhesive strength with 
anionic polymers showing the highest mucoadhesive strength followed by cationic and non-ionic 
polymers (Carreras et al., 2016; Mansuri et al., 2016). The additive mucoadhesive nature of the 
outer polymer shell can be correlated to the ex vivo mucoadhesive strength determination. 
 
The analysis of the ex vivo mucoadhesion generated the maximum detachment force and AUC 
which were computed into tensile stress (N.cm2) and work of adhesion (mJ.cm2). The tensile 
stress and work of adhesion were the maximum force and total amount of forces required for 
separation of the OCMT from the pig intestinal tissue, respectively (Manconi et al., 2010). A 
typical Force-Distance profile obtained from the mucoadhesive test is shown in Figure 5.9. The 
tensile stress result produced a value of 0.052±0.002 N.cm2, while calculations of the work of 
adhesion yielded a value 0.132±0.012 mJ.cm2. The results obtained not only corroborated the in 
vitro mucoadhesive strength determination, but also provided a reliable indicator of the 
enhanced mucoadhesion of the OCMT within a short contact time period (120s).  
 
The in vitro and ex vivo mucoadhesion results can be summarized in three steps: the first 
involving the hydration and subsequent swelling of the OCMT to facilitate the tight contact with 
the pig intestinal tissue; the second involving ionic interactions and interpenetration of the 
OCMT with the mucin chains and; lastly the combination secondary chemical interactions and 
weak interfacial forces which all leads to enhanced adhesion of OCMT to the pig intestinal 
tissue (Carvalho et al., 2010; Singh and Rana, 2012; Carreras et al., 2016). The ability of the 
OCMT to deliver on its mucoadhesive properties may significantly improve the tablets residence 
time in vivo, enhance its oral bioavailability and promote targeted delivery. 
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Figure 5.9: Typical Force-Distance profile obtained from ex vivo mucoadhesive analysis of the 
OCMT. 
 
5.3.7. Evaluation of the physicomechanical properties of the optimized OCMT 
Compressive and penetrative forces were applied to the optimized OCMT to determine the MH, 
MR, matrix rigidity and DE. Quantitative analysis of Force-Time and Force-Distance profiles 
yielded results for the surface and core textural profiling of the OCMT. The summary of the 
results obtained are provided in Table 5.7. The MH and rigidity are closely related as they both 
refer to the ability of the tablet to resist deformation when a force is applied. Both properties give 
an indication of the mechanical integrity of the tablet and its critical influence on other physical 
and chemical parameters (Tai et al., 2014). The surface matrix hardness of the OCMT was 
predictably greater than the core matrix hardness resulting from the inherent softening of the 
core at 37°C, as discussed previously (Choonara et al., 2016). The low matrix hardness of the 
core does not detract from the mechanical integrity of the OCMT but rather creates a platform 
for improved structural flexibility and hardness by facilitating the process of in situ crosslinking. 
 
Analysis of the MR result obtained reflected positively on the tablet’s ability to return to its 
original state after compression-related deformation. The deformation energy was considerably 
low, attributable to the softer core matrix. Furthermore, Figure 5.10 illustrates the multi-textural 
properties of the OCMT following penetration of the needle probe through the different layers of 
a cross-sectioned tablet and the corresponding responses observed in the Force-Time profile 
obtained. Initially, a rise to a high peak force was noted as the probe penetrates into the top 
layer of the outer polymer shell. Following further penetration into the softened core, a fracture 
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and subsequent decrease in the force is noted. The final penetration of the probe into the 
bottom layer of the outer polymer shell yields the additional increase in force observed. The 
overall results obtained from textural profiling, corroborated the structural mechanics of the 
OCMT in its achievement of desirable responses. 
 
Table 5.7: Physicomechanical properties of the optimized OCMT 
Textural Parameter Value 
Surface matrix hardness (N.mm2) 205.91 
Core matrix hardness (N.mm2) 51.54 
Matrix resilience (%) 74.66 
Matrix rigidity (N.mm) 52.26 
Deformation energy (J) 0.005 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10: Annotated multi-textural profile indicating the penetration of the needle probe 
through the different layers of the OCMT and its corresponding response: a) the top layer of the 
outer polymer shell, b) the core eutectic region and c) the bottom layer of the outer polymer 
shell. 
 
5.3.8. Dual analysis of the surface morphology and porosity of the optimized OCMT 
The porositometric characterization of the OCMT was based on the phenomenon of 
physisorption, a macroscopic method that provides critical information about the porous 
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properties and structure of materials by evaluating the nitrogen adsorption as a function of 
relative pressure (P/Po). The BET and BJH methodologies were used to determine the specific 
surface area as well as the pore size and pore volume by adsorption and desorption techniques, 
respectively (Foo and Hameed, 2010). Adsorption isotherms are often generated from 
porositometric analysis and can be divided into different types depending on the degree and 
mechanism of adsorption, the nature of the adsorbent surface and the comparative strengths of 
the adsorbate-adsorbent interactions (Foo and Hameed, 2010).  
 
According to the IUPAC classification system, the linear isotherm plot (Figure 5.11a) obtained 
for the optimized OCMT was typical of a Type II physisorption isotherm with a H3 hysteresis 
loop. This reversible physisorption isotherm is typically obtained for macroporous adsorbents, 
such as polyethylene oxide, and represents a clear monolayer-multilayer adsorption (Sing et al., 
1985; Sing and Williams, 2004; Sangwichien et al., 2002). The isotherm displayed an initial 
gradual curvature to the relative pressure axis which indicates strong interactions between 
adsorbate molecules and complete monolayer coverage followed by the linear middle region 
representative of the commencement of multilayer adsorption (Sing et al., 1985). In addition, a 
hysteresis loop was noticeable between 0.9-1.0 P/Po. The characteristic shape of the hysteresis 
loop was attributed to the capillary condensation phenomenon that occurs in mesopores, 
wherein condensation of a gas to a liquid-like phase in a pore takes place at a pressure less 
than the saturation pressure of the bulk liquid (Sing et al, 1985; Sing and Williams, 2004).  
 
Therefore, the OCMT was considered to be mesoporous with characteristic intermediate pore 
widths between 2nm and 50nm (Groen et al., 2003). This correlated with the results obtained for 
the average pore widths and diameters reported in Table 8. BET and BJH calculations yielded 
pore sizes for the OCMT ranging from 2.293nm-7.619nm. Furthermore, the hysteresis loop 
displayed a forced closure at a P/Po >0.45 which may be accredited to the process of in situ 
crosslinking (Figure 5.7) which creates an interpenetrating pore network in which larger pore 
sizes empty into smaller diameters (Sangwichien et al., 2002). Consequently, this causes a shift 
in the desorption branch to a lower pore size compared to the adsorption branch as shown in 
Figure 5.11b-c which was further corroborated by the BJH Desorption average pore diameter 
value presented in Table 5.8. The surface area and pore volume accounts for the observed 
swelling behavior of the OCMT by significantly impacting on the amount of water uptake (Figure 
5.8).  
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SEM micrographs of the OCMT showed highly porous surface structures, supporting 
quantitative porositometric analysis. Surface area and porosity studies alluded to the OCMT’s 
random size distribution and interconnected pore system. This was evidenced by the SEM 
micrographs for the OCMT shown in Figure 5.11a at different magnifications (i) and (ii). The 
honeycomb-type appearance of the micrographs represented the low-density pore domains that 
are interconnected. Comprehensive analysis of the porosity of the OCMT provides valuable 
information on its effect on other physicochemical and physicomechanical properties, 
specifically fluid uptake, in situ crosslinking and release kinetics. 
 
Table 5.8: Summative analysis of the surface area, pore volume and pore size characteristics of 
the optimized OCMT 
Surface Area OCMT 
Single point surface area at P/Po 0.199946691:6.9197 m²/g 
BET Surface Area 29.3120 m²/g 
t-Plot Micropore Area 5.8552 m²/g 
t-Plot External Surface Area 23.4568 m²/g 
BJH Adsorption cumulative surface area of pores                  
between 17.000 Å and 3000.000 Å diameter 
11.174 m²/g 
BJH Desorption cumulative surface area of pores                   
between 17.000 Å and 3000.000 Å diameter 
12.1105 m²/g   
 
Pore Volume  
Single point adsorption total pore volume of pores                      
less than 788.870 Å diameter at P/Po 
0.974834133:0.016800 cm³/g    
t-Plot micropore volume -0.007212 cm³/g   
BJH Adsorption cumulative volume of pores                     
between 17.000 Å and 3000.000 Å diameter 
0.022861 cm³/g    
BJH Desorption cumulative volume of pores                    
between 17.000 Å and 3000.000 Å diameter 
0.023067 cm³/g 
Pore Size  
Adsorption average pore width (4V/A by BET) 22.9261 Å   
BJH Adsorption average pore diameter (4V/A) 81.837 Å    
BJH Desorption average pore diameter (4V/A) 76.189    
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Figure 5.11: OCMT porosity plots: a) linear isothermic plot with insets of SEM micrograph 
images at magnifications of 3300x (i) and 4100x (ii) b) BJH Adsorption Cumulative Pore Area 
and c) BJH Desorption Cumulative Pore Area. 
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5.3.9. Analysis of the Pharma-Engineering and hydration characteristics of the 
optimized OCMT 
The hydration characteristics of the OCMT are important for evaluating the performance of the 
device as highlighted previously in the analysis of the swelling and erosional behavior. 
Therefore, MRI was used to observe and measure the internal events underlying in vitro peptide 
release as a result of solvent penetration (Richardson et al., 2005; Dorozynski et al., 2012). The 
changes in hydration over 24 hours were noted in the MRI images presented in Figure 5.12. 
The intensity scale from black to white gives an indication of the degree of hydration of the 
OCMT. The darker, low intensity regions indicate minimal degrees of hydration, whereas the 
white, high intensity regions indicate extensive hydration and swelling. The characteristic 
Pharma-Engineering of the tablet was evident in the images obtained, highlighting the hydrated 
outer polymer shell and the un-hydrated core eutectic region.  
 
The OCMT displayed a gradual increase in the swelling capacity of the outer polymer shell up to 
3 hours as was apparent by the increase in the area and intensity of the white region. Following 
30min, a clear infiltration of the SHIF into the core region was noticeable by the appearance of a 
grey area (50% hydration). The initial high swelling capacity of the outer polymer shell together 
with the slow infiltration of the core facilitated the release of the incorporated peptide. The 
border between the hydrated and non-hydrated region is known as the swelling front. Between 
3-4hrs no significant increase in the hydration was noted, attributed to the formation of the 
crosslinked interface in situ which subsequently decreased the swelling capacity. 
 
A slight collapsing of the OCMT after 4 hours was indicative of the relaxation and loose 
distribution of the polymer chains, promoting the surface erosion of the OCMT. The erosion front 
presented as a liquid layer of loosely distributed polymer chains between the simulated fluid and 
the gelled layer of the tablet. Complete hydration and continued surface erosion of the OMCT 
progressed up to 24 hours. MRI provided insight into the behavior of the OCMT’s hydrating 
polymeric matrix both in vitro and in vivo. The resultant images not only provided structural 
confirmation of the layering of the tablet but also incidentally mirrored the swelling and erosional 
behavior observed in Figure 5.8. These hydrational transitions suggest that the release of the 
peptide from the core of the OCMT may be based on a complex interplay between swelling, in 
situ crosslinking and surface erosion. 
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Figure 5.12: MRI of the OCMT over 24 hours with the intensity scale indicating the degree of 
hydration from 0% (non-hydrated) to 100% (hydrated). 
 
5.3.10. In vitro peptide release analysis  
The peptide release patterns of Octreotide from the optimized OCMT were obtained through 
evaluation of its experimental release in SHIF (pH 6.8). The concentration at each time point 
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curve generated a 4-parameter logistic curve fit as a function of the OD (Optical Density) versus 
the log concentration. The parameters obtained from the 4-P fit were used to calculate the 
unknown concentrations of the experimental samples. Results were displayed as a function of 
fractional release against time as shown in Figure 5.13a. A sustained release of Octreotide over 
the 24-study period was noted.  
 
The initial burst release within the first 3 hours was attributed to the OCMT’s porous nature 
which facilitated the high swelling capacity observed in Figure 5.8a and the MRI images 
obtained. The release of the peptide slowed following 3 hours, corresponding to the decreased 
water uptake. This was attributed to the process of in situ crosslinking, assisted by the 
characteristic softening of the core eutectic region at 37°C as demonstrated by the rheological 
profiles in Figure 5.5. The peptide release pattern alternated between phases of slow and burst 
release for up to 8 hours, followed by a more stable release profile up to 24 hours. The 
characteristic peptide release profile obtained was attributed to the combined effects of swelling, 
surface erosion and in situ crosslinking. 
 
Owing to the amorphous nature of the EPB as highlighted previously in Choonara et al, (2016), 
an enhanced dissolution and subsequent fractional release up to ±0.8 was noted. Furthermore, 
the mean dissolution time (MDT) of the OCMT provided information about the peptide release 
rate (Wadher et al., 2011; Sathish and Syed, 2013). The MDT for the optimized formulation was 
18.76 which ideally fell within the range of the desired targeted response (18.93) for the 
optimum formulation at the optimal concentrations of crosslinkers (NaCO3 and K2HPO4), pectin 
and EPB as displayed in Figure 5.13b-c. The optimum amounts of EPB (60mg) and crosslinkers 
(115mg) represented in Figure 5.13b-c corresponds to the optimal concentrations of 12%w/w and 
23%w/w, respectively, as highlighted in Figure 5.1. The MDT further corroborated the role of the 
in situ crosslinking process in producing a slower release rate. The achievement of the optimum 
MDT confirms the appropriateness of the design in producing the desired responses from an 
optimum formulation. Summative assessment revealed that the combinatory effects of different 
physicochemical and physicomechanical processes ultimately influenced the peptide release 
behavior observed. 
 
Moreover, the peptide release results were fitted into various kinetic models in order to 
determine the mechanism of release. The best-fit model for the peptide release data observed 
was based on the kinetic modelling of the regression coefficients and its proximity to the 
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numeral 1. A model depicting a value closest to 1 amongst the formulations would demonstrate 
the appropriateness of that model in explaining the peptide release mechanism. The release 
data was fitted into zero-order, first order, Higuchi and Korsmeyer–Peppas models. The best-fit 
model for the peptide release data was the Higuchi model (R2=0.98) which describes the 
release of the peptide from a matrix as a function of the square-root of a time-dependent 
process based on Fickian diffusion. Interestingly, the release data was very close to zero-order 
release (R2=0.95) and thus, the release kinetics may best be attributed to a combination of both 
models as a result of the complexity of the system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13: Profiles displaying: a) the fractional release of Octreotide from the optimized 
OCMT and b-c) contour plots depicting the effect of the crosslinkers (NaCO3 and K2HPO4), EPB 
and pectin concentrations on the MDT response.  
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5.4.  Concluding Remarks 
The OCMT was optimized for the oral delivery of gastro-sensitive proteins and synthetic 
peptides. The in-depth physicochemical and physicomechanical characterization of the OCMT 
revealed the suitability of the design in producing an optimum formulation that delivers on its 
characteristic functions. Oscillatory studies highlighted the temperature-responsive rheological 
behavior of the EPB and its correlation to previously described thermal transitions. FTIR results 
highlighted the presence of in situ crosslinking due to intra and inter-molecular interactions, 
initiated by the chemical crosslinkers. Physicomechanical profiling provided an indication of the 
multi-textural properties of the OCMT. Comprehensive porositometric and morphological 
analysis provided information about the internal architecture of the OCMT, revealed its effect on 
fluid uptake and subsequently the peptide release characteristics. This was corroborated with 
MRI which highlighted the device hydration over 24 hours as a significant predictor of the in vitro 
peptide release profile. The in vitro release of Octreotide was influenced by the combined 
effects of swelling, surface erosion and in situ crosslinking, displaying a fractional release up to 
±0.8. Owing to the complexity of the system, the mechanism of release was attributable to both 
the zero-order (R2=0.95) and Higuchi models (R2=0.98). Thus, physicochemical and 
physicomechanical characterization was necessary to confirm the suitability of the OCMT in 
vitro before proceeding to incorporation of components for Tri-functionalization, discussed in 
Chapter 6. 
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CHAPTER 6 
DESIGN OF THE CO-INHIBITORY ‘SMART’ POLYMERIC SHEET SURROUNDING A pH-
MODIFIED OCMT FOR TRI-FUNCTIONALIZATION 
 
 
To be submitted to Journal of Controlled Release 
 
Bibi F. Choonara, Yahya E. Choonara, Pradeep Kumar, Lisa C. du Toit, Viness Pillay. Design of the Co-
inhibitory ‘Smart’ Polymeric Sheet Surrounding a pH-Modified OCMT for Tri-Functionalization. 
 
 
Abstract 
An experimental design of the pHM ‘smart’ polymeric sheet encapsulated-OCMT for tri-
functionalization in the delivery of gastro-sensitive therapeutic proteins and synthetic peptides 
was investigated. Physicochemical and physicomechanical characterization techniques were 
undertaken to determine pertinent interactions of the incorporated co-inhibitor with CYP3A4 and 
P-glycoprotein (Pgp). In addition, the micro-environmental pH demonstrated the pH-lowering 
effects of citric acid and its potential in reducing the optimal environment for brush border 
enzyme activity. Comprehensive analysis of the ‘smart’ polymeric sheet via analysis of the 
rheological profile, mucoadhesion and physicomechanical strength and elasticity confirmed the 
favorable characteristics of prolamines in drug delivery applications. The in vitro release of 
Octreotide was influenced by the combined effects of swelling, surface erosion and in situ 
crosslinking, displaying fractional releases ranging from 0.79-0.89.  Due to the complexity of the 
system, the release kinetics was attributed to both the Higuchi (R2=0.98) and zero-order 
(R2=0.97) models. Conclusive results from physicochemical and physicomechanical 
characterization of the design demonstrated the applicability of the pHM ‘smart’ polymeric sheet 
encapsulated-OCMTs to provide tri-functionalization.  
 
Keywords: oral peptide delivery; prolamines; CYP3A4; Pgp; pH modifier; physicochemical 
properties; physicomechanical properties 
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6.1. Introduction 
Therapeutic protein and peptide drugs are currently administered by the less desirable 
parenteral routes of administration, resulting from the poor to limited oral bioavailability 
associated with their orally administered biotech-based pharmaceutical counterparts (Mahato et 
al., 2003). Technologies that have been used to improve the oral bioavailability of proteins and 
peptides are based on specific approaches as highlighted in Choonara et al, (2014). The 
approaches are primarily focused on preventing acid-based degradation and promoting 
epithelial permeability of proteins and peptides. Research in this field has intensified as 
pharmaceutical scientists vie for the opportunity to achieve the maximum oral absorption of 
proteins and peptides and consequently attain an optimum oral bioavailability (Arhewoh et al., 
2005).  
 
The enzymatic degradation of proteins and peptides within the acidic environment of the 
stomach has been well documented. However, the role of the small intestine in the degradative 
process cannot be discounted, as the brush border membrane accounts for a significant amount 
of the protein and peptide degradation that occurs (Carino et al., 1999; Bruno et al., 2013). The 
brush border is a microvilli-covered surface of cells that express brush border enzymes such as 
exo- and endopeptidases (Mahato et al., 2003). These enzymes contribute towards the 
cleavage of proteins and peptides into non-essential amino acids (Zhou 1994; Lee, 2002). This 
poses a significant enzymatic barrier and as a result is often a target for the successful 
development of oral protein and peptide technologies. 
 
In addition, the inter-relationship and combined action of cytochrome P450 and the multidrug 
resistance transporter P-glycoprotein (Pgp) presents a formidable hindrance towards the 
achievement of an optimum oral bioavailability of proteins and peptides (Wacher et al., 1998; 
Bruno et al., 2013). The isoform CYP3A4 is predominantly expressed in the human intestine 
and is a member of the cytochrome P450 CYP3A family, accounting for the metabolism of ±50-
70% of all administered drugs (Wacher et al., 1998; Mahato et al., 2003). Pgp is an ATP-
dependent transporter, responsible for the efflux of drugs back into the intestinal lumen as they 
are being absorbed through the intestinal mucosa (Wacher et al., 1998). The shared location of 
CYP3A4 and Pgp within the small intestinal enterocytes promotes its synergistic action in 
reducing the oral bioavailability common to their substrate specificities (Mahato et al., 2003). 
Therefore, the inhibition of CYP3A4, Pgp or both may favorably improve the oral bioavailability 
of proteins and peptides.  
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The platform on which the OCMT is based, as highlighted previously in Choonara et al, (2016), 
enables the incorporation of a pH modifier into the outer polymer shell to facilitate the indirect 
inhibition of enzyme activity at the brush border by transiently lowering the micro-environmental 
pH and subsequently reducing the optimal environment for enzyme activity (Badawy and 
Hussain, 2006; Tatarvati and Hoag, 2006). Furthermore, a co-inhibitor containing prolamine-
based ‘smart’ polymeric sheet encapsulates the OCMT. The co-inhibition of CYP3A4 and the 
Pgp efflux pump functions to reduce the metabolism and inhibit transmembrane efflux. In 
addition, the sheet possesses the inherent capabilities that enable it to interact well with 
hydrophilic molecules (i.e. proteins and peptides), allowing the passage of proteins and peptides 
through the GIT membrane and providing a protective function within the stomach.  
 
This characteristic design imparts tri-functionalization capabilities that are expected to 
significantly improve the oral bioavailability. Thus, the determination of the physicochemical and 
physicomechanical properties of the advanced OCMT is a prerequisite in defining the 
performance of the device in situ. A Face-Centered Central Composite Design (FCCCD) 
generated a series of 13 formulations which were all synthesized and analyzed for their 
individual properties. Analysis of the advanced OCMT components included the determination 
of the optimum co-inhibitory potential, measurement of the changes to the micro-environmental 
pH, gastric acid resistance, mucoadhesion, rheological properties and in depth textural analysis. 
Ultimately, these investigations would determine the suitability of the advanced OCMT to deliver 
on its purported capabilities. 
 
6.2. Materials and Methods 
 
6.2.1. Materials 
Menthol (2-isopropyl-5-methylcyclohexanol, 99% purity, MW=156,27g/mol), cetomacrogol 1000, 
poly (ethylene oxide) (PEO) (Polyox™, WSR-303), polyoxyethylene (40) stearate (Myrj® 52), 
Zein (from maize) and excipients, sodium carboxymethylcellulose (CMC), magnesium stearate 
and sucrose were purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA). The crosslinker 
sodium carbonate (NaCO3) was purchased from Associated Chemical Enterprises (ACE) (Pty) 
Ltd. (Johannesburg, Gauteng, South Africa). Pectin citrous (poly-D-galacturonic acid methyl 
ester), the crosslinker di-potassium hydrogen orthophosphate anhydrous (K2HPO4; 
MW=174.18g/mol), citric acid (≥99.5% purity, MW=210.14g/mol), methyl paraben (methyl 4-
hydrozybenzoate, MW=152.15g/mol) and polypropylene glycol (1, 2–propanediol) were procured 
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from Merck Chemicals (Pty) Ltd. (Modderfontein, Gauteng, South Africa). Octreotide acetate 
(C49H66N10O10S2; Mw=1019.247g/mol) was purchased from Bolon Pharmachem Co., Ltd. 
(Taizhou, Zheijang, China). Cytochrome P450 3A4 (CYP3A4) inhibitor screening kit 
(fluorometric) and MDR assay kit (fluorometric) were purchased from Peninsula Laboratories 
International , Inc. (San Carlos, CA, USA).  Caco-2 cell line (ATCC® HTB-37™), Dulbecco’s 
Modified Eagle’s Medium (DMEM), Foetal bovine serum (FBS), Penicillin-streptomycin, Trypsin-
EDTA (0.25mg/mL) and all other cell culture components were purchased from Separations 
(Pty) Ltd. (Randburg, Gauteng, South Africa).  All other reagents were of analytical grade and 
were employed as received. 
 
6.2.2. Formulation of the pH-modified (pHM) OCMT 
The OCMT was prepared according to the method prescribed in Choonara et al, (2016) 
comprising an outer polymer shell surrounding a core eutectic region. The core eutectic region 
of the tablet consisted of a compressed combination of; 12%w/w Eutectic Powder Blend (EPB), 
23%w/w of crosslinking agents (NaCO3 and K2HPO4) and 20mg Octreotide. The outer polymer 
shell consisted of a top and bottom layer each containing a polymeric blend of 100mg each of 
PEO, 65mg pectin, 12mg of CMC and 1mg of magnesium stearate. In addition, the pH modifier 
(citric acid) was incorporated into the outer polymer shell in concentrations ranging between the 
upper (10mg) and lower (5mg) limits generated from the FCCCD (Minitab®V15 statistical 
software, Minitab®Inc., PA, USA) as shown in Table 6.1. 
 
The OCMT with incorporated pH modifier was assembled by directly compressing the polymeric 
powder blend of the bottom layer at 2 tons of pressure using a Carver Tableting Press (Wabash, 
Indiana, USA) loaded with punch and dies with a diameter of 10mm to produce a loosely 
compressed layer. The core eutectic tablet was subsequently placed above this layer and 
centered using the tip of a needle. The polymeric powder blend for the top layer of the tablet 
was added above the core eutectic tablet and levelled out. The punch was then inserted and the 
tablet was compressed at 5 tons of pressure using a Carver Tableting Press (Wabash, Indiana, 
USA) fitted with a flat-faced punch and die (diameter of 10mm) to produce the pHM-OCMT. To 
minimize processing variables, all tablets were produced under identical conditions. 
 
6.2.3. Synthesis of the prolamine-based ‘smart’ polymeric sheet 
The ‘smart’ polymeric sheet was prepared by dissolving varying concentrations of Zein (%w/v), 
as shown in Table 6.1, in a 70%v/v aqueous ethanol solution. The solution underwent constant 
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magnetic stirring at 300rpm for ±2 hours. Following ±2hours, propylene glycol (20%v/v) and a 
methyl paraben (0.2%w/v) solution was added to the formulation to function as a plasticizer and 
preservative, respectively. The resultant solution underwent further stirring at 300rpm for 
±30minutes to ensure complete mixing and a homogenous distribution.  
 
Table 6.1: Component concentrations generated from a Face-Centered Central Composite 
Design (FCCCD) 
Formulation No. Zein (%w/v) Citric acid (mg) 
1 20 10 
2 20 5 
3 17.5 5 
4 17.5 7.5 
5 15 5 
6 17.5 10 
7 15 7.5 
8 15 10 
9 20 7.5 
10 17.5 7.5 
11 17.5 7.5 
12 17.5 7.5 
13 17.5 7.5 
 
6.2.4. Encapsulation of the pHM-OCMT with the co-inhibitory ‘smart’ polymeric sheet   
The encapsulation of the OCMT with the polymeric sheet was processed by a simple ‘dip’ and 
‘dry’ method, typically used in the coating of tablets. The experimentally determined optimal 
concentration of the co-inhibitor (polyoxyethylene (40) stearate) was dissolved in 1mL of the 
‘smart’ polymeric sheet solution. The resultant mixture was divided into equal amounts (0.5mL 
each) and placed in a 48-well microplate (well diameter-11.0mm) for dip encapsulation of both 
sides of the OCMT. The OCMT was dipped into the co-inhibitory polymeric sheet solution, 
placed on a petri dish and dried in a laboratory fumehood for ±15 minutes. This process was 
repeated several times for both sides of the OCMT until the solution was completely finished. 
Following the final coating, the OCMT was left to dry overnight to produce the thick, dried ‘smart’ 
polymeric sheet encapsulating the OCMT. A schematic of the advanced OCMT with the co-
inhibitory ‘smart’ polymeric sheet is shown in Figure 6.1. 
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Figure 6.1: Annotated schematic of the characteristic features and functions of the advanced 
components of the OCMT. 
 
6.2.5. Determination of the optimal Inhibitory Concentration (IC) of the co-inhibitor 
 
6.2.5.1.  Measurement of the polyoxyethylene (40) stearate-CYP3A4 interaction  
A fluorometric Cytochrome P450 3A4 (CYP3A4) inhibitor screening kit (BioVision Incorporated, 
Milpitas, CA, USA) was used to quantitatively determine the optimal concentration required to 
inhibit CYP3A4. The assay utilized a non-fluorescent CYP3A4 substrate that was converted into 
a highly fluorescent metabolite detectable in the visible range (Ex/Em=535/587nm) as shown in 
Figure 6.2. The assay kit provided a rapid, high-throughput screening of the interaction between 
polyoxyethylene (40) stearate and CYP3A4 and was prepared according to the kits standard 
protocol which involved: a) the standard curve preparation, b) test compound and CYP3A4 
enzyme preparation, c) reaction preparation, d) measurement and e) calculation.  
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Figure 6.2: The mechanism of the enzyme catalyzed reaction utilized by the assay, depicting 
the conversion of the non-fluorescent substrate to the highly fluorescent metabolite in the 
presence of CYP3A4 (BioVision Incorporated CYP3A4 Inhibitor Screening Kit Protocol #K702-
200).  
 
a) Standard curve preparation: The Resorufin standard provided with the kit was dissolved in 
CYP3A4 Assay buffer to generate a final concentration of 1pmol/μL. This resorufin standard 
was added to a series of wells and adjusted to 100μL with CYP assay buffer to yield a 
standard curve of 0, 4, 8, 12, 16, 20, 30 and 40 pmole/well of resorufin. The fluorescence 
was measured at Ex/Em= 535/587nm and the plot of the background-subtracted values 
were used to calculate the slope of the standard curve.  
b) Polyoxethylene (40) stearate and CYP3A4 Enzyme preparation: The polyoxyethylene (40) 
stearate was dissolved in a 1%v/v acetonitrile: CYP3A4 assay buffer to produce a stock 
solution. The stock solution was used to prepare a 5X solution of a range of concentrations 
from 0.02mg/mL-10mg/mL (Table 6.2) in order to generate a multi-point dose-response 
curve. The CYP3A4 enzyme stock was prepared by reconstituting the Recombinant Human 
CYP3A4 stock (2X) with 1mL of CYP3A4 buffer which was mixed thoroughly until a 
homogenous solution was formed. The solution was transferred to a 15mL conical tube and 
was subsequently brought up to a volume of 4.9mL with CYP3A4 assay buffer. The addition 
of 100μL of the NADPH generating system (100X) yielded a final total volume of 5mL of 
CYP3A4 enzyme stock. 
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  Table 6.2: Sample concentrations of polyoxyethylene (40) stearate prepared. 
Sample No. Concentration (mg/mL) 
1 10 
2 8.5 
3 7.5 
4 6.5 
5 6 
6 5.5 
7 5 
8 4.5 
9 3.5 
10 2.5 
11 1 
12 0.5 
13 0.25 
14 0.13 
15 0.06 
16 0.03 
17 0.02 
 
c) Reaction preparation: The reaction wells containing Test Compounds (TC), Solvent Control 
(SC), Background Control (BC) and Positive Inhibition Controls (PIC) were set up according 
to Table 6.3. Following preparation, the plate was incubated for 5-10min to allow the test 
compounds to permeate the microsomal membranes and interact with CYP3A4 in the 
absence of P450 catalytic turnover. During incubation, a CYP3A4 Substrate/ NADP+ 
mixture (3X) was prepared. The reaction was started by adding 30μl of the CYP3A4 
Substrate/ NADP+ mixture (3X) to each well using a multichannel pipette to yield a final 
reaction volume of 100μL/well. 
 
Table 6.3: Preparation of reactions wells for CYP3A4 assay 
 BC SC PIC TC 
CYP3A4 Enzyme Stock (2X) - 50μL 50μL 50μL 
Polyoxyethylene 40 stearate solution (5X) - - - 20uL 
Ketoconazole 150Μm solution (5X) - - 20μL - 
Acetonitrile: CYP3A4 assay buffer (1%v/v) - 20μL - - 
CYP3A4 assay buffer (+5X solvent) 70μL - - - 
 
d) Measurement: The fluorescence was measured immediately (within 1 min) at 
Ex/Em=535/587nm in kinetic mode for 45min using a Synergy HT multiwell fluorescence 
microplate reader equipped with curve fitting software (BioTek® Instruments, Winooski, 
Vermont, USA).  
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e) Calculation: For each reaction, two time points (T1 and T2) in the linear phase of the reaction 
progress curve was selected and the corresponding fluorescence values at these time 
points (RFU1 and RFU2) were used to calculate the rate of change in fluorescence (∆𝐹𝐹/∆𝑀𝑀): 
  
      ∆F
∆T
= RFU2−RFU1
T2 −T1                        (6.1) 
       
      Subsequently, the rate of the BC wells was subtracted from the rates of each of the SC and 
TC wells to determine the background-corrected reaction rates for each well:  
 
      RSC = ∆FSC∆TSC − ∆FBC∆TBC                                                                                                     (6.2) 
 
      Where, RSC is the background-corrected reaction rate of the solvent control, ∆FSC∆TSC  is the rate 
of change in fluorescence of the solvent control and ∆FBC
∆TBC
 is the rate of change in 
fluorescence of the background control 
 
      RTC = ∆FTC∆TTC − ∆FBC∆TBC                             (6.3) 
      
      Where, RTC is the background-corrected reaction rate of the test compound, ∆FTC∆TTC  is the rate 
of change in fluorescence of the test compound and ∆FBC
∆TBC
 is the rate of change in 
fluorescence of the background control 
 
      These values were used to calculate the relative percentage inhibition of the different 
concentrations of test compound according to Equation 6.4. 
 
      % Relative inhibition =  RSC −RTC
RSC
 × 100                                                                       (6.4) 
 
      Where,  RSC is the background-corrected reaction rate of the solvent control and RTC is the 
background-corrected reaction rate of the test compounds. 
 
The reaction rate calculations can also be expressed in terms of pmole resorufin formed per unit 
time per unit amount of protein by interpolation from the standard curve. 
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6.2.5.2. Measurement of the polyoxyethylene (40) stearate-Pgp interaction 
A fluorometric Multi-drug Resistant (MDR) assay kit (abcam®, USA) was used to determine the 
interaction between the co-inhibitor and Pgp. Pgp is an MDR1 transporter and thus, a 
fluorescent MDR indicator was used for assaying the MDR pump activity. The hydrophobic 
fluorescent dye molecule rapidly penetrates cell membranes and becomes trapped in cells, 
providing a high-throughput screening of MDR pump inhibitors. The assay was prepared 
according to the kits standard protocol and involved: a) the preparation of cells, b) preparation of 
dye-loading solution, c) running of the MDR assay and d) data analysis 
 
a) Preparation of cells:  
Cell Culture: A Caco-2 cell line (ATCC® HTB-37™) was used as it represented a reliable in 
vitro model of human small intestinal mucosa. Cells were grown on tissue culture treated 
25cm2 flasks at 37°C in a humidified 5% CO2 incubator (RS Biotech Galaxy Standard, C&M 
Scientific, Livingston, West Lothian, UK). The growth medium was Dulbecco’s Modified 
Eagle’s Medium (DMEM) containing 4.0 mM L-Glutamine, 4500mg/L Glucose and sodium 
pyruvate, supplemented with 10% Foetal bovine serum (FBS) and a 0.1% penicillin-
streptomycin solution. Cells were grown under standard conditions until 70-80% confluency 
was reached.  
Cell Detachment: Following confluency, the cells were detached from the flask using 
Trypsin-EDTA (0.25mg/mL) and centrifuged at 2000rpm for ±10minutes. The supernatant 
was discarded and the cells were resuspended in growth medium to form a cell suspension. 
Cell Counting: A sample of the cell suspension was removed and treated with Trypan Blue 
solution (0.4%) for hemocytometer counting. The Trypan blue-treated cell suspension was 
applied to a Bright-Line™ Hemocytometer (Hausser Scientific, Horsham, PA, USA). The 
hemocytometer was placed on a microscope stage (OLYMPUS CK2, Shibuya-ku, Tokyo, 
Japan) and counted using a 10x objective.  The concentration of the cells were calculated 
by averaging all 1mm2 areas counted and applying Equation 6.5. 
 C = n
v
                                                                                                                                 (6.5)   
 
Where, C is the cell concentration in cells/mL, n is the average number of cells/mm2 area 
and v is the volume counted (10-4).  
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Cell seeding: Upon completion of counting, the appropriate dilutions were made and cells 
were seeded at 40,000 to 80,000 cells/well/90μL into a 96-well microplate for overnight 
incubation in growth medium. 
b) Preparation of the dye-loading solution: An MDR sensor stock solution was prepared by 
mixing 200μL of DMSO into MDR sensor. Subsequently, 20μL of the MDR sensor stock 
solution was added into 10mL of assay buffer and mixed well to produce the MDR dye-
loading solution.  
c) Run MDR assay: Cells were treated with polyoxyethylene (40) stearate by adding 10μL of 
10X solution of polyoxyethylene (40) stearate dissolved in phosphate buffer saline (PBS) at 
concentrations shown in Table 6.2. A corresponding amount of PBS was added to blank 
wells- containing medium without cells. The cell plate was then incubated in a 37°C, 5% CO2 
incubator for ±30minutes. Following incubation, 100μL/well of MDR dye-loading solution was 
added. The plate was further incubated overnight at room temperature, protected from light. 
Following complete incubation, the fluorescence intensity was monitored at 
Ex/Em=490/525nm using a Synergy HT multiwell fluorescence microplate reader equipped 
with curve fitting software (BioTek® Instruments, Winooski, Vermont, USA).  
d) Data was analyzed by subtracting the fluorescence in the blank wells from the values of the 
wells with cells treated with the polyoxyethylene (40) stearate. The optimal concentration 
was obtained from the plot of the dose response curve. 
 
6.2.6. Determination of the micro-environmental pH of the OCMT 
The pH modulating effect of citric acid on the micro-environment was determined using a 
SevenMulti™ dual pH/conductivity meter (Mettler-Toledo International Inc., Im Langacher, 
Greifensee, Switzerland) (Badawy and Hussain, 2006; Tatarvati and Hoag, 2006). OCMT 
formulations F1-F13 containing varying concentrations of citric acid were prepared according to 
the specifications in Table 6.1. Samples were prepared by immersing the OCMT formulations 
(without the polymeric sheet) in 50mL of simulated human intestinal fluid (SHIF) pH 6.8 for a 
period of ±4 hours. The samples were hydrated for a short period of time in order to avoid the 
confounding factors that may result from complete leaching out of the pH modulator. Following 
hydration, the pH glass electrode tip was allowed to penetrate the swollen outer polymer shell of 
the tablet and held until a stable reading was obtained. The positioning of the electrode is 
important in the determination of the micro-environmental pH due to the presence of a pH 
gradient between the center and exterior of the OCMT (Tatarvati and Hoag, 2006). Thus, the 
electrode was positioned closer to the center of the swollen outer polymer shell to obtain an 
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accurate measurement of the micro-environmental pH. In addition, the influencing effects of the 
pH–modulator on the macro-environment was determined by measuring the pH of the SHIF 
immediately surrounding the OCMT formulations F1-F13.  
 
6.2.7. Elucidation of the rheological properties of the prolamine-based ‘smart’ polymeric 
sheet solution 
The flow characteristics of the zein aqueous-ethanol solutions, forming the basis of the ‘smart’ 
polymeric sheet, were evaluated by determining their intrinsic viscosities.  The viscosity (η) was 
measured at a temperature of 25°C and a shear rate of 100s-1 for 360s using a Haake Modular 
Advanced Rheometer System (MARS) (ThermoFisher Scientific, Karlsruhe, Germany) fitted 
with a C35/1° titanium rotor sensor. Samples of the zein solutions (15%w/v, 17.5%w/v and 
20%w/v) as highlighted in Table 6.1 were placed on the sample stage and measured according 
to the parameters employed in Table 6.4. Determination of the viscosity was essential for 
informing on the suitability of the zein solutions to appropriately adhere to the surface of the 
OCMT in the formation of the ‘smart’ polymeric sheet. 
 
Table 6.4: Rheological parameters employed for the analysis of the viscosity of the zein 
aqueous-ethanol solutions 
Parameter  Value 
Cone and plate gap 0.050mm 
Driver version 1.29 
Inertia 1.721 x 10-6 kg.m2 
A-factor 89051.00 Pa/Nm 
M-factor 57.010 (1/s)/((rad/s) 
Temperature 25°C 
Damping 30.00 
 
6.2.8. Mucoadhesive strength determination of the ‘smart’ polymeric sheet 
Mucoadhesive studies were performed on all the FCCCD design formulations as per Table 6.1 
to determine the influence of changes in variable concentration on the adhesiveness of the 
‘smart’ polymeric sheet. The study involved the preparation of 0.1%w/v solution of mucin in SHIF 
pH 6.8. Formulations F1-F13 were incubated in the prepared solution in an orbital shaker 
maintained at 37˚C and 50 rpm. The concentration of free mucin in the solution, after 6h 
duration, was determined by a UV spectrophotometer, at 201nm (IMPLEN NanophotometerTM, 
Implen GmbH, München Germany), using a 10 times dilution factor of path-length 0.1 mm. The 
difference in the concentration of the mucin solution before and after incubation was the 
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indication of the amount crosslinked with the ‘smart’ polymeric sheet as seen in Equation 6.6 
(He et al., 1998). 
 Mucoadhesion% = [Mucin before]−[Mucin after][Mucin before] × 100                                                                    (6.6) 
 
Where, [Mucin before] is the concentration of the mucin solution before incubation and [Mucin 
after] is the concentration of the mucin solution after incubation. 
 
6.2.9. Qualitative and quantitative determination of the physicomechanical properties of 
the ‘smart’ polymeric sheet  
The tensile characterization of the ‘smart’ polymeric sheet was determined through the use of a 
calibrated Texture Analyzer (TA.XT plus, Stable Microsystems, Surrey, UK) fitted with a 5kg 
load cell. Samples were prepared by casting the varying concentrations of zein solutions (as per 
Table 6.1) onto petri dishes and subsequently drying them in a laboratory fumehood until a thick 
film, mimicking the polymeric sheet surrounding the OCMT, was formed. Strips of the dried films 
were cut and measured for their width and thickness to an accuracy of 0.1μm at different places 
along the length of the film using a digital caliper (25 × 0.01mm capacity) (Taizhou hangyu tools 
gauge and blades Co., Ltd., Wenqiao, Zhejiang, China). The samples were subsequently fixed 
between miniature tensile grips (10mm apart) which were attached to the base plate and load 
cell carrier of the Texture Analyzer. The parameters employed for textural analysis are shown in 
Table 6.5.  
 
Table 6.5: Textural profiling parameters used for tensile characterization of the ‘smart’ polymeric 
sheet 
Parameters Settings 
Test mode Tension 
Pre-test speed 1 mm/s 
Test speed 0.5 mm/s 
Post-test speed 0.5 mm/s 
Trigger type Auto 
Trigger force 0.05 N 
 
Textural profiling of the ‘smart’ polymeric sheet was essential in determining its ability to 
adequately provide acid protection by maintaining a physicomechanically stable structure. This 
method yielded textural profiles that were used to generate the tensile stress and tensile strain 
(percent elongation) using Equations 6.7 and 6.8, respectively.  
180 
 
𝜎𝜎 = 𝐹𝐹
𝐴𝐴𝑜𝑜
                                                                                                                           (6.7) 
 
Where, 𝜎𝜎 represents the tensile stress (N/mm2), 𝐹𝐹 is the breaking force (N) and 𝐴𝐴𝑜𝑜 is the cross-
sectional area of the sample (mm2). 
 
𝜀𝜀 = 𝑙𝑙𝑖𝑖
𝑙𝑙𝑜𝑜
× 100                                                        (6.8)                                                    
 
Where, 𝜀𝜀 represents the elongation at break (%), 𝑆𝑆𝑜𝑜 is the original length of the sample and 𝑆𝑆𝑖𝑖 is 
the increase in length of the sample at breaking point 
 
The ratio of the tensile stress to the tensile strain was calculated using the Young’s modulus 
(elasticity modulus) as represented in Equation 6.9. 
 E = 𝜎𝜎
𝜀𝜀
= 𝐹𝐹.𝐿𝐿𝑜𝑜
𝐴𝐴𝑜𝑜.∆𝐿𝐿                                      (6.9) 
 
Where, E is the Young’s modulus (MPa), 𝐹𝐹 is the force at break, 𝐴𝐴𝑜𝑜 is the cross-sectional area 
of the sample, ∆𝑊𝑊 is the change in the length of the sample and 𝑊𝑊𝑜𝑜 is the original length of the 
sample. 
 
In addition, a more realistic type of testing of the mechanical strength of the ‘smart’ polymeric 
sheet-encapsulated OCMT formulations were determined using a state-of-the-art biaxial tensile 
testing system (BioTester 5000, CellScale biomaterials testing, Waterloo, Ontario, Canada) 
fitted with a load cell of 5N. Randomly selected OCMT formulations, responding to varying 
concentrations of zein within the ‘smart’ polymeric sheet were selected for analysis. Typically, 
oral dosage forms are subjected to forces within the GIT, associated with the physiological 
phases of gastric digestion, motility and contractility (Laulict et al., 2010). Thus, reproducing 
physiological conditions during testing of the OCMTs mechanical strength provides information 
on its ability to withstand these forces and aids in predicting its clinical success. The BioTester 
brings together several high-precision components for the measurement and analysis of 
biomaterials by applying biaxial forces. It is fitted with a high resolution charge coupled device 
(CCD) camera (1280 x 960 pixels) to provide excellent image quality, video tracking and 
analysis. The OCMT formulations were hydrated in SHIF pH 6.8 to simulate the hydration of the 
tablet in situ. The OCMT was mounted and secured with tungsten rakes (tine diameter=305μm, 
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tine spacing=1.0mm, puncture depth=1.9mm) symmetrically attached 5mm apart on the X and 
Y axis of the sample as shown in Figure 6.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3: High resolution image of the OCMT sample mounted in the biaxial system. The 
tungsten rakes on each side secures the sample in place. 
 
Once mounted in the testing system, the OCMT was simultaneously stretched in both the X and 
Y directions according to the parameters set out in Table 6.6. Biaxial force and displacement 
data were digitally sampled at 15Hz using the BioTester 5000 custom software (LabJoy 5.80, 
CellScale, Waterloo, Ontario, Canada).  
 
Table 6.6: Biaxial tensile testing parameters employed for the ‘smart’ polymeric sheet 
encapsulated OCMT 
Test Parameters X and Y Axis 
Control Mode Displacement 
Control Function Ramp 
Stretch Magnitude 40% strain 
Preload N/A 
Stretch Duration 40s 
Recovery Duration 40s 
Repetitions 3 
Data Output Frequency 15Hz 
Image Output Frequency 15Hz 
Y 
X 
5mm 
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6.2.10. In vitro peptide release 
The effect of the ‘smart’ polymeric sheet on the release behavior of the incorporated peptide 
was determined via in vitro analysis. In vitro peptide release studies were performed using a 
USP35 dissolution apparatus II (Caleva, Model 7ST, UK). The OCMT formulations F1-F13 were 
placed in 900mL SHIF at pH 6.8, beneath a ring mesh assembly within the dissolution vessel to 
prevent floatation. Dissolution was performed at a speed of 50rpm (37±0.5°C). Sampling of 3mL 
was undertaken at predetermined time intervals (0, 1, 2, 3, 6, 8, 10, 12, 24) and replaced with 
an equal quantity (3mL) of peptide-free dissolution medium to maintain sink conditions. Samples 
were analyzed using a Peptide Enzyme Immunoassay (Peninsula Laboratories International, 
Inc. San Carlos, CA, USA) which is a high sensitivity absorbance assay specific for the 
detection of Octreotide.  Peptide release was calculated as a mean of three determinations as 
all studies were conducted in triplicate. In addition, the mean dissolution time (MDT) (Equation 
6.10) was calculated from dissolution data to determine the peptide release rate (Sathish and 
Syed, 2013). 
 
𝑀𝑀𝑀𝑀𝑀𝑀 = ∑ 𝑑𝑑𝑚𝑚𝑖𝑖𝑚𝑚 ×∆𝑑𝑑𝑖𝑖=𝑛𝑛𝑖𝑖=1
∑ ∆𝑑𝑑𝑖𝑖=𝑛𝑛𝑖𝑖=1
                                                                                                        (6.10) 
 
Where, MDT is Mean Dissolution Time; i is the dissolution sample number; n is the number of 
dissolution sample time; tmid is time at mid-point between i and i=1; ΔM is the additional amount 
of protein dissolved between i and i=1. 
 
6.2.11. Response surface analysis and constraint optimization  
The response surface analysis of the variables for the FCCCD design formulations were 
computed using Minitab® statistical software (V15, Minitab Inc., PA, USA). Response surface 
and contour plots were derived for the measured responses (micro-environmental pH and 
degree of mucoadhesion) of the experimentally designed formulations and a statistical 
optimization was generated based on the responses obtained. 
 
6.3. Results and Discussion 
 
6.3.1. Analysis of the polyoxyethylene (40) stearate-CYP3A4 interaction 
The efficacy of proteins and peptides is profoundly influenced by the limiting effects of the CYP 
3A family and its major drug-metabolizing enzyme CYP3A4. Inhibition of CYP3A4 may 
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significantly improve the oral bioavailability of proteins and peptides. Thus, the influence of 
varying concentrations of the CYP3A4 inhibitor-polyoxyethylene (40) stearate (Table 6.2) on the 
catalytic activity of CYP3A4 was investigated. High-throughput fluorescence screening yielded 
the results shown in Figure 6.4. The reaction rates can be expressed in terms of pmole resorufin 
formed per unit time per unit amount of protein (50μg/well) by interpolation from the standard 
curve as presented in Figure 4a. The reaction kinetics of the recombinant human CYP3A4 
enzyme in the presence of higher concentrations (4.5-10mg/mL) of polyoxyethylene (40) 
stearate displayed lower intensities of the emitted light as demonstrated by the lower RFU 
values obtained in Figure 6.4b-c, attributable to the successful inhibition of catalytic oxidation. In 
addition, the positive CYP3A4 inhibitor control-ketoconazole displayed a higher RFU then the 
test concentrations in Figure 4b-c, but a noticeably lower RFU then the solvent control. Since 
the solvent control contained no inhibitor, it readily permitted the catalytic oxidation of the non-
fluorescent CYP3A4 substrate to its highly fluorescent metabolite (Figure 6.2), subsequently 
producing higher RFU values over the kinetic time period.  
 
Polyoxyethylene (40) stearate concentrations within the lower end of the spectrum (0.02-
3mg/mL) emitted more light and correspondingly displayed higher RFU values, compared to the 
higher concentrations, as depicted in Figure 6.4d-e. Noticeably, concentrations ≤0.5mg/mL 
demonstrated lower interactions with CYP3A4 then ketoconazole with the minimum 
concentrations (0.02-0.03mg/mL) approaching the RFU values of the solvent control as 
revealed by the reaction kinetics observed in Figure 6.4e. Owing to the observed interactions of 
polyoxyethylene (40) stearate with CYP3A4 at higher inhibitor concentrations, the results 
obtained were anticipated. Lower inhibitor concentrations did not significantly inhibit the catalytic 
oxidative process and predictably promoted the enzyme-substrate interaction. These results 
were further evaluated by interpreting the plot of the maximal velocity (Vmax) as a function of the 
inhibitor concentration shown in Figure 6.4f. The results obtained follow the principles of the 
Michealis-Menten model which represents the best approach for explaining enzyme kinetics 
(Ainsworth, 1977; Ritchie and Prvan, 1996). The model takes the form of an equation (Equation 
6.11) relating the reaction velocity to the substrate concentration (Ritchie and Prvan, 1996). 
 
𝑣𝑣 = 𝑉𝑉𝑚𝑚𝑎𝑎𝑚𝑚 [𝐷𝐷]
𝐾𝐾𝑚𝑚+[𝐷𝐷]                (6.11) 
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Where 𝑣𝑣 is the velocity of the reaction, 𝑉𝑉𝑚𝑚𝑎𝑎𝑚𝑚 is the maximal velocity achieved by the system at 
saturating substrate concentrations, 𝐾𝐾𝑚𝑚 is the Michaelis constant and [𝑆𝑆] is the concentration of 
the substrate. 
 
Vmax is directly proportional to the enzyme concentration. Thus, it follows that at higher 
concentrations of polyoxyethylene (40) stearate, CYP3A4 does not convert much of the 
substrate to its fluorescent metabolite per unit of time despite the enzyme being saturated with 
substrate. This leads to a maximal velocity that is relatively small as observed in Figure 6.4f. 
Correspondingly, at lower concentrations of polyoxyethylene (40) stearate, an opposite effect is 
observed and lower maximal velocities are obtained. Essentially, the maximal velocity gives an 
indication of how fast the enzyme can catalyze the reaction.  
 
Furthermore, the relative percent inhibition for the tested concentrations of polyoxyethylene (40) 
stearate were calculated by comparison to the activity of reactions containing no inhibitor and no 
enzyme. The dose-response curve obtained is presented in Figure 6.4g. The concentrations at 
50% inhibition (IC50) and maximal inhibition (IC100) were calculated as 0.5mg/mL and 5mg/mL, 
respectively. The percentage inhibition of CYP3A4 increased exponentially with an increase in 
the polyoxyethylene (40) stearate concentration until a maximum saturated inhibitory potential 
was reached (5mg/mL). This was determined as the optimum inhibitor concentration that would 
successfully inhibit CYP3A4 enzyme activity and potentially produce the desired increased oral 
bioavailability of the incorporated peptide within the OCMT.  
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Figure 6.4: a) Resorufin standard curve. One mole of resorufin corresponds to the metabolism 
of one mole of CYP3A4 substrate. b-e) Reaction kinetics of  recombinant human CYP3A4 
enzyme at 25°C in the presence of the canonical competitive CYP3A4 inhibitor ketoconazole 
and the varying concentrations of Polyoxyethylene (40) stearate (the solvent control reaction 
contained a final concentration of 1% acetonitrile). f) Plot of maximal velocity (Vmax) as a 
function of the inhibitor concentration (mg/mL) based on Michaelis-Menten kinetics. g) Dose-
response curve of the calculated percent activity for each concentration of polyoxyethylene 40 
stearate by comparison to the activity of reaction of the solvent and background controls. The 
IC50 (0.5mg/mL) and IC100 (5mg/mL) are highlighted and each value represents the mean of 
three replicate experiments. 
 
6.3.2. Analysis of the polyoxyethylene (40) stearate-Pgp interaction 
The transmembrane efflux of drugs, facilitated by the MDR1 transporter-Pgp influences the 
pharmacokinetics of oral formulations (Shugarts and Benet, 2009). Pgp in conjunction with 
CYP3A4 functions in a concomitant manner to reduce systemic oral bioavailability of drugs 
through their respective mechanisms (Kim et al., 1999). Thus, it was essential to monitor the 
MDR1 pump activity in the presence of varying concentrations of polyoxyethylene (40) stearate 
(Table 6.2) in order to determine the optimum concentration of inhibitor that would potentially 
inhibit Pgp in addition to CYP3A4. Prior to running the assay, cells needed to be prepared to 
allow the penetration of the fluorescent MDR indicator into the cell membranes. Figure 6.5 
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displays live imaging of the cultured Caco-2 cells that were used for the screening of the MDR 
pump inhibitor.   
 
Figure 6.5: Still frame from live cell imaging of confluent Caco-2 cells in growth media (DMEM, 
10% FBS), used for the preparation of the MDR assay. 
 
The MDR assay measured the cellular fluorescent intensity in response to the varying 
concentrations of polyoxyethylene (40) stearate. The cellular fluorescent intensity is dependent 
on the intracellular free dye concentration which can increase significantly following a short 
incubation. This dye is extruded by the MDR transporters in cells that express MDR1, resulting 
in a decreased cellular fluorescence intensity. However, the presence of an agent/inhibitor that 
interferes with the MDR1 pump activity can block dye extrusion and cause a significant increase 
in cellular fluorescence intensity. The effect of polyoxyethylene (40) stearate on the inhibition of 
the Pgp pump in Caco-2 cells is shown in Figure 6.6. Results demonstrated that at increasing 
concentrations of polyoxyethylene (40) stearate, the fluorescence signal increased due to the 
inhibition of the Pgp pump which enhanced the intracellular accumulation of the MDR indicator 
dye.  
 
The IC50 concentration of 0.13mg/mL was determined directly from the non-linear logistic curve 
fitting as shown in Figure 6.6. The cellular fluorescence intensity increased significantly up to an 
inhibitor concentration of 0.5mg/mL. Concentrations between 0.5mg/mL and 10mg/mL produced 
no significant increases in the cellular fluorescence intensity but rather fluctuated around a 
central RFU value of 32000. As a result, this concentration range was determined as the 
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maximum inhibitory potential of polyoxyethylene (40) stearate for inhibition of the Pgp pump in 
Caco-2 cells. Based on the analysis of the interaction of polyoxyethylene (40) stearate with both 
CYP3A4 and Pgp, it was determined that the final optimal concentration for use in the OCMT in 
the achievement of co-inhibition was 5mg/mL.  This concentration fell within the range of the 
maximum inhibitory potential of the Pgp pump and was determined as the optimal inhibitory 
concentration for CYP3A4 activity, thus achieving the desirable co-inhibitory effect and 
potentially increasing the oral bioavailability of proteins and peptides.  
 
 
 
 
 
 
 
 
   
 
 
 
 
Figure 6.6: Effect of polyoxyethylene (40) stearate on the inhibition of the Pgp pump in Caco-2 
cells. The IC50 (0.13mg/mL) was determined directly from logistic curve fitting results.  
 
6.3.3. Evaluation of the micro-environmental pH modulation 
The high enzyme activity at the intestinal brush border may significantly influence the 
degradation of proteins and peptides (Bruno et al., 2013). The enzymes predominantly found at 
the brush border membrane site include, disaccharidases and alkaline phosphatase (Holmes, 
1971; Jiang and Yan, 2008). The point at which the enzyme is most active is known as the 
optimum pH and is typically in a range of neutral to alkaline pH (6.8-7.5) for the intestinal 
enzymes, as illustrated in Figure 6.7 (Jiang and Yan, 2008). Enzymes are notably affected by 
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changes in pH, with very high or very low pH values causing a loss in enzyme activity and 
overall stability.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7: Graphical illustration of enzyme activity as a function of pH. 
 
Thus, the incorporation of the nonpolymeric acid based pH modifier (citric acid) in the OCMT 
should function to reduce the optimal environment for enzyme activity by decreasing the micro-
environmental pH. The effect of citric acid on the micro-environmental pH was monitored and 
results yielded the changes shown in Figure 6.8. The change in the pH over the 4-hour study 
period directly corresponded to the concentration of citric acid employed in the OCMT 
formulations F1-F13, presented in Table 6.1. F1, F6 and F8 contained a higher concentration 
(10mg) of citric acid, consequently producing a greater modulation in the micro-environmental 
pH ranging from 3.2-3.8. Correspondingly, lower concentrations (5mg/7.5mg) of citric acid 
produced a smaller, but nevertheless significant change in the micro-environmental pH (± 4.5). 
Furthermore, the macro-environmental pH of each formulation was determined at the start and 
end of the experiment to monitor the influence of citric acid on the surrounding environment. 
Ideally, the results shown in Figure 6.8 displayed no significant pH changes to the macro-
environment. Overall, the results demonstrated the applicability of the pH modifier to 
successfully reduce the micro-environmental pH and indirectly inhibit enzyme activity at the 
brush border.  
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Figure 6.8: The changes in the micro and macro-environmental pH of the OCMT formulations 
F1-F13 in the presence of the pH-modulating agent-citric acid. 
 
6.3.4. Assessment of the rheological characteristics of the prolamine-based ‘smart’ 
polymeric sheet solution  
Viscosity is a physical property that describes a fluid’s internal resistance to flow, influenced by 
various factors such as: concentration, temperature, pressure and shear rate (George and 
Qureshi, 2013). The measurement of the rheological behavior and more specifically, the 
viscosity of the polymeric sheet solution was necessary for determining its ability to adequately 
adhere to the surface of the OCMT during the ‘dipping’ process. Results of viscosity (η) and 
shear stress (τ) as a function of the shear strain rate (ẏ) of varying concentrations of zein (Table 
6.1) are shown in Figure 6.9.  
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Figure 6.9: Rheological profiles depicting the flow curve and viscosity shear rate curve of a) 
15%w/v zein, b) 17.5%w/v and c) 20%w/v zein. 
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An interpretation of Newton’s law of viscosity was used to characterize the flow properties of the 
polymeric solutions. Typically, Newtonian fluids display a constant viscosity at increasing shear 
rates as well as a linear relationship between the shear stress and shear rate (George and 
Qureshi, 2013; Irgens, 2014). However, the rheological profiles obtained for the zein solutions 
displayed a more complicated relationship between the viscosity, shear stress and shear rate 
and thus was characterized as a Non-Newtonian fluid. The shear viscosity decreased with an 
increase in the shear rates for all the zein solutions as shown in Figure 6.9a-c. This was 
characteristic of pseudoplastic (shear-thinning) fluids which are found for many polymer 
solutions.  
 
Pseudoplastic fluids display Newtonian regions at very high and very low shear rates where the 
shear viscosity becomes almost constant (Irgenz, 2014). This was clearly evident in the 
rheograms obtained for the solutions in Figure 6.9a-b. Figure 6.9a characteristically displayed a 
zero shear viscosity observed within the first Newtonian region, attributable to the low 
concentration of zein (15%w/v) contained within the solution causing it to be more liquid-like 
when stationery. In addition, flow curves of the shear stress as a function of shear rate 
displayed interesting Bingham-plastic type behavior for all zein concentrations. Bingham fluids 
require a yield stress (τy) to initiate flow but follow a straight line after the yield stress is reached, 
as observed in Figure 6.9a-c. Although Bingham-plastic behavior is more characteristic of 
suspensions and emulsions, the rheograms obtained for the zein solutions suggest the 
applicability of attributing the rheology to a combination of pseudoplastic and bingham-plastic 
type behaviors.   
 
Furthermore, since ethanol and plasticizer concentrations were kept constant, the major 
contributing factor to the observed viscosities was the zein concentrations. The viscosity 
increased with an increase in the zein concentrations as depicted in Table 6.7. Higher 
concentrations of zein (17.5%w/v and 20%w/v) displayed higher average viscosities as compared 
to the lower concentration of zein (15%w/v). Correspondingly, a 15%w/v concentration of the 
polymeric sheet solution displayed lower shear stress values compared to the 17.5%w/v and 
20%w/v concentrations due to lower stresses being required to initiate the flow of low viscosity 
fluids. Ideally, the solution should be viscous enough to adhere to the OCMT and form a thick 
layer during the ‘dip’ and ‘dry’ method. The results obtained were further supported by the 
observations during preparation of the OCMT which demonstrated the improved adherence of 
the polymeric sheet solution to the OCMTs based on higher respective viscosities. 
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Table 6.7: Effects of varying concentrations of zein on the viscosity and shear stress of the 
polymeric sheet solution 
Zein (%w/v) Viscosity at a shear rate of 100s-
1 (mPas) 
Shear stress (Pa) 
15 505.4 13.53 
17.5 2426 18.68 
20 2881 29.05 
 
6.3.5. Elucidation of the mucoadhesive strength of the ‘smart’ polymeric sheet 
Zein has been shown to possess mucoadhesive properties, making it desirable for multiple drug 
delivery applications (Patel et al., 2010; Wongasasulak et al., 2013; Paliwal and Palakurthi, 
2014). Thus, the effect of zein on the mucoadhesive strength of the ‘smart’ polymeric sheet was 
analyzed for the OCMT formulations F1-F13. The mucoadhesion mechanism can be divided 
into three steps involving firstly, the intimate contact of the polymer with the tissue, secondly, the 
consolidation of the polymer with the mucin chains and thirdly, the formation of weak chemical 
bonds (Carvalho et al., 2010; Singh and Rana, 2012).  The in vitro technique of measurement 
used for the determination of the mucoadhesive strength was centered around the adsorption 
theory, mechanistically based on surface forces that result in chemical bonding, by measuring 
the mucin remained after interaction (Singh and Rana, 2012).  
 
The results obtained demonstrated the effect of the zein concentrations on the mucoadhesion 
percentages obtained for each formulation as displayed in Figure 6.10. Typically, OCMT 
formulations F5, F7 and F8 containing a 15%w/v concentration of zein displayed lower 
mucoadhesion percentages (±22.49%). This was attributed to a lower degree of secondary 
chemical interactions between the polymer and the mucin. Comparatively, higher concentrations 
of zein (17.5%w/v and 20%w/v) displayed a greater interaction and improved crosslinking with 
mucin, supported by the higher mucoadhesion percentages obtained. The mucoadhesion 
provided by zein creates an opportunity for the OCMT to have an increased residence time 
within the intestine, improved permeability and enhanced bioavailability of the incorporated 
peptide. 
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Figure 6.10: In vitro mucoadhesion percentages resulting from interactions with the varying 
concentrations of zein contained with the ‘smart’ polymeric sheet of the OCMT formulations F1-
F13. 
 
6.3.6. Comprehensive textural analysis of the ‘smart’ polymeric sheet and encapsulated 
OCMT 
Comprehensive analysis of the film-casted zein solutions, mimicking the ‘smart’ polymeric sheet 
surrounding the OCMT, was analyzed with respect to their textural properties. The tensile 
strength, percentage elongation and elasticity of the varying concentrations of zein films were 
determined from quantitative analysis of the textural profiles obtained. The results are presented 
in Table 6.8, demonstrating the effects of increasing concentrations of zein on the tensile 
strength, percentage elongation and Young’s modulus. The calculated tensile properties were 
directly proportional to the increasing concentrations of zein from 15%w/v to 20%w/v. The highest 
concentration (20%w/v) of the film-casted zein solution was found to be the strongest, displaying 
the highest tensile strength (9.16 N/mm2). Similarly, the percentage elongation at break 
(194.69%) was greater for higher concentrations of zein, attributable to an improved interaction 
with the incorporated plasticizer leading to greater molecular mobility and increased flexibility 
(Lim and Hoag, 2013).  The Young’s modulus for all concentrations of zein revealed no 
Mucoadhesion (%)
0 5 10 15 20 25 30 35 40
 
F2 
 
 
F1 
 
 
F3 
  
F4 
 
 
F6 
 
 
F5 
 
 
F7 
  F8 
 
 
F10 
 
 
F9 
 
 
F11 
  
F12 
  F13 
 
 
Fo
rm
ul
at
io
n 
N
um
be
r
197 
 
significant differences, indicating the ability of all the concentrations to resist elastic deformation 
when a force is applied. The characterization of the mechanical properties of the film-casted 
zein solutions was essential for determining its ability to adequately form a strong polymeric 
sheet around the OCMT, functioning to withstand external stresses during processing or in vivo 
application. Furthermore, the intrinsic mechanical properties and the capability of the polymeric 
sheet to maintain its physical structure around the OCMT are important for providing necessary 
acid protection.   
 
Table 6.8: Summary of the tensile strength, percent elongation at break and Young’s elastic 
modulus at increasing concentrations of the film-casted zein solutions. 
Zein (%w/v) Tensile strength 
(N/mm2) 
Percent Elongation 
at break (%) 
Young’s Modulus 
(MPa) 
15 4.68 118.74 3.94 
17.5 7.02 150.47 4.67 
20 9.16 194.69 4.71 
 
Additionally, a more realistic state testing of the complete OCMT with the surrounding ‘smart’ 
polymeric sheet was evaluated by measuring biaxial forces and displacements. The profiles 
obtained for the varying concentrations of zein as part of the ‘smart’ polymeric sheet is 
graphically depicted in Figure 6.11a-c. The force-time, displacement-time and force-
displacement graphs obtained were proportional to the nominal stress, nominal strain and 
nominal stress-strain graphs, respectively (Gregory and Callaghan, 2012; Holmes et al., 2012). 
The force-time graphs showed how the measured X and Y forces change over time. The 
superimposition noticed for the X and Y data indicated the uniformity of the ‘smart’ polymeric 
sheet, requiring equal forces to stretch on both axes. A 40% strain on all the samples produced 
a 1800um displacement of the ‘smart’ polymeric sheet from its original position. The application 
and release of load on the sample within each test cycle mimicked the propulsive contraction 
and relaxation movements within the GIT presenting as stretch and recovery phases within 
each cycle as shown in Figure 6.11a-c.  
 
Oral dosage forms experience forces in vivo, resulting from muscular contractions experienced 
during gastric digestion and emptying. Laulicht and co-workers, (2010) investigated the gastric 
forces experienced in vivo by tablets via high resolution pill tracking. Results from the study 
revealed the average human gastric-emptying force in the fasted and fed state as being 
414±194 dynes (±4.14 mN) and 657±84 dynes (±6.57mN), respectively. The average stresses 
that the ‘smart’ polymeric sheet of the OCMT could withstand was significantly high for all the 
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formulations with a 20%w/v concentration displaying the highest breaking force as shown in the  
Force-time profiles obtained in Figure 6.11c. Although the breaking forces decreased with each 
test cycle, it still provided significant tensile strength which demonstrated the suitability of the 
‘smart’ polymeric sheet to appropriately withstand gastric forces in vivo. These results favorably 
supported the independent testing of the film-casted ‘smart’ polymeric sheet solutions shown in 
Table 6.8. 
 
In addition, the hysteresis loops noted in the force-displacement graphs of each of the samples 
provided a qualitative assessment of the elasticity of the sample and its ability to return back to 
its original position after a load has been removed (Jang et al., 2005). A purely elastic material 
will return along the same curve and no energy is lost. Due to the viscous properties of the zein 
solutions, as highlighted previously in Figure 6.9, the mechanical response of the ‘smart’ 
polymeric sheet experienced a time delay in returning back to its original shape indicated by the 
area between the load and unload curves. The area between the load and unload curves of the 
20%w/v concentration of zein was smaller than for the 15%w/v and 17.5%w/v, respectively. This 
indicated that less energy was absorbed by the 20%w/v polymeric sheet and a better recovery to 
its original shape.  
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Figure 6.11: Biaxial tensile testing profiles of Force-Time, Displacement-Time and Force-
Displacement in the X and Y direction for the ‘smart’ polymeric sheet-encapsulated OCMTs 
containing a) 15%w/v zein, b) 17.5%w/v zein and c) 20%w/v. 
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6.3.7. In vitro peptide release analysis  
The experimental peptide release patterns of Octreotide from the pHM ‘smart’ polymeric sheet 
encapsulated-OCMT formulations F1-F13 in SHIF (pH 6.8) was evaluated. A 4-parameter 
logistic curve generated from the peptide-specific ELISA kit was used to calculate the unknown 
concentrations of the experimental samples at each time point. Results were displayed as a 
function of fractional release against time as shown in Figure 6.12a-d. All formulations displayed 
similar release profiles to that of the optimized OCMT, containing no pH modifier or ‘smart’ 
polymeric sheet, as profiled previously (Choonara et al., 2016). 
 
Similarly, the release profiles were attributed to the combined effects of swelling, surface 
erosion and in situ crosslinking with fractional releases ranging from 0.79-0.89. Ideally, the pH 
modifier did not significantly affect the release profiles obtained, however, the ‘smart’ polymeric 
sheet accounted for the improved control of release of Octreotide, specifically from 8hr to 24hr. 
This was further supported by the MDT values obtained which gave an indication of the peptide 
release rate (Wadher et al., 2011; Sathish and Syed, 2013). The MDT values for the higher 
concentrations of zein (17.5%w/v and 20%w/v) within the ‘smart’ polymeric sheet of the OCMT 
formulations were ±21.20, indicating a slower release rate as compared to the lower 
concentrations. These results indicated the ability of the polymeric sheet to further retard the 
release of the peptide from the OCMT formulations.  
 
Moreover, the release data was fitted into zero-order, first order, Higuchi and Korsmeyer–
Peppas models to determine the mechanism of release of the peptide. The best-fit model for the 
peptide release data observed was based on the kinetic modelling of the regression coefficients 
and its proximity to the numeral 1. A model depicting a value closest to 1 amongst the 
formulations would demonstrate the appropriateness of that model in explaining the peptide 
release mechanism. Based on this premise, all formulations were best-fit into the Higuchi 
(R2=0.98) model which describes the release of the peptide from a matrix as a function of the 
square-root of a time-dependent process based on Fickian diffusion. Due to the complexity of 
the system, near zero-order (R2=0.97) release was observed for many formulations. Thus, the 
release kinetics was attributed to both the Higuchi and zero-order models.  
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Figure 6.12: Fractional release of Octreotide from the pHM ‘smart’ polymeric sheet 
encapsulated-OCMTs: a) formulations F1-F3, b) formulations F4-F6, c) formulations F7-F9 and 
d) formulations F10-F13. 
 
6.3.8. Response surface analysis of the Face-Centered Central Composite Design 
(FCCCD) 
Experimentally derived responses affecting the performance of the device were further 
evaluated to determine the distinct relationship between the variable components and the 
measured responses. The micro-environmental pH and degree of mucoadhesion were the 
measured responses that were fitted into the FCCCD design to ascertain the optimal OCMT 
formulation that would ultimately produce the desired outcome. Complete ANOVA analysis of 
the measured responses were undertaken to determine the adequacy of the model. 
 
 
Time (hours)
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
F
ra
ct
io
n
al
 R
el
ea
se
0.0
0.2
0.4
0.6
0.8
1.0
F1 
F2 
F3 
Time (hours)
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
F
ra
c
ti
o
n
a
l R
e
le
a
s
e
0.0
0.2
0.4
0.6
0.8
1.0
F4 
F5 
F6 
Time (hours)
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
F
ra
ct
io
n
al
 R
el
ea
se
0.0
0.2
0.4
0.6
0.8
1.0
F10 
F11 
F12 
F13 
Time (hours)
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
F
ra
ct
io
n
al
 R
el
ea
se
0.0
0.2
0.4
0.6
0.8
1.0
F7 
F8 
F9 
(a) (b) 
(c) (d) 
204 
 
The residuals are part of the observation that is not explained by the fitted model, thus, 
comprehensive residual analysis of the measured responses was important for determining the 
accuracy of the model produced. The residual plots shown in Figure 6.13 depict the difference 
between the observed values and predicted or fitted values. This assists in determining whether 
the ordinary least square (OLS) assumptions are being met (Myers et al., 2015). The normal 
probability plots of the responses generally followed a straight line indicating that the data was 
normally distributed with only a few outliers and no unidentified variables.  
 
This was further supported by the histogram of residuals showing a symmetrical distribution with 
slight clustering observed at the center for the micro-environmental pH response. The plots of 
residuals against their fitted values and in their observation orders appeared to be generally 
random (centered around zero) with a few outliers identified by the points far away from zero 
and from other points in the x-direction. These points were considered to be influential and were 
taken into account during statistical optimization. In addition, the same value was noted at 
certain points on the residual versus the order of data plots due to the similarity in the responses 
for the centre-points.  Overall, the results demonstrated the suitability of the regression model 
and consistency of the residuals with stochastic error (Myers et al., 2015).  
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Figure 6.13: Residual plots of the responses; micro-environmental pH and mucoadhesion (%). 
 
Furthermore, surface plots characterized the relationship between the experimental variables 
and responses achieved. The effects of citric acid on the micro-environmental pH is depicted in 
Figure 6.14a. High concentrations of citric acid (10mg) produced a greater decrease in the 
micro-environmental pH (3.2-3.8) potentially enabling the OCMT to reduce the optimal 
environment for enzyme activity to a greater degree in vivo. Contrastingly, lower concentrations 
of citric acid (5mg) produced smaller decreases in the micro-environmental pH (>4.5) and thus a 
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lessened effect on the enzyme activity. The concentration of zein did not display any significant 
effects on the pH values observed. However, the zein concentrations were a major contributing 
factor to the mucoadhesion percentages obtained as shown in Figure 6.14b. The mucoadhesion 
results demonstrated a directly proportional relationship to the concentration of zein contained 
within the ‘smart’ polymeric sheet. Predictably, citric acid did not affect display any significant 
effects on the mucoadhesion of the pHM ‘smart’ polymeric sheet encapsulated-OCMT 
formulations F1-F13. 
 
 
Figure 6.14: Response surface plots depicting the effects of citric acid (mg) and zein (%w/v) on 
a) the micro-environmental pH and b) mucoadhesion percentage. 
 
A full ANOVA analysis of response surface regressions was undertaken and results obtained 
are depicted in Table 6.9. The overall estimated analysis of variance for the regression 
coefficients for the micro-environmental pH and mucoadhesion percentages produced 
statistically significant effects for zein concentration levels on mucoadhesion, with p-values of 
0.004 and <0.001, respectively. In addition, the R2 and R2-adjusted values for the pH (87.8% 
and 79.2%) and mucoadhesion percentages (97.8% and 96.3%) were satisfactory. Ultimately, 
statistical probability distributions confirmed the reliability of the statistical design in generating 
an optimal formulation (Myers et al., 2015). 
 
Table 6.9: Estimated p-values for the measured responses.  
 p-values 
Response variable Micro-pH Mucoadhesion 
Zein (%w/v) 0.244 <0.001 
Citric acid (mg) 0.477 0.329 
Zein (%w/v)* Zein (%w/v) 0.245 <0.001 
Citric acid (mg)* Citric acid (mg) 0.074 0.383 
Zein (%w/v)* Citric acid (mg) 0.778 0.634 
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6.3.9. Response optimization of the pHM ‘smart’ polymeric sheet encapsulated-OCMTs  
A response optimization procedure (MINITAB®, V15, Minitab, USA) for the FCCCD design 
formulations was used to determine the optimum levels of the formulatory variables. An optimal 
formulation was developed following real-time constrained optimization of the micro-
environmental pH and mucoadhesion percentages. The constrained settings that were utilized 
to determine the optimized levels of the independent variables that would generate the desired 
change in the micro-environmental pH and improved mucoadhesion are presented in Table 
6.10. The optimized levels of the independent variables, the goal for the response, the predicted 
response, y, at the current factor settings, as well as the individual and composite desirability 
scores are shown in Figure 6.15. Based on the statistical desirability function, it was found that 
the composite desirabilities for the formulation was 1.0.  
 
Table 6.10: Constrained settings for response optimization.  
Response Goal Target 
Micro-environmental pH Minimize 3.8 
Mucoadhesion Maximize 34.0 
 
 
 
 
 
 
 
 
Figure 6.15: Optimization plots outlining factor settings and desirability values for the optimal 
formulation.  
 
6.4. Concluding Remarks 
Physicochemical and physicomechanical characterization of the FCCCD design formulations of 
the pHM ‘smart’ polymeric sheet encapsulated-OCMTs was essential for determining the 
capability of the characteristic design to impart tri-functionalization. The co-inhibitory potential of 
polyoxyethylene (40) stearate was demonstrated by in-depth analysis of interactions between 
 Zein (%w/v)     Citric acid (mg) 
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CYP3A4 and Pgp which generated an optimum inhibitory concentration of 5mg/mL. The micro-
environmental pH determination provided information about the change in the pH in the 
presence of the pH modifier. Analysis of the characteristic properties of the ‘smart’ polymeric 
sheet was undertaken by evaluation of the distinct rheological profiles and degree of 
mucoadhesion. In addition, critical physicomechanical characterization of the polymeric sheet 
favorably demonstrated its in vivo ability to withstand GIT forces. The in vitro release of 
Octreotide was influenced by the combined effects of swelling, surface erosion and in situ 
crosslinking, displaying fractional releases ranging from 0.79-0.89. The ‘smart’ polymeric sheet 
provided a slower release rate as evidenced by the higher MDT value (±21.20) obtained. 
Response surface analysis demonstrated the statistical significance (p < 0.05) of the regression 
model in producing single concentration variables for an optimized formulation. Conclusive 
results from physicochemical and physicomechanical characterization of the design 
demonstrated the applicability of the pHM ‘smart’ polymeric sheet encapsulated-OCMTs to 
provide Tri-functionalization. The optimized Tri-functionalized OCMT was evaluated thoroughly 
in Chapter 7 to determine the suitability of the system to proceed with in vivo studies. 
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CHAPTER 7 
COMPREHENSIVE CHARACTERIZATION OF THE STATISTICALLY OPTIMIZED TRI-
FUNCTIONALIZED ORAL CORE-MELT TABLET (OCMT) FOR ENHANCED PROTEIN AND 
SYNTHETIC PEPTIDE DELIVERY 
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Bibi F. Choonara, Yahya E. Choonara, Pradeep Kumar, Lisa C. du Toit, Viness Pillay. Comprehensive In 
vitro and In vivo Characterization of the Statistically Optimized Tri-Functionalized Oral Core-Melt Tablet 
(OCMT) for Enhanced Protein and Synthetic Peptide Delivery. 
 
 
Abstract 
In-depth analysis of the statistically optimized Tri-functionalized OCMT for the delivery of gastro-
sensitive proteins and synthetic peptides was undertaken. Physicochemical and 
physicomechanical characterization techniques demonstrated the optimum in vitro potential of 
the Tri-functionalized OCMT in the achievement of clinical efficacy. Analysis of the 
mucoadhesion and micro-environmental pH produced results that fell within the range of desired 
targeted responses. The gastro-resistant nature of the Tri-functionalized OCMT was 
demonstrated by achievement of <5% acid uptake. In addition, comprehensive mechanical 
analysis confirmed the multi-textural properties of the Tri-functionalized OCMT in the attainment 
of optimum mechanical strength. MRI imaging highlighted the hydrational transitions and unique 
pharma-engineering of the tablet. The release of Octreotide from the statistically optimized 
formulation demonstrated the effect of distinct formulatory components on the responsive 
potential of the Tri-functionalized OCMT. Fractional release reached a value of ±0.9 with the 
MDT (±21.58) indicating a slower peptide release rate. Lastly, critical cytotoxic analysis of the 
EPB showed a ±79.83% survival rate, indicating acceptable biocompatibility and safety for 
clinical use. 
 
Keywords: OCMT; tri-fucntionalization; multi-textural; gastro-resistant; physicochemical 
properties; physicomechanical properties 
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7.1. Introduction  
Therapeutic proteins and peptides have become the favored option in the treatment of multiple 
disease conditions (Park et al., 2011; Chin et al., 2012; Choonara et al., 2014). Due to their 
increased demand, pharmaceutical scientists have rallied in their efforts to produce a viable 
alternative to the conventional parenteral route of administration (Park et al., 2011). Widespread 
oral routes still remain the preeminent option for delivery of pharmaceuticals. However, the oral 
delivery of therapeutic proteins and peptides continue to face immense challenges due to the 
physical and chemical impediment of the gastrointestinal (GIT) barrier (Choonara et al., 2014). 
Despite active efforts, no clinically useful oral formulations have been developed and as a 
result, novel technologies attempting to breakthrough the field are of great interest.   
 
The rational design of the OCMT promotes tri-functionalization through the novel incorporation 
of a core-melt archetype, a pH modifier and a ‘smart’ polymer modulated co-inhibitory 
component. This creates a platform for enhanced delivery of proteins and synthetic peptides by 
triple targeting of the major contributing factors hindering successful oral delivery of proteins and 
peptides. These factors include: 1) the exposure of proteins and peptides to unfavorable 
conditions within the stomach as a result of the fluid contents and acidic functioning 
environment; 2) poor absorption and low oral bioavailability of proteins and peptides resulting 
from their large molecular mass, hydrophilic properties, CYP3A4 metabolism and P-glycoprotein 
(Pgp) facilitated transmembrane efflux and lastly; 3) the enzymatic degradation at the intestinal 
brush border (Mahato et al., 2003; Arhewoh et al., 2005; Park et al., 2011; Antunes et al., 2013). 
The overall simplified modus operandi of the Tri-functionalized OCMT is presented in Figure 
7.1. 
 
The Tri-functionalized OCMT would possess the inherent capabilities that meet the following 
design criteria, which would form the basis of ultimate optimization of the device: 
1. The characteristic design of the outer polymer shell with core-melt archetype and in situ 
crosslinking capabilities to provide structural protection and controlled release of the 
incorporated protein or synthetic peptide. 
2. A prolamine-based ‘smart’ polymeric sheet providing acid resistance and mucoadhesion, 
interacting well with hydrophilic molecules (i.e. proteins and peptides) and functioning to 
enable passage of proteins and peptides through the GIT membrane. In addition, 
provision of sustained release capabilities in direct tablet compression. 
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3. A co-inhibitor within the ‘smart’ polymeric sheet to influence the activity of Cytochrome 
P450 3A4 (CYP3A4) and P-glycoprotein (Pgp) and improve oral bioavailability by 
reducing protein and peptide metabolism and inhibiting transmembrane efflux.   
4. Incorporation of a pH modifier to facilitate indirect inhibition of enzyme activity at the 
brush border by transiently lowering the micro-environmental pH and subsequently 
reducing the optimal environment for enzyme activity. 
 
Figure 7.1: Diagrammatic representation of the proposed mechanism of action of the Tri-
functionalized OCMT. 
 
7.2. Materials and Methods 
 
7.2.1. Materials 
Menthol (2-isopropyl-5-methylcyclohexanol, 99% purity, MW=156,27g/mol), cetomacrogol 1000, 
poly (ethylene oxide) (PEO) (Polyox™, WSR-303), polyoxyethylene (40) stearate (Myrj® 52), 
Zein (from maize) and excipients, sodium carboxymethylcellulose (CMC), magnesium stearate 
and sucrose were purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA). The crosslinker 
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sodium carbonate (NaCO3) was purchased from Associated Chemical Enterprises (ACE) (Pty) 
Ltd. (Johannesburg, Gauteng, South Africa). Pectin citrous (poly-D-galacturonic acid methyl 
ester), the crosslinker di-potassium hydrogen orthophosphate anhydrous (K2HPO4; 
MW=174.18g/mol), citric acid (≥99.5% purity, MW=210.14g/mol), methyl paraben (methyl 4-
hydrozybenzoate, MW=152.15g/mol) and polypropylene glycol (1, 2–propanediol) were procured 
from Merck Chemicals (Pty) Ltd. (Modderfontein, Gauteng, South Africa). Octreotide acetate 
(C49H66N10O10S2; Mw=1019.247g/mol) was purchased from Bolon Pharmachem Co., Ltd. 
(Taizhou, Zheijang, China). In vitro Toxicology Assay kit, MTT based was purchased from 
Sigma-Aldrich Corp. (St. Louis, MO, USA). Caco-2 cell line (ATCC® HTB-37™), Dulbecco’s 
Modified Eagle’s Medium (DMEM), Foetal bovine serum (FBS), Penicillin-streptomycin, Trypsin-
EDTA (0.25mg/mL) and all other cell culture components were purchased from Separations 
(Pty) Ltd. (Randburg, Gauteng, South Africa).  All other reagents were of analytical grade and 
were employed as received. 
 
7.2.2. Formulation of the statistically optimized Tri-functionalized OCMT 
The Tri-functionalized OCMT was prepared in accordance with the detailed methods presented 
previously in Chapter 4, 5 and 6. The variables used in the preparation of the different 
components of the Tri-functionalized OCMT were statistically optimized through a combination 
of a Box-Behnken and Face-Centered Central Composite Design (FCCCD), as highlighted 
previously. The statistical optimization produced the variable concentrations shown in Table 7.1 
which were subsequently used for preparation of the Tri-functionalized OCMT. All other 
components and excipients of the Tri-functionalized OCMT were used at concentrations 
originally specified in Choonara et al, (2016) or according to their experimentally determined 
optimal values. 
 
Table 7.1: Formulation concentrations for the optimized Tri-functionalized OCMT 
Variable Optimized value 
NaCO3 and K2HPO4 (%w/w) 23.093 
Eutectic Powder Blend (%w/w) 12 
Pectin (mg) 65.314 
Zein (%w/v) 19.166 
Citric acid (mg) 10 
 
A summarized overview of the preparation method for the Tri-functionalized OCMT is presented 
in Figure 7.2. The EPB for the core eutectic region of the tablet was synthesized according to a 
co-melt method and served as a carrier for the crosslinking agents and therapeutically active 
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protein or peptide. The outer polymer shell was double layered and contained a pH modifier, 
assembling to form a pH-modified (pHM) OCMT with inner core eutectic region. The prolamine-
based ‘smart’ polymeric sheet was prepared by a simple solvation technique and successfully 
incorporated the co-inhibitor for CYP3A4 and P-glycoprotein. The complete Tri-functionalized 
OCMT was obtained by encapsulation of the pHM-OCMT with the co-inhibitory ‘smart’ polymeric 
sheet via a ‘dip’ and ‘dry’ method.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2: Overview of the preparation method for the statistically optimized Tri-functionalized 
OCMT. 
 
7.2.3. In-process validation of the Tri-functionalized OCMT  
Weight uniformity, thickness and friability analyses were performed on the statistically optimized 
Tri-functionalized OCMT. A sample of 5 units of the Tri-functionalized OCMT was analyzed to 
determine the standardization of the tablet-assembly and encapsulation process. The weight of 
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the OCMT was determined using an analytical digital balance (Mettler, Model AE 240, 
Griefensee, Switzerland) with readings recorded to 2 decimal places. The thickness of the Tri-
functionalized OCMTs were determined using a digital caliper (25 × 0.01mm capacity) (Taizhou 
hangyu tools gauge and blades Co., Ltd., Wenqiao, Zhejiang, China). The friability was 
determined using a Friabilator (Erweka D-63150, Heusenstamm, Germany) set at 25 rpm for 4 
minutes with 1% set as the upper limit of acceptability. The friability was calculated as 
percentage loss using Equation 7.1. 
 
𝑊𝑊𝑊𝑊𝑑𝑑  = (𝑊𝑊0−   𝑊𝑊𝑡𝑡)𝑊𝑊0  × 100                                                                                                               (7.1) 
 
Where, WLt  is the total weight loss; W0 is the initial weight of the tablet and Wt is the final weight 
of the tablet. 
 
7.2.4. Evaluation of the micro-environmental pH response of the statistically optimized 
Tri-functionalized OCMT 
The micro-environmental pH response resulting from the pH modulating effects of the optimized 
concentration of citric acid, as shown in Table 7.1, was determined using a SevenMulti™ dual 
pH/conductivity meter (Mettler-Toledo International Inc., Im Langacher, Greifensee, Switzerland) 
(Badawy and Hussain, 2006; Tatarvati and Hoag, 2006). The optimized OCMT formulation 
containing 10mg of citric acid (without the polymeric sheet) was prepared (n=3) for evaluation 
by immersing in 50mL of simulated human intestinal fluid (SHIF) pH 6.8 for a period of ±4 hours. 
The optimized OCMT was hydrated for a short period of time in order to avoid the confounding 
factors that may result from complete leaching out of the pH modulator. Following hydration, the 
pH glass electrode tip was allowed to penetrate the swollen outer polymer shell of the tablet and 
held until a stable reading was obtained. In addition, the pH of the SHIF immediately 
surrounding the optimized OCMT was measured to confirm the observation of an unaltered 
macro-environmental pH.  
  
7.2.5. Characterization of the molecular and vibrational transitions of the optimized co-
inhibitory ‘smart’ polymeric sheet  
The successful incorporation of polyoxyethylene (40) stearate with the optimized concentration 
of zein to form the co-inhibitory ‘smart’ polymeric sheet was evaluated by characterizing the 
vibrational and molecular transitions using Attenuated Total Reflectance-Fourier Transform 
Infrared Spectroscopy (ATR-FTIR). FTIR analysis was conducted on the native components 
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(polyoxyethylene (40) stearate and zein) as well as the blended combination to acquire critical 
microstructural information that would validate a successful incorporation process. Results were 
recorded on a PerkinElmer Spectrum 2000 FTIR spectrophotometer with a single-reflection 
diamond MIRTGS detector (PerkinElmer Spectrum 100, Llantrisant, Wales, UK) fitted with a 
universal ATR polarization accessory for the FTIR spectrum series at a resolution of 4cm-1. 
Samples were prepared by casting the optimized co-inhibitory ‘smart’ polymeric sheet solution 
into petri dishes and allowing them to dry in a laboratory fumehood overnight to form dried films 
(mimicking the dried polymeric sheet surrounding the OCMT). The films were subsequently 
placed on a diamond crystal for analysis between a scanning range of 4000-600cm-1 at a 
constant pressure of 120psi with 32 accumulations. 
 
7.2.6. Determination of the pertinent rheological properties of the optimized ‘smart’ 
polymeric sheet solution 
The flow characteristics of the optimized zein aqueous-ethanol solution, forming the basis of the 
‘smart’ polymeric sheet was evaluated for its rheological properties via measurement of intrinsic 
viscosity.  The viscosity (η) was measured at a temperature of 25°C and a shear rate of 100s-1 
for 360s using a Haake Modular Advanced Rheometer System (MARS) (ThermoFisher 
Scientific, Karlsruhe, Germany) fitted with a C35/1° titanium rotor sensor. An optimized 
concentration of the zein solution (19.166%w/v) was placed on the sample stage and measured 
according to the parameters employed in Table 7.2. Evaluation of the viscosity was important in 
validating the suitability of the zein solution to optimally adhere to the surface of OCMT during 
encapsulation. 
 
Table 7.2: Parameters employed for analysis of the viscosity of the optimized ‘smart’ polymeric 
sheet solution  
Parameter  Value 
Cone and plate gap 0.050mm 
Driver version 1.29 
Inertia 1.721 x 10-6 kg.m2 
A-factor 89051.00 Pa/Nm 
M-factor 57.010 (1/s)/((rad/s) 
Temperature 25°C 
Damping 30.00 
 
 
 
219 
 
7.2.7. Determination of the in vitro and ex vivo mucoadhesive response of the 
statistically optimized Tri-functionalized OCMT  
The inherent mucoadhesivity imparted by the ‘smart’ polymeric sheet encapsulating the OCMT 
was evaluated both in vitro and ex vivo. The in vitro mucoadhesive strength determination 
involved the preparation of a 0.1%w/v solution of mucin in SHIF pH 6.8. The optimized Tri-
functionalized OCMT formulation was incubated in the prepared solution in an orbital shaker 
maintained at 37˚C and 50 rpm for 6 hours (n=3). Following incubation, the concentration of free 
mucin in the solution was determined by a UV spectrophotometer, at 201nm (IMPLEN 
NanophotometerTM, Implen GmbH, München Germany), using a 10 times dilution factor of 
path-length 0.1 mm. The difference in the concentration of the mucin solution before and after 
incubation was the indication of the amount crosslinked with the optimized ‘smart’ polymeric 
sheet as calculated using Equation 7.2 (He et al., 1998). 
 Mucoadhesion% = [Mucin before]−[Mucin after][Mucin before] × 100                                                                    (7.2) 
 
Where, [Mucin before] is the concentration of the mucin solution before incubation and [Mucin 
after] is the concentration of the mucin solution after incubation. 
 
In addition, pig intestinal tissue was used to determine the ex vivo bioadhesivity of the Tri-
functionalized OCMT. A Texture Analyzer (TA.XT plus, Stable Microsystems, Surrey, UK) fitted 
with a mucoadhesion rig provided a vessel of a temperature-controlled (37°C) intestinal fluid 
and mucin environment for the pig intestinal tissue set-up. The Tri-functionalized OCMT was 
slightly hydrated in SHIF and attached to a cylindrical probe of the mucoadhesion rig using 
double-sided bioadhesive tape. The probe with attached OCMT was lowered at a constant 
speed of 0.1mm/s to bond with the mucin-coated tissue at a predetermined compression force 
(0.08N) for a period of 120s. After the contact time, the probe withdrew at a constant speed 
(0.1mm/s) from the intestinal tissue and the adhesive properties were measured.  The work of 
adhesion was calculated from the Force-Distance profile obtained, using Equation 7.3 (Cevher 
et al., 2008). 
 Work of adhesion (mJ. cm2) = AUCF−D
πr2
              (7.3) 
 
Where, AUC is the area under the curve of the Force-Distance profile and 𝜋𝜋𝐸𝐸2 is the surface 
area of the Tri-functionalized OCMT. 
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7.2.8. Determination of the gastric acid uptake of the optimized Tri-functionalized OCMT 
Acid uptake tests in accordance with USP standards were performed to assess the gastric acid 
uptake and resistance of the gastro-resistant ‘smart’ polymeric sheet of the OCMT. The 
optimized ‘smart’ polymeric sheet encapsulated OCMTs were weighed prior to being subjected 
to dissolution conditions (n=6). The weighed OCMTs were placed in USP Simulated Gastric 
Fluid (SGF) pH 1.2 in a USP35 dissolution apparatus II (Caleva, Model 7ST, UK) at 37°C, 
50rpm for 2 hours. Following 2 hours, the tablets were removed and excess SGF was drained 
and blotted dry with filter paper. The tablets were then reweighed and the SGF uptake was 
calculated according to Equation 7.4 (Liu et al., 2011; Czarnocka and Alhnan, 2015).  
 SGF uptake (%) = 𝑊𝑊𝑓𝑓−𝑊𝑊𝑖𝑖
𝑊𝑊𝑖𝑖
 × 100                                                                                                (7.4) 
 
Where, 𝑊𝑊𝑓𝑓 is the final weight of the tablet and 𝑊𝑊𝑖𝑖 is the initial weight of the tablet. 
 
7.2.9. Evaluation of the surface and core matrix hardness, matrix resilience and 
deformation energy of the optimized Tri-functionalized OCMT 
Textural profiling of the optimized Tri-functionalized OCMT was assessed using a calibrated 
Texture Analyzer (TA.XT plus, Stable Microsystems, Surrey, UK) fitted with a 5kg load cell 
(n=3). The Matrix Hardness (MH), Matrix Resilience (MR), Deformation Energy (DE) and rigidity 
of the Tri-functionalized OCMT were collectively determined. A flat-tipped steel probe (2mm 
diameter) was used for surface determination of MH and MR values of the OCMT. Further 
textural analyses of the OCMT were undertaken using a needle-tipped steel probe (2mm 
diameter) for determination of the MH and DE through penetration of the complete thickness of 
the Tri-functionalized OCMT. The samples were prepared and placed in a Temperature 
Controlled Peltier Cabinet (XT/PC) coupled to a Peltier Control Unit (PCU) (Stable 
Microsystems, Surrey, UK) for analysis by Texture Analyzer to mimic the internal body 
temperature environment. The Thermal Cabinet was equilibrated to 37°C (body temperature) to 
enable the melting of the core region of the Tri-functionalized OCMT before testing was 
performed within the cabinet. Data was captured at a rate of 200 points per second using 
Texture Exponent Software (V3.2). MR was computed as a percentage of the ratio between the 
Area under the Curve (AUC) of the peak to baseline (AUC2–3) and the baseline to peak (AUC1–2) 
from a Force-Time profile as shown in Equation 7.5.  
 Resilience % = �Area 2:3
Area 1:2� × 100                                                                                                 (7.5) 
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The DE and matrix rigidity were both obtained from the AUC and gradient of the Force-Distance 
profiles, respectively. The MH was calculated using the Brinell Hardness Number (BHN) 
(Equation 7.6). Textural analysis on the OCMT was performed in triplicate. The parameters 
employed for the analysis are listed in Table 7.3. 
 
 BHN =  2F
πD �D−√D2−d2�                                                                                                (7.6) 
 
Where, BHN is Brinell Hardness Number; D is diameter of indenter (mm); F is elucidated from 
the gradient of the initial force and the final force obtained and d is diameter of indentation 
(mm). 
 
Table 7.3: Parameters employed for physicomechanical profiling of the optimized Tri-
functionalized OCMT 
Parameters Matrix Hardness, Deformation 
Energy & matrix rigidity 
Matrix Resilience 
Pre-test speed 1 mm/s 1 mm/s 
Test speed 0.5 mm/s 1mm/s 
Post-test speed 1 mm/s 1mm/s 
Trigger type Auto Auto 
Trigger force 0.05 N 0.05 N 
Compression strain N/A 40% 
*The distance for probe penetration into the tablet was set at 4mm for the needle-tipped steel probe 
 
7.2.10. Biaxial tensile testing of the optimized Tri-functionalized OCMT 
A realistic type of testing of the mechanical strength of the optimized Tri-functionalized OCMT 
was determined using a state-of-the-art biaxial tensile testing system (BioTester 5000, CellScale 
biomaterials testing, Waterloo, Ontario, Canada), fitted with a load cell of 5N. Typically, oral 
dosage forms are subjected to forces within the GIT, associated with the physiological phases 
of gastric digestion, motility and contractility (Laulict et al., 2010). Thus, reproducing 
physiological conditions during testing of the OCMTs mechanical strength provides information 
on its ability to withstand these forces and aids in predicting its clinical success. The BioTester 
brings together several high-precision components for the measurement and analysis of 
biomaterials. It measures biaxial forces to mirror the multidirectional tension experienced by 
materials in vivo. The system is fitted with a high resolution charge coupled device (CCD) 
camera (1280 x 960 pixels) to provide high quality images, video tracking and analysis. 
Samples were prepared by hydrating the Tri-functionalized OCMT in SHIF pH 6.8 for 30 
minutes to simulate hydration of the tablet in situ. Following hydration, the OCMT was mounted 
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and secured with tungsten rakes (tine diameter=305μm, tine spacing=1.0mm, puncture 
depth=1.9mm) symmetrically attached 5mm apart on the X and Y axis of the sample as shown 
in Figure 7.3.   
 
 
 
 
 
 
 
 
 
 
Figure 7.3: Image of the Tri-functionalized OCMT mounted in the biaxial system. Small rake 
one either side secure the sample in place. X and Y orientation is noted in the upper right hand 
corner.  
 
Once mounted in the testing system, the OCMT was simultaneously stretched in both the X and 
Y directions according to the parameters set out in Table 7.4. The interior strains, resulting from 
the material stretching evenly in two directions, were tracked using image-tracking software 
(LabJoy 5.80, CellScale, Waterloo, Ontario, Canada).  In addition, biaxial force and rake 
displacement data were digitally sampled at 15Hz using the BioTester 5000 custom software 
(LabJoy 5.80, CellScale, Waterloo, Ontario, Canada). Cross-sectional areas and rake 
displacement normalization values were used to calculate the stress and strain, respectively. 
Consequently, the ratio of the tensile stress to the tensile strain was calculated using the 
Young’s modulus (elasticity modulus) as represented in Equation 7.7.  
 E = 𝜎𝜎
𝜀𝜀
= 𝐹𝐹.𝐿𝐿𝑜𝑜
𝐴𝐴𝑜𝑜.∆𝐿𝐿                                      (7.7) 
 
Y 
X 
5mm 
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Where, E is the Young’s modulus (MPa), 𝐹𝐹 is the force at break, 𝐴𝐴𝑜𝑜 is the cross-sectional area 
of the sample, ∆𝑊𝑊 is the change in the length of the sample and 𝑊𝑊𝑜𝑜 is the original length of the 
sample. 
 
Table 7.4: Biaxial tensile testing parameters employed for the Tri-functionalized OCMT 
Test Parameters X and Y Axis 
Control Mode Displacement 
Control Function Ramp 
Stretch Magnitude 40% strain 
Preload N/A 
Stretch Duration 40s 
Recovery Duration 40s 
Repetitions 3 
Data Output Frequency 15Hz 
Image Output Frequency 15Hz 
 
7.2.11. Gravimetric evaluation of the swelling and erosion of the optimized Tri-
functionalized OCMT 
The mean percentage water uptake and erosion of the Tri-functionalized OCMT was determined 
by gravimetric analysis of the degree of swelling and erosion over a 24-hour period. The initial 
weight of the optimized Tri-functionalized OCMT was recorded prior to being placed in 50mL of 
SHIF pH 6.8 for 24 hours. At predetermined time intervals (0, 1, 2, 3, 6, 8, 12, 24 hours) the Tri-
functionalized OCMTs were removed and blotted dry to remove surface water before being 
weighed on a calibrated electronic scale. The percentage increase in tablet weight, attributed to 
fluid uptake at each time point was determined using Equation 7.8. The erosion of the matrix, 
following its drying to a constant weight at each time interval was calculated using Equation 7.9. 
 % ∆ Swelling =  Wf−Wi
Wi
× 100                                                                                                    (7.8)       
 
Where, 𝑊𝑊𝑓𝑓 is the weight of the swollen tablet at time t and 𝑊𝑊𝑖𝑖 is the initial weight of the tablet. 
(n=3). 
 % Erosion = Wi−Wf
Wi
 × 100                       (7.9) 
 
Where, 𝑊𝑊𝑖𝑖 is the initial weight of the tablet and 𝑊𝑊𝑓𝑓 is the final dried weight of the tablets after 24 
hours. (n=3). 
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7.2.12. Magnetic Resonance Imaging (MRI) of the optimized Tri-functionalized OCMT 
Magnetic Resonance Imaging (MRI) provides an opportunity for non-destructive and non-
invasive monitoring of the fate of the dosage form in vivo. It extends the knowledge of the 
structural and physico-chemical properties of the sample and assists in correlating the in vitro 
behavior with in vivo performance. Live-acquisition of the pH- responsive transitions of the Tri-
functionalized OCMT was determined using a digital MARAN-i System configured with a DRX2 
HF Spectrometer console (Oxford Instruments Magnetic Resonance, Oxon, UK) equipped with 
a compact 0.5 Tesla permanent magnet and stabilized at 37°C in SHIF pH 6.8. The dynamics of 
fluid ingress into a drug delivery system is a contributing factor towards controlling drug release 
(Tajiri et al., 2010). The hydrational and erosional morphological transitions of the Tri-
functionalized OCMT was captured every 10 min with MARAN-i version 1.0 software. MARAN-i 
software comprises image acquisition software and image analysis software. The image 
acquisition parameters are depicted in Table 7.5. 
 
Table 7.5: MARAN-i image acquisition parameters employed for magnetic resonance imaging 
S.No. Parameter Value 
1. Imaging protocol FSHEF 
2. Requested gain (%) 4.17 
3. Signal strength 68.92 
4. Average 2 
5. Matrix size 128 
6. Repetition time (ms) 1000.00 
7. Spin Echo Tau (ms) 6.80 
8. Image acquired after 60min 
9. Total scans 64 
 
T1 weighted images were produced in the spin echo method and the signal intensity of the MRI 
images were defined according to Equation 7.10.  
 
𝑆𝑆 = MO + exp −TET2  × �1 − exp −TRT1 �           (7.10) 
 
Where, MO is magnetization, T1 and T2 are relaxation times, TR is repetition time and TE is echo 
time. 
 
7.2.13. In vitro peptide release 
Determination of the in vitro release of the peptide from the Tri-functionalized OCMT is critical 
towards understanding the effects of the formulatory components on the mechanism of release 
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noted. In vitro peptide release studies were performed using a USP35 dissolution apparatus II 
(Caleva, Model 7ST, UK). The Tri-functionalized OCMT was placed in 900mL SHIF at pH 6.8, 
beneath a ring mesh assembly within the dissolution vessel to prevent floatation. Dissolution 
was performed at a speed of 50rpm (37±0.5°C). Sampling of 3mL was undertaken at 
predetermined time intervals (0, 1, 2, 3, 6, 8, 10, 12, 24) and replaced with an equal quantity 
(3mL) of peptide-free dissolution medium to maintain sink conditions. Samples were analyzed 
using a Peptide Enzyme Immunoassay Kit (Peninsula Laboratories International, Inc. San 
Carlos, CA, USA) which is a high sensitivity absorbance assay specific for the detection of 
Octreotide. Peptide release was calculated as a mean of three determinations as all studies 
were conducted in triplicate. The concentrations at each time point were calculated using results 
obtained from the standard curve. The resultant in vitro peptide release data were fitted into 
various mathematical modelling equations to determine the mechanism of peptide release from 
the Tri-functionalized OCMT. Furthermore, the mean dissolution time (MDT) (Equation 7.11) 
was calculated from dissolution data to determine the peptide release rate (Sathish and Syed, 
2013).  
 MDT = ∑ tmid ×∆Mi=ni=1
∑ ∆Mi=ni=1
                                                                                                         (7.11) 
 
Where, MDT is the Mean Dissolution Time; i is the dissolution sample number; n is the number 
of dissolution sample time; tmid is time at mid-point between i and i=1; ΔM is the additional 
amount of protein dissolved between i and i=1. 
 
7.2.14. Evaluation of the cytotoxicity of the Eutectic Powder Blend (EPB) in the core 
eutectic region of the Tri-functionalized OCMT 
Due to the novel synthesis of the EPB, in vitro determination of its cytotoxic effects became 
necessary prior to the OCMT’s evaluation in vivo. Traditionally, in vitro determination of toxic 
effects of compounds has been performed by counting viable cells after staining with a vital dye. 
Thus, a Caco-2 human intestinal cell line was selected as it represented the best in vitro model 
to assess the toxic effects of formulation components on the intestinal barrier. An MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide)-based in vitro toxicology assay kit 
provided a simple, accurate and highly reproducible method for measuring the activity of living 
cells via mitochondrial dehydrogenases (Kowapradit et al., 2010; Zhang et al., 2013). The kit 
was carried out according to the standard protocol and involved the a) preparation of cells, b) 
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treatment with test compounds, c) running the MTT assay and d) calculation of the relative cell 
viability. 
 
a) Preparation of cells:  
Cell Culture: A Caco-2 cell line (ATCC® HTB-37™) was used as it represented a reliable in 
vitro model of human small intestinal mucosa. Cells were grown on tissue culture treated 
25cm2 flasks at 37°C in a humidified 5% CO2 incubator (RS Biotech Galaxy Standard, C&M 
Scientific, Livingston, West Lothian, UK). The growth medium was Dulbecco’s Modified 
Eagle’s Medium (DMEM) containing 4.0 mM L-Glutamine, 4500mg/L Glucose and sodium 
pyruvate, supplemented with 10% Foetal bovine serum (FBS) and a 0.1% penicillin-
streptomycin solution. Cells were grown under standard conditions until 70-80% confluency 
was reached.  
Cell Detachment: Following confluency, the cells were detached from the flask using 
Trypsin-EDTA (0.25mg/mL) and centrifuged at 2000rpm for ±10minutes. The supernatant 
was discarded and the cells were resuspended in growth medium to form a cell suspension.  
Cell Counting: A sample of the cell suspension was removed and treated with Trypan Blue 
solution (0.4%) for hemocytometer counting. The Trypan blue-treated cell suspension was 
applied to a Bright-Line™ Hemocytometer (Hausser Scientific, Horsham, PA, USA). The 
hemocytometer was placed on a microscope stage (OLYMPUS CK2, Shibuya-ku, Tokyo, 
Japan) and counted using a 10x objective. The concentration of cells was calculated by 
averaging all 1mm2 areas counted and applying Equation 7.12. 
 C = n
v
                                                                                                                               (7.12)   
 
Where, C is the cell concentration in cells/mL, n is the average number of cells/mm2 area 
and v is the volume counted (10-4).  
Cell seeding: Upon completion of counting, the appropriate dilutions were made and cells 
were seeded at 2 x 104 cells/well in a 96-well microplate for overnight incubation in growth 
medium. 
b) Treatment with test compounds: 
The optimized concentration of the EPB (12%w/w), as determined previously in Choonara et 
al, (2016), was dissolved in serum-free medium and sterilized overnight under UV radiation. 
The resultant solution (500uL) was added to the 96-well plate after removal of the growth 
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medium and incubated for a further 24 hours. After treatment, the solutions were removed 
and replaced with fresh growth medium for 1 hour to stabilize the cells. 
c) Running the MTT assay: 
      Following stabilization, the media was removed and 100uL of MTT (0.1mg/mL MTT in 
serum-free medium) was added and incubated for 4 hours. After the incubation period, the 
resultant formazan crystals were dissolved by adding an amount of MTT Solubilization 
Solution equal to the original culture medium volume. Following complete dissolution of the 
MTT formazan crystals, the absorbance was spectrophotometrically measured at a 
wavelength of 570/690nm using a Synergy HT multiwell microplate reader (BioTek® 
Instruments, Winooski, Vermont, USA). 
d) The relative cell viability was determined by comparing the mean Optical Density (OD) of the 
treated cells with the blank wells (medium with no cells) and non-treated control cells using 
Equation 7.13. The background absorbance at 690nm was subtracted from the 570nm 
measurement. 
 Relative cell viability (%) = OD570 (sample)−OD570 (blank) 
OD570 (control)−OD570 (blank) × 100                                               (7.13)   
Where, OD570 (sample) is the optical density of the EPB sample, OD570 (blank) is the optical 
density of the blank wells (medium without cells) and OD570 (control) is the non-treated control 
cells. 
 
7.3. Results and Discussion 
 
7.3.1. Analysis of weight uniformity, thickness and friability of the optimized Tri-
functionalized OCMT 
The optimized Tri-functionalized OCMTs (n=5) displayed a uniformity in mass, each having an 
average weight of 585.52±0.25mg. Measurement of the thickness of the Tri-functionalized 
OCMTs yielded average readings of 4.5±0.03mg.  In addition, evaluation of the friability 
revealed a result of 0.55±0.02%. The friability value desirably fell within the 1% limit of 
acceptability as defined in the USP and as a result reflected positively on the ability of the Tri-
functionalized OCMT to withstand external stresses during storage. Overall, the results obtained 
for weight uniformity, thickness and friability validated the tablet assembly and encapsulation 
process and reliably demonstrated its reproducibility. Figure 7.4 displays the dimensions of the 
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optimized Tri-functionalized OCMT with in-process validation results as well as a digital image 
of the optimized tablet. 
 
 
 
 
 
 
 
 
Figure 7.4: a) Schematic representation of the dimensions of the OCMT and b) a digital image 
of the optimized Tri-functionalized OCMT. 
 
7.3.2. Influence of the pH modifier on the micro-environmental pH 
The effect of the pH modifier-citric acid contained within the Tri-functionalized OCMT was 
evaluated. Enzymatic degradation at the intestinal brush border accounts for a significant 
amount of degradation of therapeutic proteins and peptides (Bruno et al., 2013). Typically, the 
brush border enzymes function optimally at a pH of 6.8-7.5 (Jiang and Yan, 2008). Thus, citric 
acid should preferably function to disrupt this optimal environment by decreasing the micro-
environmental pH. Results from evaluation of the statistically optimized variable concentration of 
citric acid (10mg) contained within the Tri-functionalized OCMT, as shown in Table 7.1, yielded 
an approximate 3 point decrease in the micro-environmental pH from 6.8 to 3.4. This pH value 
ideally fell within the range of the desired targeted response, statistically generated for the 
optimized Tri-functionalized OCMT. At optimal concentrations of citric acid (10mg) and zein 
(19.166%w/v), the formulation should produce a pH of <3.6 as shown in Figure 7.5. Predictably 
no change in the macro-environmental pH (6.8) was noted, favorably supporting the ability of 
citric acid to influence the micro-environmental pH at the brush border via indirect enzyme 
inhibition and subsequent leading to improvement in the stability of therapeutic proteins and 
peptides. 
Core  
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Sheet 
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Figure 7.5: Contour plot depicting the effect of citric acid and zein concentrations on the micro-
environmental pH response.  
 
7.3.3. Analysis of the chemical structure transitions of the co-inhibitory ‘smart’ 
polymeric sheet 
FTIR studies confirmed the appropriate blending of polyoxyethylene (40) stearate with the 
aqueous ethanol zein solution in the formation of the co-inhibitory ‘smart’ polymeric sheet, as 
evidenced by the spectra shown in Figure 7.6. As expected, transmittance bands characteristic 
to the native components (zein and polyoxyethylene (40) stearate) were apparent in the 
transmittance spectra obtained for the film-casted co-inhibitory ‘smart’ polymeric sheet solution. 
In the IR spectrum in Figure 7.6a, zein exhibited a broad band at 3312cm-1, representative of 
parallel hydrogen-bonded O-H and N-H stretching frequencies (Coates, 2000; Müller et al., 
2011). Furthermore, in the C-H stretch region of the spectrum, a high intensity peak at 2975cm-1 
was assigned to symmetrical -CH3 stretching vibrations. Zein also displayed intense spectral 
bands at 1650cm-1 and 1543cm-1, assigned to amide I and amide II bands, respectively.  The 
amide I band displayed a predominance of C=O vibrational stretching frequencies with N-H 
bending predominating the amide II band (Coates, 2000). These bands are characteristic to zein 
and allude to the presence of an alpha helix secondary protein structure (Hsu et al., 2005). The 
sharp peak from 1043cm-1-1083cm-1 signifies the presence of a primary amine group frequency 
(Coates, 2000). 
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Polyoxyethylene (40) stearate displayed a sharp, intense band at 2882cm-1, as seen in Figure 
7.6b, which was attributed to symmetrical -CH3 stretching vibrations (Coates, 2000). Predictably, 
a C=O band at 1736cm-1 was observed in the transmittance spectra for polyoxyethylene (40) 
stearate, highlighting the ester carbonyl groups typical of stearates (Coates, 2000). Moreover, 
the characteristically related appearance of the first and second absorptions at 1464cm-1 and 
840cm-1 suggests the presence of a carbonate ion functional group frequency. A sharp, narrow 
peak at 1341cm-1 was assigned to aliphatic bending vibrations with group frequencies between 
1240cm-1 and 1270cm-1 within the fingerprint spectral region indicating C-O stretching vibrations. 
The high intensity peak at 1099cm-1 further supported the C-O stretching vibrations noted, 
resulting from intense hydrogen bonding causing a characteristically larger shift to lower 
frequencies (Coates, 2000). 
 
The final film-casted solution of the co-inhibitory ‘smart’ polymeric sheet showed the presence of 
bands inherent to all its components, as shown in Figure 7.6c, with a shifting and change in 
intensity of certain bands indicating inter and intra-molecular interactions between the 
components. The shifting of the amide I and II bands of zein to lower frequencies at 1639cm-1 
and 1536cm-1, respectively, indicate a possible interaction between the individual components 
triggered by orthogonal dipolar interactions between amide carbonyl groups (Fischer et al., 
2008). In addition, the first carbonate ion band characteristic of polyoxyethylene (40) stearate 
was dwarfed by the appearance of a spectral band at 1449cm-1. This band was characteristic to 
the reactive nature of large quantities of glutamic acid (glutamine) making up the amino acid 
composition of zein (Hsu et al., 2005; Gelder et al., 2007). Certain peaks within the fingerprint 
spectral region of the film-casted co-inhibitory ‘smart’ polymeric sheet spectrum confirmed the 
presence of polyoxyethylene (40) stearate. Furthermore, the distinct broadening of the 
transmittance band between the group frequencies of 1045cm-1-1107cm-1 indicated the 
overlapping of amine groups and C-O stretching vibrations characteristic to the vibrational 
transitions of zein and polyoxyethylene (40) stearate, respectively. Summations inferred form 
the FTIR spectra ultimately corroborated the successful incorporation of polyoxyethylene (40) 
stearate with zein to form the co-inhibitory ‘smart’ polymeric sheet surrounding the Tri-
functionalized OCMT.  
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Figure 7.6: Comparative FTIR spectra of a) zein, b) polyoxyethylene (40) stearate and c) the 
film-casted blend forming the co-inhibitory ‘smart’ polymeric sheet. 
 
7.3.4. Assessment of the rheological behavior of the optimized ‘smart’ polymeric sheet 
solution  
Zein, forming the basis of the ‘smart’ polymeric sheet solution, has been used as a coating in 
pharmaceutical applications wherein the rheological characterization of the coating solution is a 
major physical property influencing the process design (Foo and Weller, 1999; Selling et al., 
2005). Although the ‘smart’ polymeric sheet provides numerous functionalities, it structurally 
resembles a much thicker conventional tablet coating. Thus, it follows that characterization of its 
viscosity and overall rheological profile would be crucial in determining its ability to adequately 
adhere to the surface of the OCMT. Rheological characterization of the statistically optimized 
concentration of zein (19.166%w/v) produced the rheogram shown in Figure 7.7. The viscosity 
(η) and shear stress (τ) were represented as a function of the shear strain rate (ẏ). Due to the 
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complexity of the system, the rheological profile differed from Newton’s viscous laws and was 
considered to exhibit non-Newtonian behavior.   
 
Further characterization of the non-Newtonian behavior of the optimized polymeric sheet 
solution demonstrated both pseudoplastic and bingham-plastic type fluidity, as shown in Figure 
7.7. The assignment of pseudoplastic and bingham-plastic behavior was based on the apparent 
observation of an exponential decrease in the viscosity with increasing shear rates and the 
presence of a yield stress in the flow curve required to initiate flow, respectively (Irgenz, 2014). 
The viscosity of the polymeric sheet at zero shear rate was 2761mPas. The high viscosity 
obtained reliably supports optimum adherence of the polymeric sheet solution to the OCMT 
during formulation processing.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.7: Graphical representation of the flow curve and viscosity shear rate curve of the 
optimized ‘smart’ polymeric sheet solution.  
 
7.3.5. Comprehensive analysis of the mucoadhesive strength of the Tri-functionalized 
OCMT 
The mucoadhesivity imparted by the ‘smart’ polymeric sheet surrounding the Tri-functionalized 
OCMT was evaluated by in vitro and ex vivo mucoadhesion methodologies. The phenomenon 
of mucoadhesion has been extensively exploited in oral drug delivery technologies and remains 
the preferred technique for prolonging the residence time at the site of absorption, facilitating 
improved contact and interaction with the mucus-lined epithelial barrier (Carvalho et al., 2010; 
Singh and Rana, 2012; Carreras et al., 2016). The in vitro mucoadhesive potential of zein in the 
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design of the ‘smart’ polymeric sheet of the Tri-functionalized OCMT has been previously 
evaluated in Chapter 6. Optimization of the design variables and subsequent in vitro testing of 
the amount of mucin crosslinked yielded a 37.34% mucoadhesion for the optimized Tri-
functionalized OCMT, ideally falling within the range of the desired targeted response at 
statistically optimized concentrations of zein (19.166%w/v) and citric acid (10mg), as shown in 
Figure 7.8. 
 
 
 
 
 
 
 
 
 
 
Figure 7.8: Contour plot depicting the effect of zein and citric acid on the mucoadhesive 
response of the Tri-functionalized OCMT. 
 
Furthermore, the consolidation of the Tri-functionalized OCMT with the intestinal tissue was 
evaluated by determining the force as well as the work required to detach the tablet from the 
tissue surface. Results revealed a maximum detachment force (Fmax) and work of adhesion of 
0.02±0.005N and 0.09±0.008mJ.cm2, respectively. These results supported the in vitro 
mucoadhesive percentage obtained and demonstrated the ability of the ‘smart’ polymeric sheet 
to impart notable bioadhesive properties. The dual mucoadhesion provided by the ‘smart’ 
polymeric sheet and outer polymer shell (demonstrated in Chapter 5) makes the Tri-
functionalized OCMT the optimum formulation to deliver on its bioadhesive potential and site-
specific delivery in vivo. 
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7.3.6. Evaluation of the gastro-resistant Tri-functionalized OCMT  
Protein and peptide degradation is highest in the stomach, as a result of the acidic gastric 
environment and high enzyme activity, causing the irreversible cleavage of proteins and 
peptides into non-essential amino acids and small, absorbable oligopeptides (Fei et al., 1994; 
Choonara et al., 2014). Consequently, protection from this harsh environment is critical towards 
achieving a clinically viable system for the oral delivery of proteins and peptides. Zein, forming 
the basis of the ‘smart’ polymeric sheet, possesses gastro-resistant properties and thus has 
gained increased attention due to its attractiveness in providing a protective coating for 
pharmaceuticals (Shukla and Cheryan, 2001; Hussan et al., 2012; Paliwal and Palakurthi, 
2014). Therefore, acid uptake tests were undertaken for the Tri-functionalized OCMT to 
expound the capabilities of the prolamine-based ‘smart’ polymeric sheet. Results displayed low 
acid uptake values of 4.23±0.12%. This showed acceptable acid protection as it displayed a 
value less than 5%, indicating that the incorporated protein and peptide could be protected from 
degradation in the gastric environment (Kumar et al., 2011; Liu et al., 2011; Czarnocka and 
Alhnan, 2015). In addition, the Tri-functionalized OCMT remained intact and displayed no 
physical changes after being exposed to the SGF. 
 
7.3.7. Multi-textural analysis of the Tri-functionalized OCMT  
The complete MH, MR, DE and matrix rigidity of the Tri-functionalized OCMT was determined 
through the comprehensive analysis of the textural response to compressive and penetrative 
forces. The surface and core textural profiling of the Tri-functionalized OCMT was obtained by 
quantitative analysis of the Force-Time and Force-Distance profiles. A summary of the results 
obtained are presented in Table 7.6. The high values for the MH and rigidity indicated the ability 
of the Tri-functionalized OCMT to resist deformation when a force is applied, alluding to the 
overall mechanical integrity of the tablet. The ‘smart’ polymeric sheet imparted an improved 
hardness to the tablet, attributable to the high tensile strength of zein (forming the basis of the 
sheet) as highlighted previously in Chapter 6.  Unsurprisingly, the surface matrix hardness was 
much greater than the core matrix hardness due to the softening of the core at 37°C. The low 
matrix hardness of the core does not detract from the mechanical integrity of the OCMT but 
rather creates a platform for improved structural flexibility and hardness by facilitating the 
process of in situ crosslinking. Further analysis and calculation of the MR revealed the ability of 
the tablet to recover almost completely to its original structure after being exposed to external 
forces. This property aptly reflects the ability of the Tri-functionalized OCMT to withstand 
external stresses during handling, processing and storage.  
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Qualitative analysis of a Force-Time profile, produced from the penetration of a needle probe 
through the complete thickness of the Tri-functionalized OCMT, revealed the multi-textural 
profile observed in Figure 7.9. The initial increase in the gradient is due to the penetration into 
the ‘smart’ polymeric sheet, followed by a further increase in the force resulting from further 
penetration of the probe into the top layer of the outer polymer shell. At approximately 2N, a 
fracture is observed in the profile causing a notable decrease in the gradient and appearance of 
a noisy pattern. This was attributed to the penetration of the needle probe into the softened core 
eutectic region of the tablet. Following further penetration into the relatively hard bottom layer of 
the outer polymer shell, the force increased substantially. This supports the theory that greater 
forces are required to penetrate harder surfaces as opposed to their softer counterparts. The 
withdrawal of the probe yielded the decrease in the force and the recovery of the tablet with a 
slight negative peak at the end representing the adhesiveness of the ‘smart’ polymeric sheet. 
Summations inferred from overall textural profiling demonstrated the desired multi-textural 
properties of the Tri-functionalized OCMT for attaining optimal functionality.  
 
Table 7.6: Quantitative textural profiling results of the Tri-functionalized OCMT  
Textural Parameter Value 
Surface matrix hardness (N.mm2) 242.32 
Core matrix hardness (N.mm2) 53.12 
Matrix resilience (%) 71.61 
Matrix rigidity (N.mm) 49.07 
Deformation energy (J) 0.003 
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Figure 7.9: Multi-textural profile indicating needle probe penetration into the different layers of 
the Tri-functionalized OCMT. 
 
7.3.8. Qualitative and quantitative analysis of the biaxial tensile strength of the Tri-
functionalized OCMT 
Critical analysis of the tensile strength of the Tri-functionalized OCMT was undertaken to 
determine the ability of the tablet to withstand maximum GIT forces in vivo. Biaxial tensile 
testing permitted the tracking of the response of the Tri-functionalized OCMT by measuring the 
force and displacement at 40% strain. Image tracking of the displacement and strain is shown in 
Figure 7.10. The displacement tracking images indicated the movement of the ‘smart’ polymeric 
sheet of the Tri-functionalized OCMT from its original position after the first stretch cycle 
occurred in both directions, as shown in Figure 7.10a-b. The displacement of the ‘smart’ 
polymeric sheet was quite irregular in both directions, revealing only slight changes in the 
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shifting modalities which was further supported by the average displacement value obtained 
(1600um).  
 
Image tracking analysis of the strain during cyclic stretching produced the results shown in 
Figure 7.10c-d. The increase in intensity from the original yellow color signifies the weak points 
in the sample. As stretching increases from the original position, a predictable increase in the 
strain on the sample is noted. This manifests as the high intensity, weaker boundary areas 
shown in Figure 7.10c-d. Regardless, the ‘smart’ polymeric sheet displayed uniform interior 
strains in both directions, attractively demonstrating its resistance to failure. The complete 
response of strain and displacement with data overlays, following cyclic stretch and recovery, 
are presented in Video 7.1 and Video 7.2, respectively (See Video CD in the back cover of this 
Thesis). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.10: Image tracking analysis of a) displacement before cyclic stretch, b) displacement 
after cyclic stretch c) strain at mid-cyclic stretch and d) strain after complete cyclic stretch. 
(a) (b) 
(c) (d) 
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Furthermore, the force and rake displacement data obtained was used to calculate the ratio of 
the tensile stress to tensile strain. Results generated elastic moduli of 0.38MPa for the X and Y 
directions, indicating suitable stiffness and resistance to deformation of the ‘smart’ polymeric 
sheet. The Force-Time profile, displayed in Figure 7.11, further confirmed the ability of the Tri-
functionalized OCMT to resist gastric forces. Laulicht and co-workers, (2010) determined the 
average human gastric-emptying forces in the fasted and fed state as being 414±194 dynes 
(±4.14 mN) and 657±84 dynes (±6.57mN), respectively. The Force-Time profile obtained 
showed a much higher withstanding force (2500-4000mN) before breaks in the ‘smart’ 
polymeric sheet occurred, following repeated stretch and recovery cycles in both directions. 
Ultimately, the results obtained demonstrated the rational design of the Tri-functionalized OCMT 
in providing remarkable mechanical strength for optimal in vivo delivery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.11: Biaxial tensile testing profile of the Force-Time in the X and Y directions for the Tri-
functionalized OCMT.  
 
7.3.9. Analysis of the fluid uptake and erosional behavior of the Tri-functionalized OCMT 
The analysis of the fluid uptake and erosional behavior of the optimized Tri-functionalized 
OCMT was evaluated by monitoring the change in weight of the tablet over a 24-hour period. 
The water uptake of the tablet was calculated as a percentage in reference to the original 
weight, as shown in Figure 7.12. The tablet displayed a 40-80% increase in fluid uptake within 
the first 2 hours, notably lower than the fluid uptake percentages presented in Chapter 5 for the 
optimized OCMT without the ‘smart’ polymeric sheet. This was attributed to the characteristically 
different properties of zein and PEO contained within the ‘smart’ polymeric sheet and outer 
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polymer shell, respectively. The hydrophobic nature of zein retards the fluid uptake and thus 
smaller percentages are noted.  
 
Further analysis of the fluid uptake behavior revealed the indirectly proportionate effects of in 
situ crosslinking between 2-4 hours. Following 4 hours, slow dissolution of the ‘smart’ polymeric 
sheet and greater exposure of the outer polymer shell resulted in the sharp increase in fluid 
uptake between 6-8 hours. The uptake increased steadily up to 12 hours after which slow 
surface erosion dominated, evident by observations of a loss in the physical structure. The 
pectin-controlled surface erosion produced a result of 38.32% after 24 hours as the ‘smart’ 
polymeric sheet still remained partially intact. The fluid uptake and erosional behavior noted is a 
critical determinant that influences numerous functional characteristics of the Tri-functionalized 
OCMT such as mucoadhesion, in situ crosslinking and in vitro peptide release behavior. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.12: Fluid uptake profile of the Tri-functionalized OCMT in response to different 
processes occurring within the tablet. 
 
7.3.10. Imaging analysis of the Pharma-Engineering and hydration characteristics of the 
Tri-functionalized OCMT 
Qualitative evaluation of the changes in hydration, underpinning the performance of the Tri-
functionalized OCMT was evaluated using MRI. The images obtained, shown in Figure 7.13, 
represents the internal events unfolding as a consequence of solvent penetration into the tablet.  
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In each image, a lower degree of hydration or gelling of the Tri-functionalized OCMT is 
visualized as lower intensity, darker areas and more extensive hydration or gelling presents a 
whiter appearance falling towards the higher intensity region of the scale. Due to its hydrophobic 
nature, a slow increase in the fluid uptake by the ‘smart’ polymeric sheet was noticed up to 2 
hours. Following 2 hours, further solvent penetration into the tablet proposedly facilitated the 
process of in situ crosslinking which further retarded the hydration of the tablet. The slow 
dissolution and exposure of the outer polymer shell to SHIF promoted increased hydration of the 
tablet up to 12 hours. The imagery after 12 hours shows complete hydration and loss in the 
physical structure suggesting the prevalence of surface erosion. The results supported the fluid 
uptake behavior shown in Figure 7.12, essentially demonstrating the importance of MRI in 
studying the internal mechanisms of the Tri-functionalized OCMT in vitro and predicting its 
performance in vivo. In addition, the MRI images impeccably elucidated the internal structure 
and pharma-engineering of the Tri-functionalized OCMT.  
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Figure 7.13: MRI of the Tri-functionalized OCMT over 24 hours with the intensity scale 
indicating the degree of hydration from 0% (non-hydrated) to 100% (hydrated). 
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7.3.11. In vitro peptide release analysis of the Tri-functionalized OCMT 
The peptide release profile obtained for the statistically optimized formulation demonstrates the 
culmination of distinct formulatory components on the responsive potential of the Tri-
functionalized OCMT. A 4-parameter logistic curve generated from the peptide-specific ELISA 
kit was used to calculate the unknown concentrations of the optimized formulation at each time 
point. The plot of the fractional release against time is represented in Figure 7.14. Sustained 
release of octreotide was noted over the 24 hour study period with an overall fractional release 
of ±0.9.  Upon further evaluation of the release profile, patterns of burst and slow release were 
noted. This was attributed to the combined effects of swelling, surface and in situ crosslinking, 
as previously demonstrated. Interestingly, the outline of the release profile obtained was 
identical to the swelling behavior observed in Figure 7.12. This reinforced the effect of swelling 
on the release patterns generated. Although the pH modifier did not significantly affect the 
release behavior, the ‘smart’ polymeric sheet functioned to further sustain the peptide release 
from 8-24 hours. These results were corroborated by the MDT value of ±21.58 obtained, which 
gave an indication of a slow peptide release rate (Wadher et al., 2011; Sathish and Syed, 2013). 
These results highlight the potential of the system to adequately release the incorporated 
peptide. The successful translation of the in vitro profile to in vivo performance will be 
ascertained in Chapter 8. 
 
 
 
 
 
 
 
 
 
 
Figure 7.14: Profile displaying the fractional release of Octreotide from the Tri-functionalized 
OCMT. 
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Furthermore, the release data was fitted into various kinetic models to determine the 
mechanism of peptide release. The regression coefficients (R2) obtained for the optimized 
formulation is presented in Table 7.7. A model depicting a value closest to 1 would demonstrate 
the appropriateness of that model in explaining the peptide release mechanism. Thus, the 
release kinetics of the Tri-functionalized OCMT was best exemplified by the Higuchi model, 
signifying release of the peptide from the matrix as a function of the square-root of a time-
dependent process based on Fickian diffusion.  Since near zero-order release was observed, 
the kinetics was attributed to a combination of both the Higuchi models and zero-order models, 
ultimately attesting to the complexity of the system. 
 
Table 7.7: Kinetic modelling of the Tri-functionalized OCMT. 
 
 
 
Zero-order 
 
First order Higuchi Korsmeyer–
Peppas 
 
Regression 
Coefficient (R2) 
Regression 
Coefficient (R2) 
Regression 
Coefficient (R2) 
Regression 
Coefficient (R2) 
Best-fit Model 
Tri-
functionalized 
OCMT 
 
0.9714 
 
0.8832 
 
0.9832 
 
0.924 
 
Higuchi 
 
7.3.12. Cytotoxic analysis of the EPB in the Tri-functionalized OCMT  
The EPB of the Tri-functionalized OCMT was evaluated for its potential cytotoxicity by using an 
MTT cell culture assay. This cytotoxic test provides a quantitative evaluation of the in vitro 
toxicity and irritancy potential of the EPB prior to in vivo testing in animals. The mechanistic 
action of the assay is based on the cleavage of the tetrazolium ring of MTT by mitochondrial 
dehydrogenases of viable cells, yielding the purple formazan crystals shown in Figure 7.15. An 
increase or decrease in the cell number results in a concomitant change in the amount of 
formazan formed. Results from screening of the cytotoxic potential of the EPB, at the optimized 
concentration of 12%w/w, yielded a relative cell viability of ±79.83%. Consequently, the EPB was 
considered to be safe as there was ~80% cell survival following exposure to the EPB. These 
results essentially demonstrated the biocompatibility of the system and its clinical potential for 
safe administration in vivo.  
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Figure 7.15: Still frame from live cell imaging of the purple formazan crystals formed following 
tetrazolium ring cleavage. 
 
7.4. Concluding Remarks  
Deductions from in-depth physicochemical and physicomechanical characterization of the Tri-
functionalized OCMT demonstrated its optimal in vitro potential for achievement of clinical 
efficacy. Micro-environmental pH studies favorably supported the ability of the Tri-functionalized 
OCMT to influence the micro-environmental pH at the brush border via indirect enzyme 
inhibition leading to improvement in the stability of therapeutic proteins and peptides. FTIR 
analysis highlighted the successful incorporation of the co-inhibitor into the ‘smart’ polymeric 
sheet for achievement of its characteristic co-inhibitory function. In vitro and ex vivo 
mucoadhesive studies demonstrated the potential of the entire system to provide increased 
residence time at the absorption site via prolonged contact and increased interaction with 
mucin. Textural profiling and acid uptake tests revealed the enhanced mechanical strength and 
gastro-resistant nature provided by the ‘smart’ polymeric sheet of the Tri-functionalized OCMT, 
respectively. MRI highlighted the hydrational transitions within the Tri-functionalized OCMT and 
together with gravimetric swelling profiles can be considered a significant predictor of in vitro 
peptide release and in vivo performance of the device. The release of octreotide from the 
statistically optimized formulation demonstrated the effect of distinct formulatory components on 
the responsive potential of the Tri-functionalized OCMT. Fractional release reached a value of 
±0.9 with the MDT (±21.58) indicating a slow peptide release rate. Finally, critical cytotoxic 
analysis of the EPB showed a ±79.83% survival rate, indicating acceptable biocompatibility and 
safety for clinical use. Comprehensive physicochemical and physicomechanical characterization 
was therefore an essential determinant for evaluating the in vitro potential of the system and 
predicting its in vivo performance prior to testing in the animal model.  
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CHAPTER 8 
IN VIVO EVALUATION OF OCTREOTIDE AND EXENATIDE RELEASE FROM THE TRI-
FUNCTIONALIZED OCMT IN THE LARGE WHITE PIG MODEL 
 
 
To be submitted in conjunction with Chapter 5 and Chapter 7 to International Journal of 
Pharmaceutics and Nature Biotechnology, respectively 
 
Bibi F. Choonara, Yahya E. Choonara, Pradeep Kumar, Lisa C. du Toit, Viness Pillay.  In Vitro and In 
Vivo Evaluation of a Novel Oral Core-Melt Tablet (OCMT). 
 
Bibi F. Choonara, Yahya E. Choonara, Pradeep Kumar, Lisa C. du Toit, Viness Pillay. Comprehensive In 
vitro and In vivo Characterization of the Statistically Optimized Tri-Functionalized Oral Core-Melt Tablet 
(OCMT) for Enhanced Protein and Synthetic Peptide Delivery. 
 
 
Abstract  
In vivo analysis of the Tri-functionalized OCMT in the Large White pig model was undertaken to 
determine the effectiveness of the device in delivering proteins and peptides via the oral route. 
Octreotide and exenatide release from the Tri-functionalized OCMT was compared to their 
conventional subcutaneous counterparts, respectively. Comprehensive pharmacokinetic 
analysis of release profiles revealed an enhanced oral bioavailability represented by a three-fold 
and five-fold increase in AUC0- of octreotide and exenatide as compared to their conventional 
subcutaneous systems, respectively.  In addition, the peak plasma concentrations for the 
conventional systems were much higher than those obtained for release from the Tri-
functionalized OCMT, possibly reaching toxic levels and increasing the side effect profile. 
Analysis of in vivo profiles demonstrated sustained therapeutic levels of octreotide (>0.5ng/mL) 
and exenatide (>0.05ng/mL) over the 24 hour study period. Moreover, the Level A IVIVC 
analysis that was undertaken for both octreotide and exenatide showed a good correlation 
between in vitro dissolution and in vivo performance with an overall predictability error of <15%. 
 
Keywords: octreotide; exenatide; large white pig model; bioavailability; minimum effective 
concentration; IVIVC 
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Animal ethics clearance for this in vivo investigation was obtained from the Animal Ethics 
Screening Committee (AESC) of the University of the Witwatersrand. 
Ethics Clearance Number: 2014/38/C (Appendix 10.3) 
 
8.1. Introduction 
Performance of in vivo studies is crucial towards determining the clinical efficacy of a system. 
While in vitro and ex vivo testing provides important insights into the fundamental mechanisms 
and release of therapeutic actives from drug delivery systems, it cannot completely simulate in 
vivo conditions. Thus, in vivo release of therapeutic actives from the Tri-functionalized OCMT 
was undertaken to foster an in vitro-in vivo correlation (IVIVC) and define critical 
pharmacokinetic parameters.  The selection of an appropriate animal model for evaluation of the 
system was based on its accuracy in providing a suitable correlation of data with respect to 
humans. Typically, larger animals such as monkeys, dogs and pigs are used for evaluation of 
oral drug delivery systems on account of the size of the dosage form excluding the use of 
smaller animals. The pig has been established as a good animal model for research as they are 
easier to handle and more socially acceptable than other animal models. More importantly, pigs 
share anatomical and physiological characteristics with humans which make them a viable 
model for biomedical research (Swindle and Smith, 1998; Kobayashi et al., 2012; Bassols et al., 
2014). The widespread use of the pig model in multiple studies further validated the 
appropriateness of the model in providing a reliable in vivo evaluation of oral dosage forms 
(Dorkoosh et al., 2002; Brunet et al., 2006; Persson et al., 2008; Bergman et al., 2009). Thus,    
the Large White Pig was selected as the appropriate model for evaluation of the Tri-
functionalized OCMT.  
 
The characteristic design of the Tri-functionalized OCMT should enable enhanced oral delivery 
of gastro-sensitive proteins and peptides. The individual release and analysis of the synthetic 
peptides, octreotide and exenatide, from the Tri-functionalized OCMT was investigated. 
Octreotide is a synthetic octapeptide responsible for inhibiting growth hormone and other 
chemical messengers such as gastrin and vasoactive intestinal peptide that cause disease 
symptoms. Exenatide is a glucagon-like peptide-1 agonist (GLP-1 agonist) that is used in the 
treatment of type 2 diabetes by reducing the blood glucose levels. Both these peptides are 
currently administered via the parenteral routes as no clinically useful oral formulations are 
available. They often require multiple and frequent dosing to maintain therapeutic levels. The 
Tri-functionalized OCMT attempts to breakthrough this market by providing a clinically useful 
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oral formulation that delivers sustained therapeutic levels of these peptides following a single 
daily dose. In vivo analysis of novel delivery systems cannot be complete without comparison to 
their therapeutic gold standards. Thus, thorough analysis of the release profiles of the 
conventional systems of octreotide and exenatide were examined to provide notable 
comparisons for the Tri-functionalized OCMT.  
 
This chapter essentially emphasizes the preclinical efficacy as a culmination of the unique 
features and functions of the Tri-functionalized OCMT by providing an in-depth in vivo 
evaluation of peptide concentrations and pharmacokinetic analysis with establishment of an 
IVIVC. Ultimately, in vivo studies are central to demonstrating the performance, safety, 
tolerability, efficacy and clinical potential of the Tri-functionalized OCMT in the oral delivery of 
therapeutic proteins and peptides.  
 
8.2. Materials and Methods  
 
8.2.1. Materials  
The materials used for the preparation of the optimized Tri-functionalized OCMT have been 
highlighted previously as per the requirements found in Chapter 7, Section 7.2.1. The bioactive 
peptides; Octreotide acetate (C49H66N10O10S2; Mw=1019.247g/mol) was purchased from Bolon 
Pharmachem Co., Ltd. (Taizhou, Zheijang, China) and Exenatide Acetate (C184H282N50O60S; 
Mw=4246.62g/mol) was purchased from BCN peptides (Sant Quintí de Mediona, Barcelona, 
Spain). The conventional subcutaneous delivery systems for Octreotide and Exenatide were 
purchased from Netcare Park Lane Pharmacy (Johannesburg, Gauteng, South Africa) and 
GenScipt® (Piscataway, New Jersey, USA), respectively. The peptide-specific Enzyme-linked 
Immunosorbent Assay (ELISA) kits for analysis of octreotide and exenatide were purchased 
from Peninsula Laboratories International, Inc. (San Carlos, CA, USA) and AB Biolabs (Ballwin, 
MO, USA), respectively. The peptide plasma extraction kit was purchased from Peninsula 
Laboratories International, Inc. (San Carlos, CA, USA). All other reagents were of analytical 
grade and were employed as received. 
 
A total of 6 female Large White Pigs with an average weight of ±35kg were utilized in this study 
and were obtained as per the standard procurement protocols of the Central Animal Services 
(CAS) of the University of the Witwatersrand (Johannesburg, Gauteng, South Africa). 
Anesthetics, painkillers and antibiotics for administration to the pigs pre and post-operatively 
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were supplied and managed by the chief veterinarian of the Central Animal Services (CAS) of 
the University of the Witwatersrand (Johannesburg, Gauteng, South Africa).  
 
8.2.2. Preparation of the optimized Tri-functionalized OCMT for in vivo analysis  
The Tri-functionalized OCMT components were prepared according to the detailed 
methodologies and statistically optimized concentrations presented in Chapter 4 (Section 4.2.2., 
4.2.3., 4.2.4., 4.2.5.) and Chapter 7 (Section 7.2.2) involving: 
a. Synthesis of the lyophilized Eutectic Powder Blend (EPB) for the core eutectic region of 
the tablet 
b. Formulation of the of the core eutectic region of the tablet. 
c. Manufacture of the outer polymer shell of the tablet. 
d. Incorporation of a pH modifier into the outer polymer shell. 
e. Assembly of the pHM-OCMT. 
f. Synthesis of a prolamine-based smart’ polymeric sheet. 
g. Incorporation of a co-inhibitor into the ‘smart’ polymeric sheet. 
h. Encapsulation of the pHM-OCMT with the co-inhibitory ‘smart’ polymeric sheet to form 
the Tri-functionalized OCMT. 
The concentrations of octreotide and exenatide used in the preparation of the Tri-functionalized 
OCMT were 20mg and 5mg, respectively.  
 
8.2.3. Animal husbandry and habituation of pigs prior to commencement of the study  
The pigs were housed in the farm unit in large, single, straw-bedded pens that allowed access 
to water ad libitum (Figure 8.1a-b). Since pigs are very social animals, they were housed in 
pens adjacent to each other that provided them visual access to the other animals. The farm 
unit was maintained under a 12/12 light/dark cycle and all pens were fitted with UV heat lamps 
to provide radiant heat and minimize stress to the animals. The pigs were fed twice a day 
according to the specific diets set out by the CAS staff. The habituation of animals prior to 
dosage form administration was critical towards improving interaction with the pigs and 
essentially easing the handling of the pigs during dose administration and multiple blood 
samplings. Habituation occurred for 7 days and involved visits with the pigs twice a day. 
Distributing of treats and brushing down of the pigs were some of the activities carried out 
during habituation as shown in Figure 8.1c. In addition, pigs were given play items as part of 
their environmental enrichment.  
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Figure 8.1: Digital images of a-b) farm unit housing of pigs in single, straw-bedded pens and c) 
daily feeding of treats as part of the habituation process. 
 
8.2.4. Surgical implantation of an intra-jugular catheter into the Large White Pig 
 
8.2.4.1. Pre-operative procedure  
Insertion of a catheter into the left jugular vein of the pig was considered the most efficient portal 
for blood sampling. The pre-operative preparation procedure involved the anesthetization of the 
Large White Pig prior to catheterization using Ketamine HCL (11mg/kg) and Midazolam 
(0.3mg/kg). The pigs were subsequently intubated and anaesthesia was maintained with 100% 
medical oxygen and 2% isoflurane gas for the remainder of the procedure (Figure 8.2a). The 
pigs were prepared for surgery by shaving and sterilizing the surgical sites and inserting a 
Jelco® peripheral catheter into a vein of the right ear for rapid delivery of drugs during surgery, 
as shown in Figure 8.2b-c. Buprenorphine 0.05mg/kg intramuscularly and Carpofen 4mg/kg 
intramuscularly was administered prior to surgery to manage pain and inflammation. Following 
completion of the pre-operative procedure, the pigs were wheeled into the sterile theatre room 
for surgical catheter implantation. All surgical procedures were performed by the chief 
veterinarian, veterinary nurse and support staff of the Central Animal Services (CAS) at the 
University of the Witwatersrand.  
 
 
 
 
 
 
 
 
a) b) c) 
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Figure 8.2: Digital images of a) intubation and maintenance of anaesthesia with medical oxygen 
and isoflurane gas, b) shaving and sterilization of the surgical site and c) insertion of catheter 
into the right ear vein. 
 
8.2.4.2. Surgical procedure  
Under aseptic conditions, a 7 gauge double lumen 35cm catheter (CS- 28702, Arrow 
Deutchland GmdH, and Erding, Germany) was surgically inserted into the left jugular vein.  The 
detailed surgical procedure involved the exposure of the jugular vein by an incision made dorsal 
to the jugular groove on the left lateral aspect of the neck. The jugular vein was then isolated by 
blunt dissection and insertion of 10cm of the catheter into the lumen of the vein. The inserted 
catheter was fastened to the wall of the vein using a purse suture technique. Following this, the 
remaining 25cm of the catheter was tunneled subcutaneously to an exit point cranial at the 
dorsal aspect of the scapula with the use of a trocar. The external injection ports of the catheter 
were sutured to the skin to prevent excess bending and detachment. The functionality of the 
catheter was determined by blood sampling and subsequent flushing with heparinised saline 
(5000IU heparin in 1L of 0.9% saline). Vital signs such as heart rate, blood pressure, respiratory 
rate and body temperature of the pigs were monitored throughout the surgery. Upon completion 
of the surgery, the pigs were sutured up and returned to their pens to recover under 
observation. Digital images of the surgical procedure are presented in Figure 8.3a-i. 
 
8.2.4.3. Post-operative procedure  
The pigs were monitored closely after surgery for any signs of infection or inflammatory 
reactions. The pigs were given a 10 day recovery period after surgery. During this time, blood 
sampling and flushing of ports with heparinized saline was done twice a day to prevent blockage 
of ports. In addition, the surgical entry and exit points were monitored daily for signs of infection.  
 
 
a) b) 
c) 
c) 
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Figure 8.3: Photographic representation of the intra-jugular surgery procedure done on the 
anaesthetized pigs in a) the 7 gauge double lumen 35cm catheter, b) the incision made dorsal 
to the jugular groove on the left lateral aspect of the neck, c) exposure of the jugular vein, d) 
blunt dissection of the jugular vein and insertion of 10cm of the catheter into the lumen of the 
vein, e) fastening of the catheter using a purse suture technique, f-g) the remaining 25cm of the 
catheter subcutaneously tunneled to an exit point cranial at the dorsal aspect of the scapula with 
the use of a trocar, h)  the sutured external ports of the catheter to the dorsal aspect of the neck 
and i) functional evaluation of the catheter via blood sampling and heparin flushing. 
 
 
 
 
a) b)  c) 
d) e) f) 
g) h) i) 
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8.2.5. Administration of the conventional delivery systems and the optimized 
formulations to the Large White Pig 
The animal studies were conducted in a total of 6 pigs which were dosed as per the 
experimental design highlighted in Figure 8.4, following wash-out periods between each dosing 
corresponding to the half-life of the drug.  Dosage administration was divided into three groups 
namely; the experimental, the conventional and the placebo group. Within each group, 5 pigs 
were dosed and 1 pig served as a control. In addition, the experimental groups for both 
octreotide and exenatide included formulation controls which were identified as the optimized 
OCMTs containing no polymeric sheet or pH modifier. The conventional systems are only 
available as parenteral formulations, thus, octreotide and exenatide were injected 
subcutaneously into the dorsal aspect of the Large White Pig. Anaesthetization was not 
necessary for the conventional system as pigs were administered the SC injection whilst in their 
respective pens. 
 
The dosing procedure for the experimental and placebo groups involved the use of an intra-
gastric tube. This enabled consistent administration of the dosage form to the pigs and 
prevented damage to the OCMTs characteristic structural features that may be caused by 
chewing. The oral dosing procedure involved initial anaesthetization of pigs with Ketamine HCL 
(11mg/kg) and Midazolam (0.3mg/kg) followed by maintenance of anaesthesia using medical 
oxygen (100%) and isoflurane gas (2%). All pigs were weighed prior to each dosing procedure 
to monitor changes in weights. Following weight monitoring, the intra-gastric tube was lubricated 
with KY jelly and inserted into the stomach of the pig (Figure 8.5a). The pig was then held 
upright and the dosage form was placed into the tube and washed down with 10-50mL of water 
(Figure 8.5b-c). After the intra-gastric tube was removed, the pig was returned to its housing unit 
for recovery under observation.  
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Figure 8.4: Schematic of the experimental design of the in vivo study indicating the distinctive 
groups and procedural steps involved.  
*Formulation controls for the experimental groups can be identified as the optimized OCMT formulation 
containing no polymeric sheet or pH modifier 
Administration of Experimental and Placebo Groups: 
Via intragastric tube while under anaesthesia 
Administration of Conventional Group: 
Subcutaneous injection to the dorsal aspect of the pig 
 
Analysis:  
Plasma peptide concentrations of stored samples are analyzed using peptide-specific 
Octreotide and Exenatide Elisa Kits. 
Blood Sampling:  
5mL blood samples are withdrawn from the catheterized jugular vein at predetermined 
time intervals and collected in EDTA vacutainers. Samples are centrifuged and stored 
at -70˚ C until further analysis. 
Wash-out Period: 
Pigs returned to the study for subsequent dosing after a wash-out period corresponding 
to the elimination half-life of the peptide used 
Anaesthesia: 
Anaket injection 11mg/kg + Dormicum (midazolam) 0.3mg/kg and Isofor® Gas (0.5-5%) 
maintained for approximately 1 hour 
 
6 Pigs 6 Pigs 6 Pigs 
Total number of Large White 
Pigs:  
18 
Group 1 (Experimental): 
Optimized Tri-Functionalized OCMT 
Set A: Octreotide-loaded 
Set A1: Formulation Control* 
Set B: Exenatide-loaded 
Set B1: Formulation Control* 
Group 2 (Conventional): 
Set A: Octreotide SC injection 
(0.1mg/mL) 
Set B: Exenatide SC injection 
(50μg/mL) 
Group 3 (Placebo): 
Tri-Functionalized OCMT 
Peptide-free delivery system 
Return to stock: 
Pigs returned to stock following completion of the study 
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Figure 8.5: Digital images of the oral dosing procedure for the experimental and placebo groups 
in a) insertion of the gastric tube, b) holding the pig upright and c) placing the dosage form into 
the intra-gastric tube.  
 
8.2.6. Blood sampling procedure from the surgically implanted intra-jugular catheter  
Following dose administration to the pigs and reversal of anaesthesia, blood sampling was 
undertaken at pre-determined time intervals over a 24 hour study period. The blood sampling 
time periods for the experimental and placebo groups were 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 22 
and 24 hours. Blood sampling for the conventional systems were undertaken at shorter time 
intervals within the first hour after dosing due to the predictably faster reaching of peak levels 
following subcutaneous administration. The habituation process greatly facilitated easier 
handling and blood sampling of pigs. Prevention of infection at the catheter external port entry 
sites was critical to maintaining a healthy pig throughout the entire study, thus, hands were 
washed and disinfected thoroughly before blood sampling was undertaken. The blood sampling 
procedure involved the disinfection of the intra-jugular catheter external ports using a veterinary 
disinfectant spray (Figure 8.6a). The ports were than flushed with heparinized saline and the 
first blood withdrawn was discarded (Figure 8.6b-c). Further withdrawal of 5ml of blood was 
placed in EDTA vacutainers®. Following withdrawal, the ports were again flushed with heparin 
and disinfected. The collected blood samples were centrifuged at 5000rpm for 15 minutes and 
the plasma supernatant was extracted and stored at -70°C until further analysis.  
 
 
 
 
 
 
 
 
 
a) b) c) 
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Figure 8.6: Digital images of the blood sampling procedure in a) disinfection of the external 
ports, b) flushing of the ports with heparinized saline and c) blood withdrawal.  
 
8.2.7. Quantification of the in vivo release of the experimental groups and conventional 
systems using peptide specific Enzyme-linked Immunosorbent Assays (ELISA) 
Competitive immunoassay-based ELISA kits were used for the quantification of plasma 
concentrations of octreotide and exenatide. Competitive enzyme immunoassays kits are based 
on the principle of competition between the peptide and its tracer (biotinylated peptide) for a 
limited number of antiserum binding sites. Typically, the antiserum is captured by antibodies 
coated on a 96-well plate. The addition of a constant concentration of Bt-tracer (biotinylated 
tracer) and varying concentrations of unlabeled standard or sample peptide compete for binding 
specifically to the antiserum. Captured Bt-tracer is subsequently bound by SA-HRP 
(streptavidin-conjugated horseradish peroxidase), producing a soluble colored product after 
substrate addition as illustrated in Figure 8.7. 
 
Figure 8.7: Schematic representation of the mechanistic principle of the competitive ELISA kit 
used for quantification of plasma concentrations (Peninsula Laborotories International, Peptide 
Enzyme Immunoassay Datasheet). 
a) b) c) 
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8.2.8. Summarized technical procedure for ELISA kit evaluation of plasma peptide 
sample concentrations  
The ELISA kits for individual evaluation of octreotide and exenatide plasma samples were 
prepared according to the kits standard operating protocol and involved; a) preparation of 
peptide standards, b) sample extraction and c) preparation of immunoplate and running of the 
assay. All materials used were provided with the kit. 
a) Preparation of peptide standards: 
The peptide standards provided were reconstituted and serially diluted to the standard 
concentrations suggested by the kit. Octreotide standards were prepared at 
concentrations of 1000ng/mL, 10ng/mL, 2.5ng/mL, 0.63ng/mL, 0.16ng/mL, 0.04ng/mL, 
0.01ng/mL and 0ng/mL. Exenatide standards were prepared at concentrations of 
1000ng/mL, 100ng/mL, 10ng/mL, 1ng/mL, 0.1ng/mL and 0.01ng/mL.  
b) Sample extraction: 
The extraction of peptides from plasma samples is important for eliminating potentially 
interfering substances, such as albumin. A solid phase extraction (SPE) kit was used for 
extraction of the peptides. In vivo octreotide and exenatide plasma samples were 
thawed to room temperature (±25°C). Two buffers, Buffer A (1% trifluoroacetic acid) and 
Buffer B (60% acetonitrile with 1% trifluroacetic acid) were provided with the kit. The 
extraction involved adding an equal amount of Buffer A to the plasma samples and 
centrifuging at 6000xg for 20 minutes at 4°C. Thereafter, a SEP-COLUMN containing 
200mg of C18 was equilibrated with Buffer B (1mL, once) followed by Buffer A (3mL, 
three times). The plasma solution was loaded onto the pre-treated C-18 SEP-COLUMN 
and a light vacuum was applied. Subsequently, the column was slowly washed with 
Buffer A (3mL, twice) and the resultant wash was discarded. Following this step, the 
peptide was slowly eluted with Buffer B (3mL, once) and the eluent was collected in a 
polypropylene tube. Finally, the eluent was evaporated to dryness and the residue was 
dissolved in EIA buffer.  
c) Preparation of immunoplate and running of the assays: 
The immunoplate was prepared by adding 50μL of standard or sample (in diluent), 25μL 
of antiserum in EIA buffer and 25μL of Bt-tracer in EIA buffer into each well. All samples 
and standards were assayed in duplicate. Blank wells were prepared by adding 75μL of 
diluent and 25μL of Bt-tracer. The plate was covered and incubated at room temperature 
for 2 hours. Orbital shaking (300-400rpm) during incubation was recommended for the 
exenatide kit and was carried out using a ThermoStar microplate incubator (BMG 
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LABTECH, Ortenburg, Bavaria, Germany). Following incubation, the immunoplate was 
washed using a ELx50 microplate washer (BioTek® Instruments, Winooski, Vermont, 
USA), 3/5 times with 350μL/well and 300μL/well of EIA buffer for the exenatide and 
octreotide assay kits, respectively. On completion of washing, 100μL of SA-HRP solution 
was added to each well. The plate was subsequently covered and incubated for 1 hour 
at room temperature with orbital shaking (300-400rpm) recommended for the exenatide 
kit. The plate was washed again after incubation as per the washing procedure 
mentioned previously. The TMB substrate solution (100μL) was added to each well and 
further incubated at room temperature for 30-60 minutes for optimum development of the 
blue color. Lastly, the reaction was terminated by adding 100μL 2N HCL to each well, 
causing a color change from blue to yellow. The absorbance was read at 450nm within 
ten minutes using a Synergy HT multiwell microplate reader equipped with curve fitting 
software (BioTek® Instruments, Winooski, Vermont, USA). 
 
8.2.9. Pharmacokinetic modelling of peptide release data using compartmental and non-
compartmental algorithms  
The in vivo release of octreotide and exenatide was subjected to extensive pharmacokinetic 
data analysis by fitting the concentration-time data obtained into PKSolver, a menu-driven add-
in program for Microsoft Excel written in Visual Basic for Applications (VBA), facilitating 
compartmental and non-compartmental analysis of the in vivo release data (Zhang et al., 2010). 
 
Non-compartmental analysis is the simplest and most commonly used pharmacokinetic analysis 
that does not assume compartments. Calculation of the area under the zero and area under the 
first moment curves from 0 to last time t, (AUC0-t, AUMC0-t) as well as from the last sampling 
time to infinity (AUCt-; AUMCt-) were determined via the trapezoidal method and calculations 
based on the last or predicted concentrations; respectively (Equation 8.1 and 8.2).  
 AUC = AUC0−t + Clast𝜆𝜆𝑧𝑧                                                                                                      (8.1) 
 
Where, Clast is the last observed or predicted concentration and 𝜆𝜆𝑧𝑧 is the terminal elimination 
slope. 
 AUMC = AUMC0−t + Clast×tlast𝜆𝜆𝑧𝑧  + Clast𝜆𝜆𝑧𝑧2                                                                              (8.2) 
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Where, 𝐶𝐶𝑙𝑙𝑎𝑎𝑠𝑠𝑑𝑑 is the last observed or predicted concentration, 𝑡𝑡𝑙𝑙𝑎𝑎𝑠𝑠𝑑𝑑 is the time at last observed or 
predicted concentration and 𝜆𝜆𝑧𝑧 is the terminal elimination slope. 
 
The terminal elimination slope, 𝜆𝜆𝑧𝑧, can be calculated using user-specified terminal data points or 
automatically estimated using the regression with the largest R2, as shown in Equation 8.3.  
 Adjusted R2 = 1 − (1−R2)×(n−1)
n−2
                                                                                      (8.3) 
 
Where, n is the number of data points in the regression and R2 is the square of the correlation 
coefficient. 
 
Additional parameters calculated included the half-life (t1/2), mean residence time (MRT), 
clearance (Cl) and volume of distribution based on the terminal slope. 
 
Furthermore, compartmental analysis was used to quantitatively determine the in vivo fate of the 
peptide by fitting the concentration-time data obtained into an appropriate pharmacokinetic 
compartmental model (Zhang et al., 2010). Administration of the Tri-functionalized OCMT was 
considered as a single extravascular dose and thus, the system was inputted into three distinct 
pharmacokinetic algorithms: 
1. Non-compartmental Model (Extravascular) 
2. One-compartmental Model (Extravascular) 
3. Two-compartmental Model (Extravascular) 
 
The model diagnostics such as correlation coefficient, sum of squares of residuals (SS), 
standard error of weighted residuals (SE), Akaike’s information criterion (AIC) and Schwarz 
criterion (SC) are generated from the pharmacokinetic models and are essential towards 
selecting the appropriate model for the fitted concentration-time data. The quantitative 
evaluation provides valuable information about the drug transport processes in the body (Zhang 
et al., 2010). AIC and SC are considered the most important diagnostics for enabling the 
selection of a model with small bias and good precision, and were calculated according to 
Equation 8.4 and 8.5, respectively (Ludden et al., 1994; Zhang et al., 2010).  
 AIC = N ∙ ln(WSS) + 2p                                                                                                 (8.4) 
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SC = N ∙ ln (WSS) + p ∙ ln (N)                           (8.5) 
 
Where, N is the number of observations, WSS is the weighted sum of squared residuals and p 
is the number of estimated parameters.  
 
8.2.10. Establishment of an in vitro-in vivo correlation (IVIVC) 
Establishing a mathematical relationship between in vitro release data and in vivo performance 
is essential towards further optimization and development of the device. Four levels of IVIVC for 
extended release dosage forms have been identified by the Food and Drug Administration 
(FDA) and include; Level A, B, C and Multi-level C as defined in Table 8.1 (Ostrowski and 
Baczek, 2010; Chakraborty et al., 2014). Level D is considered as a rank order correlation, 
providing qualitative analysis and thus is not considered useful for regulatory purposes. The 
levels of correlation are based on the ability of the correlation to reproduce the complete plasma 
concentration-time profiles resulting from administration of a dosage form. 
 
Table 8.1: Levels of IVIVC as identified by the Food and Drug Administration (FDA)  
Levels of IVIVC   
Level A 
 
IVIVC that predicts the entire in vivo time course from the in 
vitro data. It is generally a linear correlation that represents a 
point-to-point relationship between in vitro dissolution data and 
in vivo input rate. Non-linear relationships may also be 
appropriate. 
Level B 
 
Based on the principles of statistical moment analysis in which 
the mean in vitro dissolution time (MDTin vitro) is compared to 
either the mean in vivo residence time (MRT) or the mean in 
vivo dissolution time (MDTin vivo). This correlation does not 
reflect the actual in vivo plasma curves as different in vivo 
curves produce similar MRT values. 
Level C IVIVC that establishes a single-point relationship between a 
dissolution parameter (e.g. t50%,t90%) and a pharmacokinetic 
parameter (e.g. AUC, Cmax). Considered a weak correlation as 
it does reflect complete shape of a plasma drug concentration 
time curve. 
Multiple Level C Establishes a relationship between one or more 
pharmacokinetic parameters of interest and amount of drug 
dissolved at several time points of the dissolution profile. 
 
Based on the distinct properties of each level, a Level A IVIVC was identified as the highest 
category of correlation as it is considered the most informative for predicting the in vivo 
performance of a drug product from its in vitro dissolution. Thus, WinNonLin® software (V5.3 
with IVIVC Toolkit Build 20091211139, Pharsight Software, Statistical Consultants Inc., Apex, 
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NC, USA) was used to establish a Level A IVIVC. The inputted data included; in vitro octreotide 
and exenatide release data and in vivo plasma concentration data. Establishment of an IVIVC 
model involves development and validation processes. Accordingly, the Level A IVIVC was 
developed using a two-stage process (Chakraborty et al., 2014).  
1. Deconvolution: This technique requires the comparison of in vivo dissolution profiles with 
in vitro dissolution profiles. The observed fraction of the drug absorbed is estimated 
based on the Wagner-Nelson method. Once the pharmacokinetic parameters were 
estimated using a non-linear regression tool, the predicted fraction of the drug absorbed 
was calculated from the observed fraction of the drug dissolved.  
2. Convolution: the prediction fraction of the drug absorbed is then convolved to the 
predicted plasma concentrations instituting the convolution method.  
 
Following development of the IVIVC model, the validity of the correlation was determined by 
evaluating the magnitude of the predictive performance. The percentage prediction error (P.E.) 
was calculated for Cmax and AUC using Equation 8.6 and 8.7, respectively (Chakraborty et al., 
2014). 
 % P. E. = 𝐶𝐶𝑚𝑚𝑎𝑎𝑚𝑚𝑜𝑜𝑜𝑜𝑠𝑠𝑜𝑜𝑄𝑄𝑜𝑜𝑜𝑜𝑑𝑑−𝐶𝐶𝑚𝑚𝑎𝑎𝑚𝑚𝑝𝑝𝑄𝑄𝑜𝑜𝑑𝑑𝑖𝑖𝑝𝑝𝑑𝑑𝑜𝑜𝑑𝑑
𝐶𝐶𝑚𝑚𝑎𝑎𝑚𝑚𝑜𝑜𝑜𝑜𝑠𝑠𝑜𝑜𝑄𝑄𝑜𝑜𝑜𝑜𝑑𝑑
× 100                                                                                 (8.6) 
 % P. E. = 𝐴𝐴𝐴𝐴𝐶𝐶𝑜𝑜𝑜𝑜𝑠𝑠𝑜𝑜𝑄𝑄𝑜𝑜𝑜𝑜𝑑𝑑−𝐴𝐴𝐴𝐴𝐶𝐶𝑝𝑝𝑄𝑄𝑜𝑜𝑑𝑑𝑖𝑖𝑝𝑝𝑑𝑑𝑜𝑜𝑑𝑑
𝐴𝐴𝐴𝐴𝐶𝐶𝑜𝑜𝑜𝑜𝑠𝑠𝑜𝑜𝑄𝑄𝑜𝑜𝑜𝑜𝑑𝑑
× 100                                                                               (8.7) 
 
Where, P.E. is the prediction error, 𝐶𝐶𝑚𝑚𝑎𝑎𝑚𝑚 is the maximum plasma concentration and AUC is the 
Area under the curve.  
 
8.3. Results and Discussion  
 
8.3.1. Clinical and behavioral assessment of the pig model following surgical 
implantation of the intra-jugular catheter and dosage form administration  
The pigs were monitored closely for any signs of infection, pain and inflammation following post-
surgical implantation. All pigs displayed a quick recovery, despite being initially drowsy, 
returning fully to their normal levels of activity and appetite relative to their observed behaviors 
before surgery. Ideally, the pigs displayed no signs of infection or inflammation during recovery 
and throughout the study. Furthermore, the pigs showed no side effects following the 
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administration of the octreotide and exenatide experimental systems. This confirmed the 
biocompatibility of the optimized Tri-functionalized OCMT. The pigs experienced the common 
side effects of lethargy and a loss of appetite within the first 2 hours following administration of 
the exenatide conventional system. This was attributed to the reaching of possibly high plasma 
concentrations of exenatide following SC injection. Generally, the pigs were monitored twice a 
day throughout the entire study and any clinical or behavioral changes observed were recorded 
on a monitoring chart.  
 
8.3.2. A calibration curve for the quantification of plasma octreotide and exenatide 
concentrations 
Evaluation of the octreotide and exenatide standards generated 4-parameter logistic curve fits 
as shown in Figure 8.8a-b, respectively. The calibration curves were deemed satisfactory for the 
determination of the unknown plasma sample concentrations as they displayed excellent fits, 
indicated by the R2 values obtained of 0.99.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.8: Calibration curves of a) octreotide measured at 450nm and b) exenatide measured 
at 450nm. 
 
8.3.3. In vivo release profile analysis of octreotide from the Tri-functionalized OCMT and 
the conventional system 
The comparative in vivo concentration profiles of octreotide from the Tri-functionalized OCMT, 
formulation control (optimized OCMT containing no co-inhibitory ‘smart’ polymeric sheet or pH 
modifier) and conventional system are presented in Figure 8.9a-b. Results revealed the 
effectiveness of the Tri-functionalized OCMT in delivering therapeutic levels of octreotide 
(a) (b) 
𝒚𝒚 = 𝒂𝒂−𝒅𝒅
𝟏𝟏+(𝒙𝒙/𝒄𝒄)𝒃𝒃 + 𝒅𝒅  𝒚𝒚 = 𝒂𝒂−𝒅𝒅𝟏𝟏+(𝒙𝒙/𝒄𝒄)𝒃𝒃 + 𝒅𝒅  
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following oral administration. Profiling analysis demonstrated an initial similar concentration-time 
pattern for the formulation control and Tri-functionalized OCMT (Figure 8.9a). However, 
noticeable changes were observed between 2-3 hours wherein, the formulation control 
displayed higher peak plasma levels (±2.2ng/mL) as compared to the Tri-functionalized OCMT 
(±1.5ng/mL). This was followed by a rapid decrease in the plasma concentrations after 3 hours, 
in sharp contrast to the concentrations quantified for the Tri-functionalized OCMT. This was 
attributed to the absence of the co-inhibitory ‘smart’ polymeric sheet and pH modifier. These 
components ideally function to directly or indirectly control the release of the incorporated 
peptide by virtue of its characteristic properties that have been extensively highlighted in 
previous Chapters. However, despite the absence of these functional components, the 
formulation control still displayed an acceptable controlled release profile possibly resulting from 
the effects of in situ crosslinking.  
 
The in vivo concentration profile obtained for the Tri-functionalized OCMT supported the 
functional effects of the co-inhibitory ‘smart’ polymeric sheet and pH modifier as well as other 
functional components by attractively displaying a slower sustained release of octreotide 
between biphasic peak concentrations for up to 12 hours. This was followed by achievement of 
steady state plasma concentrations. In addition, therapeutic levels were maintained up to 22 
hours for both the Tri-functionalized OCMT and the formulation control. Furthermore, 
comparison of the Tri-functionalized OCMT to the conventionally administered subcutaneous 
injection emphasized the inability of the latter to provide sustained release capabilities, as 
evidenced by results obtained in Figure 8.9b.  
 
Although the conventional system displayed much higher peak plasma concentrations 
(±5.8ng/mL), it failed to achieve steady-state plasma concentrations and reached sub-
therapeutic levels after only 4 hours. This indicates the need for frequent and multiple doses to 
achieve consistent therapeutic levels. The attainment of consistent and sustained therapeutic 
levels over a 24 hour period, as observed for the Tri-functionalized OCMT, promotes once-daily 
dosing and greatly minimizes the side effect profile associated with higher plasma 
concentrations. Summations inferred from overall octreotide in vivo plasma profile analysis for 
the experimental and conventional groups revealed the exemplary performance of the Tri-
functionalized OCMT in providing sustained, therapeutic levels of octreotide following oral 
administration. Overall, the in vivo results alluded to the potential of the optimized Tri-
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functionalized OCMT to provide a viable alternative to the parenteral route of administration for 
gastro-sensitive proteins and peptides. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.9: In vivo plasma octreotide concentration-time profiles for a) the orally administered 
Tri-functionalized OCMT and formulation control (optimized OCMT with no polymeric sheet or 
pH modifier) and b) the subcutaneously administered conventional system indicating the 
minimum effective concentration (MEC) for octreotide (0.5ng/mL). 
 
8.3.4. In vivo release profile analysis of exenatide from the Tri-functionalized OCMT and 
the conventional system 
The comparative in vivo concentration profiles of exenatide from the Tri-functionalized OCMT, 
formulation control (optimized OCMT containing no co-inhibitory ‘smart’ polymeric sheet or pH 
modifier) and conventional system are presented in Figure 8.10a-b. Results revealed the 
achievement of therapeutic levels of exenatide from the Tri-functionalized OCMT and 
formulation control, as evidenced by the observation of peak and sustained plasma 
concentrations levels above the minimum effective concentration (MEC) of 50pg/mL 
(0.05ng/mL).  The concentration-time profile for the formulation control of exenatide followed the 
same profiling pattern as that of the Tri-functionalized OCMT with peak plasma levels reaching 
±1.55ng/mL and ±1.6ng/mL for the Tri-functionalized OCMT and formation control, respectively 
(Figure 8.10a). However, the Tri-functionalized OCMT displayed higher consistent levels of 
exenatide up to 24 hours as compared to the formulation control, attributable to the mechanistic 
action of the co-inhibitor, contained within the ‘smart’ polymeric sheet, which functions to inhibit 
drug metabolism and prevent transmembrane efflux. Interestingly, an apparent tri-phasic 
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release of exenatide was noticeable for the Tri-functionalized OCMT as evidenced by the 
increased concentrations following phases of sustained release.  
 
Comparison of the Tri-functionalized OCMT to the conventional system, as shown in Figure 
8.10b, demonstrated a significantly high dose-related peak plasma concentration following 
subcutaneous administration. Typically, the conventional system provides higher concentrations 
of exenatide for a short period of time followed by diminished levels, compared to the 
continuous but lower, yet effective, concentration of exenatide observed over the entire 24-hour 
period for the Tri-functionalized OCMT. The high concentrations achieved for the conventional 
system increased the likelihood of observed side effects, as evident by the behavioral 
observation of lethargy and loss of appetite in the pigs following subcutaneous administration. 
Conversely, the lower concentrations of the Tri-functionalized OCMT translates into a reduced 
side effect profile. In addition, sub-therapeutic levels of exenatide from the conventional system 
were observed after 8 hours, indicating the need for multiple dosing to achieve steady-state 
plasma concentrations. Generally, the sustained release capabilities and plasma concentration 
levels of exenatide from the Tri-functionalized OCMT was attributed to the functional effects of 
distinct formulatory components that have been highlighted extensively in previous Chapters. 
The results obtained further supported the potential of the Tri-functionalized OCMT to 
successfully deliver therapeutic proteins and peptides via the oral route, consequently 
increasing patient compliance and acceptability.  
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Figure 8.10: In vivo plasma exenatide concentration-time profiles for a) the orally administered 
Tri-functionalized OCMT and formulation control (optimized OCMT with no polymeric sheet or 
pH modifier) and b) the subcutaneously administered conventional system indicating the 
minimum effective concentration (MEC) for exenatide (0.05ng/mL). 
 
8.3.5. Pharmacokinetic analysis 
 
8.3.5.1. Octreotide non-compartmental and compartmental analysis 
The results of the extravascular non-compartmental and compartmental analysis for octreotide 
are presented in Figure 8.11a-b, respectively. The one compartmental and two compartmental 
pharmacokinetic analysis of octreotide release indicated favorably small AIC and SC values. 
Further evaluation of the R2 values indicated a higher value for the two compartmental model as 
compared to the non-compartmental model and one compartment model. Evaluation of the 
combined diagnostics of AIC, SC and R2 values obtained indicated that the octreotide release 
from the Tri-functionalized OCMT was best described by the two compartment model shown in 
Table 8.2.  
 
Moreover, pharmacokinetic analysis of the subcutaneously administered conventional system 
revealed that octreotide release was best described by the non-compartmental model, as it 
displayed a higher R2 value and enabled identification of dual Cmax and Tmax peaks, as shown in 
Table 8.3. The maximum plasma concentration (Cmax) and corresponding time (Tmax) were 
obtained from the fitted plasma concentration-time data shown in Figure 8.9a-b. Following 
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administration of the subcutaneous injection, higher plasma concentrations were reached more 
rapidly as indicated by Cmax1 (3.238ng/mL) and Cmax2 (5.5810ng/mL) which were reached at Tmax 
of 15min and 2 hours, respectively. In contrast, the Cmax of octreotide from the Tri-functionalized 
OCMT was 1.5062ng/mL at a corresponding Tmax of 4.5669 hours. The higher Tmax obtained in 
comparison to the conventional system indicates a slower release of octreotide from the Tri-
functionalized OCMT. In addition, the first order absorption rate (Ka) for octreotide in the 
intestine was 0.5761/h and the elimination rate constant (Kel) was 0.0528/h. The 
pharmacokinetic parameters generated for the Tri-functionalized OCMT thus all point to the 
prolonged release of octreotide.  
 
Furthermore, the MRT for octreotide following oral administration of the Tri-functionalized OCMT 
was predictably higher at 20.6761 hours as compared to the conventional system at 5.9454 
hours. This supported the observed prolonged release of octreotide and was further attributed to 
the inhibition of CYP3A4 causing a reduced metabolism and a subsequent decreased 
elimination of the peptide. Lastly, the achievement of a good oral bioavailability is a critical 
determinant in evaluating the possible therapeutic potential of an oral system for the delivery of 
gastro-sensitive therapeutic proteins and peptides. Thus, the relative bioavailability was 
determined by measuring the area under the curve (AUC) for both the oral and subcutaneous 
systems (Musther et al., 2014). This value represented the total extent of octreotide 
absorption/uptake into the systemic circulation following their respective administrations. 
Results revealed an AUC0-inf of octreotide following SC administration of the conventional 
system at 11.9485ng/mL*h as compared to the oral administration of the Tri-functionalized 
OCMT which generated an AUC0-inf value of 36.3075ng/mL*h, indicating a three-fold increase in 
the oral bioavailability of octreotide compared to the SC injection. The overall results obtained 
from pharmacokinetic analysis demonstrated the feasibility of the Tri-functionalized OCMT in 
delivering sustained, therapeutic levels of octreotide with an enhanced oral bioavailability.  
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Figure 8.11: Graphical results showing the observed and predicted values for a) non-
compartmental and b) compartmental pharmacokinetic analysis of octreotide release from the 
Tri-functionalized OCMT.  
 
Table 8.2: Results of two compartmental analysis of octreotide release from the orally 
administered Tri-functionalized OCMT 
Parameter  Unit  Value  Diagnostics  Value  
A  ng/ml 0.000001 r obs-pre  0.9066 
Alpha  1/h 0.2694 SS  0.5600 
B  ng/ml 2.1104 WSS  0.5600 
Beta  1/h 0.0528 R2  0.9639 
Ka  1/h 0.5761 WR2 0.9639 
k10  1/h 0.0528 SE  0.2646 
k12  1/h 0.00000005 AIC  2.4631 
k21  1/h 0.2694 SC  5.2879 
t1/2Alpha  H 2.5732   
t1/2Beta  H 13.1283   
t1/2ka  H 1.2032   
V/F  (mg)/(ng/ml) 10.4332   
CL/F  (mg)/(ng/ml)/h 0.5508   
V2/F  (mg)/(ng/ml) 0.00000187   
CL2/F  (mg)/(ng/ml)/h 0.00000050   
Tmax  H 4.5669   
Cmax  ng/ml 1.5062   
AUC 0-t  ng/ml*h 25.0504   
AUC 0-inf  ng/ml*h 36.3075   
AUMC  ng/ml*h2 750.6979   
MRT  H 20.6761   
 
 
 
(b) (a) 
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Table 8.3: Results of non-compartmental analysis of octreotide release from the 
subcutaneously administered conventional system 
Parameter Unit Value 
𝜆𝜆𝑧𝑧 1/h 0.1079 
t1/2 h 6.4227 
Tmax h 2 
Cmax ng/mL 5.5810 
Tlag h 0 
Clast_obs/Cmax  0.0158 
AUC 0-t ng/mL*h 11.1331 
AUC 0-inf_obs ng/mL*h 11.9485 
AUC 0-t/0-inf_obs  0.9318 
AUMC 0-inf_obs ng/mL*h2 71.0385 
MRT 0-inf_obs h 5.9454 
Cl/F_obs (mg)/(ng/ml)/h 0.0775 
Tmax1 h 0.08 
Cmax1 ng/ml 3.238 
Tmax2 h 2 
Cmax2 ng/ml 5.581 
TmaxH h 2 
CmaxH ng/ml 5.581 
CmaxL/CmaxH  0.580182763 
CmaxH-L ng/ml 2.343 
NumBtwPeaks  5 
DuraBtwPeaks h 1.92 
 
8.3.5.2. Exenatide non-compartmental and compartmental analysis 
The results of the extravascular non-compartmental and compartmental analysis for exenatide 
are presented in Figure 8.12a-b, respectively. Evaluation of analysis revealed that exenatide 
release was similarly best described by a two compartmental model with the most favorable AIC 
and SC values determined with this algorithm (Table 8.4). In addition, the diagnostic evaluation 
of the regression coefficients (R2) indicated a significantly greater fit for the two compartmental 
model as compared to the non-compartmental model and one compartmental model. Further 
diagnostic of the sum of squares (SS) and standard error (SE) with compartmental analysis 
revealed SS=13.5370; SE=1.1635 and SS=1.2097; SE=0.3889 for the one compartment and 
two compartment analysis, respectively. This indicated the variance in the modelled values, 
further supporting the two compartmental model fit. Furthermore, the pharmacokinetic analysis 
of the subcutaneously administered conventional system revealed that exenatide release was 
best described by a one compartmental model with the most favorable AIC and SC values 
obtained, as shown in Table 8.5.  
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The pharmacokinetic parameters determined by the one compartmental model for the 
conventional system indicated a first order absorption rate constant (Ka) of 0.9806/h and an 
elimination rate constant (Kel) of 0.8333/h. This confirmed the rapid absorption and equally rapid 
elimination of exenatide following SC administration of the conventional system. As a result of 
the rapid absorption, a peak plasma concentration (Cmax=7.6783ng/mL) was reached at 1.1050 
hours (Tmax). In contrast, the two compartmental analysis of octreotide release from the Tri-
functionalized OCMT indicated a lower Cmax (1.1981ng/mL) at a corresponding Tmax of 2.2597 
hours. Consideration of the large comparative differences between the peak plasma 
concentrations of the conventional system and the Tri-functionalized OCMT, retrospectively 
accounts for the side effects observed in the pig following SC injection. Higher peak plasma 
concentrations may enter the toxic range and significantly increase the side effect profile. Thus, 
the lower Cmax values observed for exenatide following oral administration of the Tri-
functionalized OCMT may greatly reduce the side effect profile while still maintaining therapeutic 
levels of exenatide over a sustained period of time as indicated by the higher MRT (99.37h) 
value obtained.  
 
The MRT further supported the prolonged release and slow elimination rate (Kel =0.0126/h) of 
exenatide which may be attributed to the inhibition of CYP3A4 which causes a reduction in 
exenatide metabolism, consequently affecting its ADME profile. A final critical parameter in 
pharmacokinetic evaluations, following oral and SC administration, is the AUC as it is used as a 
measure of oral bioavailability (Musther et al., 2014). Understanding the bioavailability is a key 
consideration in the evaluation of the feasibility of a dosage form, specifically oral formulations, 
as its availability can be affected by additional elements along the GIT pathway. Thus, 
parametric evaluation revealed an AUC0-inf of exenatide following SC administration of the 
conventional system at 23.1396ng/mL*h as compared to the oral administration of the Tri-
functionalized OCMT which generated an AUC0-inf value of 117.3464ng/mL*h. Comparative 
analysis indicated a five-fold increase in the oral bioavailability of exenatide compared to the SC 
injection. The improved oral bioavailability, sustained release and comprehensive 
pharmacokinetic profiling analysis demonstrated the feasibility of the Tri-functionalized OCMT to 
provide an alternative therapeutic tool for exenatide delivery, potentially substituting the 
conventional SC administration.   
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Figure 8.12: Logarithmic graph results showing the observed and predicted values for a) non-
compartmental and b) compartmental pharmacokinetic analysis of exenatide release from the 
Tri-functionalized OCMT.  
 
Table 8.4: Results of two compartmental analysis of exenatide release from the orally 
administered Tri-functionalized OCMT 
Parameter  Unit  Value  Diagnostics  Value  
A  ng/ml 0.7127 r obs-pre  0.8125 
Alpha  1/h 0.8599 SS  1.2097 
B  ng/ml 1.1901 WSS  1.2097 
Beta  1/h 0.0101 R2  0.9313 
Ka  1/h 1.4788 WR2 0.9313 
k10  1/h 0.0126 SE  0.3889 
k12  1/h 0.1687 AIC  12.4745 
k21  1/h 0.6886 SC  15.2992 
t1/2Alpha  H 0.8061   
t1/2Beta  H 68.6098   
t1/2ka  H 0.4687   
V/F  (mg)/(ng/mL) 3.3777   
CL/F  (mg)/(ng/mL)/h 0.0426   
V2/F  (mg)/(ng/mL) 0.8276   
CL2/F  (mg)/(ng/mL)/h 0.5699   
Tmax  h 2.2597   
Cmax  ng/ml 1.1981   
AUC 0-t  ng/ml*h 24.9065   
AUC 0-inf  ng/ml*h 117.3464   
AUMC  ng/ml*h2 11660.7134   
MRT  h 99.3700   
 
(a) (b) 
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Table 8.5: Results of one compartmental analysis of exenatide release from the subcutaneously 
administered conventional system 
Parameter  Unit  Value  Diagnostics  Value  
A  ng/mL  128.4042 r obs-pre  0.9424 
Ka  1/h  0.9806 SS  11.6327 
k10  1/h  0.8333 WSS  11.6327 
t1/2ka  h  0.7069 R2 0.9344 
t1/2k10  h  0.8318 WR2  0.9344 
V/F  (mg)/(ng/mL)  0.0041 SE  1.1369 
CL/F  (mg)/(ng/mL)/h  0.0035 AIC  35.4458 
Tmax  h  1.1050 SC  36.9006 
Cmax  ng/mL  7.6783   
AUC 0-t  ng/mL*h  23.1396   
AUC 0-inf  ng/mL*h  23.1396   
AUMC  ng/mL*h2 51.3642   
MRT h  2.2198   
 
8.3.6. Establishment of an IVIVC for peptide release from the Tri-functionalized OCMT 
 
8.3.6.1. Establishment of in vitro-in vivo correlation for octreotide 
A Level A IVIVC was established for evaluation of octreotide release using all the information of 
the in vitro dissolution and in vivo absorption curves, generating a one-to-one relationship based 
directly on each of the assayed time points (Emami, 2006). The amount of peptide absorbed 
following oral administration of the Tri-functionalized OCMT, which is important in terms of its 
further pharmaceutical development, was calculated by the Wagner-Nelson deconvolution 
technique using the linear trapezoidal rule. For the analysis of a Level A IVIVC, the percentage 
of peptide absorbed up to time t was plotted versus the amount of peptide released in vitro. The 
pharmacokinetic conditions derived from this investigation conforms to the requirements of the 
two-stage developmental process of deconvolution through convolution since the octreotide 
release from the Tri-functionalized OCMT was best described by a two compartmental 
pharmacokinetic model. Deconvolution of observed plasma octreotide concentration-time data 
against the in vitro release profile (Figure 8.13a) provided the predicted in vitro and in vivo 
release profiles, shown in Figure 8.13b.   
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Figure 8.13: In vitro and in vivo release profiles in a) observed octreotide release from the Tri-
functionalized OCMT and b) predicted octreotide release extracted using deconvolution 
analysis. 
 
Level A IVIVC analysis for octreotide yielded a levy plot with an R2 value of 0.9366 and a slope 
of 0.026, as shown in Figure 8.14. Thus, in vitro data was predictive of in vivo data with 93.66% 
accuracy. However, the slope of the curve was lower than 1, indicating that the in vivo 
absorption rate was underestimated which may be attributed to the hepatic first pass effect 
(Sirisuth and Eddington, 2002). Central to development of an IVIVC is the validation of the 
model and thus, the prediction errors (PE) for Cmax and AUC0- were calculated in order to 
determine the validity of the correlation.  According to the FDA guidelines, the mean absolute 
%PE should be ≤10% and the absolute prediction error should be ≤15%. The calculated PE for 
Cmax and AUC0- were 12.70% and 0%, respectively. These results indicated a good validation 
of the IVIVC model with a 0% PE indicating no error between the observed and predicted AUC0-
 value. Based on qualitative parameters, a Level A correlation was approached despite the 
plots not being perfectly superimposable. The complexity of the Tri-functionalized OCMT 
accounts for the slight variations between the in vitro and in vivo data. Generally, the in vitro 
data seems to run ahead of in vivo data as in vivo conditions cannot be completely simulated in 
vitro, specifically with respect to the co-inhibition of CYP3A4 and Pgp by the Tri-functionalized 
OCMT. Nevertheless, the in vitro data did display a good predictability of the in vivo data, 
reliably demonstrating that the IVIVC model can possibly be used a surrogate for 
bioequivalence studies. 
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Figure 8.14: A levy plot depicting the relationship between the percentage of octreotide release 
in vitro and the percentage of octreotide absorbed in vivo. 
 
8.3.6.2. Establishment of in vitro-in vivo correlation for exenatide  
A Level A IVIVC was established for exenatide release via a two-stage process of deconvolution 
through convolution (Chakraborty et al., 2014). Deconvolution of all the observed data of the in 
vitro dissolution and in vivo absorption curves (Figure 8.15a) at each assayed time point was 
used to calculate the predicted in vitro and in vivo release profiles (Figure 8.15b) using the 
Wagner-Nelson method.  
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Figure 8.15: In vitro and in vivo release profiles of a) observed exenatide release from the Tri-
functionalized OCMT and b) predicted exenatide release extracted using deconvolution 
analysis. 
 
The established Level A IVIVC analysis for exenatide release yielded a levy plot with an R2 
value of 0.9407 and a slope of 0.022, as shown in Figure 8.16. Thus, in vitro data was predictive 
of in vivo data with 94.07% accuracy. However, the slope of the curve was lower than 1, 
indicating an underestimation of the in vivo absorption rate which may be attributed to the 
hepatic first pass effect (Sirisuth and Eddington, 2002). Central to development of an IVIVC is 
the validation of the model and thus, the prediction errors (PE) for Cmax and AUC0- were 
calculated in order to determine the validity of the correlation.  According to the FDA guidelines, 
the mean absolute %PE should be ≤10% and the absolute prediction error should be ≤15%. 
The calculated PE for Cmax and AUC0- were 10.81% and 0%, respectively. These results 
indicated a good validation of the IVIVC model with a 0% PE indicating no error between the 
observed and predicted AUC0- value. The plots were not directly superimposable; however, 
based on the qualitative patterns of this fit, a Level A correlation was approached. The 
complexity of the Tri-functionalized OCMT accounts for the slight variations between the in vitro 
and in vivo data. Generally, the in vitro data seems to run ahead of in vivo data as in vivo 
conditions cannot be completely simulated in vitro, specifically with respect to the co-inhibition of 
CYP3A4 and Pgp by the Tri-functionalized OCMT. Nevertheless, the in vitro data did display a 
good predictability, matching the in vivo data more closely than octreotide and reliably 
demonstrating that the IVIVC model can possibly be used a surrogate for bioequivalence 
studies. 
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Figure 8.16: A levy plot depicting the relationship between the percentage of exenatide release 
in vitro and the percentage of exenatide absorbed in vivo. 
 
8.4. Concluding Remarks   
In vivo analysis of the Tri-functionalized OCMT in the Large White pig model has demonstrated 
the potential of the device to successfully delivery therapeutic peptides orally. The novel 
features of the Tri-functionalized OCMT function synergistically to provide an optimal 
therapeutic profile. The oral bioavailability of both octreotide and exenatide was enhanced as 
evidenced by the three-fold and five-fold increase in AUC0- as compared to their conventional 
subcutaneous systems, respectively. Octreotide displayed a Cmax of 1.5062ng/mL at a 
corresponding Tmax of 4.5669 hours and exenatide displayed a Cmax of 1.1981ng/mL at a 
corresponding Tmax of 2.2597 hours. Both of the Cmax values obtained were significantly lower 
than the conventional systems but still higher than the minimum effective concentration (MEC).  
Generally, the in vivo profiles of both octreotide and exenatide displayed sustained therapeutic 
levels over the 24 hour period with phases of peak concentrations attributed to a combination of 
the distinct functionalities of formulatory components, producing in situ crosslinking and co-
inhibition of CYP3A4 and Pgp, causing further sustained release. In addition, the evaluation of 
the IVIVC undertaken for both octreotide and exenatide attained a Level A correlation with a 
good predictability, providing further evidence of the feasibility of the Tri-functionalized OCMT, 
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and advancing the development for clinical application. Conclusive in vivo analysis of both 
octreotide and exenatide demonstrated the capability of the Tri-functionalized OCMT to serve as 
prototypical device for incorporation and delivery of a multitude of gastro-sensitive proteins and 
peptides, potentially replacing the conventional parenteral routes of administration.  
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CHAPTER 9 
CONCLUSIONS, RECOMMENDATIONS AND FUTURE OUTLOOK 
 
9.1. Conclusion 
The global pharmaceutical biotechnology industry is continually growing and increased amounts 
of protein and peptide-based therapeutics are entering into the market. The interest in this field 
stems from the high specificity and activity of these molecules which make them the preferred 
choice for multiple disease conditions. However, the conventional delivery systems available for 
these therapeutic proteins and peptides limit patient acceptability and convenience.  
 
Thus, pharmaceutical companies and research-based institutions are progressively focusing 
their efforts towards developing simple and effective delivery alternatives. Oral dosage forms 
still remain the simplest and most preferred delivery route, however it poses numerous physical 
and chemical challenges with regards to the successful delivery of therapeutic proteins and 
peptides. Therefore, any developments in this field need to successfully overcome these 
challenges in order to provide a clinically useful oral formulation. 
 
The Tri-functionalized OCMT device that was formulated in this study was designed with the 
intention of overcoming the challenges relating to the oral administration of therapeutic proteins 
and peptides by triple targeting three major issues, namely; 1) the exposure of proteins and 
peptides to unfavorable conditions within the gastrointestinal tract (GIT), 2) poor absorption 
through the GIT membrane and 3) enzymatic degradation within the GIT.  
 
This was achieved by incorporating the bioactive into a core-melt archetype within the tablet and 
facilitating the process of in situ crosslinking which significantly affects the way the bioactive is 
protected within the compressed tablet matrix as well providing desirable bioactive release 
kinetics. In addition, the incorporation of a co-inhibitory ‘smart’ polymeric sheet provided added 
protection and enabled an improved absorption by virtue of its intrinsic properties and co-
inhibition of the major determinants, CYP3A4 and Pgp, of poor absorption and low oral 
bioavailability. Lastly, targeting of enzymatic degradation was achieved by incorporation of a pH 
modifier that functions to transiently lower the micro-environmental pH and reduce the optimal 
environment for enzyme activity.  
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The combination of the distinct formulatory components contained within the Tri-functionalized 
OCMT was extensively evaluated through in-depth in vitro physicochemical and 
physicomechanical characterization, ex vivo analyses and in vivo performance. In vitro and ex 
vivo characterization enabled the optimization of design variables and promoted the 
achievement of desirable functionalities for attainment of optimum in vivo performance. In vivo 
analyses of the Tri-functionalized OCMT in the Large White pig model revealed an enhanced 
oral bioavailability of the incorporated peptides, octreotide and exenatide, following oral 
administration, as compared to their conventionally administered subcutaneous counterparts. In 
addition, pharmacokinetic analysis of the Tri-functionalized OCMT confirmed the maintenance 
of sustained, therapeutic levels of both octreotide and exenatide over the 24 hour period, 
supporting a convenient once-daily dosing.  
 
The advanced research presented in this thesis has brought the Tri-functionalized OCMT from 
the stage of conceptual design to the completion of preclinical studies. Essentially, it has been 
successfully demonstrated that the Tri-functionalized OCMT enhances the oral delivery of 
therapeutic proteins and peptides, potentially serving as a viable alternative to the conventional 
parenteral route of administration for multiple disease conditions. 
 
9.2. Recommendations 
In vivo studies that were undertaken successfully demonstrated the achievement of peptide 
levels above the minimum effective concentration. However, the Cmax for both octreotide and 
exenatide was much lower than the parenterally administered conventional systems. This can 
be overcome by increasing the concentration of peptide incorporation into the Tri-functionalized 
OCMT, however, care must be taken that plasma concentrations do not reach toxic levels as 
this could result in unwanted side effects that are commonly associated with the high peak 
plasma concentrations reached with parenteral formulations.  
 
Although animal studies provided valuable information regarding the in vivo fate of the Tri-
functionalized OCMT, alternative methods for modeling intestinal absorption may eliminate the 
need for animal testing. The ex vivo permeation studies that were undertaken provide an 
approximate correlation to the permeation-enhancing effects of certain components, however,  
advanced cellular transport studies may prove to be more useful in determining the exact 
mechanism facilitating the permeation process across the intestinal membrane, in addition to 
providing a reliable estimate of oral absorption.  
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Whilst the Tri-functionalized OCMT has been refined to a stage of formulation optimization and 
preclinical investigation, implications for further considerations becomes paramount in 
advancing the system to clinical stage development. An important consideration is the scaling-
up of the manufacturing process. The Tri-functionalized OCMT is relatively cost-effective to 
produce. However, due to the incorporation of different components and the formation of a core-
melt archetype, specialized machinery may be required to provide a reproducible tablet 
assembly process.  
 
9.3. Future Outlook 
The novel Tri-functionalized OCMT certainly opens up clinical advancement opportunities with 
respect to the development of innovator devices for oral protein and peptide delivery. The Tri-
functionalized OCMT was evaluated for its clinical potential using octreotide and exenatide, 
however the versatility of the formulation renders the Tri-functionalized OCMT applicable for 
incorporation of a multitude of therapeutic proteins and peptides. Moreover, the device can aid 
in the delivery of Biopharmaceutics Classification System (BCS) Class drugs which possess 
varying degrees of solubility and permeability. This ultimately increases the disease targeting 
database of the device and enhances its clinical potential. The intellectual property of the Tri-
functionalized OCMT device has been by protected its provisional patent. In addition, the 
licensing of the technology to a suitable pharmaceutical company has been instigated and 
potential positive outcomes may promote economic growth within South Africa. The 
development of this technology in South Africa will not only enable the country to compete on an 
international level against the importation of innovator and generic products but also, enable the 
recognition of the country as being capable of achieving research excellence on par with 
international standards. 
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10.2. Research Presentations  
2015 School of Therapeutic Sciences Research Day, University of the Witwatersrand, South 
Africa 
 
Design of a Novel Oral Core-Melt Tablet (OCMT) for Enhanced Delivery of Gastro-
Sensitive Biotech Drug Molecules 
Bibi F. Choonara, Yahya E. Choonara, Lisa C. du Toit, Pradeep Kumar, Viness 
Pillay* 
University of the Witwatersrand, Faculty of Health Sciences, Department of Pharmacy and 
Pharmacology, 7 York Road, Parktown, Johannesburg 2193, South Africa 
* Corresponding Author: viness.pillay@wits.ac.za 
 
PURPOSE: 
The oral delivery of proteins and peptides is limited by the gastrointestinal (GIT) barrier which acts a 
physical and chemical impediment towards achieving successful oral delivery. Advancements towards 
achieving successful oral delivery of proteins and peptides remains an active area of research and thus, 
this technology aims to collectively target the major challenges by significantly improving permeation, 
increasing structural protection and enabling controlled release of the incorporated protein/peptide. 
METHODS: 
The premise of the design is the formulation of an innovative matrix-type tablet technology by utilizing a 
mixture of salts and temperature-responsive polymer composites capable of creating prefabricated core-
melt archetypes within tablets. The tablet provides structural protection and ensures controlled release of 
the biotech drug molecule due to in situ crosslinking within the tablet core, facilitated by the proposed 
melting of the temperature-responsive polymer composite at body temperature (37°C). An experimental 
design of 15 formulations for the OCMTs was generated and each formulation was characterized with 
respect to in vitro protein/peptide release, ex vivo permeation capabilities (Franz diffusion), swelling and 
erosion, in situ crosslinking abilities (Fourier Transform Infrared Spectroscopy-FTIR), Magnetic 
Resonance Imaging (MRI) and textural analysis. In addition, advanced thermal (Differential Scanning 
Calorimetry and Thermogravimetric Analysis) and crystallinity analysis (Scanning Electron Microscopy 
(SEM) and X-ray Diffraction) was performed on the temperature-responsive polymer composite. 
RESULTS:   
Physicochemical and physicomechanical characterization tests confirmed successful formation of the 
temperature-responsive polymer composite. Protein/peptide release from the OCMTs was calculated as a 
function of fractional release versus time with all formulations displaying similar controlled release 
patterns over the 24hour study period with a maximum fractional release of ±0.8 for all formulations. 
Mathematical modelling of the protein release kinetics corresponded best with the Higuchi model with 
near zero order (R2≈0.9787) release obtained. The permeation enhancing effect of the temperature-
responsive polymer composite was investigated and results displayed an enhanced drug flux (0.0576-
0.0720mg.cm−2h−1) across the porcine intestinal tissue model. FTIR results indicated successful in situ 
crosslinking. Textural analysis of the OCMTs revealed the softening of the polymer composite at 37°C, 
which mirrored the MRI image and thermal analysis results obtained. Essentially, this novel technology 
demonstrates the applicability of the design in improving the oral delivery of a multitude of proteins and 
peptides and may potentially serve as a viable alternative to the parenteral route of administration for 
sensitive proteins and peptides. 
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The 2015 Academy of Pharmaceutical Sciences of the Pharmaceutical Society of South Africa 
(APSSA) Conference, South Africa 
 
Design of a Novel In Situ Cross-linked Eutectic Tablet for Enhanced Delivery of Gastro-Sensitive 
Biotech Drug Molecules 
Bibi F. Choonara1, Yahya E. Choonara1, Lisa C. du Toit1, Pradeep Kumar1, Viness Pillay1 
1Department of Pharmacy and Pharmacology, Faculty of Health Sciences, University of the 
Witwatersrand, 7 York Road, Parktown, 2193, Johannesburg, South Africa 
PURPOSE: Polymer eutectics was used in the design of an innovative In Situ Cross-linked Eutectic 
Tablet- utilizing a suite of salts and eutectic polymer composites capable of creating prefabricated core-
melt archetypes within a tablet, producing a controlled release system that provides structural protection, 
increased permeation and enhanced the oral delivery of proteins and peptides. This study assessed the 
in vitro potential of the In Situ Cross-linked Eutectic Tablet and the applicability of the design in improving 
the oral delivery of proteins and peptides. 
 
METHODS: An experimental design of 15 formulations for the In Situ Cross-linked Eutectic Tablets was 
generated and each formulation was characterized with respect to in vitro protein/peptide release; ex vivo 
permeation capabilities through the pig intestinal tissue model; swelling and erosion; in situ crosslinking 
abilities; and physicomechanical profiling. In addition, advanced thermal analysis was significant for 
characterizing and comparing pertinent transitions such as melting, glass transitions, phase changes and 
heat of fusion of the eutectic composite and its reagents. Qualitative and quantitative crystallinity analysis 
was performed on the eutectic composite to determine fingerprint changes in crystallinity. 
 
RESULTS: Characterization tests confirmed eutectic composite formation as was evidenced by the 
lowering of the melting point to 37°C, the decreased crystallinity percentage for the eutectic powder melt 
(9.6%) as compared to the eutectic reagents menthol (30%) and cetomacrogol (16%), as well as the shift 
in the SEM images to an amorphous structure which is typically characteristic of eutectic mixtures. 
Protein/peptide release from the tablets displayed similar controlled release patterns over the 24hour 
study period with a maximum fractional release of ±0.8 for all formulations. The release pattern alternated 
between phases of burst and slow release which was attributed to the combined effects of swelling, 
surface erosion and in situ crosslinking. Mathematical modelling of the protein release kinetics 
corresponded best with the Higuchi model with near zero order (R2≈0.9787) release obtained. The 
permeation enhancing effect of menthol contained within the eutectic powder melt (EPM) was 
investigated and results displayed an enhanced drug flux (0.0576-0.0720mg.cm−2h−1) across the intestinal 
tissue model as compared to the control (EPM-free) formulation which displayed a drug flux of 
0.0289mg.cm−2 h−1. FTIR results highlighted the shifting and changing of band intensities as well as the 
appearance of new bands and the disappearance of bands indicating successful in situ crosslinking within 
the core eutectic region with higher concentrations of crosslinkers displaying superior crosslinking 
abilities. Textural analysis of the tablets revealed the softening of the core region at 37°C, which mirrored 
the MRI and thermal analysis results obtained. 
 
CONCLUSION: Physicochemical and physicomechanical characterization that was undertaken was 
essential for delineating the in vitro attributes, predicting the in vivo performance of the device and 
demonstrating the applicability of the design in improving the oral delivery of a multitude of proteins and 
peptides. Essentially, this novel technology may potentially serve as a viable alternative to the parenteral 
route of administration for sensitive proteins and peptides.      
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The 2015 AAPS Annual Meeting and Exposition, United States of America 
 
TITLE: Design of a Novel Oral Core-Melt Tablet (OCMT) for Enhanced Delivery of Gastro-Sensitive 
Biotech Drug Molecules 
AUTHORS: Bibi F. Choonara, Yahya E. Choonara, Lisa C. du Toit, Pradeep Kumar, Viness Pillay 
PURPOSE: The oral delivery of proteins and peptides is limited by the gastrointestinal (GIT) barrier which 
acts a physical and chemical impediment towards achieving successful oral delivery. Pharmaceutical 
technologies and approaches targeting the complications in the oral delivery of proteins and peptides 
although useful in some instances, nevertheless hold limitations that enable optimal delivery. 
Consequently, advancements towards achieving successful delivery of proteins and peptides remains an 
active area of research and thus, this technology aims to collectively target the major challenges by 
significantly improving permeation, increasing structural protection and enabling controlled release of the 
incorporated protein/peptide  
 
METHODS: The premise of the design is the formulation of a tablet with an outer polymer shell 
surrounding a core eutectic region that contains the incorporated protein or peptide and suitable 
crosslinking agents which provides structural protection and ensures controlled release of the biotech 
drug molecule due to in situ crosslinking within the tablet core which is facilitated by the ingress of fluid 
into the outer polymer shell and the proposed melting of the core eutectic region at body temperature 
(37°C). This was achieved through the utilization of a suite of salts and eutectic polymer composites 
capable of creating prefabricated core-melt archetypes within tablets. An experimental design of 15 
formulations for the OCMTs was generated and each formulation was characterized with respect to in 
vitro protein/peptide release, ex vivo permeation capabilities (Franz diffusion), swelling and erosion, in 
situ crosslinking abilities (Fourier Transform Infrared Spectroscopy-FTIR), Magnetic Resonance Imaging 
(MRI) and textural analysis. In addition, advanced thermal (Differential Scanning Calorimetry and 
Thermogravimetric Analysis) and crystallinity analysis (Scanning Electron Microscopy (SEM) and X-ray 
Diffraction) was performed on the eutectic powder melt. 
 
RESULTS:  Physicochemical and physicomechanical characterization tests confirmed eutectic formation 
as was evidenced by the lowering of the melting point to 37°C (Figure 1a), the decreased crystallinity 
percentage for the eutectic powder melt (9.6%) as compared to the eutectic reagents menthol (30%) and 
cetomacrogol (16%), as well as the shift in the SEM images to an amorphous structure which is typically 
characteristic of eutectic mixtures. Protein/peptide release from the OCMTs was calculated as a function 
of fractional release versus time with all formulations displaying similar controlled release patterns over 
the 24hour study period with a maximum fractional release of ±0.8 for all formulations. The release 
pattern alternated between phases of burst and slow release which was attributed to the combined effects 
of swelling, surface erosion and in situ crosslinking. Mathematical modelling of the protein release kinetics 
corresponded best with the Higuchi model with near zero order (R2≈0.9787) release obtained. The 
permeation enhancing effect of menthol contained within the eutectic powder melt (EPM) was 
investigated and results displayed an enhanced drug flux (0.0576-0.0720mg.cm−2h−1) across the intestinal 
tissue model as compared to the control (EPM-free) formulation which displayed a drug flux of 
0.0289mg.cm−2 h−1. FTIR results highlighted the shifting and changing of band intensities as well as the 
appearance of new bands and the disappearance of bands indicating successful in situ crosslinking within 
the core eutectic region with higher concentrations of crosslinkers displaying superior crosslinking 
abilities. Textural analysis of the OCMTs revealed the softening of the core region at 37°C, which 
mirrored the MRI image (Figure 1b) and thermal analysis results obtained. 
 
CONCLUSION: Physicochemical and physicomechanical characterization that was undertaken was 
essential for delineating the in vitro attributes, predicting the in vivo performance of the device and 
demonstrating the applicability of the design in improving the oral delivery of a multitude of proteins and 
peptides. Essentially, this novel technology may potentially serve as a viable alternative to the parenteral 
route of administration for sensitive proteins and peptides.      
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7th APS International PharmSci Conference, 2015, United Kingdom  
INTRODUCTION 
 
 Polymer eutectics was used in the design of an 
innovative In Situ Crosslinked OCMT- utilizing a suite of 
salts and eutectic polymer composites capable of creating 
prefabricated core-melt archetypes within a tablet, 
producing a controlled release system that provides 
structural protection, increased permeation and enhanced the 
oral delivery of proteins and peptides. This study assessed 
the in vitro potential of the In Situ Cross-linked Eutectic 
Tablet and the applicability of the design in improving the 
oral delivery of proteins and peptides 
 
MATERIALS AND METHODS 
 
 An experimental design of 15 formulations was 
generated and each formulation was characterized with 
respect to in vitro protein/peptide release; ex vivo 
permeation capabilities through the pig intestinal tissue 
model; swelling and erosion; in situ crosslinking abilities; 
and physicomechanical profiling. In addition, advanced 
thermal analysis was significant for characterizing and 
comparing pertinent transitions such as melting, glass 
transitions, phase changes and heat of fusion of the eutectic 
composite and its reagents. Qualitative and quantitative 
crystallinity analysis was performed on the eutectic 
composite to determine fingerprint changes in crystallinity. 
  
RESULTS AND DISCUSSION 
 
Physicochemical and physicomechanical 
characterization tests confirmed eutectic formation as was 
evidenced by the lowering of the melting point to 37°C 
(Figure 1a), the decreased crystallinity for the eutectic 
powder blend (EPB) as compared to the eutectic reagents 
menthol and cetomacrogol and  the shift in the SEM images 
to an amorphous structure which is typically characteristic 
of eutectic mixtures. Protein/peptide release from the 
OCMTs was calculated as a function of fractional release 
versus time with all formulations displaying similar 
controlled release patterns over the 24hour study period with 
a maximum fractional release of ±0.8 for all formulations. 
The release pattern alternated between phases of burst and 
slow release which was attributed to the combined effects of 
swelling, surface erosion and in situ crosslinking. 
Mathematical modelling of the protein release kinetics 
corresponded best with the Higuichi model with near zero 
order (R2≈0.9787) release obtained. The permeation 
enhancing effect of menthol contained within the EPB was 
investigated and results displayed an enhanced protein flux 
(0.0576-0.0720mg.cm−2h−1) across the intestinal tissue 
model as compared to the control (EPB-free) formulation 
which displayed a protein flux of 0.0289mg.cm−2 h−1. FTIR 
results highlighted the shifting and changing of band 
intensities as well as the appearance of new bands and the 
disappearance of bands indicating successful in situ 
crosslinking within the core eutectic region with higher 
concentrations of crosslinkers displaying superior 
crosslinking abilities. Textural analysis of the OCMTs 
revealed the softening of the core region at 37°C, which 
mirrored the MRI image (Figure 1b) and thermal analysis 
results obtained. 
 
 
 
Fig. 1. a) Binary phase diagram constructed for the EPB using thermal 
analysis results and b) Magnetic Resonance Imaging (MRI) of the OCMT 
with the red arrow indicating the outer polymer shell and the green arrow 
indicating the softened core at 37°C. 
 
CONCLUSIONS 
 
 Physicochemical and physicomechanical 
characterization that was undertaken was essential for 
delineating the in vitro attributes, predicting the in vivo 
performance of the device and demonstrating the 
applicability of the design in improving the oral delivery of 
a multitude of proteins and peptides. Essentially, this novel 
technology may potentially serve as a viable alternative to 
the parenteral route of administration for sensitive proteins 
and peptides. 
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